June 20242TITLE OF REPORT|5Investment Landscape9The Patient Journey14Adoption17Authors&Acknowledgeme.
2024-08-23
20页
5星级
simon-Joerg TritschlerMartin SlusarczykSantiago WochnerThe wild west of sales forecasting in pharmac.
2024-08-22
18页
5星级
Reinventing R&D in the age of AIHow intelligent technologies are transforming the Biopharma Industry.
2024-08-21
33页
5星级
2024 Advertising Insights ReportFor Pharma2024 Advertising Insights Report For PharmaThe 100%digital.
2024-08-19
16页
5星级
Citi is one of the worlds largest financial institutions,operating in all major established and emer.
2024-08-16
70页
5星级
Top Pharma Trends to Watch in 2024Whats Inside1 Introduction2 CHAPTER 1 How the Pharmaceutical Indus.
2024-08-15
14页
5星级
North America Genetic Testing Services Market Market Size and Forecast(2020-2030)Regional Growth Opportunity Analysis Coverage:By Service Service TypeType(Predictive Testing,Carrier Testing,Prenatal Testing,Newborn Screening,and Others),DiseaseDisease(Cancer,Metabolic Diseases,Cardiovascular Diseases,and Other Diseases),Service ProviderService Provider(Hospital-Based Laboratories,Diagnostic Laboratories,and Others),and CountryCountry 2 North America Genetic Testing Services Market,2020-2030 |The Insight Partners Table of Content 1.Introduction.12 1.1 The Insight Partners Research Report Guidance.12 1.2 Market Segmentation.13 2.Executive Summary.14 2.1 Key Insights.14 3.Research Methodology.15 3.1 Coverage.16 3.2 Secondary Research.16 3.3 Primary Research.16 4.North America Genetic Testing Services Market-Key Industry Dynamics.18 4.1 Key Market Drivers.18 4.1.1 Rising Prevalence of Genetic Diseases.18 4.1.2 Increasing Awareness and Acceptance of Personalized Medicines.19 4.1.3 Growing Preference for Direct-To-Consumer(DTC)Genetic Testing.19 4.2 Market Restraints.21 4.2.1 Social and Ethical Implications of Genetic Testing.21 4.2.2 Affordability of Genetic Services.21 4.3 Market Opportunities.22 4.3.1 Untapped Emerging Markets in Developing Countries.22 4.4 Future Trends.22 4.4.1 Artificial Intelligence-Powered Genetic Testing.22 4.5 Impact Analysis:.23 5.Genetic Testing Services Market-North America Market Analysis.24 5.1 North America Genetic Testing Services Market Revenue(US$Mn),2022 2030.24 6.North America Genetic Testing Services Market Revenue and Forecast to 2030 by Service Type.25 6.1 Overview.25 6.2 North America Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%).25 6.3 Predictive Testing.26 6.3.1 Overview.26 3 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.3.2 Predictive Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).26 6.4 Carrier Testing.28 6.4.1 Overview.28 6.4.2 Carrier Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).28 6.5 Prenatal Testing.29 6.5.1 Overview.29 6.5.2 Prenatal Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).29 6.6 Newborn Screening.30 6.6.1 Overview.30 6.6.2 Newborn Screening:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).30 6.7 Others.32 6.7.1 Overview.32 6.7.2 Others:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).32 7.North America Genetic Testing Services Market Revenue and Forecast to 2030 by Disease.34 7.1 Overview.34 7.2 North America Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%).34 7.3 Cancer.35 7.3.1 Overview.35 7.3.2 Cancer:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).35 7.4 Cardiovascular Diseases.36 7.4.1 Overview.36 7.4.2 Cardiovascular Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).36 7.5 Metabolic Diseases.37 7.5.1 Overview.37 7.5.2 Metabolic Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).37 7.6 Other Diseases.38 7.6.1 Overview.38 7.6.2 Other Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).38 4 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 8.North America Genetic Testing Services Market Revenue and Forecast to 2030 by Service Provider.40 8.1 Overview.40 8.2 North America Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%).40 8.3 Hospital-Based Laboratories.41 8.3.1 Overview.41 8.3.2 Hospital-Based Laboratories:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).41 8.4 Diagnostic Laboratories.42 8.4.1 Overview.42 8.4.2 Diagnostic Laboratories:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).42 8.5 Others.43 8.5.1 Overview.43 8.5.2 Others:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).43 9.North America Genetic Testing Services Market-Country Analysis.44 9.1 North America.44 9.1.1 North America Genetic Testing Services Market,by Country.44 9.1.1.1 US.45 9.1.1.1.1 Overview.45 9.1.1.1.2 US:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).45 9.1.1.1.3 US:North America Genetic Testing Services Market,by Service Type,20202030(US$Million).46 9.1.1.1.4 US:North America Genetic Testing Services Market,by Disease,20202030(US$Million).47 9.1.1.1.5 US:North America Genetic Testing Services Market,by Service Provider,20202030(US$Million).47 9.1.1.2 Canada.48 9.1.1.2.1 Overview.48 9.1.1.2.2 Canada:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).48 9.1.1.2.3 Canada:North America Genetic Testing Services Market,by Service Type,20202030(US$Million).49 9.1.1.2.4 Canada:North America Genetic Testing Services Market,by Disease,20202030(US$Million).49 9.1.1.2.5 Canada:North America Genetic Testing Services Market,by Service Provider,20202030(US$Million).49 5 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.3 Mexico.50 9.1.1.3.1 Overview.50 9.1.1.3.2 Mexico:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).51 9.1.1.3.3 Mexico:North America Genetic Testing Services Market,by Service Type,20202030(US$Million).51 9.1.1.3.4 Mexico:North America Genetic Testing Services Market,by Disease,20202030(US$Million).52 9.1.1.3.5 Mexico:North America Genetic Testing Services Market,by Service Provider,20202030(US$Million).52 10.Genetic Testing Services MarketIndustry Landscape.53 10.1 Overview.53 10.2 Growth Strategies in North America Genetic Testing Services Market.53 10.3 Organic Growth Strategies.54 10.3.1 Overview.54 10.4 Inorganic Growth Strategies.56 10.4.1 Overview.56 11.Company Profiles.57 11.1 Eurofins Scientific SE.57 11.1.1 Key Facts.57 11.1.2 Business Description.57 11.1.3 Products and Services.58 11.1.4 Financial Overview.59 11.1.5 SWOT Analysis.60 11.1.6 Key Developments.61 11.2 Exact Sciences Corp.62 11.2.1 Key Facts.62 11.2.2 Business Description.62 11.2.3 Products and Services.62 11.2.4 Financial Overview.63 11.2.5 SWOT Analysis.64 11.2.6 Key Developments.65 11.3 Laboratory Corp of America Holdings.66 11.3.1 Key Facts.66 11.3.2 Business Description.66 11.3.3 Products and Services.66 6 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 11.3.4 Financial Overview.67 11.3.5 SWOT Analysis.68 11.3.6 Key Developments.69 11.4 23andMe Holding Co.70 11.4.1 Key Facts.70 11.4.2 Business Description.70 11.4.3 Products and Services.71 11.4.4 Financial Overview.71 11.4.5 SWOT Analysis.72 11.4.6 Key Developments.73 11.5 Ambry Genetics Corp.74 11.5.1 Key Facts.74 11.5.2 Business Description.74 11.5.3 Products and Services.75 11.5.4 Financial Overview.75 11.5.5 SWOT Analysis.75 11.5.6 Key Developments.76 11.6 Quest Diagnostics Inc.77 11.6.1 Key Facts.77 11.6.2 Business Description.77 11.6.3 Products and Services.78 11.6.4 Financial Overview.78 11.6.5 SWOT Analysis.79 11.6.6 Key Developments.80 11.7 Illumina Inc.81 11.7.1 Key Facts.81 11.7.2 Business Description.81 11.7.3 Products and Services.82 11.7.4 Financial Overview.82 11.7.5 SWOT Analysis.83 11.7.6 Key Developments.84 11.8 F.Hoffmann-La Roche Ltd.85 11.8.1 Key Facts.85 11.8.2 Business Description.85 11.8.3 Products and Services.86 7 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 11.8.4 Financial Overview.86 11.8.5 SWOT Analysis.88 11.8.6 Key Developments.90 11.9 NeoGenomics Inc.91 11.9.1 Key Facts.91 11.9.2 Business Description.91 11.9.3 Products and Services.91 11.9.4 Financial Overview.92 11.9.5 SWOT Analysis.93 11.9.6 Key Developments.94 11.10 Centogene AG.95 11.10.1 Key Facts.95 11.10.2 Business Description.95 11.10.3 Products and Services.95 11.10.4 Financial Overview.96 11.10.5 SWOT Analysis.97 11.10.6 Key Developments.98 12.Appendix.99 12.1 About Us.99 12.2 Glossary of Terms.100 8 North America Genetic Testing Services Market,2020-2030 |The Insight Partners List of Tables Table 1.North America Genetic Testing Services Market Segmentation.13 Table 2.US:North America Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).46 Table 3.US:North America Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).47 Table 4.US:North America Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).47 Table 5.Canada:North America Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).49 Table 6.Canada North America Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).49 Table 7.Canada:North America Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).49 Table 8.Mexico:North America Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).51 Table 9.Mexico:North America Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).52 Table 10.Mexico:North America Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).52 Table 11.Recent Organic Growth Strategies in North America Genetic Testing Services Market.54 Table 12.Recent Inorganic Growth Strategies in the North America Genetic Testing Services Market.56 Table 13.Glossary of Terms,North America Genetic Testing Services Market.100 9 North America Genetic Testing Services Market,2020-2030 |The Insight Partners List of Figures Figure 1.North America Genetic Testing Services Market Segmentation,By Country.13 Figure 2.North America Genetic Testing Services Market-Key Industry Dynamics.18 Figure 3.Impact Analysis of Drivers and Restraints.23 Figure 4.North America Genetic Testing Services Market Revenue(US$Mn),2022 2030.24 Figure 5.North America Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%).25 Figure 6.Predictive Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).27 Figure 7.Carrier Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).28 Figure 8.Prenatal Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).29 Figure 9.Newborn Screening:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).31 Figure 10.Others:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).33 Figure 11.North America Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%).34 Figure 12.Cancer:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).35 Figure 13.Cardiovascular Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).36 Figure 14.Metabolic Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).37 Figure 15.Other Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).39 Figure 16.North America Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%).40 Figure 17.Hospital-Based Laboratories:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).41 Figure 18.Diagnostic Laboratories:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).42 Figure 19.Others:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).43 10 North America Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 20.North America:North America Genetic Testing Services Market,by Key Country Revenue(2022)(US$Million).44 Figure 21.North America Genetic Testing Services Market,By Key Countries,2022 and 2030(%).44 Figure 22.US:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).46 Figure 23.Canada:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).48 Figure 24.Mexico:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).51 Figure 25.Growth Strategies in North America Genetic Testing Services Market.53 11 North America Genetic Testing Services Market,2020-2030 |The Insight Partners NOTES:The list of companies included in the scope are as per standard report format and the list can be modified/expanded as per clients requirement The sequence/list of companies do not represent their current position in the market.The list of countries provided in the report are part of standard report and can be customized as per clients requirement RELATED REPORTS Newborn Genetic Testing Market DTC Genetic Testing Market 12 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 1.Introduction 1.1 The Insight Partners Research Report Guidance The report provides qualitative and quantitative trends of North America genetic testing services market across service type,disease,service provider,and country.The report starts with the key takeaways(chapter 2),highlighting the key trends and outlook of the North America genetic testing services market.Chapter 3 provides the research methodology of the study.Chapter 4 further provides PEST analysis for each region.Chapter 5 highlights the key industry dynamics in the North America genetic testing services market,including factors that are driving the market,prevailing deterrent,potential opportunities as well as future trends.Impact analysis of these drivers and restraints is also covered in this section.Chapter 6 discusses the North America genetic testing services market scenario,in terms of historical market revenues,and forecast till 2030.Chapter 7 to 10 discuss genetic testing services market segments by service type,disease,service provider,and countries across North America.They cover market revenue forecast,and factors driving and governing growth.Chapter 11 describes the industry landscape analysis.It provides detailed description of various business activities such as market initiatives,new developments,mergers,and joint ventures globally along with a competitive landscape.Chapter 12 provides the detailed profiles of the key companies operating in the North America genetic testing services market.The companies have been profiled on the basis of their key facts,business description,products and services,financial overview,SWOT analysis,and key developments.Chapter 13,i.e.the appendix is inclusive of a brief overview of the company,glossary of terms,contact information,and the disclaimer section.13 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 1.2 Market Segmentation Table 1.North America Genetic Testing Services Market Segmentation SERVICE TYPESERVICE TYPE DISEASEDISEASE SERVICE PROVIDERSERVICE PROVIDER PREDICTIVE TESTING CANCER HOSPITAL-BASED LABORATORIES CARRIER TESTING CARDIOVASCULAR DISEASES DIAGNOSTIC LABORATORIES PRENATAL TESTING METABOLIC DISEASES OTHERS NEWBORN SCREENING OTHER DISEASES OTHERS Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources Figure 1.North America Genetic Testing Services Market Segmentation,By Country Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources The North America genetic testing services market is segmented based on service type,disease,service provider,and country.The segmentation in this research study has been finalized post in-depth secondary research and extensive primary research.In addition,the market is also segmented on the basis of services offered by the leading participants in the industry in order to understand widely used market specific terminologies.Thus,we have incorporated the segments of the research and have finalized the market segmentation.USCANADAMEXICONORTH AMERICA 14 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 2.Executive Summary 2.1 Key Insights OverviewMarket SegmentationMarket DynamicsRegional OverviewMarket SegmentationKey PlayersMarket DynamicsCAGR(2022-2030)15.2%Market Size 2022$1,604.32MnMarket Size 2030$4,984.25MnService TypeDisease Predictive Testing Carrier Testing Prenatal Testing Newborn Screening Others Cancer Cardiovascular Diseases Metabolic Diseases Other Diseases Laboratory Corporation of America Holdings F.Hoffmann-La Roche Ltd Illumina,Inc.Quest Diagnostics Incorporated Exact Sciences Corp(Genomic Health)NeoGenomics Laboratories,Inc.Eurofins Scientific Ambry Genetics 23andMe,IncGROWTH DRIVERSFUTURE TRENDSGROWTH DRIVERSFUTURE TRENDS Rising Prevalence of Genetic Diseases Increasing Awareness and Acceptance of Personalized Medicines Artificial Intelligence-Powered Genetic TestingRESTRAINTSOPPORTUNITY Social and Ethical Implications of Genetic Testing Affordability of Genetic Services Untapped Emerging Markets in Developing CountriesService Provider Hospital-Based Laboratories Diagnostic Laboratories OthersNORTH AMERICA15.2 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 3.Research Methodology The Insight Partners dedicated research and analysis team consist of experienced professionals with advanced statistical expertise in market research and consulting backgrounds in various industries including Aerospace and Defense,Automotive and Transportation,Biotechnology,Chemicals and Materials,Food and Beverages,Electronics and Semiconductor,Healthcare IT,Manufacturing and Construction,Medical Device,Technology,Media and Telecommunications.Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources FinalMarket sizeValidation from Primary InterviewSummation of Revenue Generated from Companies to arrive Total Market SizeRevenue Generated by the Products and Services Offered by Companies in the Genetic Testing Service MarketFinal Market Size Break-Up To Rest Of Segmentation(i.e.,Service Type,Disease,Service Provider,and Region)Arriving at the Market Size of each Segment Validation of Number with Primary Interviews and Subject Matter Expert BOTTOM-UP ANALYSISTOP-DOWN ANALYSIS 16 North America Genetic Testing Services Market,2020-2030 |The Insight Partners The Insight Partners adheres to the codes of practice of the Market Research Society(www.mrs.org.uk)and Strategic and Competitive Intelligence Professionals(www.scip.org).The following methodology has been followed for the collection and analysis of data presented in this report:3.1 Coverage The objective of updating“The Insight Partners”coverage is to ensure that it represents the most up-to-date vision of the industry possible.The estimated revenues of all major companies,including private and governmental,are gathered and used to prioritize coverage.Companies which are making the news,or which are of particular interest due to their innovative approach,are prioritized.3.2 Secondary Research The research process begins with exhaustive secondary research using internal and external sources to obtain qualitative and quantitative information relating to each Market.The secondary research sources that are typically referred to include,but are not limited to:Company websites,annual reports,financial reports,broker reports and investor presentations Industry trade journals and other literature National government documents,statistical databases and market reports News articles,press releases and web-casts specific to the companies operating in the market NOTE:All the financials considered in Company Profiles section have been standardized to US$.This has been achieved after converting the financials(for those not in US$)with respective currency exchange rates of the particular year.3.3 Primary Research“The Insight Partners”conducts hundreds of primary interviews a year with industry participants and commentators in order to validate its data and analysis.A typical research interview fulfils the following functions:Provides first-hand information on the market size,market trends,growth trends,competitive landscape and future outlook Validates and strengthens secondary research findings Further develops the analysis teams expertise and market understanding 17 North America Genetic Testing Services Market,2020-2030 |The Insight Partners Primary research involves email interactions and telephone interviews for each market,category,segment and sub-segment across countries.The participants who typically take part in such a process include,but are not limited to:Industry participants:VPs,business development managers,market intelligence managers and national sales managers Outside experts:Valuation experts,research analysts and key opinion leaders specializing in the industry 18 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 4.North America Genetic Testing Services Market-Key Industry Dynamics Figure 2.North America Genetic Testing Services Market-Key Industry Dynamics Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 4.1 Key Market Drivers 4.1.1 Rising Prevalence of Genetic Diseases The prevalence of genetic diseases is rising across the world and impacting the health of people at a severe level.Genetic diseases show many symptoms that are uncommon and are mostly non-curable.Most of the genetic diseases are rare and are developed due to the mutation in the genetic makeup of the people.According to The World Health Organization(WHO)2021,10 out of every 1,000 people are affected by single-gene diseases,signifying that 70 million and 80 million people worldwide are living with any one type of single-gene disease.As per the Global Genes,7,000 known rare diseases and disorders have been identified worldwide,and more are being discovered every year.According to the University of Sheffield research,300 million people are living with genetic diseases around the world.In 2022,a report by MJH Life Sciences(US)estimated that 300,000 newborns worldwide are born with sickle cell disease every year,accounting for 5%of the global population.Also,as per the study titled Sickle Cell Disease,published in August 2023,1 in 500 African Americans is affected by sickle cell disease,and 1 in 12 African Americans carry the autosomal recessive mutation.Thus,the rising prevalence of genetic diseases fuels the demand for genetic testing,which in turn drives genetic testing services market growth.DROTDRIVERSRESTRAINTSOPPORTUNITIESTRENDSRising Prevalence of Genetic DiseasesIncreasing Awareness and Acceptance of Personalized MedicinesGrowing Preference for Direct-To-Consumer Genetic TestingSocial and Ethical Implications of Genetic TestingAffordability of Genetic ServicesArtificial Intelligence-Powered Genetic TestingUntapped Emerging Markets in Developing Countries 19 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 4.1.2 Increasing Awareness and Acceptance of Personalized Medicines Personalized medicine is the field that utilizes patients genetic and environmental data to deliver optimal healthcare.It is based on the principle that every patient is unique and requires individualistic pharmacological treatment.Since it is a rapidly evolving area,it is presently incorporated into several healthcare systems.The successful completion of the Human Genome Project(HGP)in 2003 and the fast-decreasing human genome sequencing costs encouraged the development of a new medical approach,which is called personalized medicine.With an expanding repository of personalized data at the molecular level,molecular diagnostics companies are exceptionally positioned to unlock value.The awareness of personalized medicine has increased since the commencement of the Precision Medicine Initiative,announced by Barack Obama in 2015.Not only in the US but also in Germany,personalized medicine,better known as individualized medicine(IM),has gained more attention.By the end of 2010,The German Federal Ministry of Education and Research(BMBF)named personalized medicine as one of the six priorities.It introduced the Action Plan called Individualized Medicine.Moreover,the 100,000 Genomes Project is also strengthening the National Health Services position as one of the most advanced healthcare systems in the world.Also,the project is consolidating the foundation for personalized medicine,and this,in turn,contributes to the genetic testing services market growth.Large-scale drug discovery is a key to increasing the viability and usefulness of personalized medicines for the diagnosis of diseases and disorders.Genomics is one of the fastest-growing divisions of medical science.It is driving a paradigm shift in the research methodology of a disease,as well as diagnosing and treating illness.Genetic testing has been extensively used in pharmacogenomics,also known as drug-gene testing.It helps in accelerating drug discovery and its development.In January 2023,The Human Genome Project is ensuring an era of personalized healthcare.Now,new research shows that precision prescribing using genetic testing has ultimately reached a global tipping point for adoption.Published by Cambridge University Press,the peer-reviewed research examines the maturation of critical factors required for the use of clinical genetics at scale.These advancements pave the way for supporting genome-informed clinical decision-making to be established as the new standard of care.Genetically informed prescribing offers one of the realistic mechanisms to successfully reduce the overall costs of the healthcare system and improve individual patient care.Genetic testing encourages the adoption of a personalized medicine approach by understanding the science behind the disease,the impact of treatment,and the development of therapies for specific individual characteristics.It also helps healthcare personnel make informed decisions about disease diagnosis,treatment,and prevention by utilizing genetic testing results,leading to improved patient outcomes.4.1.3 Growing Preference for Direct-To-Consumer(DTC)Genetic Testing Personalized genetic testing and treatment have long been used globally to help individuals and families learn more about hereditary diseases.Most of the time,genetic testing is done through healthcare personnel,such as genetic counselors.Healthcare providers decide which test is needed,order the test from a test center,collect and send the DNA sample,read the test results,and share the results with the patient.Thus,these tests have traditionally been ordered and interpreted in a clinical or medical research setting.In contrast,DTC genetic testing has witnessed tremendous growth in the past decade and is becoming increasingly widespread.A genetic test offered,advertised,and sold by companies directly to the consumer,without the direct involvement of a conventional healthcare system,is called DTC genetic testing.DTC genetic testing is relatively new and helps people find out about the disease-associated genes they may carry without the need for a prescription or guidance from a genetic 20 North America Genetic Testing Services Market,2020-2030 |The Insight Partners counselor or medical practitioner.Several consumers of DTC testing view it as another method of gathering medical information about themselves.Unlike other genetic tests performed in clinics or hospitals,the consumer independently initiates and completes a DTC genetic test.The public understanding and acceptance of genetic testing is gradually increasing.Additionally,there is a rise in consumers seeking customized products and experiences for the identification and addressing of unique needs.The launch of innovative products and the increase in the adoption of DTC genetic testing kits have made genetic testing more accessible to people.These kits enable users to undergo personalized health management within the comfort of their homes.Key industry players are also developing DTC genetic tests and implementing special marketing efforts that positively impact sales of DTC tests.In April 2017,the US Food and Drug Administration(FDA)gave genetics company 23andMe the consent to market DNA tests evaluating the users level of risk for ten health conditions,including late-onset Alzheimers disease and Parkinsons disease.These remain the only FDA-approved DTC tests for genetic risk of infection.The brand offers specialized,evidence-based genetic screening tests that provide insights into ones health prior to the onset of symptoms.In July 2023,Quest Diagnostics,a US-based diagnostic information service provider,introduced its first direct-consumer genetic test,Genetic Insights.The test uses next-generation sequencing to evaluate the risk for inheritable health conditions.The test inspects 36 genes using a saliva sample.It can investigate the potential risk of up to 24 genetically inheritable conditions,including breast cancer,heart disorders,blood disorders,and sickle cell anemia.A rising number of manufacturers are providing direct-to-consumer genetic testing that covers various health conditions and traits.The increasing demand for direct-to-consumer genetic testing products to learn about the genetic makeup and assess the risk of developing hereditary conditions for early disease detection or prevention drives the market.21 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 4.2 Market Restraints 4.2.1 Social and Ethical Implications of Genetic Testing Genetic testing is poised to play an important role in the practice of obstetrics and gynecology.Physicians are required to become familiar with the presently accessible collection of genetic tests and their limitations to guarantee patients the utmost quality of care.However,the knowledge of genetic risks can result in potential social and psychological consequences for the people undergoing such tests.Socially,knowledge from genetic tests may lead to stigmatization and judgment within the community.Refusing to undergo genetic testing,as well as choosing to undergo genetic testing,can both lead to discrimination and stigmatization,depending on the prevalent public standards concerning acceptance and use of the technology.Privacy and security concerns also arise as the availability and commercialization of personal genetic data can lead to unauthorized access or misuse of sensitive information.The storage of genetic testing data and registries of patients generates concern,given that the results can negatively impact the family members.In addition,lack of informed consent can lead to adverse reactions,such as increased anxiety and unnecessary preventive measures during the disclosure of genetic test results.Lack of proper counseling regarding the information about genetic risk and choices regarding genetic testing and its management can cause potential psychological distress.Therefore,the reluctance of patients to prefer genetic testing due to the social and ethical stigma impedes market growth.4.2.2 Affordability of Genetic Services At present,genetic services are expensive and,therefore,not accessible to all.Genetic research is presently underrepresented in health research;however,studies are being conducted to establish the feasibility of such services.Present inequalities in the affordability and feasibility of genetic services are a cause of concern for the WHO and other prominent international organizations that are centered around public health and development concerns.According to The National Library of Medicine,the average cost of genetic testing can range from less than US$100 to over US$2,000,depending on the complexity and nature of the genetic test.In several cases,health insurance plans cover the cost of the tests when professionals recommend it.Health insurance providers vary greatly in their policies and coverage.In addition,for people who dont have insurance,the cost of these tests becomes a significant hurdle.For people without insurance seeking more specialized genetic testing,such as whole genome sequencing or advanced health risk prediction tests,the costs rise greatly.On average,these tests can cost between US$1,000 to US$2,500.The cost of the test also increases if more than one test is needed or if multiple family members need to be tested to obtain a significant result.For newborn screening,costs differ as per the state.Several states cover part of the overall cost,although most charge a fee of US$30 to US$150 per infant.Various factors,including the type of test,the complexity of analysis,and laboratory processing fees,influence the cost of these tests.Thus,the high costs,along with its affordability in emerging economies,restrain the market growth.22 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 4.3 Market Opportunities 4.3.1 Untapped Emerging Markets in Developing Countries Emerging countries such as China,India,Brazil,and Mexico offer significant growth opportunities to market players.The high growth can majorly be attributed to the increasing public healthcare expenditure,improving healthcare infrastructure,and the presence of a large target patient population.The need for genetic testing has also increased owing to a rise in awareness of genetic disorders in developing economies and their early diagnosis.The quality and availability of genetic services may differ between high-income countries and low-to middle-income countries.For instance,in the US,Australia,Canada,the UK,and other European countries,genetic services are well-advanced,established,and extensive.These services include newborn screening,carrier identification screening,and prenatal diagnosis.Yet,in many high-income countries,genetic services that are offered in multiple settings still need improved systems of assessment.The ease and applicability of genetic testing procedures have benefitted R&D activities in developing regions worldwide.Major market players are focusing on strategies and initiatives,such as agreements,collaborations,partnerships,and expansions,to improve their product availability,accessibility,and distribution networks in these countries,as it will help them address the growing need for early diagnosis and treatment.For instance,in 2022,in an effort to advance personalized healthcare throughout Latin America,Nordic Group,a leader in nutrigenomics,has partnered with a Mexican laboratory to manage its DNAlife genetic testing platform.Through the partnership,Vitage Lab will oversee the nationwide training of medical professionals in the usage of Nordic Groups DNAlife genetic testing platform and distribute it.In addition,rising consumer awareness regarding DTC genetic tests in developing economies offers growth opportunities to the DTC industry.Therefore,emerging markets in developing countries are expected to offer significant opportunities to the players operating in the market and boost the market growth during the forecast period.4.4 Future Trends 4.4.1 Artificial Intelligence-Powered Genetic Testing As of 2018,there were 75,000 genetic tests available in the market,with nearly ten new tests entering the market every day.As per the study Trends in Availability of Genetic Tests in the United States,20122022,published in 2023,129,624 and 197,779 genetic tests in the US and globally,respectively,have been made accessible and submitted to the genetic testing registry as of November 2022.These tests have been extended from single-gene tests to panels that look at multiple genes.Whole-genome sequencing and now whole-exome sequencing have also become more popular.To solve the growing problem of health data exhaust,the field of medicine is increasingly revolving around enhanced clinical tools,such as artificial intelligence(AI)and machine learning,which have been mentioned as a way to improve the acceptance of genomic medicine.Today,many companies have turned to machine learning to process the vast amount of data needed to correctly analyze and understand clinical data in fields such as radiology and cardiology.Many of the consumer-facing genetic testing technologies that are available in the market are using machine learning or AI to function.In numerous ways,genetic testing of diseases is the perfect field for machine learning because of the vast volumes of data that these programs need to struggle with.For example,working on the human genome includes reading billions of bits of information,and prior to the introduction of machine learning,many of these tasks were pretty tricky.AI offers great potential when it comes to analyzing genetic data and supporting clinical specialists in making diagnoses.Google has a program called Deep Variant that can now be used to plot the human genome thoroughly and can be used on the full range of a persons genetic information.Moreover,agencies such as the National Institutes of Health are 23 North America Genetic Testing Services Market,2020-2030 |The Insight Partners working on ways through which machine learning and AI can add to a better understanding of genetics and genomics.Furthermore,Blueprint Genetics is using AI in clinical interpretation.Machine learning and AI are acting as a catalyst for faster and more diverse improvement in genetic research and engineering.These tools are simple to integrate and extremely scalable,putting genetic laboratories in a unique position to scale their operations and match the fast growth of the genetic testing field.Thus,through the successful integration of these tools,clinicians will be able to diagnose rare genetic diseases more efficiently and effectively,bringing hope to the millions of people affected by them globally.4.5 Impact Analysis:The following figure depicts the impact of factors driving and restraining the North America genetic testing services market.The factors driving the market growth include increasing prevalence of genetic diseases,increasing awareness and acceptance of personalized medicines,and growing preference for direct-to-consumer genetic testing.However,social and ethical implications of genetic testing and affordability of genetic services hinders the market growth.Figure 3.Impact Analysis of Drivers and Restraints Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources Rising Prevalence of Genetic DiseasesGrowing Preference towards for Direct-To-Consumer Genetic TestingSocial and Ethical Implications of Genetic TestingLOWMEDIUMHIGHIncreasing Awareness and Acceptance of Personalized Medicines 24 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 5.Genetic Testing Services Market-North America Market Analysis The North America genetic testing services market in North America is segmented into the US,Canada,and Mexico.In 2022,the US held the largest market share in this region and is expected to continue its dominance during 20222030.The North America genetic testing services market in North America is expected to grow due to the rising number of cancer patients,increasing government funding,and rising incidence of genetic diseases among the population in the US and Canada during recent years.Moreover,increasing focus on advanced method incorporation in healthcare,government and private initiatives for the promotion of precision medicine,and massive funds from government and private bodies for genetic research contribute to exceptional revenue generation for the North America genetic testing services market in North America.5.1 North America Genetic Testing Services Market Revenue(US$Mn),2022 2030 The North America genetic testing services market is expected to reach US$4,984.25 million by 2030 from US$1,604.32 million in 2022.The market is estimated to grow at a CAGR of 15.2%from 2022 to 2030.The factors driving the market growth include the increasing prevalence of genetic diseases,growing preference for direct-to-consumer genetic testing,and increasing awareness and acceptance of personalized medicines.However,social and ethical implications of genetic testing and affordability of genetic services restrain the growth of the market.Figure 4.North America Genetic Testing Services Market Revenue(US$Mn),2022 2030 Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 1,277.491,430.911,604.321,809.842,054.232,345.832,695.073,114.963,621.834,236.264,984.2512.0.1.8.5.2.9.6.3.0.7%0.0%2.0%4.0%6.0%8.0.0.0.0.0.0 .0 20202120222023202420252026202720282029203001,0002,0003,0004,0005,0006,0002020-2030Historical YearBase YearForecast Year 25 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.North America Genetic Testing Services Market Revenue and Forecast to 2030 by Service Type 6.1 Overview The North America genetic testing services market,by service type,is segmented into predictive testing,carrier testing,prenatal testing,newborn screening,and others.In 2022,the predictive testing segment held the largest share of the market and is expected to register the highest CAGR in the market during the coming years.6.2 North America Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%)Figure 5.North America Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%)Source:The Insight Partners Analysis The predictive testing segment led the market in 2022 with a share of 39.7%and is expected to retain its dominance during 20222030 by accounting for 43.4%of the total market by 2030.39.7$.2.8.2%8.1 22Predictive TestingCarrier TestingPrenatal TestingNew-born ScreeningOthers43.4$.9.1.4%4.2 30 26 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.3 Predictive Testing 6.3.1 Overview Predictive genetic testing examines any genetic changes or mutations that are linked to disease.These tests are done prior to an individual displaying any signs of a disease.Predictive testing can be helpful to people who have a family history of a treatable genetic disorder and display no signs of illness.This testing can identify mutations that increase an individuals risk of developing disorders with a genetic foundation,such as certain types of cancer.An example is testing for the BRCA1 and BRCA2 gene variants(altered genes)linked with an increased risk of breast cancer.The results of predictive testing can provide information about the probability of developing a specific disorder and help in making decisions about medical care.Breast cancer is one of the most common types of cancer in the US.A report published by Breastcancer.org in January 2022 stated that 287,850 new incidences of invasive breast cancer,along with 51,400 new cases of noninvasive breast cancer,were detected in women in the US in 2022.Similarly,in 2022,according to the Canadian Cancer Society,28,600 Canadian women were diagnosed with breast cancer,accounting for nearly 25%of all new cancer cases in women.The increasing prevalence of multiple types of cancer is driving the market for the predictive testing segment.The increasing demand for genetic counseling is expected to drive the market for predictive testing as more people understand the importance of genetics in disease etiology.The ongoing advancements and upgrading of platforms to improve the efficiency of genome analysis techniques are expected to boost the adoption of predictive testing solutions.A growing focus on reducing the growing healthcare burden of rare genetic diseases and rapid integration of technologies such as artificial intelligence and machine learning will enhance product development and fuel the need for predictive testing to assess and prevent future complications arising from diseases effectively.6.3.2 Predictive Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Predictive testing segment was valued at US$637.06 million in 2022 and is expected to reach US$2,165.31 million by 2030.The growth rate of this segment is projected to be 16.5%during 20222030.27 North America Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 6.Predictive Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 495.46561.58637.06727.07834.79964.211,120.321,309.421,539.441,820.462,165.31202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 28 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.4 Carrier Testing 6.4.1 Overview Carrier testing is a kind of genetic test that can tell whether one carries a gene for certain genetic disorders or not.When it is done before or during pregnancy,it helps to find out the chances of having a child with a genetic disorder.Carrier testing is used to identify people carrying one copy of a gene mutation(a genetic change)that,when present in two copies,results in a genetic disorder.Carriers generally do not have symptoms or have only mild symptoms.They often are unaware that they have a gene for a disorder.Carrier screening is offered for a limited number of diseases,including cystic fibrosis,sickle cell disease,fragile X syndrome,and TaySachs disease.A few of these disorders occur commonly in certain ethnic groups.For example,sickle cell disease occurs most frequently in African Americans.TaySachs disease is most common in Eastern or Central European Jewish people,French Canadian people,and Cajun descent.Although,anyone can have one of these disorders as they are not restricted to these groups.With the increasing prevalence of genetic diseases caused by chromosome and gene mutations,carrier testing has grown exponentially.The majority of cases of genetic mutations are due to preexisting conditions,a family history of abortion,or congenital disabilities.Pregnant women often undergo carrier screening in order to determine the risk of transmitting a specific genetic disease to their progeny.In addition,the increasing recognition of the importance of early diagnosis and screening of gene illness fuels the need to develop strategies to tackle these diseases.6.4.2 Carrier Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Carrier testing segment was valued at US$387.74 million in 2022 and is expected to reach US$1,241.51 million by 2030.The growth rate of this segment is projected to be 15.7%during 20222030.Figure 7.Carrier Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 306.42344.52387.74439.07500.25573.42661.28767.19895.401,051.241,241.51202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 29 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.5 Prenatal Testing 6.5.1 Overview Genetics can have an impact on the color of a babys eyes and hair and can also result in the development of some birth defects or genetic disorders.This testing helps to detect abnormalities in a fetuss genes or chromosomes and syndromes before birth.Thats why women are regularly offered a wide range of prenatal genetic testing in the first and second trimesters of pregnancy to evaluate the problems in their unborn babies.According to the WHO,congenital disabilities affect 8 million newborns every year.Nine out of every ten children are born with a serious birth defect in low-and middle-income countries.Congenital disabilities can occur at any point through the pregnancy;however,most of them occur during the first trimester when the babys organs are formed.With the ease of availability,pregnant females and their families are showing increased adoption toward the conduction of prenatal tests.According to the National Human Genome Research Institute(US),since December 2016,the adoption of prenatal genetic tests has notably increased with the introduction of noninvasive prenatal tests for the diagnosis of a range of genetic disorders in females.The segment is expected to show rapid growth in the coming years owing to the increasing prenatal testing and screening in developed regions such as North America and Europe and the new genetic tests introduced by the players in the market.For instance,in February 2019,Invitae Corporation,one of the leading genetics companies,introduced a noninvasive prenatal screening that offers in-depth genetic information about the child in early pregnancy.The company announced the launch in Las Vegas in conjunction with the Society for Maternal-Fetal Medicine meeting.6.5.2 Prenatal Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Prenatal testing segment was valued at US$205.00 million in 2022 and is expected to reach US$601.15 million by 2030.The growth rate of this segment is projected to be 14.4%during 20222030.Figure 8.Prenatal Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 165.57184.15205.00229.63258.78293.40334.66384.01443.27514.70601.15202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 30 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.6 Newborn Screening 6.6.1 Overview A newborn screening test looks for various developmental,genetic,and metabolic disease disorders in the newborn.Newborn screening allows measures to be taken before symptoms develop.Most of these illnesses are extremely rare but can be treated if detected early.The offspring has a high risk of having genetic diseases in cases where the parents have another child with a genetic disease,a family history of a genetic disorder,or if either of a parent has a chromosomal abnormality.Early testing for these conditions allows physicians and parents to take timely measures to manage,treat,or intervene in disease progression,allowing the baby to lead a healthy,normal life.All babies must be screened at birth,irrespective of whether they look healthy or not,since there can be conditions that may not manifest in ways that make the child look unhealthy.In the US,all states require newborns to be tested for specific genetic and metabolic defects that cause specific conditions.As per the Newborn Screening Contingency Plan Version II,over 12,000 infants of nearly four million babies born in the US each year are diagnosed with detectable and treatable disorders.Most babies are screened at birth by state newborn screening programs to detect certain conditions that may threaten their long-term health.If diagnosed timely,conditions such as congenital hypothyroidism,sickle cell disease,or phenylketonuria can be successfully managed or treated to prevent severe and lifelong health consequences.These genetic diseases are also responsible for infant mortality worldwide.For instance,according to the World Health Organization 2023,an estimated 240,000 newborns across the world die within 28 days of birth every year due to congenital disorders.According to the Centers for Disease Control and Prevention(CDC)statistics,congenital disabilities affect every 1 in 33 infants born in the US.The same source further states that chromosomal abnormalities such as Down syndrome are the most common chromosomal disorder that affects 1 in 700 babies born in the US.This means that 6,000 infants in the US have Down Syndrome yearly.Thus,the increasing prevalence of genetic diseases among infants surges the demand for newborn genetic tests,thus contributing to the growth of the North America genetic testing services market.6.6.2 Newborn Screening:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Newborn screening segment was valued at US$243.95 million in 2022 and is expected to reach US$766.08 million by 2030.The growth rate of this segment is projected to be 15.4%during 20222030.31 North America Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 9.Newborn Screening:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 193.73217.29243.95275.57313.20358.15412.02476.85555.19650.24766.08202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 32 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.7 Others 6.7.1 Overview The others segment is comprised of preimplantation testing and pharmacogenomics.These tests are performed to screen for genetic disorders.Pharmacogenomics testing is a type of genetic test that is used to identify the right medication for a person.Pharmacogenomics is one of the key emerging trends in the field of medical science,which significantly impacts the drug development process.With the use of pharmacogenomics,target identification by drugs has become comparatively easy,which confirms much higher chances of success for the approval of drugs.Clinical pharmacogenetic testing has progressively become available for healthcare providers,comprising some academic medical center programs that support pre-emptive pharmacogenetic testing earlier to patients being prescribed certain medications.Although most pharmacogenetic programs are currently involved in adult patient populations,pharmacogenetic testing will likely have service for the pediatric population as childhood adverse drug reactions(ADRs)account for 16.5%of all ADR-related emergency visits in the US.Currently,various ongoing initiatives of pharmacogenomics implementation have been launched in the US,Europe,and Asia.In the US,27 institutions are involved in programs that are applying pharmacogenomics,some of which have been using it for over ten years.In 2007,a wide network of several associations was introduced with the creation of the Electronic Medical Records and Genomics(eMERGE)Network.Afterward,they started a study named eMERGE-PGx together with the Pharmacogenomics Research Network(PGRN),with the aim of testing genetic variation in 82 pharmacogenes through targeted sequencing.Moreover,since September 2010,with the Vanderbilt Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment program(PREDICT),more than 10,000 patients have undergone preemptive,panel-based pharmacogenomic testing.In 2011,PGRN also commenced the Translational Pharmacogenetics Program to assess PGx implementation in routine care by identifying barriers and developing solutions.Moving ahead to Asia,the Southeast Asian Pharmacogenomics Research Network(SEAPharm)platform was introduced by five Asian countries(Korea,Indonesia,Malaysia,Taiwan,and Thailand)to conduct pilot studies of adverse drug effects and develop strategies modified for Asian populations,which could guide drug usage and prove useful in disease prediction and diagnosis.Pharmacogenomics has also found diseases in the cure of cancer patients by anticipating the possible changes in drug response,efficacy,resistance,and toxicity of the chemotherapeutic and targeted immune biological agents.Therefore,pharmacogenomics for cancer therapy has achieved a number of important discoveries in the existing cancer treatment,thereby driving market growth.Preimplantation genetic testing is also for couples who are at risk of having a child with a specific genetic or chromosome disorder,e.g.,cystic fibrosis or sickle cell disease.In this procedure,egg cells are removed from the womans ovaries and fertilized with sperm cells outside the body.The fertilized embryos develop for three days,and subsequently,one or two cells are removed from each embryo.The genetic material(DNA and chromosomes)from the cells is tested for the genetic disorder in the family history.One or two of the unaltered embryos are then relocated into the mothers womb(uterus).If the pregnancy is successful,the baby will not be affected by the disorder it was tested for.6.7.2 Others:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Others segment was valued at US$130.56 million in 2022 and is expected to reach US$210.20 million by 2030.The growth rate of this segment is projected to be 6.1%during 20222030.33 North America Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 10.Others:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 116.31123.37130.56138.50147.21156.66166.79177.49188.54199.62210.20202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 34 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 7.North America Genetic Testing Services Market Revenue and Forecast to 2030 by Disease 7.1 Overview The North America genetic testing services market,by disease,is segmented into cancer,cardiovascular diseases,metabolic diseases,and other diseases.In 2022,the cancer segment held the largest share of the market and is anticipated to grow at the highest CAGR during the coming years.7.2 North America Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%)Figure 11.North America Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%)Source:The Insight Partners Analysis The cancer segment led the market in 2022 with a share of 45.1%and is expected to retain its dominance during 20222030 by accounting for 49.4%of the total market by 2030.45.1.4.1.4 22CancerCardiovascularDiseasesMetabolic DiseasesOther Diseases49.4#.5.7%9.5 30 35 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 7.3 Cancer 7.3.1 Overview Genetic testing is a potential tool to identify individuals who are at higher risk for developing certain cancers because of family history.Genetic tests are available to examine inherited variants and alterations in the DNA sequence,which could result in excessive cell growth and can cause tumors or cancer.For example,genetic testing for the detection of PALB2(linked with increased risks of breast and pancreatic cancers),BRIP1(ovarian cancer),RAD51C and RAD51D(ovarian cancer),and CHEK2(breast and colorectal cancers).The worldwide growing prevalence of various cancers,such as breast,lung,and bowel,are the major drivers of this segment.According to the American Cancer Society,1,898,160 new cancer cases and 608,570 cancer deaths were anticipated to occur in the US in 2021.Nearly 10%to 20%of all cancers are related to gene mutations that are inherited or passed down through the family.Approximately 510%of cancers diagnosed in the US are associated with hereditary cancer syndromes.During the last decade,efforts have been made by the public health,medical,and scientific community to update the public about ideas such as family history,hereditary cancer risk,and genetic testing for inherited cancer.For instance,CDCs Cancer Genomics Program develops best practices in education,surveillance,and policy and systems transformation approaches.It establishes an evidence base for the application of family history and cancer genomics in public health practice.Other factors that might impact cancer genetic testing awareness include DTC marketing of cancer genetic testing and federal regulations of genetic information,high awareness regarding the availability of quality cancer diagnostics tests,and the escalating incidence of hereditary diseases.In addition,a growing number of companies providing genomic profiling services for health assessment,including cancer risk prediction,and the availability of numerous laboratories offering genetic testing for BRCA,and other genes associated with hereditary breast,ovarian,and related cancers propel the market for the segment.7.3.2 Cancer:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Cancer segment was valued at US$723.77 million in 2022 and is expected to reach US$2,460.90 million by 2030.The growth rate of this segment is projected to be 16.5%during 20222030.Figure 12.Cancer:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 562.72637.92723.77826.13948.631,095.781,273.261,488.221,749.672,069.042,460.90202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 36 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 7.4 Cardiovascular Diseases 7.4.1 Overview Heart diseases are a prominent cause of death worldwide and often run in families.In addition,as per the World Heart Federation 2023,rare cardiovascular diseases(CVD)are common,affecting 5%of the global population.There are over 6,000 known rare diseases,a handful of which impact the heart and circulatory system.And 83%of physicians agree that genetic testing is useful in finding the diagnosis.Certain CVD conditions,such as cardiomyopathy,arrhythmia,and connective tissue disease,are caused by a single harmful DNA variation(or mutation).However,others,such as heart attack and high blood pressure,are usually caused by the combined effect of many smaller-impact DNA variations.More than 1 in 200 people have an inherited form of CVD disease,but most are unaware of it.Patients with an inherited cardiovascular condition display few or no symptoms but still face significant risk of heart disease,including sudden cardiovascular arrest.Genetic testing can help save lives and is informative and useful for the clinical management and treatment of numerous inherited CVDs.7.4.2 Cardiovascular Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Cardiovascular diseases segment was valued at US$359.90 million in 2022 and is expected to reach US$1,169.40 million by 2030.The growth rate of this segment is projected to be 15.9%during 20222030.Figure 13.Cardiovascular Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 283.41319.22359.90408.27466.00535.13618.25718.60840.24988.321,169.40202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 37 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 7.5 Metabolic Diseases 7.5.1 Overview Diagnosis through genetic testing can strongly help discover the cause of persistent,often debilitating,undiagnosed signs in individuals suffering from suspected genetic metabolic disease disorders.With knowledge of variants in over 1,250 metabolic disease disorders genes,the rapid testing and experience of metabolic diseases can help to diagnose and manage the patients metabolic disease disorders quickly and correctly.Ultimately,this can provide new insights into treatment choices and the probability of passing the inherited condition on to the offspring or the presence of it elsewhere in the extended family.CentoICU is a comprehensive next-generation sequencing panel that includes genes explicitly chosen for the genetic testing of extremely ill newborns and children under 24 months in intensive care units.In addition,Prevention Genetics offers a wide variety of genetic testing for inherited metabolic disease disorders,also known as inborn errors of metabolism.Panels specific to one disorder are available,as well as comprehensive metabolic diseases panels that cover broader phenotypic features or groups of similar disorders are also offered,including tests for hyperammonemia(37 genes),metabolic diseases hypoglycemia(38 genes),and metabolic diseases myopathies,rhabdomyolysis,and exercise intolerance(83 genes).Over the past year,the company has started to offer several new tests related to these metabolic disorders,and many of the existing panels have been updated to include more genes and increase clinical sensitivity.7.5.2 Metabolic Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Metabolic diseases segment was valued at US$305.81 million in 2022 and is expected to reach US$881.42 million by 2030.The growth rate of this segment is projected to be 14.1%during 20222030.Figure 14.Metabolic Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 247.92275.22305.81341.87384.50435.03495.16566.94652.96756.44881.42202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 38 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 7.6 Other Diseases 7.6.1 Overview The others segment by disease comprises Duchenne Muscular Dystrophy(DMD),Thalassemia,Huntingtons Disease,and Fragile X Syndrome,among others.Genetic mutations that cause DMD fail to produce dystrophin protein.Recessive diseases caused by alterations in genes on the X chromosome include DMD and fragile X syndrome.Genetic testing is used to diagnose Duchenne,to access mutation-specific therapies,and for family planning.For Duchenne,the dystrophin gene is examined to detect the presence of any changes or mutations that can inhibit the gene from working properly.Genetic testing is generally performed on a blood or saliva sample.A thalassemia is a group of inherited,genetic blood disorders that occur when the production of hemoglobin is disrupted.The disease is passed to children by parents carrying the mutated thalassemia gene.A kid who inherits one mutated gene is a carrier,and most carriers lead a completely normal and healthy life.At the same time,a child who inherits two thalassemia trait genes,i.e.,one from each parent,will have the disease.A child of two carriers has a 25 percent chance of developing the disease and a 50 percent chance of being a carrier.Thus,in such cases,genetic testing is helpful in detecting and diagnosing thalassemia.Currently,two major approaches are used in DNA diagnosis and study of genetic disease,namely direct tests and indirect tests(linkage analysis).Direct tests are being conducted for thalassemia and DMD.Carrier testing can be conducted for X-linked recessive disorders,such as DMD or fragile X syndrome.In these cases,the mother of an affected child with no other affected relatives may desire carrier testing to confirm whether the disease is a heritable trait or a new mutation.Many diseases may become apparent only in middle age or later.Predictive or presymptomatic testing and screening can provide symptoms that people may later develop these disorders.In some cases,a family history of a monogenic disorder in a relative informs other members of the family that they are at high risk for developing the disease.Suitable genetic testing can help to resolve whether the mutant gene is present or not.Examples include Huntingtons disease.7.6.2 Other Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Other diseases segment was valued at US$214.83 million in 2022 and is expected to reach US$472.53 million by 2030.The growth rate of this segment is projected to be 10.4%during 20222030.39 North America Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 15.Other Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 183.44198.55214.83233.57255.11279.89308.40341.20378.97422.46472.53202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 40 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 8.North America Genetic Testing Services Market Revenue and Forecast to 2030 by Service Provider 8.1 Overview The North America genetic testing services market,by service provider,is segmented into hospital-based laboratories,diagnostic laboratories,and others.In 2022,the hospital-based laboratories segment held the largest share of the market and is estimated to grow at the highest CAGR during 20222030.8.2 North America Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%)Figure 16.North America Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%)Source:The Insight Partners Analysis The hospital-based laboratories segment led the market in 2022 with a share of 62.7%and is expected to retain its dominance during 20222030 by accounting for 67.4%of the total market by 2030.62.7&.7.6 22Hospital-BasedLaboratoriesDiagnostic LaboratoriesOther End Users67.4.6%5.0 30 41 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 8.3 Hospital-Based Laboratories 8.3.1 Overview Hospital-based laboratories are genetic testing service providers that operate within a hospital setting.For extremely specialized tests,samples may go to a research laboratory.Nearly all hospitals contain a laboratory,which is commonly proportionate in size to the population it serves.The hospitals process hundreds of samples in very les time.Tests that are performed include those needed in emergencies,such as markers for heart attack and tests where results are required rapidly for patient care.They may also offer carrier testing to determine if an individual is carriers of certain genetic conditions that can be passed on to their children.Hospital laboratories can be segmented by type of testing and staffed by personnel trained in particular specialties.For instance,some sections can focus on microbiology,hematology,chemistry,and blood banking.At the same time,some units may perform highly specialized genetic tests using electron microscopy and immunohistochemistry,and others can focus on surgical pathology and cytology,which are all linked with the investigation of cell and tissue structure.The market growth for the segment can be due to the compulsory newborn screening for genetic disorders and the growing prevalence of cancer in many regions.Seattle Childrens Hospital in Washington,Wyoming,Alaska,Montana,and Idaho(WWAMI)region provides comprehensive genetic testing and consultative services to healthcare workers and families.Their genetics laboratories consist of molecular genetics,cytogenetics,biochemical genetics,and a research and development laboratory devoted to bringing the most existing and specific research tests into the clinical field.Overall,these laboratories play a crucial role in helping to diagnose genetic disorders,guide treatment decisions,and improve patient outcomes.8.3.2 Hospital-Based Laboratories:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Hospital-based laboratories segment was valued at US$1,005.93 million in 2022 and is expected to reach US$3,356.93 million by 2030.The growth rate of this segment is projected to be 16.3%during 20222030.Figure 17.Hospital-Based Laboratories:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 786.28888.951,005.931,145.251,311.781,511.591,752.282,043.412,397.022,828.393,356.93202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 42 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 8.4 Diagnostic Laboratories 8.4.1 Overview Diagnostics laboratories are independent entities that provide all the diagnostic tests,screening tests,and others to the patient.These centers may be found attached to a private or public hospital.The tests performed in the diagnostic centers are obtained earlier than hospitals.The diagnostic centers also offer packages for whole-body check-ups that are cost-effective for the patients.Tests such as cell-free fetal DNA testing,triple or quadruple screening tests,sequential screening,and others require advanced techniques,equipment,and skilled labor.However,some of the hospitals and clinics do not have all the required equipment and techniques for efficient diagnosis.Therefore,various hospitals and clinics prefer to outsource tests to diagnostics centers.The diagnostics centers are well equipped and offer better results for the tests performed for diseases and health conditions.The diagnostic centers provide multiple tests under one roof and offer all the prenatal diagnostics services such as screening,imaging,blood tests,chorionic villus sampling,and amniocentesis.Thus,it becomes easier for people to undergo genetic testing in such facilities.The growing partnerships and collaboration of diagnostic laboratories with genetic testing companies and the rise in the incidences of genetic diseases across the world are anticipated to offer growth to the market.For instance,Thermo Fisher Scientific allows laboratories to perform different genetic research and genetic testing by offering technologies such as NGS and quantitative PCR.8.4.2 Diagnostic Laboratories:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Diagnostic laboratories segment was valued at US$428.56 million in 2022 and is expected to reach US$1,378.01 million by 2030.The growth rate of this segment is projected to be 15.7%during 20222030.Figure 18.Diagnostic Laboratories:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 338.32380.60428.56485.55553.50634.79732.44850.20992.801,166.211,378.01202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 43 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 8.5 Others 8.5.1 Overview The others segment by service provider comprises academic and research institutions,pharmaceutical and biotechnology companies,and government agencies.Government agencies use genetic testing services to evaluate drugs for regulatory compliance for public health monitoring and research initiatives.Academic and research institutions are integral to the North America genetic testing services market.They help in identifying genetic markers,developing new genetic testing methodologies,and improving existing tests.These institutions validate and ensure the quality of genetic tests through rigorous studies,establishing their reliability and credibility.Clinical trials and studies conducted by these institutions provide essential evidence on the clinical utility and effectiveness of genetic tests.Their expertise and research efforts advance the growth of the market,benefiting both patients and healthcare providers.In addition,research and academic institutes are among the leading users of genetic testing services.Academic institutes for medical sciences and biotechnology utilize analytical testing services to support their studies on drugs.Thus,the increasing demand for genetic testing services from government agencies and research institutes will likely continue to drive the North America genetic testing services market for the segment.8.5.2 Others:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Others segment was valued at US$169.83 million in 2022 and is expected to reach US$249.31 million by 2030.The growth rate of this segment is projected to be 4.9%during 20222030.Figure 19.Others:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 152.89161.37169.83179.04188.95199.45210.35221.35232.02241.67249.31202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 44 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.North America Genetic Testing Services Market-Country Analysis 9.1 North America Figure 20.North America:North America Genetic Testing Services Market,by Key Country Revenue(2022)(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 9.1.1 North America Genetic Testing Services Market,by Country Figure 21.North America Genetic Testing Services Market,By Key Countries,2022 and 2030(%)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources NORTH AMERICA(2022)137.61 159.77 1,306.93 MexicoCanadaUS81.5.0%8.6 22USCanadaMexico84.4%9.4%6.2 30 45 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.1 US 9.1.1.1.1 Overview According to the Centers for Disease Control and Prevention(CDC),1,603,844 new cancer cases were diagnosed in 2020,with 602,347 cancer deaths in the US.For every 100,000 individuals,403 new cancer cases were reported.In the US,1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in 2023.Additionally,as per the International Agency for Research on Cancer,new cancer incidences were projected to reach 30.2 million by 2040.Cancer is the second highest death-causing disease worldwide,after heart disease.Several types of cancers are inherited from one generation to another generation due to genes.Genetic tests help in providing information on risk factors associated with the development of cancers among individuals with a family history of cancers.Thus,genetic testing is extensively applicable to study its pattern for prevention,treatment,and drug discovery.As per the estimates of the US Government Accountability Office published in October 2021,25 to 30 million people suffer from rare diseases in the country;nearly 50%of patients with rare diseases are children.Rare diseases are often the result of a genetic mutation;it is estimated that 80%of rare diseases are genetic.Genetic testing has been an essential part of the healthcare industry in the US for the last few decades.With the increased adoption of genetic testing,there has been a need to look after the quality of the tests being conducted across the US.Regulation of genetic testing laboratories has been undertaken by the Clinical Laboratory Improvement Amendments(CLIA),which extends federal regulation over nearly all US clinical laboratories.CLIA requires laboratories to participate in quality control and quality assurance schemes and requires laboratory inspections.Also,the quality of genetic testing kits that the clinical laboratory purchases from an external provider is regulated by the US FDA.The demand for genetic testing in the US is expected to witness growth since the service encompasses a broad range of applications,such as cancer,autoimmune diseases,and infectious diseases.In the US,the products for genetic testing of pediatric as well as rare diseases have increased significantly.For instance,in July 2021,Avellino Labs launched AvaGen,the genetic eye test,in the US.The test is designed to determine the risk of keratoconus and other corneal dystrophies in patients.In February 2020,the US FDA authorized the marketing of the first genetic test to detect a condition known as Fragile X Syndrome,which is one of the common causes of inherited developmental delay and intellectual disability among people.Thus,innovation in product design,improvement in quality,and strong distribution partnerships help to retain a competitive edge in the market.Therefore,the presence of regulatory policies associated with the use and the sale of genetic testing products,the rising cases of rare and genetic diseases in the US,and the development of innovative genetic testing products are anticipated to fuel the growth of the North America genetic testing services market during 20222030.9.1.1.1.2 US:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)The US genetic testing services market accounted for US$1,306.93 Mn in 2022 and it is expected to grow at a CAGR of 15.7%during the period 2022-2030,to reach US$4,208.99 Mn in 2030.46 North America Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 22.US:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 9.1.1.1.3 US:North America Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 2.US:North America Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 398.46 453.93 517.53 593.60 684.90 794.95 928.12 1,089.97 1,287.52 1,529.69 1,827.92 17.1rrier Testing 246.43 278.42 314.87 358.27 410.13 472.36 547.30 637.94 748.00 882.25 1,046.72 16.2%Prenatal Testing 135.55 151.44 169.35 190.54 215.67 245.60 281.34 324.21 375.82 438.21 513.93 14.9%Newborn Screening 158.60 178.64 201.40 228.45 260.72 299.36 345.81 401.85 469.77 552.42 653.45 15.9%Others 92.13 97.90 103.78 110.25 117.32 124.96 133.11 141.64 150.37 158.97 166.96 6.1%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The North America genetic testing services market for the predictive testing segment was worth US$517.53 million in 2022 and is projected to reach US$1,827.92 million by 2030;it is expected to grow at a CAGR of 17.1%from 2022 to 2030.1,031.161,160.341,306.931,481.111,688.761,937.232,235.682,595.613,031.483,561.554,208.99202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 47 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.1.4 US:North America Genetic Testing Services Market,by Disease,20202030(US$Million)Table 3.US:North America Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 453.33 516.31 588.51 674.84 778.46 903.32 1,054.41 1,238.01 1,462.07 1,736.71 2,074.86 17.1rdiovascular Diseases 228.08 258.32 292.84 333.99 383.24 442.41 513.78 600.23 705.37 833.83 991.45 16.5%Metabolic Diseases 200.88 224.00 249.99 280.70 317.07 360.31 411.87 473.60 547.78 637.27 745.69 14.6%Others 148.86 161.70 175.59 191.58 209.99 231.19 255.62 283.78 316.26 353.74 396.98 10.7%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The North America genetic testing services market for the cancer segment was worth US$588.51 million in 2022 and is projected to reach US$2,074.86 million by 2030;it is expected to grow at a CAGR of 17.1%from 2022 to 2030.9.1.1.1.5 US:North America Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 4.US:North America Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 634.67 721.15 820.11 938.31 1,080.02 1,250.57 1,456.67 1,706.79 2,011.62 2,384.77 2,843.59 16.8%Diagnostic Laboratories 274.39 310.15 350.90 399.44 457.47 527.10 610.99 712.47 835.75 986.16 1,170.48 16.3%Others 122.11 129.04 135.91 143.35 151.27 159.56 168.02 176.35 184.11 190.62 194.92 4.6%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The North America genetic testing services market for the hospital-based laboratories segment was worth US$820.11 million in 2022 and is projected to reach US$2,843.59 million by 2030;it is expected to grow at a CAGR of 16.8%from 2022 to 2030.48 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.2 Canada 9.1.1.2.1 Overview The increasing incidences of cancer have resulted in a higher demand for genetic testing services and prenatal testing.According to the data published by Statistics Canada,233,900 people in the country were diagnosed with cancer in 2022,and it caused 85,100 cancer-related mortality.The most commonly diagnosed cancers in the Canadian population are lung,breast,prostate,and colorectal.Additionally,in 2022,as per the Canadian Cancer Society,28,600 women were diagnosed with breast cancer,representing 25%of all new cancer cases in women in the country.It is also estimated that about one in eight Canadian women will develop breast cancer during their lifespan.Since breast cancer is the second leading reason of cancer deaths,genetic testing for the BRCA1 and BRCA2 gene variants linked with an increased risk of breast cancer can identify mutations that increase an individuals risk of developing cancer with a genetic foundation.Therefore,it is expected that the incidences of cancer are likely to increase,which will fuel the demand for genetic testing services.Various regulatory authorities in the country also recommend prenatal and newborn genetic testing to prevent the underlying risks of various diseases at early life stages.For instance,The Society of Obstetrics and Gynecology of Canada advises pregnant women to undergo a range of prenatal screening to identify the risk of pregnancies and determine specific chromosome abnormalities.Furthermore,various healthcare providers and private laboratories are including prenatal genetic testing in their diagnostic offerings,which is expected to increase the demand for noninvasive prenatal test kits in Canada.For instance,in October 2015,LifeLabs became the first laboratory in Canada to perform noninvasive prenatal tests in Canada.In addition,in June 2022,Devyser won a breakthrough contract in Canada for noninvasive fetal RHD testing.It is used to determine fetal RHD status from maternal plasma in early pregnancy.Thus,owing to the factors mentioned above,the market for genetic testing services is expected to grow over the years to come.9.1.1.2.2 Canada:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)The Canada genetic testing services market accounted for US$159.77 Mn in 2022 and it is expected to grow at a CAGR of 14.3%during the period 2022-2030,to reach US$466.20 Mn in 2030.Figure 23.Canada:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 129.16143.59159.77178.87201.47228.29260.24298.43344.25399.45466.20202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 49 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.2.3 Canada:North America Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 5.Canada:North America Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 48.92 55.12 62.15 70.49 80.43 92.31 106.56 123.72 144.48 169.69 200.44 15.8rrier Testing 30.25 33.80 37.80 42.54 48.15 54.84 62.82 72.40 83.93 97.86 114.78 14.9%Prenatal Testing 16.64 18.38 20.33 22.62 25.32 28.50 32.29 36.79 42.16 48.60 56.36 13.6%Newborn Screening 19.47 21.67 24.13 27.04 30.49 34.58 39.45 45.28 52.28 60.72 70.94 14.4%Others 13.88 14.62 15.36 16.18 17.09 18.07 19.12 20.24 21.39 22.56 23.69 5.6%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The North America genetic testing services market for the predictive testing segment was worth US$62.15 million in 2022 and is projected to reach US$200.44 million by 2030;it is expected to grow at a CAGR of 15.8%from 2022 to 2030.9.1.1.2.4 Canada:North America Genetic Testing Services Market,by Disease,20202030(US$Million)Table 6.Canada North America Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 57.36 64.54 72.67 82.32 93.81 107.53 123.98 143.78 167.71 196.75 232.14 15.6rdiovascular Diseases 29.15 32.51 36.30 40.77 46.07 52.38 59.91 68.92 79.76 92.85 108.72 14.7%Metabolic Diseases 24.66 27.22 30.07 33.41 37.36 42.02 47.54 54.10 61.94 71.32 82.60 13.5%Others 17.99 19.32 20.74 22.36 24.23 26.37 28.82 31.63 34.84 38.53 42.75 9.5%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The North America genetic testing services market for the cancer segment was worth US$72.67 million in 2022 and is projected to reach US$232.14 million by 2030;it is expected to grow at a CAGR of 15.6%from 2022 to 2030.9.1.1.2.5 Canada:North America Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 7.Canada:North America Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 79.49 89.05 99.83 112.60 127.76 145.84 167.46 193.43 224.73 262.63 308.70 15.2%Diagnostic Laboratories 33.68 37.58 41.96 47.13 53.27 60.57 69.28 79.72 92.27 107.42 125.80 14.7%Others 15.98 16.96 17.99 19.14 20.44 21.88 23.50 25.28 27.25 29.39 31.71 7.3%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 50 North America Genetic Testing Services Market,2020-2030 |The Insight Partners The North America genetic testing services market for the hospital-based laboratories segment was worth US$99.83 million in 2022 and is projected to reach US$308.70 million by 2030;it is expected to grow at a CAGR of 15.2%from 2022 to 2030.9.1.1.3 Mexico 9.1.1.3.1 Overview As per the Global Cancer Observatory data 2020,29,929 new breast cancer cases were registered in the country,representing 15.3%of all new cancer cases.According to a study,Clinical Evaluation of BRCA1/2 Mutation in Mexican Ovarian Cancer Patients,published in 2020,4700 new cases of ovarian cancer are diagnosed yearly in the country,causing 2,700 ovarian cancer-related mortality.Germline mutations in BRCA1/2 genes are present in 1318%of ovarian cancer cases.Genetic testing services are used to diagnose,treat,and monitor cancer.Mexico faces challenges regarding chronic and degenerative diseases and experiences changes in important demographic and epidemiological transitions that result in significant patterns of disease,disability,and death.Therefore,preventing these diseases has become a key strategy in order to improve the economy and health of the Mexican population.Therefore,for the Mexican government,genomic medicine became a priority as a means of finding new strategies to tackle common diseases.In 2000,strategic planning for genomic medicine was started,and in 2004,the Mexican Congress commenced the creation of a National Institute of Genomic Medicine.Furthermore,the Institute of Genomic Medicine is a joint project by the Independent National University of Mexico,the Secretariat of Health,the National Council of Science and Technology,and the Mexican Foundation for Health.The aims of the Institute include genomics in economical methods of prevention,diagnosis,and treatment of disease.The goal also includes the plan to enhance genomics training and research,to educate the public,and to make available advances in technology.Companies operating in the region undertake various strategic efforts that led to the growth of the market in Mexico.For instance,in October 2023,Mexican Biobank launched the countrys most complete genetic database so far.A study completed as a part of a joint venture between Mexicos Cinvestav UGA-Langebio and NDMs Wellcome Centre for Human Genetics has revealed an extremely rich tapestry of genetics revealing population histories and diverse genetic make-up of the countrys population.The study aims to reveal the relationship between genetics,migration,mating patterns,and the environment that has shaped the current diversity of the countrys population.Thus,due to the factors mentioned above,the market for genetic testing services in Mexico is anticipated to witness significant growth during 20222030.51 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.3.2 Mexico:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Mexico genetic testing services market accounted for US$137.61 Mn in 2022 and it is expected to grow at a CAGR of 10.6%during the period 2022-2030,to reach US$309.06 Mn in 2030.Figure 24.Mexico:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 9.1.1.3.3 Mexico:North America Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 8.Mexico:North America Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 48.09 52.54 57.38 62.98 69.45 76.95 85.64 95.72 107.44 121.07 136.95 11.5rrier Testing 29.74 32.30 35.07 38.27 41.96 46.22 51.15 56.86 63.46 71.12 80.01 10.9%Prenatal Testing 13.38 14.32 15.32 16.47 17.79 19.30 21.03 23.01 25.28 27.89 30.87 9.2%Newborn Screening 15.66 16.98 18.42 20.08 22.00 24.21 26.76 29.71 33.13 37.09 41.68 10.8%Others 10.30 10.85 11.42 12.07 12.80 13.63 14.56 15.61 16.78 18.09 19.55 7.0%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The North America genetic testing services market for the predictive testing segment was worth US$57.38 million in 2022 and is projected to reach US$136.95 million by 2030;it is expected to grow at a CAGR of 11.5%from 2022 to 2030.117.17126.99137.61149.87164.00180.31199.15220.92246.10275.27309.06202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 52 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.3.4 Mexico:North America Genetic Testing Services Market,by Disease,20202030(US$Million)Table 9.Mexico:North America Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 52.03 57.08 62.59 68.97 76.36 84.93 94.87 106.43 119.89 135.58 153.89 11.9rdiovascular Diseases 26.18 28.38 30.76 33.51 36.68 40.34 44.56 49.45 55.10 61.65 69.23 10.7%Metabolic Diseases 22.37 24.01 25.75 27.76 30.06 32.71 35.75 39.24 43.24 47.84 53.13 9.5%Others 16.59 17.53 18.51 19.62 20.89 22.33 23.96 25.80 27.87 30.19 32.81 7.4%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The North America genetic testing services market for the cancer segment was worth US$62.59 million in 2022 and is projected to reach US$153.89 million by 2030;it is expected to grow at a CAGR of 11.9%from 2022 to 2030.9.1.1.3.5 Mexico:North America Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 10.Mexico:North America Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 72.12 78.75 85.98 94.34 104.00 115.19 128.15 143.19 160.66 180.99 204.65 11.5%Diagnostic Laboratories 30.25 32.87 35.70 38.98 42.75 47.12 52.17 58.01 64.78 72.62 81.73 10.9%Others 14.80 15.37 15.93 16.55 17.24 18.00 18.83 19.72 20.67 21.66 22.68 4.5%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The North America genetic testing services market for the hospital-based laboratories segment was worth US$85.98 million in 2022 and is projected to reach US$204.65 million by 2030;it is expected to grow at a CAGR of 11.5%from 2022 to 2030.53 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 10.Genetic Testing Services MarketIndustry Landscape 10.1 Overview The developments in the North America genetic testing services market have been characterized by organic and inorganic growth strategies.Various companies are focusing on organic growth strategies such as launches,expansion,enhancement,and relocation.Inorganic growth strategies witnessed in the market include mergers&acquisitions,partnerships,and collaborations.These activities have paved the way for the expansion of business and the customer base of market players.Additionally,growth strategies such as acquisitions and partnerships helped in strengthening their customer base and increase the product portfolio.The companies have maximized their growth with several inorganic strategies to enhance the market value and position in the market.The organic developments hold 73.33%of the total strategic developments in the market.Whereas the inorganic strategies helped by 26.67%for the growth of the companies.10.2 Growth Strategies in North America Genetic Testing Services Market Figure 25.Growth Strategies in North America Genetic Testing Services Market Source:The Insight Partners Analysis 26.67s.33%Inorganic StrategiesOrganic Strategies 54 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 10.3 Organic Growth Strategies 10.3.1 Overview Various companies have adopted organic growth strategies in genetic testing services market.Some of the activities that have helped the companies promote their growth are launches,expansion,relocation activities.23andMe Holding Co is among the companies that have been implementing organic strategies,which,in turn,have brought about various changes in the global health economics and outcomes research services market.The companies have utilized strategies such as new product launch to expand their geographic reach and capacity to cater to a large number of customers.Some of the organic developments are listed below.Table 11.Recent Organic Growth Strategies in North America Genetic Testing Services Market CompanyCompany Month&YearMonth&Year CategoryCategory DescriptionDescription 23andMe Holding Co Nov-2023 Product Launch 23andMe Holding Co launched 23andMe Total Health,a new membership that offers that provides clinical grade exome sequencing,biannual blood testing,and access to genetics-based clinical care.Illumina Inc.Nov-2023 Company News Illumina Inc.announced the launch of the Global Health Access Initiative.It is anticipated that the effort will help low-and middle-income nations have access to pathogen sequencing tools for public health.The program will address major international logistics and supply chain challenges and offer discounted pricing structures for Illuminas eligible sequencing products to qualified global health funding entities.It was developed with input from customers,funders,and market facilitators,including the nonprofit FIND.23andMe Holding Co Oct-2023 Product Launch 23andMe Holding Co launched Health Action Plan,a new digital tool that utilizes results from genetic reports,health history survey data,and blood and biomarker data to provide a tailored set of health recommendations to its members.CENTOGENE Oct-2023 Product Launch The company expanded its Multiomic Diagnostic Portfolio with incorporation of transcriptomic analysis.It allows to combine DNA sequencing,biochemical testing,and RNA sequencing to improve testing capability.NeoGenomics Inc Oct-2023 Product Launch NeoGenomics Inc launched two new tests to expand its portfolio of cancer products including Early-stage Non-Small Cell Lung Cancer Panel and the Neo Comprehensive-Heme Cancers Panel.Quest Diagnostics Inc Jul-2023 Product Launch Quest Diagnostics Inc announced launch of first consumer-initiated genetic test,Genetic Insights.The test can be accessed at via its consumer health business.With the launch
2024-08-12
101页
5星级
Europe Genetic Testing Services Market Market Size and Forecast(2020-2030)Regional Growth Opportunity Analysis Coverage:By Service Service TypeType(Predictive Testing,Carrier Testing,Prenatal Testing,Newborn Screening,and Others),DiseaseDisease(Cancer,Metabolic Diseases,Cardiovascular Diseases,and Other Diseases),Service Service ProviderProvider(Hospital-Based Laboratories,Diagnostic Laboratories,and Others),and CountryCountry 2 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners Table of Content 1.Introduction.14 1.1 The Insight Partners Research Report Guidance.14 1.2 Market Segmentation.15 2.Executive Summary.16 2.1 Key Insights.16 3.Research Methodology.17 3.1 Coverage.18 3.2 Secondary Research.18 3.3 Primary Research.18 4.Europe Genetic Testing Services Market-Key Industry Dynamics.20 4.1 Key Market Drivers.20 4.1.1 Rising Prevalence of Genetic Diseases.20 4.1.2 Increasing Awareness and Acceptance of Personalized Medicines.21 4.1.3 Growing Preference for Direct-To-Consumer(DTC)Genetic Testing.21 4.2 Market Restraints.22 4.2.1 Social and Ethical Implications of Genetic Testing.22 4.2.2 Affordability of Genetic Services.22 4.3 Market Opportunities.23 4.3.1 Rising Demand for Pharmacogenomics.23 4.4 Future Trends.23 4.4.1 Artificial Intelligence-Powered Genetic Testing.23 4.5 Impact Analysis:.24 5.Genetic Testing Services Market-Europe Market Analysis.25 5.1 Europe Genetic Testing Services Market Revenue(US$Mn),2022 2030.25 6.Europe Genetic Testing Services Market Revenue and Forecast to 2030 by Service Type.26 6.1 Overview.26 6.2 Europe Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%).26 6.3 Predictive Testing.27 6.3.1 Overview.27 3 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 6.3.2 Predictive Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).27 6.4 Carrier Testing.28 6.4.1 Overview.28 6.4.2 Carrier Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).28 6.5 Prenatal Testing.29 6.5.1 Overview.29 6.5.2 Prenatal Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).29 6.6 Newborn Screening.30 6.6.1 Overview.30 6.6.2 Newborn Screening:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).30 6.7 Others.31 6.7.1 Overview.31 6.7.2 Others:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).31 7.Europe Genetic Testing Services Market Revenue and Forecast to 2030 by Disease.33 7.1 Overview.33 7.2 Europe Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%).33 7.3 Cancer.34 7.3.1 Overview.34 7.3.2 Cancer:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).34 7.4 Cardiovascular Diseases.35 7.4.1 Overview.35 7.4.2 Cardiovascular Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).35 7.5 Metabolic Diseases.36 7.5.1 Overview.36 7.5.2 Metabolic Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).36 7.6 Other Diseases.37 7.6.1 Overview.37 7.6.2 Other Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).37 4 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 8.Europe Genetic Testing Services Market Revenue and Forecast to 2030 by Service Provider.39 8.1 Overview.39 8.2 Europe Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%).39 8.3 Hospital-Based Laboratories.40 8.3.1 Overview.40 8.3.2 Hospital-Based Laboratories:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).40 8.4 Diagnostic Laboratories.41 8.4.1 Overview.41 8.4.2 Diagnostic Laboratories:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).41 8.5 Others.42 8.5.1 Overview.42 8.5.2 Others:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).42 9.Europe Genetic Testing Services Market-Country Analysis.43 9.1 Europe.43 9.1.1 Europe Genetic Testing Services Market,by Country.43 9.1.1.1 UK.44 9.1.1.1.1 Overview.44 9.1.1.1.2 UK Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).44 9.1.1.1.3 UK Genetic Testing Services Market,by Service Type,20202030(US$Million).45 9.1.1.1.4 UK Genetic Testing Services Market,by Disease,20202030(US$Million).45 9.1.1.1.5 UK Genetic Testing Services Market,by Service Provider,20202030(US$Million).45 9.1.1.2 Germany.46 9.1.1.2.1 Overview.46 9.1.1.2.2 Germany:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).46 9.1.1.2.3 Germany:Europe Genetic Testing Services Market,by Service Type,20202030(US$Million).47 9.1.1.2.4 Germany:Europe Genetic Testing Services Market,by Disease,20202030(US$Million).48 9.1.1.2.5 Germany:Europe Genetic Testing Services Market,by Service Provider,20202030(US$Million).48 9.1.1.3 France.49 5 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.3.1 Overview.49 9.1.1.3.2 France Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).49 9.1.1.3.3 France Genetic Testing Services Market,by Service Type,20202030(US$Million).50 9.1.1.3.4 France Genetic Testing Services Market,by Disease,20202030(US$Million).51 9.1.1.3.5 France Genetic Testing Services Market,by Service Provider,20202030(US$Million).51 9.1.1.4 Italy.52 9.1.1.4.1 Overview.52 9.1.1.4.2 Italy Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).52 9.1.1.4.3 Italy Genetic Testing Services Market,by Service Type,20202030(US$Million).53 9.1.1.4.4 Italy Genetic Testing Services Market,by Disease,20202030(US$Million).53 9.1.1.4.5 Italy Genetic Testing Services Market,by Service Provider,20202030(US$Million).53 9.1.1.5 Spain.54 9.1.1.5.1 Overview.54 9.1.1.5.2 Spain Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).54 9.1.1.5.3 Spain Genetic Testing Services Market,by Service Type,20202030(US$Million).55 9.1.1.5.4 Spain Genetic Testing Services Market,by Disease,20202030(US$Million).55 9.1.1.5.5 Spain Genetic Testing Services Market,by Service Provider,20202030(US$Million).55 9.1.1.6 Rest of Europe.56 9.1.1.6.1 Overview.56 9.1.1.6.2 Rest of Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).56 9.1.1.6.3 Rest of Europe Genetic Testing Services Market,by Service Type,20202030(US$Million).57 9.1.1.6.4 Rest of Europe Genetic Testing Services Market,by Disease,20202030(US$Million).57 9.1.1.6.5 Rest of Europe Genetic Testing Services Market,by Service Provider,20202030(US$Million).58 10.Genetic Testing Services MarketIndustry Landscape.59 10.1 Overview.59 10.2 Growth Strategies in Genetic Testing Services Market.59 6 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 10.3 Organic Growth Strategies.60 10.3.1 Overview.60 10.4 Inorganic Growth Strategies.62 10.4.1 Overview.62 11.Company Profiles.63 11.1 Eurofins Scientific SE.63 11.1.1 Key Facts.63 11.1.2 Business Description.63 11.1.3 Products and Services.64 11.1.4 Financial Overview.65 11.1.5 SWOT Analysis.66 11.1.6 Key Developments.67 11.2 Exact Sciences Corp.68 11.2.1 Key Facts.68 11.2.2 Business Description.68 11.2.3 Products and Services.68 11.2.4 Financial Overview.69 11.2.5 SWOT Analysis.70 11.2.6 Key Developments.71 11.3 Laboratory Corp of America Holdings.72 11.3.1 Key Facts.72 11.3.2 Business Description.72 11.3.3 Products and Services.72 11.3.4 Financial Overview.73 11.3.5 SWOT Analysis.74 11.3.6 Key Developments.75 11.4 23andMe Holding Co.76 11.4.1 Key Facts.76 11.4.2 Business Description.76 11.4.3 Products and Services.77 11.4.4 Financial Overview.77 11.4.5 SWOT Analysis.78 11.4.6 Key Developments.79 11.5 Quest Diagnostics Inc.80 11.5.1 Key Facts.80 7 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 11.5.2 Business Description.80 11.5.3 Products and Services.81 11.5.4 Financial Overview.81 11.5.5 SWOT Analysis.82 11.5.6 Key Developments.83 11.6 Illumina Inc.84 11.6.1 Key Facts.84 11.6.2 Business Description.84 11.6.3 Products and Services.85 11.6.4 Financial Overview.85 11.6.5 SWOT Analysis.86 11.6.6 Key Developments.87 11.7 F.Hoffmann-La Roche Ltd.88 11.7.1 Key Facts.88 11.7.2 Business Description.88 11.7.3 Products and Services.89 11.7.4 Financial Overview.89 11.7.5 SWOT Analysis.91 11.7.6 Key Developments.93 11.8 NeoGenomics Inc.94 11.8.1 Key Facts.94 11.8.2 Business Description.94 11.8.3 Products and Services.94 11.8.4 Financial Overview.95 11.8.5 SWOT Analysis.96 11.8.6 Key Developments.97 11.9 Centogene AG.98 11.9.1 Key Facts.98 11.9.2 Business Description.98 11.9.3 Products and Services.98 11.9.4 Financial Overview.99 11.9.5 SWOT Analysis.100 11.9.6 Key Developments.101 12.Appendix.102 12.1 About Us.102 8 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 12.2 Glossary of Terms.103 9 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners List of Tables Table 1.Europe Genetic Testing Services Market Segmentation.15 Table 2.UK Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).45 Table 3.UK Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).45 Table 4.UK Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).45 Table 5.Germany:Europe Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).47 Table 6.Germany:Europe Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).48 Table 7.Germany:Europe Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).48 Table 8.France Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).50 Table 9.France Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).51 Table 10.France Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).51 Table 11.Italy Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).53 Table 12.Italy Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).53 Table 13.Italy Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).53 Table 14.Spain Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).55 Table 15.Spain Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).55 Table 16.Spain Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).55 Table 17.Rest of Europe Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).57 10 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners Table 18.Rest of Europe Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).57 Table 19.Rest of Europe Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).58 Table 20.Recent Organic Growth Strategies in Europe Genetic Testing Services Market.60 Table 21.Recent Inorganic Growth Strategies in the Europe Genetic Testing Services Market.62 Table 22.Glossary of Terms,Europe Genetic Testing Services Market.103 11 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners List of Figures Figure 1.Europe Genetic Testing Services Market Segmentation,By Country.15 Figure 2.Europe Genetic Testing Services Market-Key Industry Dynamics.20 Figure 3.Impact Analysis of Drivers and Restraints.24 Figure 4.Europe Genetic Testing Services Market Revenue(US$Mn),2022 2030.25 Figure 5.Europe Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%).26 Figure 6.Predictive Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).27 Figure 7.Carrier Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).28 Figure 8.Prenatal Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).29 Figure 9.Newborn Screening:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).30 Figure 10.Others:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).32 Figure 11.Europe Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%).33 Figure 12.Cancer:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).34 Figure 13.Cardiovascular Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).35 Figure 14.Metabolic Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).36 Figure 15.Other Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).38 Figure 16.Europe Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%).39 Figure 17.Hospital-Based Laboratories:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).40 Figure 18.Diagnostic Laboratories:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).41 Figure 19.Others:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).42 12 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 20.Europe Genetic Testing Services Market,by Key Country Revenue,2022(US$Million).43 Figure 21.Europe Genetic Testing Services Market,By Key Countries,2022 and 2030(%).43 Figure 22.UK Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).44 Figure 23.Germany:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).47 Figure 24.France Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).50 Figure 25.Italy Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).52 Figure 26.Spain Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).54 Figure 27.Rest of Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).56 Figure 28.Growth Strategies in Genetic Testing Services Market.59 13 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners NOTES:The list of companies included in the scope are as per standard report format and the list can be modified/expanded as per clients requirement The sequence/list of companies do not represent their current position in the market.The list of countries provided in the report are part of standard report and can be customized as per clients requirement RELATED REPORTS Newborn Genetic Testing Market DTC Genetic Testing Market 14 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 1.Introduction 1.1 The Insight Partners Research Report Guidance The report provides qualitative and quantitative trends of Europe genetic testing services market across service type,disease,service provider,and country.The report starts with the key takeaways(chapter 2),highlighting the key trends and outlook of the Europe genetic testing services market.Chapter 3 provides the research methodology of the study.Chapter 4 highlights the key industry dynamics in the Europe genetic testing services market,including factors that are driving the market,prevailing deterrent,potential opportunities as well as future trends.Impact analysis of these drivers and restraints is also covered in this section.Chapter 5 discusses the Europe genetic testing services market scenario,in terms of historical market revenues,and forecast till 2030.Chapter 6 to 9 discuss genetic testing services market segments by service type,disease,service provider,and countries across Europe.They cover market revenue forecast,and factors driving and governing growth.Chapter 10 describes the industry landscape analysis.It provides detailed description of various business activities such as market initiatives,new developments,mergers,and joint ventures globally along with a competitive landscape.Chapter 11 provides the detailed profiles of the key companies operating in the Europe genetic testing services market.The companies have been profiled on the basis of their key facts,business description,products and services,financial overview,SWOT analysis,and key developments.Chapter 12,i.e.the appendix is inclusive of a brief overview of the company,glossary of terms,contact information,and the disclaimer section.15 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 1.2 Market Segmentation Table 1.Europe Genetic Testing Services Market Segmentation SERVICE TYPESERVICE TYPE DISEASEDISEASE SERVICE SERVICE PROVIDERPROVIDER PREDICTIVE TESTING CANCER HOSPITAL-BASED LABORATORIES CARRIER TESTING CARDIOVASCULAR DISEASES DIAGNOSTIC LABORATORIES PRENATAL TESTING METABOLIC DISEASES OTHERS NEWBORN SCREENING OTHER DISEASES OTHERS Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources Figure 1.Europe Genetic Testing Services Market Segmentation,By Country Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources The Europe genetic testing services market is segmented based on service type,disease,service provider,and country.The segmentation in this research study has been finalized post in-depth secondary research and extensive primary research.In addition,the market is also segmented on the basis of services offered by the leading participants in the industry in order to understand widely used market specific terminologies.Thus,we have incorporated the segments of the research and have finalized the market segmentation.EUROPEFRANCE GERMANY UK SPAINITALY RoE 16 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 2.Executive Summary 2.1 Key Insights OverviewMarket SegmentationMarket DynamicsRegional OverviewMarket SegmentationKey PlayersMarket DynamicsCAGR(2022-2030)14.6%Market Size 2022$931.11MnMarket Size 2030$2,778.42MnService TypeDisease Predictive Testing Carrier Testing Prenatal Testing Newborn Screening Others Cancer Cardiovascular Diseases Metabolic Diseases Other Diseases Laboratory Corporation of America Holdings F.Hoffmann-La Roche Ltd Illumina,Inc.Quest Diagnostics Incorporated Exact Sciences Corp(Genomic Health)NeoGenomics Laboratories,Inc.Eurofins Scientific Centogene AG 23andMe,IncGROWTH DRIVERSFUTURE TRENDSGROWTH DRIVERSFUTURE TRENDS Rising Prevalence of Genetic Diseases Increasing Awareness and Acceptance of Personalized Medicines Artificial Intelligence-Powered Genetic TestingRESTRAINTSOPPORTUNITY Social and Ethical Implications of Genetic Testing Affordability of Genetic Services Untapped Emerging Markets in Developing CountriesService Provider Hospital-Based Laboratories Diagnostic Laboratories OthersEUROPE14.6 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 3.Research Methodology The Insight Partners dedicated research and analysis team consist of experienced professionals with advanced statistical expertise in market research and consulting backgrounds in in various industries including Aerospace and Defense,Automotive and Transportation,Biotechnology,Chemicals and Materials,Food and Beverages,Electronics and Semiconductor,Healthcare IT,Manufacturing and Construction,Medical Device,Technology,Media and Telecommunications.Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources FinalMarket sizeValidation from Primary InterviewSummation of Revenue Generated from Companies to arrive Total Market SizeRevenue Generated by the Products and Services Offered by Companies in the Genetic Testing Service MarketFinal Market Size Break-Up To Rest Of Segmentation(i.e.,Service Type,Disease,Service Provider,and Region)Arriving at the Market Size of each Segment Validation of Number with Primary Interviews and Subject Matter Expert BOTTOM-UP ANALYSISTOP-DOWN ANALYSIS 18 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners The Insight Partners adheres to the codes of practice of the Market Research Society(www.mrs.org.uk)and Strategic and Competitive Intelligence Professionals(www.scip.org).The following methodology has been followed for the collection and analysis of data presented in this report:3.1 Coverage The objective of updating“The Insight Partners”coverage is to ensure that it represents the most up-to-date vision of the industry possible.The estimated revenues of all major companies,including private and governmental,are gathered and used to prioritize coverage.Companies which are making the news,or which are of particular interest due to their innovative approach,are prioritized.3.2 Secondary Research The research process begins with exhaustive secondary research using internal and external sources to obtain qualitative and quantitative information relating to each Market.The secondary research sources that are typically referred to include,but are not limited to:Company websites,annual reports,financial reports,broker reports and investor presentations Industry trade journals and other literature National government documents,statistical databases and market reports News articles,press releases and web-casts specific to the companies operating in the market NOTE:All the financials considered in Company Profiles section have been standardized to US$.This has been achieved after converting the financials(for those not in US$)with respective currency exchange rates of the particular year.3.3 Primary Research“The Insight Partners”conducts hundreds of primary interviews a year with industry participants and commentators in order to validate its data and analysis.A typical research interview fulfils the following functions:Provides first-hand information on the market size,market trends,growth trends,competitive landscape and future outlook Validates and strengthens secondary research findings Further develops the analysis teams expertise and market understanding 19 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners Primary research involves email interactions and telephone interviews for each market,category,segment and sub-segment across countries.The participants who typically take part in such a process include,but are not limited to:Industry participants:VPs,business development managers,market intelligence managers and national sales managers Outside experts:Valuation experts,research analysts and key opinion leaders specializing in the industry 20 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 4.Europe Genetic Testing Services Market-Key Industry Dynamics Figure 2.Europe Genetic Testing Services Market-Key Industry Dynamics Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 4.1 Key Market Drivers 4.1.1 Rising Prevalence of Genetic Diseases The prevalence of genetic diseases is rising across the world and impacting the health of people at a severe level.Genetic diseases show many symptoms that are uncommon and are mostly non-curable.Most of the genetic diseases are rare and are developed due to the mutation in the genetic makeup of the people.According to The World Health Organization(WHO)2021,10 out of every 1,000 people are affected by single-gene diseases,signifying that 70 million and 80 million people worldwide are living with any one type of single-gene disease.As per the Global Genes,7,000 known rare diseases and disorders have been identified worldwide,and more are being discovered every year.According to the University of Sheffield research,300 million people are living with genetic diseases around the world.In June 2020,as per Novartis AG(Switzerland)report,15,000 individuals were suffering from sickle cell disease in the UK,and 270 newborns are diagnosed with the condition every year.Thus,the rising prevalence of genetic diseases fuels the demand for genetic testing,which in turn drives genetic testing services market growth.DROTDRIVERSRESTRAINTSOPPORTUNITIESTRENDSRising Prevalence of Genetic DiseasesIncreasing Awareness and Acceptance of Personalized MedicinesGrowing Preference for Direct-To-Consumer Genetic TestingSocial and Ethical Implications of Genetic TestingAffordability of Genetic ServicesArtificial Intelligence-Powered Genetic TestingRising Demand for Pharmacogenomics 21 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 4.1.2 Increasing Awareness and Acceptance of Personalized Medicines Personalized medicine is the field that utilizes patients genetic and environmental data to deliver optimal healthcare.It is based on the principle that every patient is unique and requires individualistic pharmacological treatment.Since it is a rapidly evolving area,it is presently incorporated into several healthcare systems.The successful completion of the Human Genome Project(HGP)in 2003 and the fast-decreasing human genome sequencing costs encouraged the development of a new medical approach,which is called personalized medicine.With an expanding repository of personalized data at the molecular level,molecular diagnostics companies are exceptionally positioned to unlock value.Large-scale drug discovery is a key to increasing the viability and usefulness of personalized medicines for the diagnosis of diseases and disorders.Genomics is one of the fastest-growing divisions of medical science.It is driving a paradigm shift in the research methodology of a disease,as well as diagnosing and treating illness.Genetic testing has been extensively used in pharmacogenomics,also known as drug-gene testing.It helps in accelerating drug discovery and its development.France also developed a national plan for personalized medicine known as Genomic Medicine France 2025.The program was presented to Prime Minister Manuel Valls by Yves Lvy,President of the National Alliance for Life and Health SciencesAviesan and CEO of Inserm,in June 2016.It appeals to healthcare and manufacturing firms to pilot genomic sequencing platforms.The plan was supported by the government and launched with a public financing of US$760.8 million(670 million)in 2020 for genomics and personalized medicine programs.It is expected to place France as a leader among countries involved in genomic medicine within the next ten years.In January 2023,The Human Genome Project is ensuring an era of personalized healthcare.Now,new research shows that precision prescribing using genetic testing has ultimately reached a global tipping point for adoption.Published by Cambridge University Press,the peer-reviewed research examines the maturation of critical factors required for the use of clinical genetics at scale.These advancements pave the way for supporting genome-informed clinical decision-making to be established as the new standard of care.Genetically informed prescribing offers one of the realistic mechanisms to successfully reduce the overall costs of the healthcare system and improve individual patient care.Genetic testing encourages the adoption of a personalized medicine approach by understanding the science behind the disease,the impact of treatment,and the development of therapies for specific individual characteristics.It also helps healthcare personnel make informed decisions about disease diagnosis,treatment,and prevention by utilizing genetic testing results,leading to improved patient outcomes.4.1.3 Growing Preference for Direct-To-Consumer(DTC)Genetic Testing Personalized genetic testing and treatment have long been used globally to help individuals and families learn more about hereditary diseases.Most of the time,genetic testing is done through healthcare personnel,such as genetic counselors.Healthcare providers decide which test is needed,order the test from a test center,collect and send the DNA sample,read the test results,and share the results with the patient.Thus,these tests have traditionally been ordered and interpreted in a clinical or medical research setting.In contrast,DTC genetic testing has witnessed tremendous growth in the past decade and is becoming increasingly widespread.A genetic test offered,advertised,and sold by companies directly to the consumer,without the direct involvement of a conventional healthcare system,is called DTC genetic testing.DTC genetic testing is relatively new and helps people find out about the disease-associated genes they may carry without the need for a prescription or guidance from a genetic counselor or medical practitioner.Several consumers of DTC testing view it as another method of gathering medical information about themselves.22 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners Unlike other genetic tests performed in clinics or hospitals,the consumer independently initiates and completes a DTC genetic test.The public understanding and acceptance of genetic testing is gradually increasing.Additionally,there is a rise in consumers seeking customized products and experiences for the identification and addressing of unique needs.The launch of innovative products and the increase in the adoption of DTC genetic testing kits have made genetic testing more accessible to people.These kits enable users to undergo personalized health management within the comfort of their homes.Key industry players are also developing DTC genetic tests and implementing special marketing efforts that positively impact sales of DTC tests.A rising number of manufacturers are providing direct-to-consumer genetic testing that covers various health conditions and traits.The increasing demand for direct-to-consumer genetic testing products to learn about the genetic makeup and assess the risk of developing hereditary conditions for early disease detection or prevention drives the market.4.2 Market Restraints 4.2.1 Social and Ethical Implications of Genetic Testing Genetic testing is poised to play an important role in the practice of obstetrics and gynecology.Physicians are required to become familiar with the presently accessible collection of genetic tests and their limitations to guarantee patients the utmost quality of care.However,the knowledge of genetic risks can result in potential social and psychological consequences for the people undergoing such tests.Socially,knowledge from genetic tests may lead to stigmatization and judgment within the community.Refusing to undergo genetic testing,as well as choosing to undergo genetic testing,can both lead to discrimination and stigmatization,depending on the prevalent public standards concerning acceptance and use of the technology.Privacy and security concerns also arise as the availability and commercialization of personal genetic data can lead to unauthorized access or misuse of sensitive information.The storage of genetic testing data and registries of patients generates concern,given that the results can negatively impact the family members.In addition,lack of informed consent can lead to adverse reactions,such as increased anxiety and unnecessary preventive measures during the disclosure of genetic test results.Lack of proper counseling regarding the information about genetic risk and choices regarding genetic testing and its management can cause potential psychological distress.Therefore,the reluctance of patients to prefer genetic testing due to the social and ethical stigma impedes market growth.4.2.2 Affordability of Genetic Services At present,genetic services are expensive and,therefore,not accessible to all.Genetic research is presently underrepresented in health research;however,studies are being conducted to establish the feasibility of such services.Present inequalities in the affordability and feasibility of genetic services are a cause of concern for the WHO and other prominent international organizations that are centered around public health and development concerns.The cost of the test also increases if more than one test is needed or if multiple family members need to be tested to obtain a significant result.For newborn screening,costs differ as per the state.Several states cover part of the overall cost,although most charge a fee of US$30 to US$150 per infant.Various factors,including the type of test,the complexity of analysis,and laboratory processing fees,influence the cost of these tests.Thus,the high costs,along with its affordability in emerging economies,restrain the market growth.23 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 4.3 Market Opportunities 4.3.1 Rising Demand for Pharmacogenomics Pharmacogenomics presents a lucrative opportunity within the genetic testing market,offering personalized insights into medication response based on an individuals genetic profile.By scrutinizing genetic variations influencing drug metabolism,pharmacogenomics testing empowers healthcare providers to customize medication selection and dosing,enhancing treatment efficacy while minimizing adverse reactions.The tailored approach not only improves patient outcomes but also enhances safety in medication management.With the rising focus on precision medicine,the demand for pharmacogenomic testing services spans diverse medical specialties such as cardiology,psychiatry,oncology,and primary care.Companies equipped with pharmacogenomic testing solutions,complemented by robust interpretation and reporting capabilities,stand poised to meet this demand.By supporting informed clinical decision-making and optimizing medication regimes,these companies play a pivotal role in advancing personalized healthcare and improving patient welfare across healthcare settings.4.4 Future Trends 4.4.1 Artificial Intelligence-Powered Genetic Testing Whole-genome sequencing and now whole-exome sequencing have also become more popular.To solve the growing problem of health data exhaust,the field of medicine is increasingly revolving around enhanced clinical tools,such as artificial intelligence(AI)and machine learning,which have been mentioned as a way to improve the acceptance of genomic medicine.Today,many companies have turned to machine learning to process the vast amount of data needed to correctly analyze and understand clinical data in fields such as radiology and cardiology.Many of the consumer-facing genetic testing technologies that are available in the market are using machine learning or AI to function.In numerous ways,genetic testing of diseases is the perfect field for machine learning because of the vast volumes of data that these programs need to struggle with.For example,working on the human genome includes reading billions of bits of information,and prior to the introduction of machine learning,many of these tasks were pretty tricky.AI offers great potential when it comes to analyzing genetic data and supporting clinical specialists in making diagnoses.Google has a program called Deep Variant that can now be used to plot the human genome thoroughly and can be used on the full range of a persons genetic information.Moreover,agencies such as the National Institutes of Health are working on ways through which machine learning and AI can add to a better understanding of genetics and genomics.Furthermore,Blueprint Genetics is using AI in clinical interpretation.Machine learning and AI are acting as a catalyst for faster and more diverse improvement in genetic research and engineering.These tools are simple to integrate and extremely scalable,putting genetic laboratories in a unique position to scale their operations and match the fast growth of the genetic testing field.Thus,through the successful integration of these tools,clinicians will be able to diagnose rare genetic diseases more efficiently and effectively,bringing hope to the millions of people affected by them globally.24 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 4.5 Impact Analysis:The following figure depicts the impact of factors driving and restraining the Europe genetic testing services market.The factors driving the market growth include increasing prevalence of genetic diseases,increasing awareness and acceptance of personalized medicines,and growing preference for direct-to-consumer genetic testing.However,social and ethical implications of genetic testing and affordability of genetic services hinders the market growth.Figure 3.Impact Analysis of Drivers and Restraints Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources Rising Prevalence of Genetic DiseasesGrowing Preference towards for Direct-To-Consumer Genetic TestingSocial and Ethical Implications of Genetic TestingLOWMEDIUMHIGHIncreasing Awareness and Acceptance of Personalized Medicines 25 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 5.Genetic Testing Services Market-Europe Market Analysis European genetic testing services market is segmented into Germany,the UK,France,Italy,Spain,and the Rest of Europe.Genetic testing has been growing at an exceptional rate;a large panel of tests are now offered to screen a number of genetic diseases.Treatments are available for a number of rare genetic diseases,and the process is gaining importance in scenarios such as carrier testing,newborn screening,and predictive and pre-symptomatic testing,among others.Moreover,European countries have undertaken a number of initiatives to increase awareness among people about the benefits of genetic testing.The ultimate goal is to ensure that all aspects of genetic testing are of high quality,thereby providing accurate and reliable results for the benefit of the patients.5.1 Europe Genetic Testing Services Market Revenue(US$Mn),2022 2030 The Europe genetic testing services market is expected to reach US$2,778.42 million by 2030 from US$931.11 million in 2022.The market is estimated to grow at a CAGR of 14.6%from 2022 to 2030.The factors driving the market growth include the increasing prevalence of genetic diseases,growing preference for direct-to-consumer genetic testing,and increasing awareness and acceptance of personalized medicines.However,social and ethical implications of genetic testing and affordability of genetic services restrain the growth of the market.Figure 4.Europe Genetic Testing Services Market Revenue(US$Mn),2022 2030 Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 748.82834.61931.111,045.171,180.381,341.191,533.121,763.062,039.602,373.522,778.4211.5.6.2.9.6.3.0.7.4.1%0.0%2.0%4.0%6.0%8.0.0.0.0.0.0 20202120222023202420252026202720282029203005001,0001,5002,0002,5003,0002020-2030Historical YearBase YearForecast Year 26 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 6.Europe Genetic Testing Services Market Revenue and Forecast to 2030 by Service Type 6.1 Overview The Europe genetic testing services market,by service type,is segmented into predictive testing,carrier testing,prenatal testing,newborn screening,and others.In 2022,the predictive testing segment held the largest share of the market and is expected to register the highest CAGR in the market during the coming years.6.2 Europe Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%)Figure 5.Europe Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%)Source:The Insight Partners Analysis The predictive testing segment led the market in 2022 with a share of 38.9%and is expected to retain its dominance during 20222030 by accounting for 42.7%of the total market by 2030.38.9#.8.0.2%9.1 22Predictive TestingCarrier TestingPrenatal TestingNew-born ScreeningOthers42.7$.4.3.3%5.3 30 27 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 6.3 Predictive Testing 6.3.1 Overview Predictive genetic testing examines any genetic changes or mutations that are linked to disease.These tests are done prior to an individual displaying any signs of a disease.Predictive testing can be helpful to people who have a family history of a treatable genetic disorder and display no signs of illness.This testing can identify mutations that increase an individuals risk of developing disorders with a genetic foundation,such as certain types of cancer.An example is testing for the BRCA1 and BRCA2 gene variants(altered genes)linked with an increased risk of breast cancer.The results of predictive testing can provide information about the probability of developing a specific disorder and help in making decisions about medical care.The increasing demand for genetic counseling is expected to drive the market for predictive testing as more people understand the importance of genetics in disease etiology.The ongoing advancements and upgrading of platforms to improve the efficiency of genome analysis techniques are expected to boost the adoption of predictive testing solutions.A growing focus on reducing the growing healthcare burden of rare genetic diseases and rapid integration of technologies such as artificial intelligence and machine learning will enhance product development and fuel the need for predictive testing to assess and prevent future complications arising from diseases effectively.6.3.2 Predictive Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Predictive testing segment was valued at US$362.50 million in 2022 and is expected to reach US$1,185.45 million by 2030.The growth rate of this segment is projected to be 16.0%during 20222030.Figure 6.Predictive Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 284.59321.06362.50411.77470.53540.88625.44727.48851.121,001.571,185.45202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 28 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 6.4 Carrier Testing 6.4.1 Overview Carrier testing is a kind of genetic test that can tell whether one carries a gene for certain genetic disorders or not.When it is done before or during pregnancy,it helps to find out the chances of having a child with a genetic disorder.Carrier testing is used to identify people carrying one copy of a gene mutation(a genetic change)that,when present in two copies,results in a genetic disorder.Carriers generally do not have symptoms or have only mild symptoms.They often are unaware that they have a gene for a disorder.TaySachs disease is most common in Eastern or Central European Jewish people,French Canadian people,and Cajun descent.Although,anyone can have one of these disorders as they are not restricted to these groups.With the increasing prevalence of genetic diseases caused by chromosome and gene mutations,carrier testing has grown exponentially.The majority of cases of genetic mutations are due to preexisting conditions,a family history of abortion,or congenital disabilities.Pregnant women often undergo carrier screening in order to determine the risk of transmitting a specific genetic disease to their progeny.In addition,the increasing recognition of the importance of early diagnosis and screening of gene illness fuels the need to develop strategies to tackle these diseases.6.4.2 Carrier Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Carrier testing segment was valued at US$221.43 million in 2022 and is expected to reach US$678.79 million by 2030.The growth rate of this segment is projected to be 15.0%during 20222030.Figure 7.Carrier Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 176.85197.80221.43249.41282.64322.24369.60426.46495.00577.96678.79202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 29 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 6.5 Prenatal Testing 6.5.1 Overview Genetics can have an impact on the color of a babys eyes and hair and can also result in the development of some birth defects or genetic disorders.This testing helps to detect abnormalities in a fetuss genes or chromosomes and syndromes before birth.Thats why women are regularly offered a wide range of prenatal genetic testing in the first and second trimesters of pregnancy to evaluate the problems in their unborn babies.According to the WHO,congenital disabilities affect 8 million newborns every year.Nine out of every ten children are born with a serious birth defect in low-and middle-income countries.Congenital disabilities can occur at any point through the pregnancy;however,most of them occur during the first trimester when the babys organs are formed.With the ease of availability,pregnant females and their families are showing increased adoption toward the conduction of prenatal tests.According to the National Human Genome Research Institute(US),since December 2016,the adoption of prenatal genetic tests has notably increased with the introduction of noninvasive prenatal tests for the diagnosis of a range of genetic disorders in females.The segment is expected to show rapid growth in the coming years owing to the increasing prenatal testing and screening in developed regions such as North America and Europe and the new genetic tests introduced by the players in the market.For instance,in February 2019,Invitae Corporation,one of the leading genetics companies,introduced a noninvasive prenatal screening that offers in-depth genetic information about the child in early pregnancy.The company announced the launch in Las Vegas in conjunction with the Society for Maternal-Fetal Medicine meeting.6.5.2 Prenatal Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Prenatal testing segment was valued at US$121.00 million in 2022 and is expected to reach US$342.00 million by 2030.The growth rate of this segment is projected to be 13.9%during 20222030.Figure 8.Prenatal Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 98.59109.17121.00134.92151.37170.84193.98221.56254.56294.20342.00202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 30 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 6.6 Newborn Screening 6.6.1 Overview A newborn screening test looks for various developmental,genetic,and metabolic disease disorders in the newborn.Newborn screening allows measures to be taken before symptoms develop.Most of these illnesses are extremely rare but can be treated if detected early.The offspring has a high risk of having genetic diseases in cases where the parents have another child with a genetic disease,a family history of a genetic disorder,or if either of a parent has a chromosomal abnormality.Early testing for these conditions allows physicians and parents to take timely measures to manage,treat,or intervene in disease progression,allowing the baby to lead a healthy,normal life.6.6.2 Newborn Screening:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Newborn screening segment was valued at US$141.37 million in 2022 and is expected to reach US$424.53 million by 2030.The growth rate of this segment is projected to be 14.7%during 20222030.Figure 9.Newborn Screening:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 113.51126.62141.37158.82179.50204.12233.52268.76311.16362.38424.53202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 31 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 6.7 Others 6.7.1 Overview The others segment is comprised of preimplantation testing and pharmacogenomics.These tests are performed to screen for genetic disorders.Pharmacogenomics testing is a type of genetic test that is used to identify the right medication for a person.Pharmacogenomics is one of the key emerging trends in the field of medical science,which significantly impacts the drug development process.With the use of pharmacogenomics,target identification by drugs has become comparatively easy,which confirms much higher chances of success for the approval of drugs.Currently,various ongoing initiatives of pharmacogenomics implementation have been launched in the US,Europe,and Asia.In the US,27 institutions are involved in programs that are applying pharmacogenomics,some of which have been using it for over ten years.In 2007,a wide network of several associations was introduced with the creation of the Electronic Medical Records and Genomics(eMERGE)Network.Afterward,they started a study named eMERGE-PGx together with the Pharmacogenomics Research Network(PGRN),with the aim of testing genetic variation in 82 pharmacogenes through targeted sequencing.Moreover,since September 2010,with the Vanderbilt Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment program(PREDICT),more than 10,000 patients have undergone preemptive,panel-based pharmacogenomic testing.In 2011,PGRN also commenced the Translational Pharmacogenetics Program to assess PGx implementation in routine care by identifying barriers and developing solutions.Preimplantation genetic testing is also for couples who are at risk of having a child with a specific genetic or chromosome disorder,e.g.,cystic fibrosis or sickle cell disease.In this procedure,egg cells are removed from the womans ovaries and fertilized with sperm cells outside the body.The fertilized embryos develop for three days,and subsequently,one or two cells are removed from each embryo.The genetic material(DNA and chromosomes)from the cells is tested for the genetic disorder in the family history.One or two of the unaltered embryos are then relocated into the mothers womb(uterus).If the pregnancy is successful,the baby will not be affected by the disorder it was tested for.6.7.2 Others:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Others segment was valued at US$84.80 million in 2022 and is expected to reach US$147.65 million by 2030.The growth rate of this segment is projected to be 7.2%during 20222030.32 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 10.Others:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 75.2879.9684.8090.2596.33103.10110.59118.81127.77137.41147.65202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 33 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 7.Europe Genetic Testing Services Market Revenue and Forecast to 2030 by Disease 7.1 Overview The Europe genetic testing services market,by disease,is segmented into cancer,cardiovascular diseases,metabolic diseases,and other diseases.In 2022,the cancer segment held the largest share of the market and is anticipated to grow at the highest CAGR during the coming years.7.2 Europe Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%)Figure 11.Europe Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%)Source:The Insight Partners Analysis The cancer segment led the market in 2022 with a share of 45.3%and is expected to retain its dominance during 20222030 by accounting for 49.0%of the total market by 2030.45.3.5.5.7 22CancerCardiovascular DiseasesMetabolic DiseasesOther Diseases49.0#.1.7.2 30 34 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 7.3 Cancer 7.3.1 Overview Genetic testing is a potential tool to identify individuals who are at higher risk for developing certain cancers because of family history.Genetic tests are available to examine inherited variants and alterations in the DNA sequence,which could result in excessive cell growth and can cause tumors or cancer.For example,genetic testing for the detection of PALB2(linked with increased risks of breast and pancreatic cancers),BRIP1(ovarian cancer),RAD51C and RAD51D(ovarian cancer),and CHEK2(breast and colorectal cancers).The worldwide growing prevalence of various cancers,such as breast,lung,and bowel,are the major drivers of this segment.According to the American Cancer Society,1,898,160 new cancer cases and 608,570 cancer deaths were anticipated to occur in the US in 2021.Nearly 10%to 20%of all cancers are related to gene mutations that are inherited or passed down through the family.Approximately 510%of cancers diagnosed in the US are associated with hereditary cancer syndromes.During the last decade,efforts have been made by the public health,medical,and scientific community to update the public about ideas such as family history,hereditary cancer risk,and genetic testing for inherited cancer.For instance,CDCs Cancer Genomics Program develops best practices in education,surveillance,and policy and systems transformation approaches.It establishes an evidence base for the application of family history and cancer genomics in public health practice.Other factors that might impact cancer genetic testing awareness include DTC marketing of cancer genetic testing and federal regulations of genetic information,high awareness regarding the availability of quality cancer diagnostics tests,and the escalating incidence of hereditary diseases.In addition,a growing number of companies providing genomic profiling services for health assessment,including cancer risk prediction,and the availability of numerous laboratories offering genetic testing for BRCA,and other genes associated with hereditary breast,ovarian,and related cancers propel the market for the segment.7.3.2 Cancer:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Cancer segment was valued at US$421.40 million in 2022 and is expected to reach US$1,362.63 million by 2030.The growth rate of this segment is projected to be 15.8%during 20222030.Figure 12.Cancer:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 331.78373.76421.40477.98545.41626.07722.93839.69981.031,152.861,362.63202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 35 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 7.4 Cardiovascular Diseases 7.4.1 Overview Heart diseases are a prominent cause of death worldwide and often run in families.In addition,as per the World Heart Federation 2023,rare cardiovascular diseases(CVD)are common,affecting 5%of the global population.There are over 6,000 known rare diseases,a handful of which impact the heart and circulatory system.And 83%of physicians agree that genetic testing is useful in finding the diagnosis.Certain CVD conditions,such as cardiomyopathy,arrhythmia,and connective tissue disease,are caused by a single harmful DNA variation(or mutation).However,others,such as heart attack and high blood pressure,are usually caused by the combined effect of many smaller-impact DNA variations.More than 1 in 200 people have an inherited form of CVD disease,but most are unaware of it.Patients with an inherited cardiovascular condition display few or no symptoms but still face significant risk of heart disease,including sudden cardiovascular arrest.Genetic testing can help save lives and is informative and useful for the clinical management and treatment of numerous inherited CVDs.7.4.2 Cardiovascular Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Cardiovascular diseases segment was valued at US$209.74 million in 2022 and is expected to reach US$643.07 million by 2030.The growth rate of this segment is projected to be 15.0%during 20222030.Figure 13.Cardiovascular Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 167.51187.35209.74236.24267.72305.24350.11403.98468.92547.53643.07202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 36 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 7.5 Metabolic Diseases 7.5.1 Overview Diagnosis through genetic testing can strongly help discover the cause of persistent,often debilitating,undiagnosed signs in individuals suffering from suspected genetic metabolic disease disorders.With knowledge of variants in over 1,250 metabolic disease disorders genes,the rapid testing and experience of metabolic diseases can help to diagnose and manage the patients metabolic disease disorders quickly and correctly.Ultimately,this can provide new insights into treatment choices and the probability of passing the inherited condition on to the offspring or the presence of it elsewhere in the extended family.CentoICU is a comprehensive next-generation sequencing panel that includes genes explicitly chosen for the genetic testing of extremely ill newborns and children under 24 months in intensive care units.In addition,Prevention Genetics offers a wide variety of genetic testing for inherited metabolic disease disorders,also known as inborn errors of metabolism.Panels specific to one disorder are available,as well as comprehensive metabolic diseases panels that cover broader phenotypic features or groups of similar disorders are also offered,including tests for hyperammonemia(37 genes),metabolic diseases hypoglycemia(38 genes),and metabolic diseases myopathies,rhabdomyolysis,and exercise intolerance(83 genes).Over the past year,the company has started to offer several new tests related to these metabolic disorders,and many of the existing panels have been updated to include more genes and increase clinical sensitivity.7.5.2 Metabolic Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Metabolic diseases segment was valued at US$172.07 million in 2022 and is expected to reach US$490.56 million by 2030.The growth rate of this segment is projected to be 14.0%during 20222030.Figure 14.Metabolic Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 139.93155.10172.07192.07215.70243.70277.00316.73364.31421.51490.56202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 37 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 7.6 Other Diseases 7.6.1 Overview The others segment by disease comprises Duchenne Muscular Dystrophy(DMD),Thalassemia,Huntingtons Disease,and Fragile X Syndrome,among others.Genetic mutations that cause DMD fail to produce dystrophin protein.Recessive diseases caused by alterations in genes on the X chromosome include DMD and fragile X syndrome.Genetic testing is used to diagnose Duchenne,to access mutation-specific therapies,and for family planning.For Duchenne,the dystrophin gene is examined to detect the presence of any changes or mutations that can inhibit the gene from working properly.Genetic testing is generally performed on a blood or saliva sample.A thalassemia is a group of inherited,genetic blood disorders that occur when the production of hemoglobin is disrupted.The disease is passed to children by parents carrying the mutated thalassemia gene.A kid who inherits one mutated gene is a carrier,and most carriers lead a completely normal and healthy life.At the same time,a child who inherits two thalassemia trait genes,i.e.,one from each parent,will have the disease.A child of two carriers has a 25 percent chance of developing the disease and a 50 percent chance of being a carrier.Thus,in such cases,genetic testing is helpful in detecting and diagnosing thalassemia.Currently,two major approaches are used in DNA diagnosis and study of genetic disease,namely direct tests and indirect tests(linkage analysis).Direct tests are being conducted for thalassemia and DMD.Carrier testing can be conducted for X-linked recessive disorders,such as DMD or fragile X syndrome.In these cases,the mother of an affected child with no other affected relatives may desire carrier testing to confirm whether the disease is a heritable trait or a new mutation.Many diseases may become apparent only in middle age or later.Predictive or presymptomatic testing and screening can provide symptoms that people may later develop these disorders.In some cases,a family history of a monogenic disorder in a relative informs other members of the family that they are at high risk for developing the disease.Suitable genetic testing can help to resolve whether the mutant gene is present or not.Examples include Huntingtons disease.7.6.2 Other Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Other diseases segment was valued at US$127.90 million in 2022 and is expected to reach US$282.16 million by 2030.The growth rate of this segment is projected to be 10.4%during 20222030.38 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 15.Other Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 109.60118.40127.90138.88151.54166.18183.09202.67225.34251.63282.16202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 39 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 8.Europe Genetic Testing Services Market Revenue and Forecast to 2030 by Service Provider 8.1 Overview The Europe genetic testing services market,by service provider,is segmented into hospital-based laboratories,diagnostic laboratories,and others.In 2022,the hospital-based laboratories segment held the largest share of the market and is estimated to grow at the highest CAGR during 20222030.8.2 Europe Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%)Figure 16.Europe Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%)Source:The Insight Partners Analysis The hospital-based laboratories segment led the market in 2022 with a share of 63.4%and is expected to retain its dominance during 20222030 by accounting for 68.5%of the total market by 2030.63.4%.9.7 22Hospital-BasedLaboratoriesDiagnostic LaboratoriesOther End Users68.5&.2%5.3 30 40 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 8.3 Hospital-Based Laboratories 8.3.1 Overview Hospital-based laboratories are genetic testing service providers that operate within a hospital setting.For extremely specialized tests,samples may go to a research laboratory.Nearly all hospitals contain a laboratory,which is commonly proportionate in size to the population it serves.The hospitals process hundreds of samples in very les time.Tests that are performed include those needed in emergencies,such as markers for heart attack and tests where results are required rapidly for patient care.They may also offer carrier testing to determine if an individual is carriers of certain genetic conditions that can be passed on to their children.Hospital laboratories can be segmented by type of testing and staffed by personnel trained in particular specialties.For instance,some sections can focus on microbiology,hematology,chemistry,and blood banking.At the same time,some units may perform highly specialized genetic tests using electron microscopy and immunohistochemistry,and others can focus on surgical pathology and cytology,which are all linked with the investigation of cell and tissue structure.The market growth for the segment can be due to the compulsory newborn screening for genetic disorders and the growing prevalence of cancer in many regions.Seattle Childrens Hospital in Washington,Wyoming,Alaska,Montana,and Idaho(WWAMI)region provides comprehensive genetic testing and consultative services to healthcare workers and families.Their genetics laboratories consist of molecular genetics,cytogenetics,biochemical genetics,and a research and development laboratory devoted to bringing the most existing and specific research tests into the clinical field.Overall,these laboratories play a crucial role in helping to diagnose genetic disorders,guide treatment decisions,and improve patient outcomes.8.3.2 Hospital-Based Laboratories:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Hospital-based laboratories segment was valued at US$590.51 million in 2022 and is expected to reach US$1,903.84 million by 2030.The growth rate of this segment is projected to be 15.8%during 20222030.Figure 17.Hospital-Based Laboratories:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 465.37524.00590.51669.50763.63876.211,011.381,174.321,371.531,611.231,903.84202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 41 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 8.4 Diagnostic Laboratories 8.4.1 Overview Diagnostics laboratories are independent entities that provide all the diagnostic tests,screening tests,and others to the patient.These centers may be found attached to a private or public hospital.The tests performed in the diagnostic centers are obtained earlier than hospitals.The diagnostic centers also offer packages for whole-body check-ups that are cost-effective for the patients.Tests such as cell-free fetal DNA testing,triple or quadruple screening tests,sequential screening,and others require advanced techniques,equipment,and skilled labor.However,some of the hospitals and clinics do not have all the required equipment and techniques for efficient diagnosis.Therefore,various hospitals and clinics prefer to outsource tests to diagnostics centers.The diagnostics centers are well equipped and offer better results for the tests performed for diseases and health conditions.The diagnostic centers provide multiple tests under one roof and offer all the prenatal diagnostics services such as screening,imaging,blood tests,chorionic villus sampling,and amniocentesis.Thus,it becomes easier for people to undergo genetic testing in such facilities.The growing partnerships and collaboration of diagnostic laboratories with genetic testing companies and the rise in the incidences of genetic diseases across the world are anticipated to offer growth to the market.For instance,Thermo Fisher Scientific allows laboratories to perform different genetic research and genetic testing by offering technologies such as NGS and quantitative PCR.8.4.2 Diagnostic Laboratories:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Diagnostic laboratories segment was valued at US$241.30 million in 2022 and is expected to reach US$727.00 million by 2030.The growth rate of this segment is projected to be 14.8%during 20222030.Figure 18.Diagnostic Laboratories:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 193.60216.03241.30271.19306.64348.83399.23459.66532.39620.30727.00202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 42 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 8.5 Others 8.5.1 Overview The others segment by service provider comprises academic and research institutions,pharmaceutical and biotechnology companies,and government agencies.Government agencies use genetic testing services to evaluate drugs for regulatory compliance for public health monitoring and research initiatives.Academic and research institutions are integral to the Europe genetic testing services market.They help in identifying genetic markers,developing new genetic testing methodologies,and improving existing tests.These institutions validate and ensure the quality of genetic tests through rigorous studies,establishing their reliability and credibility.Clinical trials and studies conducted by these institutions provide essential evidence on the clinical utility and effectiveness of genetic tests.Their expertise and research efforts advance the growth of the market,benefiting both patients and healthcare providers.In addition,research and academic institutes are among the leading users of genetic testing services.Academic institutes for medical sciences and biotechnology utilize analytical testing services to support their studies on drugs.Thus,the increasing demand for genetic testing services from government agencies and research institutes will likely continue to drive the Europe genetic testing services market for the segment.8.5.2 Others:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Others segment was valued at US$99.30 million in 2022 and is expected to reach US$147.59 million by 2030.The growth rate of this segment is projected to be 5.1%during 20222030.Figure 19.Others:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 89.8594.5899.30104.48110.11116.15122.51129.09135.68141.99147.59202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 43 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.Europe Genetic Testing Services Market-Country Analysis 9.1 Europe Figure 20.Europe Genetic Testing Services Market,by Key Country Revenue,2022(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 9.1.1 Europe Genetic Testing Services Market,by Country Figure 21.Europe Genetic Testing Services Market,By Key Countries,2022 and 2030(%)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources EUROPE(2022)152.3873.8495.32197.51196.79215.28Rest ofEuropeSpainItalyFranceUKGermany21.1#.1!.2%7.9.2.4 22UKGermanyFranceSpainItalyRest of Europe22.6$.0!.6%7.7%9.6.4 30 44 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.1 UK 9.1.1.1.1 Overview The UK genetic testing services market growth is attributed to the rise in the prevalence of genetic disorders and cancer.For instance,as per Genetic Alliance UK 2021,rare diseases affect 3.5 million people in the country;that is 1 in 17 people.As per Gene People UK 2023,it is estimated that 1 in 25 children suffer from a genetic disorder,meaning that 30,000 babies and children are newly diagnosed yearly in the UK,and over 2.4 million children and adults are suffering from a genetic disorder.Various initiatives by the government further spur market growth.For instance,the UK Genetic Testing Network(UKGTN),an advisory organization in the UK,promotes equity of access to genetic testing and provides contracting support to the National Health Service(NHS).In addition,Genetic Disorders UK has established a registered charity with an aim to improve the lives of people and families affected by genetic disorders.Moreover,the 100,000 Genomes Project launched by the UK government in 2012 is strengthening the NHSs position as one of the most advanced healthcare systems worldwide.In addition,the project is consolidating the foundation for personalized medicine,and this,in turn,contributes to the growth of genetic testing in the country.Great advances are being made in genomics,paving the way for enhanced access to personalized medicine.The country established the infrastructure to support greater access to genomic testing,including a national network of genomic laboratories and Genomic Medicine Centers that provide clinical services.These were established with the objective of embedding personalized medicine as part of routine clinical practice.In 2019,the government announced Early Disease Detection Research Project UK,which is a significant new initiative that focuses on the major chronic diseases of adult life,including all cancers,cardiovascular disease,and other such diseases.9.1.1.1.2 UK Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)The UK genetic testing services market accounted for US$196.79 Mn in 2022 and it is expected to grow at a CAGR of 15.6%during the period 2022-2030,to reach US$629.10 Mn in 2030.Figure 22.UK Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 155.44174.82196.79222.86253.92291.04335.58389.23454.13532.95629.10202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 45 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.1.3 UK Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 2.UK Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 59.61 68.02 77.66 89.19 103.03 119.72 139.90 164.44 194.38 231.09 276.28 17.2rrier Testing 36.96 41.59 46.85 53.09 60.52 69.41 80.08 92.93 108.49 127.40 150.47 15.7%Prenatal Testing 20.05 22.46 25.17 28.39 32.21 36.76 42.20 48.74 56.62 66.15 77.75 15.1%Newborn Screening 23.41 26.28 29.53 33.39 37.97 43.45 50.01 57.90 67.43 78.99 93.08 15.4%Others 15.40 16.47 17.57 18.81 20.19 21.71 23.39 25.22 27.20 29.32 31.52 7.6%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the predictive testing segment was worth US$.66 million in 2022 and is projected to reach US$276.28 million by 2030;it is expected to grow at a CAGR of 17.2%from 2022 to 2030.9.1.1.1.4 UK Genetic Testing Services Market,by Disease,20202030(US$Million)Table 3.UK Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 68.95 78.20 88.76 101.36 116.43 134.54 156.38 182.84 215.02 254.34 302.58 16.6rdiovascular Diseases 34.64 39.14 44.26 50.36 57.64 66.37 76.87 89.56 104.96 123.73 146.71 16.2%Metabolic Diseases 29.11 32.62 36.58 41.27 46.85 53.50 61.45 71.00 82.52 96.48 113.44 15.2%Others 22.73 24.86 27.18 29.87 33.00 36.64 40.88 45.82 51.61 58.40 66.37 11.8%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the cancer segment was worth US$88.76 million in 2022 and is projected to reach US$302.58 million by 2030;it is expected to grow at a CAGR of 16.6%from 2022 to 2030.9.1.1.1.5 UK Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 4.UK Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 96.89 110.10 125.21 143.24 164.85 190.83 222.21 260.26 306.60 363.27 432.88 16.8%Diagnostic Laboratories 40.70 45.87 51.74 58.72 67.03 76.99 88.95 103.39 120.87 142.13 168.11 15.9%Others 17.85 18.85 19.84 20.90 22.03 23.21 24.41 25.58 26.66 27.55 28.11 4.5%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 46 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners The Europe genetic testing services market for the hospital-based laboratories segment was worth US$125.21 million in 2022 and is projected to reach US$432.88 million by 2030;it is expected to grow at a CAGR of 16.8%from 2022 to 2030.9.1.1.2 Germany 9.1.1.2.1 Overview Medical genetics has become a vital part of clinical practice.It has provided doctors with a valued diagnostic and an analytical pre-symptomatic tool,which they can use more effectively to manage patients diseases and even take preventive actions.As per a study titled Awareness and Knowledge of Rare Diseases in German Dentists,Dental Specialists,and Oral and Maxillofacial Surgeons,published in 2022,rare diseases affect about four million patients in the country.Moreover,the rising prevalence of rare diseases and the development of custom-made testing kits for niche therapeutic areas,along with the adoption of genetic testing kits,are aiding the rapid growth of the market.As per Globocan 2020,69,697 new breast cancer cases were reported in 2020 in Germany,representing 11.1%of all registered cancer cases.It caused 20,579 fatalities,and the five-year prevalence rate of breast cancer in all ages was 707.38 per 100,000 population.Nearly 16%of women with triple-negative breast cancer carry a BRCA mutation in Germany.In 2018,the government of the country announced a strategy to include BRCA genetic testing in Germanys national cancer plan,which was initiated in 2008 with the goal of ensuring women with high genetic risk of breast cancer are legally entitled to intensified screening and risk-reducing options.The increasing focus by the government to regulate and create awareness regarding genetic tests has effectively resulted in the faster adoption of tests across the country.In Germany,noninvasive prenatal testing became available as a publicly reimbursed test in 2022.In addition,the introduction of reimbursement programs,increasing demand for efficient treatment options,and implementation of innovative technologies in research centers are expected to drive market expansion in the country.Growing awareness about the advantages of genetic testing,knowledge among healthcare professionals,and the rise in consumer spending on healthcare propels the market.9.1.1.2.2 Germany:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Germany genetic testing services market accounted for US$215.28 Mn in 2022 and it is expected to grow at a CAGR of 15.2%during the period 2022-2030,to reach US$668.15 Mn in 2030.47 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 23.Germany:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 9.1.1.2.3 Germany:Europe Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 5.Germany:Europe Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 63.13 71.59 81.25 92.75 106.52 123.06 143.00 167.15 196.51 232.36 276.34 16.5rrier Testing 39.16 44.16 49.85 56.61 64.68 74.34 85.96 99.99 116.99 137.68 162.99 16.0%Prenatal Testing 23.25 25.81 28.68 32.06 36.06 40.80 46.44 53.17 61.22 70.91 82.61 14.1%Newborn Screening 26.61 29.94 33.71 38.19 43.52 49.90 57.56 66.80 77.97 91.55 108.12 15.7%Others 19.25 20.50 21.79 23.24 24.86 26.64 28.61 30.75 33.06 35.52 38.08 7.2%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the predictive testing segment was worth US$81.25 million in 2022 and is projected to reach US$276.34 million by 2030;it is expected to grow at a CAGR of 16.5%from 2022 to 2030.171.40192.00215.28242.86275.65314.75361.58417.85485.75568.03668.15202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 48 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.2.4 Germany:Europe Genetic Testing Services Market,by Disease,20202030(US$Million)Table 6.Germany:Europe Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 76.02 86.16 97.73 111.52 128.02 147.83 171.71 200.62 235.76 278.66 331.27 16.5rdiovascular Diseases 38.59 43.29 48.62 54.92 62.43 71.39 82.13 95.05 110.66 129.59 152.65 15.4%Metabolic Diseases 32.09 35.75 39.86 44.72 50.47 57.30 65.44 75.19 86.91 101.04 118.15 14.6%Others 24.69 26.79 29.07 31.70 34.73 38.24 42.29 46.99 52.43 58.75 66.09 10.8%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the cancer segment was worth US$97.73 million in 2022 and is projected to reach US$331.27 million by 2030;it is expected to grow at a CAGR of 16.5%from 2022 to 2030.9.1.1.2.5 Germany:Europe Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 7.Germany:Europe Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 106.83 121.05 137.27 156.60 179.73 207.49 240.95 281.46 330.69 390.79 464.47 16.5%Diagnostic Laboratories 44.44 49.73 55.70 62.77 71.17 81.19 93.17 107.56 124.90 145.91 171.45 15.1%Others 20.13 21.22 22.31 23.48 24.74 26.08 27.45 28.83 30.16 31.33 32.23 4.7%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the hospital-based laboratories segment was worth US$137.27 million in 2022 and is projected to reach US$464.47 million by 2030;it is expected to grow at a CAGR of 16.5%from 2022 to 2030.49 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.3 France 9.1.1.3.1 Overview As per Globocan 2020 data,France recorded 58,083 new breast cancer cases,representing 12.4%of all registered cases.The five-year prevalence rate for breast cancer in all ages was 702.58 per 100,000 population.It was also the major cause of cancer deaths in women,causing 14,183 deaths in 2020 in the country.It is estimated that 2 in 1,000 women carry a BRCA1 or BRCA2 mutation.A woman in France has a lifetime risk of breast cancer of 5175%if she carries a BRCA1 mutation and 3355%if she has a BRCA2 mutation,compared with 12%for the general population.Additionally,as per the study titled RaDiCo,the French national research program on rare disease cohorts,published in 2021,rare diseases affect 3 million people in the country.The country developed a national plan for personalized medicine,namely Genomic Medicine France 2025,which was announced in 2016 and is overseen and supported by the State.The program appeals to healthcare and manufacturing firms to pilot genomic sequencing platforms.By 2020,the aim was to establish a network of centers able to process nearly 235,000 samples for whole genome sequencing.This ambitious plan aimed at positioning the country as a leader among the major countries involved in genomic medicine within the next ten years.In addition,France has well-developed policies and strategies in place for improving the prevention of hereditary cancers and other genetic diseases.For instance,BRCA-France is also involved in public support,aiming to expand genetic testing criteria.The organization is also calling for genetic testing criteria to be expanded to include the 8,00010,000 women in France with metastatic breast cancer.Similarly,the national neonatal screening program concerns all newborns in the country.It focuses on detecting rare,severe,and most often genetic diseases on a collected blood sample.In 2020,the newborn screening program detected 557 major sickle cell syndromes,98 congenital hypothyroidism,93 hyperphenylalaninemia,37 congenital adrenal hyperplasia,and 122 cystic fibrosis.Thus,the factors mentioned above significantly support the growth of the market in the country.9.1.1.3.2 France Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)France genetic testing services market accounted for US$197.51 Mn in 2022 and it is expected to grow at a CAGR of 14.9%during the period 2022-2030,to reach US$600.13 Mn in 2030.50 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 24.France Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 9.1.1.3.3 France Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 8.France Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 62.21 70.30 79.51 90.46 103.53 119.21 138.06 160.85 188.49 222.16 263.37 16.2rrier Testing 38.51 43.11 48.31 54.47 61.80 70.53 80.98 93.54 108.70 127.05 149.38 15.2%Prenatal Testing 19.75 21.89 24.28 27.10 30.44 34.38 39.08 44.67 51.37 59.42 69.13 14.0%Newborn Screening 23.09 25.79 28.84 32.45 36.73 41.83 47.92 55.23 64.04 74.70 87.63 14.9%Others 14.57 15.55 16.57 17.73 19.03 20.50 22.14 23.96 25.98 28.20 30.61 8.0%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the predictive testing segment was worth US$79.51 million in 2022 and is projected to reach US$263.37 million by 2030;it is expected to grow at a CAGR of 16.2%from 2022 to 2030.158.12176.64197.51222.21251.53286.45328.18378.26438.57511.52600.13202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 51 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.3.4 France Genetic Testing Services Market,by Disease,20202030(US$Million)Table 9.France Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 69.96 79.00 89.29 101.53 116.13 133.63 154.69 180.11 210.95 248.50 294.44 16.1rdiovascular Diseases 35.18 39.45 44.28 50.00 56.81 64.94 74.68 86.39 100.54 117.69 138.58 15.3%Metabolic Diseases 30.20 33.48 37.15 41.48 46.58 52.63 59.82 68.40 78.67 91.01 105.90 14.0%Others 22.78 24.70 26.79 29.21 32.00 35.24 38.99 43.35 48.42 54.32 61.21 10.9%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the cancer segment was worth US$89.29 million in 2022 and is projected to reach US$294.44 million by 2030;it is expected to grow at a CAGR of 16.1%from 2022 to 2030.9.1.1.3.5 France Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 10.France Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 97.73 110.19 124.34 141.16 161.22 185.24 214.11 248.94 291.14 342.50 405.26 15.9%Diagnostic Laboratories 41.43 46.43 52.07 58.75 66.70 76.19 87.55 101.21 117.69 137.67 161.99 15.2%Others 18.95 20.02 21.10 22.30 23.60 25.01 26.52 28.11 29.74 31.35 32.88 5.7%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the hospital-based laboratories segment was worth US$124.34 million in 2022 and is projected to reach US$405.26 million by 2030;it is expected to grow at a CAGR of 15.9%from 2022 to 2030.52 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.4 Italy 9.1.1.4.1 Overview The increasing investments and rising funds dedicated to manufacturing companies,as well as academic and research institutes for the development of gene synthesis-based end products,such as precision medicine and other therapeutics,are the key factors fueling the market growth.In Italy,the approval of genetic and genomics applications for funding by the National Healthcare System is mostly unregulated.For this reason,the National Plan for Public Health Genomics proposed the development of a more comprehensive evaluation framework for genetic and genomic applications.Also,Italy was the first country in Europe to develop a plan and structure for Public Health Genomics.It also has guidelines on medical genetics and a national strategy to support people with rare diseases.These factors significantly boost the growth of the market in Italy.As per UniCamillusSaint Camillus International University of Health and Medical Sciences data,there are 500 Down syndrome newborns annually in Italy,and 38,000 people are affected with Down syndrome.The number of centers providing genetic testing for such conditions in Italy is growing due to the increasing demand for genetic tests.Moreover,various organizations work toward raising awareness about genetic testing in the country.Salute Donna Onlus is an association engaged in several awareness-raising and encouragement initiatives,including organizing a conference and supporting the Italian Senate to increase access to genetic testing across the country.9.1.1.4.2 Italy Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Italy genetic testing services market accounted for US$95.32 Mn in 2022 and it is expected to grow at a CAGR of 13.8%during the period 2022-2030,to reach US$267.99 Mn in 2030.Figure 25.Italy Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 77.7786.0695.32106.22119.09134.32152.41173.97199.74230.69267.99202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 53 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.4.3 Italy Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 11.Italy Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 28.64 31.98 35.74 40.18 45.44 51.70 59.17 68.12 78.88 91.87 107.61 14.8rrier Testing 18.13 20.16 22.43 25.10 28.27 32.03 36.50 41.85 48.26 55.98 65.32 14.3%Prenatal Testing 11.09 12.24 13.53 15.05 16.84 18.95 21.46 24.44 28.01 32.28 37.42 13.6%Newborn Screening 12.21 13.51 14.96 16.67 18.68 21.07 23.90 27.28 31.32 36.17 42.01 13.8%Others 7.70 8.17 8.67 9.22 9.86 10.57 11.37 12.27 13.28 14.40 15.63 7.7%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the predictive testing segment was worth US$35.74 million in 2022 and is projected to reach US$107.61 million by 2030;it is expected to grow at a CAGR of 14.8%from 2022 to 2030.9.1.1.4.4 Italy Genetic Testing Services Market,by Disease,20202030(US$Million)Table 12.Italy Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 34.49 38.61 43.27 48.78 55.31 63.10 72.39 83.55 96.97 113.21 132.92 15.1rdiovascular Diseases 17.52 19.47 21.66 24.24 27.30 30.93 35.25 40.40 46.59 54.04 63.04 14.3%Metabolic Diseases 13.57 14.96 16.51 18.34 20.48 23.02 26.03 29.60 33.87 38.97 45.11 13.4%Others 12.20 13.01 13.88 14.86 15.99 17.28 18.74 20.41 22.31 24.46 26.91 8.6%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the cancer segment was worth US$43.27 million in 2022 and is projected to reach US$132.92 million by 2030;it is expected to grow at a CAGR of 15.1%from 2022 to 2030.9.1.1.4.5 Italy Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 13.Italy Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 48.46 54.13 60.51 68.06 77.00 87.63 100.32 115.52 133.80 155.88 182.65 14.8%Diagnostic Laboratories 18.80 20.78 22.99 25.59 28.66 32.29 36.59 41.72 47.85 55.19 64.04 13.7%Others 10.50 11.15 11.81 12.58 13.44 14.41 15.50 16.73 18.09 19.61 21.29 7.6%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 54 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners The Europe genetic testing services market for the hospital-based laboratories segment was worth US$60.51 million in 2022 and is projected to reach US$182.65 million by 2030;it is expected to grow at a CAGR of 14.8%from 2022 to 2030.9.1.1.5 Spain 9.1.1.5.1 Overview According to the Global Cancer Observatory 2020,34,088 new breast cancer cases were registered in the country,representing 12.1%of all new cancer cases.The five-year prevalence rate for breast cancer cases among all age groups was 577.34 per 100,000 population.According to the Spanish Network of Cancer Registries,the incidence of breast cancer in females was 34,750 in November 2022,with an increase of 0.9%yearly.Breast cancer patients have at least one hereditary risk cancer,which requires genetic counseling.Thus,the rising incidences of breast cancer are likely to propel the growth of the market.According to the article Myths and Truths about Down Syndrome,published in 2021,34,000 individuals with Down syndrome reside in Spain.As per WCRF International and Globocan,40,441 new colorectal cancer cases were diagnosed in 2020 in Spain in both genders,including 24,610 colorectal cancer incidences among males and 15,831 in females.Genetic testing can be utilized in such conditions to check the probability of a person acquiring them in the future and get treatment accordingly.The presence of well-established companies in the country is further going to propel the growth.For instance,LabGenetics specializes in prenatal genetic testing and collaborates with public and private hospitals,clinics,and centers,both in Spain and globally.Also,NIMGenetics is a privately owned Spanish biomedical company specializing in the design and commercialization of products and services for clinical genetic diagnosis.9.1.1.5.2 Spain Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Spain genetic testing services market accounted for US$73.84 Mn in 2022 and it is expected to grow at a CAGR of 14.1%during the period 2022-2030,to reach US$212.72 Mn in 2030.Figure 26.Spain Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 59.8966.4773.8482.5292.79104.98119.48136.79157.55182.53212.72202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 55 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.5.3 Spain Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 14.Spain Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 23.19 26.04 29.26 33.07 37.61 43.03 49.51 57.31 66.72 78.13 92.01 15.4rrier Testing 14.36 15.99 17.82 19.98 22.54 25.58 29.21 33.56 38.77 45.06 52.69 14.5%Prenatal Testing 7.64 8.41 9.27 10.27 11.46 12.85 14.51 16.47 18.80 21.60 24.95 13.2%Newborn Screening 8.88 9.87 10.98 12.28 13.83 15.66 17.84 20.45 23.58 27.35 31.90 14.3%Others 5.82 6.16 6.51 6.91 7.36 7.86 8.41 9.02 9.68 10.40 11.17 7.0%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the predictive testing segment was worth US$29.26 million in 2022 and is projected to reach US$92.01 million by 2030;it is expected to grow at a CAGR of 15.4%from 2022 to 2030.9.1.1.5.4 Spain Genetic Testing Services Market,by Disease,20202030(US$Million)Table 15.Spain Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 26.51 29.75 33.41 37.75 42.91 49.06 56.42 65.27 75.95 88.89 104.64 15.3rdiovascular Diseases 13.37 14.88 16.58 18.59 20.97 23.80 27.17 31.21 36.06 41.91 48.99 14.5%Metabolic Diseases 11.38 12.54 13.83 15.35 17.14 19.24 21.74 24.71 28.24 32.47 37.56 13.3%Others 8.63 9.29 10.00 10.83 11.78 12.87 14.14 15.60 17.30 19.26 21.53 10.1%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the cancer segment was worth US$33.41 million in 2022 and is projected to reach US$104.64 million by 2030;it is expected to grow at a CAGR of 15.3%from 2022 to 2030.9.1.1.5.5 Spain Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 16.Spain Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 37.10 41.57 46.63 52.62 59.73 68.22 78.37 90.56 105.26 123.06 144.70 15.2%Diagnostic Laboratories 15.65 17.41 19.37 21.70 24.45 27.71 31.60 36.25 41.84 48.57 56.71 14.4%Others 7.14 7.49 7.83 8.20 8.61 9.05 9.51 9.98 10.46 10.91 11.31 4.7%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 56 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners The Europe genetic testing services market for the hospital-based laboratories segment was worth US$46.63 million in 2022 and is projected to reach US$144.70 million by 2030;it is expected to grow at a CAGR of 15.2%from 2022 to 2030.9.1.1.6 Rest of Europe 9.1.1.6.1 Overview The Europe genetic testing services market in the Rest of Europe is segmented into Poland,Austria,Switzerland,Sweden,Norway,Denmark,Belgium,and the Netherlands.According to the Spanish Network of Cancer Registries,11,734 breast cancer cases were diagnosed in November 2022 in Belgium.Breast cancer was responsible for 2,362 deaths in the country in the same year.As per the same source,24,644 breast cancer cases were registered in 2020.In Poland,it caused 8,805 breast cancer-related deaths.The increasing technological advancements and growing product launches have opened up numerous market expansion opportunities for the companies.For instance,Estonian scientists invented a genetic testing technology in 2018 named the Endometrial Receptivity Test that grants the number of clinical biomarkers to be analyzed at the single-molecule level.In February 2022,Eurofins Clinical Testing Lux Sarl(Eurofins Scientifics subsidiary)acquired Genetic Testing Service JSC.Through the acquisition,the company aimed to expand its network and strengthen its global network of clinical diagnostic laboratories,which mostly focus on specialized and advanced genetic testing.In September 2022,Eurofins Genoma(part of the Eurofins),one of the most advanced European molecular diagnostics laboratories,introduced niPGTa noninvasive preimplantation genetic aneuploidy screening test.Preimplantation genetic testing for aneuploidy plays a crucial role in assisted reproductive technology applications.Therefore,the growing incidents of breast cancer and the launch of innovative products by the market players favor the market growth.9.1.1.6.2 Rest of Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)The Rest of Europe genetic testing services market accounted for US$152.38 Mn in 2022 and it is expected to grow at a CAGR of 12.8%during the period 2022-2030,to reach US$400.33 Mn in 2030.Figure 27.Rest of Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 126.21138.63152.38168.49187.40209.65235.90266.97303.86347.80400.33202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 57 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.6.3 Rest of Europe Genetic
2024-08-12
104页
5星级
South&Central America Genetic Testing Services Market Market Size and Forecast(2020-2030)Regional Growth Opportunity Analysis Coverage:By Service Type(Predictive Testing,Carrier Testing,Prenatal Testing,Newborn Screening,and Others),Disease(Cancer,Metabolic Diseases,Cardiovascular Diseases,and Other Diseases),Service Provider(Hospital-Based Laboratories,Diagnostic Laboratories,and Others),and Country 2 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners Table of Content 1.Introduction.11 1.1 The Insight Partners Research Report Guidance.11 1.2 Market Segmentation.12 2.Executive Summary.13 2.1 Key Insights.13 3.Research Methodology.14 3.1 Coverage.15 3.2 Secondary Research.15 3.3 Primary Research.15 4.South&Central America Genetic Testing Services Market-Key Industry Dynamics.17 4.1 Key Market Drivers.17 4.1.1 Rising Prevalence of Genetic Diseases.17 4.1.2 Increasing Awareness and Acceptance of Personalized Medicines.18 4.1.3 Growing Preference for Direct-To-Consumer(DTC)Genetic Testing.18 4.2 Market Restraints.19 4.2.1 Social and Ethical Implications of Genetic Testing.19 4.2.2 Affordability of Genetic Services.19 4.3 Market Opportunities.20 4.3.1 Untapped Emerging Markets in Developing Countries.20 4.4 Future Trends.20 4.4.1 Artificial Intelligence-Powered Genetic Testing.20 4.5 Impact Analysis:.21 5.Genetic Testing Services Market-South&Central America Market Analysis.22 5.1 South&Central America Genetic Testing Services Market Revenue(US$Mn),2022 2030.22 6.South&Central America Genetic Testing Services Market Revenue and Forecast to 2030 by Service Type.23 6.1 Overview.23 6.2 South&Central America Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%).23 6.3 Predictive Testing.24 6.3.1 Overview.24 3 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.3.2 Predictive Testing:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).24 6.4 Carrier Testing.25 6.4.1 Overview.25 6.4.2 Carrier Testing:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).25 6.5 Prenatal Testing.26 6.5.1 Overview.26 6.5.2 Prenatal Testing:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).26 6.6 Newborn Screening.27 6.6.1 Overview.27 6.6.2 Newborn Screening:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).27 6.7 Others.28 6.7.1 Overview.28 6.7.2 Others:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).28 7.South&Central America Genetic Testing Services Market Revenue and Forecast to 2030 by Disease.30 7.1 Overview.30 7.2 South&Central America Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%).30 7.3 Cancer.31 7.3.1 Overview.31 7.3.2 Cancer:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).31 7.4 Cardiovascular Diseases.32 7.4.1 Overview.32 7.4.2 Cardiovascular Diseases:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).32 7.5 Metabolic Diseases.33 7.5.1 Overview.33 7.5.2 Metabolic Diseases:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).33 7.6 Other Diseases.34 7.6.1 Overview.34 7.6.2 Other Diseases:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).34 4 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 8.South&Central America Genetic Testing Services Market Revenue and Forecast to 2030 by Service Provider.36 8.1 Overview.36 8.2 South&Central America Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%).36 8.3 Hospital-Based Laboratories.37 8.3.1 Overview.37 8.3.2 Hospital-Based Laboratories:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).37 8.4 Diagnostic Laboratories.38 8.4.1 Overview.38 8.4.2 Diagnostic Laboratories:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).38 8.5 Others.39 8.5.1 Overview.39 8.5.2 Others:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).39 9.South&Central America Genetic Testing Services Market-Country Analysis.40 9.1 South&Central America.40 9.1.1 South&Central America Genetic Testing Services Market,by Country.40 9.1.1.1 Brazil.41 9.1.1.1.1 Overview.41 9.1.1.1.2 Brazil Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).41 9.1.1.1.3 Brazil Genetic Testing Services Market,by Service Type,20202030(US$Million).42 9.1.1.1.4 Brazil Genetic Testing Services Market,by Disease,20202030(US$Million).42 9.1.1.1.5 Brazil Genetic Testing Services Market,by Service Provider,20202030(US$Million).43 9.1.1.2 Argentina.44 9.1.1.2.1 Overview.44 9.1.1.2.2 Argentina Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).44 9.1.1.2.3 Argentina Genetic Testing Services Market,by Service Type,20202030(US$Million).45 9.1.1.2.4 Argentina Genetic Testing Services Market,by Disease,20202030(US$Million).45 9.1.1.2.5 Argentina Genetic Testing Services Market,by Service Provider,20202030(US$Million).45 5 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.3 Rest of South&Central America.46 9.1.1.3.1 Overview.46 9.1.1.3.2 Rest of South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).46 9.1.1.3.3 Rest of South&Central America Genetic Testing Services Market,by Service Type,20202030(US$Million).47 9.1.1.3.4 Rest of South&Central America Genetic Testing Services Market,by Disease,20202030(US$Million).47 9.1.1.3.5 Rest of South&Central America Genetic Testing Services Market,by Service Provider,20202030(US$Million).48 10.Genetic Testing Services MarketIndustry Landscape.49 10.1 Overview.49 10.2 Growth Strategies in South&Central America Genetic Testing Services Market.49 10.3 Organic Growth Strategies.50 10.3.1 Overview.50 10.4 Inorganic Growth Strategies.52 10.4.1 Overview.52 11.Company Profiles.53 11.1 Eurofins Scientific SE.53 11.1.1 Key Facts.53 11.1.2 Business Description.53 11.1.3 Products and Services.54 11.1.4 Financial Overview.55 11.1.5 SWOT Analysis.56 11.1.6 Key Developments.57 11.2 Exact Sciences Corp.58 11.2.1 Key Facts.58 11.2.2 Business Description.58 11.2.3 Products and Services.58 11.2.4 Financial Overview.59 11.2.5 SWOT Analysis.60 11.2.6 Key Developments.61 11.3 Laboratory Corp of America Holdings.62 11.3.1 Key Facts.62 11.3.2 Business Description.62 11.3.3 Products and Services.62 6 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 11.3.4 Financial Overview.63 11.3.5 SWOT Analysis.64 11.3.6 Key Developments.65 11.4 Quest Diagnostics Inc.66 11.4.1 Key Facts.66 11.4.2 Business Description.66 11.4.3 Products and Services.67 11.4.4 Financial Overview.67 11.4.5 SWOT Analysis.68 11.4.6 Key Developments.69 11.5 Illumina Inc.70 11.5.1 Key Facts.70 11.5.2 Business Description.70 11.5.3 Products and Services.71 11.5.4 Financial Overview.71 11.5.5 SWOT Analysis.72 11.5.6 Key Developments.73 11.6 F.Hoffmann-La Roche Ltd.74 11.6.1 Key Facts.74 11.6.2 Business Description.74 11.6.3 Products and Services.75 11.6.4 Financial Overview.75 11.6.5 SWOT Analysis.77 11.6.6 Key Developments.79 11.7 NeoGenomics Inc.80 11.7.1 Key Facts.80 11.7.2 Business Description.80 11.7.3 Products and Services.80 11.7.4 Financial Overview.81 11.7.5 SWOT Analysis.82 11.7.6 Key Developments.83 12.Appendix.84 12.1 About Us.84 12.2 Glossary of Terms.85 7 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners List of Tables Table 1.South&Central America Genetic Testing Services Market Segmentation.12 Table 2.Brazil Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).42 Table 3.Brazil Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).42 Table 4.Brazil South&Central America Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).43 Table 5.Argentina Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).45 Table 6.Argentina Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).45 Table 7.Argentina Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).45 Table 8.Rest of South&Central America Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).47 Table 9.Rest of South&Central America Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).47 Table 10.Rest of South&Central America Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).48 Table 11.Recent Organic Growth Strategies in South&Central America Genetic Testing Services Market.50 Table 12.Recent Inorganic Growth Strategies in the South&Central America Genetic Testing Services Market.52 Table 13.Glossary of Terms,South&Central America Genetic Testing Services Market.85 8 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners List of Figures Figure 1.South&Central America Genetic Testing Services Market Segmentation,By Country.12 Figure 2.South&Central America Genetic Testing Services Market-Key Industry Dynamics.17 Figure 3.Impact Analysis of Drivers and Restraints.21 Figure 4.South&Central America Genetic Testing Services Market Revenue(US$Mn),2022 2030.22 Figure 5.South&Central America Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%).23 Figure 6.Predictive Testing:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).24 Figure 7.Carrier Testing:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).25 Figure 8.Prenatal Testing:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).26 Figure 9.Newborn Screening:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).27 Figure 10.Others:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).29 Figure 11.South&Central America Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%).30 Figure 12.Cancer:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).31 Figure 13.Cardiovascular Diseases:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).32 Figure 14.Metabolic Diseases:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).33 Figure 15.Other Diseases:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).35 Figure 16.South&Central America Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%).36 Figure 17.Hospital-Based Laboratories:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).37 Figure 18.Diagnostic Laboratories:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).38 9 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 19.Others:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).39 Figure 20.South&Central America Genetic Testing Services Market,by Key Country Revenue,2022(US$Million).40 Figure 21.South&Central America Genetic Testing Services Market,By Key Countries,2022 and 2030(%).40 Figure 22.Brazil Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).41 Figure 23.Argentina Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).44 Figure 24.Rest of South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).46 Figure 25.Growth Strategies in South&Central America Genetic Testing Services Market.49 10 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners NOTES:The list of companies included in the scope are as per standard report format and the list can be modified/expanded as per clients requirement The sequence/list of companies do not represent their current position in the market.The list of countries provided in the report are part of standard report and can be customized as per clients requirement RELATED REPORTS Newborn Genetic Testing Market DTC Genetic Testing Market 11 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 1.Introduction 1.1 The Insight Partners Research Report Guidance The report provides qualitative and quantitative trends of South&Central America genetic testing services market across service type,disease,service provider,and country.The report starts with the key takeaways(chapter 2),highlighting the key trends and outlook of the South&Central America genetic testing services market.Chapter 3 provides the research methodology of the study.Chapter 4 highlights the key industry dynamics in the South&Central America genetic testing services market,including factors that are driving the market,prevailing deterrent,potential opportunities as well as future trends.Impact analysis of these drivers and restraints is also covered in this section.Chapter 5 discusses the South&Central America genetic testing services market scenario,in terms of historical market revenues,and forecast till 2030.Chapter 6 to 9 discuss genetic testing services market segments by service type,disease,service provider,and countries across South&Central America.They cover market revenue forecast,and factors driving and governing growth.Chapter 10 describes the industry landscape analysis.It provides detailed description of various business activities such as market initiatives,new developments,mergers,and joint ventures globally along with a competitive landscape.Chapter 11 provides the detailed profiles of the key companies operating in the South&Central America genetic testing services market.The companies have been profiled on the basis of their key facts,business description,products and services,financial overview,SWOT analysis,and key developments.Chapter 12,i.e.the appendix is inclusive of a brief overview of the company,glossary of terms,contact information,and the disclaimer section.12 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 1.2 Market Segmentation Table 1.South&Central America Genetic Testing Services Market Segmentation SERVICE TYPESERVICE TYPE DISEASEDISEASE SERVICE PROVIDERSERVICE PROVIDER PREDICTIVE TESTING CANCER HOSPITAL-BASED LABORATORIES CARRIER TESTING CARDIOVASCULAR DISEASES DIAGNOSTIC LABORATORIES PRENATAL TESTING METABOLIC DISEASES OTHERS NEWBORN SCREENING OTHER DISEASES OTHERS Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources Figure 1.South&Central America Genetic Testing Services Market Segmentation,By Country Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources The South&Central America genetic testing services market is segmented based on service type,disease,service provider,and country.The segmentation in this research study has been finalized post in-depth secondary research and extensive primary research.In addition,the market is also segmented on the basis of services offered by the leading participants in the industry in order to understand widely used market specific terminologies.Thus,we have incorporated the segments of the research and have finalized the market segmentation.13 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 2.Executive Summary 2.1 Key Insights OverviewMarket SegmentationMarket DynamicsRegional OverviewMarket SegmentationKey PlayersMarket DynamicsCAGR(2022-2030)12.9%Market Size 2022$165.42MnMarket Size 2030$436.36MnService TypeDisease Predictive Testing Carrier Testing Prenatal Testing Newborn Screening Others Cancer Cardiovascular Diseases Metabolic Diseases Other Diseases Laboratory Corporation of America Holdings F.Hoffmann-La Roche Ltd Illumina,Inc.Quest Diagnostics Incorporated Exact Sciences Corp(Genomic Health)Eurofins Scientific Centogene AGGROWTH DRIVERSFUTURE TRENDSGROWTH DRIVERSFUTURE TRENDS Rising Prevalence of Genetic Diseases Increasing Awareness and Acceptance of Personalized Medicines Artificial Intelligence-Powered Genetic TestingRESTRAINTSOPPORTUNITY Social and Ethical Implications of Genetic Testing Affordability of Genetic Services Untapped Emerging Markets in Developing CountriesService Provider Hospital-Based Laboratories Diagnostic Laboratories OthersSOUTH&CENTRALAMERICA12.9 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 3.Research Methodology The Insight Partners dedicated research and analysis team consist of experienced professionals with advanced statistical expertise in market research and consulting backgrounds in in various industries including Aerospace and Defense,Automotive and Transportation,Biotechnology,Chemicals and Materials,Food and Beverages,Electronics and Semiconductor,Healthcare IT,Manufacturing and Construction,Medical Device,Technology,Media and Telecommunications.Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources FinalMarket sizeValidation from Primary InterviewSummation of Revenue Generated from Companies to arrive Total Market SizeRevenue Generated by the Products and Services Offered by Companies in the Genetic Testing Service MarketFinal Market Size Break-Up To Rest Of Segmentation(i.e.,Service Type,Disease,Service Provider,and Region)Arriving at the Market Size of each Segment Validation of Number with Primary Interviews and Subject Matter Expert BOTTOM-UP ANALYSISTOP-DOWN ANALYSIS 15 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners The Insight Partners adheres to the codes of practice of the Market Research Society(www.mrs.org.uk)and Strategic and Competitive Intelligence Professionals(www.scip.org).The following methodology has been followed for the collection and analysis of data presented in this report:3.1 Coverage The objective of updating“The Insight Partners”coverage is to ensure that it represents the most up-to-date vision of the industry possible.The estimated revenues of all major companies,including private and governmental,are gathered and used to prioritize coverage.Companies which are making the news,or which are of particular interest due to their innovative approach,are prioritized.3.2 Secondary Research The research process begins with exhaustive secondary research using internal and external sources to obtain qualitative and quantitative information relating to each Market.The secondary research sources that are typically referred to include,but are not limited to:Company websites,annual reports,financial reports,broker reports and investor presentations Industry trade journals and other literature National government documents,statistical databases and market reports News articles,press releases and web-casts specific to the companies operating in the market NOTE:All the financials considered in Company Profiles section have been standardized to US$.This has been achieved after converting the financials(for those not in US$)with respective currency exchange rates of the particular year.3.3 Primary Research“The Insight Partners”conducts hundreds of primary interviews a year with industry participants and commentators in order to validate its data and analysis.A typical research interview fulfils the following functions:Provides first-hand information on the market size,market trends,growth trends,competitive landscape and future outlook Validates and strengthens secondary research findings Further develops the analysis teams expertise and market understanding 16 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners Primary research involves email interactions and telephone interviews for each market,category,segment and sub-segment across countries.The participants who typically take part in such a process include,but are not limited to:Industry participants:VPs,business development managers,market intelligence managers and national sales managers Outside experts:Valuation experts,research analysts and key opinion leaders specializing in the industry 17 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 4.South&Central America Genetic Testing Services Market-Key Industry Dynamics Figure 2.South&Central America Genetic Testing Services Market-Key Industry Dynamics Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 4.1 Key Market Drivers 4.1.1 Rising Prevalence of Genetic Diseases The prevalence of genetic diseases is rising across the world and impacting the health of people at a severe level.Genetic diseases show many symptoms that are uncommon and are mostly non-curable.Most of the genetic diseases are rare and are developed due to the mutation in the genetic makeup of the people.According to The World Health Organization(WHO)2021,10 out of every 1,000 people are affected by single-gene diseases,signifying that 70 million and 80 million people worldwide are living with any one type of single-gene disease.As per the Global Genes,7,000 known rare diseases and disorders have been identified worldwide,and more are being discovered every year.According to the University of Sheffield research,300 million people are living with genetic diseases around the world.As per studies,around 40 to 50 million in Latin America are living with genetic disorders.Even while a growing number of American nations have passed legislation ensuring people with rare diseases access to diagnosis and treatment,many of them lack the means and expertise to offer quality care.Thus,the rising prevalence of genetic diseases fuels the demand for genetic testing,which in turn drives genetic testing services market growth.DROTDRIVERSRESTRAINTSOPPORTUNITIESTRENDSRising Prevalence of Genetic DiseasesIncreasing Awareness and Acceptance of Personalized MedicinesGrowing Preference for Direct-To-Consumer Genetic TestingSocial and Ethical Implications of Genetic TestingAffordability of Genetic ServicesArtificial Intelligence-Powered Genetic TestingUntapped Emerging Markets in Developing Countries 18 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 4.1.2 Increasing Awareness and Acceptance of Personalized Medicines Personalized medicine is the field that utilizes patients genetic and environmental data to deliver optimal healthcare.It is based on the principle that every patient is unique and requires individualistic pharmacological treatment.Since it is a rapidly evolving area,it is presently incorporated into several healthcare systems.The successful completion of the Human Genome Project(HGP)in 2003 and the fast-decreasing human genome sequencing costs encouraged the development of a new medical approach,which is called personalized medicine.With an expanding repository of personalized data at the molecular level,molecular diagnostics companies are exceptionally positioned to unlock value.Large-scale drug discovery is a key to increasing the viability and usefulness of personalized medicines for the diagnosis of diseases and disorders.Genomics is one of the fastest-growing divisions of medical science.It is driving a paradigm shift in the research methodology of a disease,as well as diagnosing and treating illness.Genetic testing has been extensively used in pharmacogenomics,also known as drug-gene testing.It helps in accelerating drug discovery and its development.In January 2023,The Human Genome Project is ensuring an era of personalized healthcare.Now,new research shows that precision prescribing using genetic testing has ultimately reached a global tipping point for adoption.Published by Cambridge University Press,the peer-reviewed research examines the maturation of critical factors required for the use of clinical genetics at scale.These advancements pave the way for supporting genome-informed clinical decision-making to be established as the new standard of care.Genetically informed prescribing offers one of the realistic mechanisms to successfully reduce the overall costs of the healthcare system and improve individual patient care.Genetic testing encourages the adoption of a personalized medicine approach by understanding the science behind the disease,the impact of treatment,and the development of therapies for specific individual characteristics.It also helps healthcare personnel make informed decisions about disease diagnosis,treatment,and prevention by utilizing genetic testing results,leading to improved patient outcomes.4.1.3 Growing Preference for Direct-To-Consumer(DTC)Genetic Testing Personalized genetic testing and treatment have long been used globally to help individuals and families learn more about hereditary diseases.Most of the time,genetic testing is done through healthcare personnel,such as genetic counselors.Healthcare providers decide which test is needed,order the test from a test center,collect and send the DNA sample,read the test results,and share the results with the patient.Thus,these tests have traditionally been ordered and interpreted in a clinical or medical research setting.In contrast,DTC genetic testing has witnessed tremendous growth in the past decade and is becoming increasingly widespread.A genetic test offered,advertised,and sold by companies directly to the consumer,without the direct involvement of a conventional healthcare system,is called DTC genetic testing.DTC genetic testing is relatively new and helps people find out about the disease-associated genes they may carry without the need for a prescription or guidance from a genetic counselor or medical practitioner.Several consumers of DTC testing view it as another method of gathering medical information about themselves.Unlike other genetic tests performed in clinics or hospitals,the consumer independently initiates and completes a DTC genetic test.The public understanding and acceptance of genetic testing is gradually increasing.Additionally,there is a rise in consumers seeking customized products and experiences for the identification and addressing of unique needs.The launch of innovative products and the increase in the adoption of DTC genetic testing kits have made genetic testing more accessible to people.These kits enable users to undergo personalized health management within the comfort of their homes.19 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners Key industry players are also developing DTC genetic tests and implementing special marketing efforts that positively impact sales of DTC tests.A rising number of manufacturers are providing direct-to-consumer genetic testing that covers various health conditions and traits.The increasing demand for direct-to-consumer genetic testing products to learn about the genetic makeup and assess the risk of developing hereditary conditions for early disease detection or prevention drives the market.4.2 Market Restraints 4.2.1 Social and Ethical Implications of Genetic Testing Genetic testing is poised to play an important role in the practice of obstetrics and gynecology.Physicians are required to become familiar with the presently accessible collection of genetic tests and their limitations to guarantee patients the utmost quality of care.However,the knowledge of genetic risks can result in potential social and psychological consequences for the people undergoing such tests.Socially,knowledge from genetic tests may lead to stigmatization and judgment within the community.Refusing to undergo genetic testing,as well as choosing to undergo genetic testing,can both lead to discrimination and stigmatization,depending on the prevalent public standards concerning acceptance and use of the technology.Privacy and security concerns also arise as the availability and commercialization of personal genetic data can lead to unauthorized access or misuse of sensitive information.The storage of genetic testing data and registries of patients generates concern,given that the results can negatively impact the family members.In addition,lack of informed consent can lead to adverse reactions,such as increased anxiety and unnecessary preventive measures during the disclosure of genetic test results.Lack of proper counseling regarding the information about genetic risk and choices regarding genetic testing and its management can cause potential psychological distress.Therefore,the reluctance of patients to prefer genetic testing due to the social and ethical stigma impedes market growth.4.2.2 Affordability of Genetic Services At present,genetic services are expensive and,therefore,not accessible to all.Genetic research is presently underrepresented in health research;however,studies are being conducted to establish the feasibility of such services.Present inequalities in the affordability and feasibility of genetic services are a cause of concern for the WHO and other prominent international organizations that are centered around public health and development concerns.The cost of the test also increases if more than one test is needed or if multiple family members need to be tested to obtain a significant result.For newborn screening,costs differ as per the state.Several states cover part of the overall cost,although most charge a fee of US$30 to US$150 per infant.Various factors,including the type of test,the complexity of analysis,and laboratory processing fees,influence the cost of these tests.Thus,the high costs,along with its affordability in emerging economies,restrain the market growth.20 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 4.3 Market Opportunities 4.3.1 Untapped Emerging Markets in Developing Countries Emerging countries such as China,India,Brazil,and Mexico offer significant growth opportunities to market players.The high growth can majorly be attributed to the increasing public healthcare expenditure,improving healthcare infrastructure,and the presence of a large target patient population.The need for genetic testing has also increased owing to a rise in awareness of genetic disorders in developing economies and their early diagnosis.The quality and availability of genetic services may differ between high-income countries and low-to middle-income countries.For instance,in the US,Australia,Canada,the UK,and other European countries,genetic services are well-advanced,established,and extensive.These services include newborn screening,carrier identification screening,and prenatal diagnosis.Yet,in many high-income countries,genetic services that are offered in multiple settings still need improved systems of assessment.The ease and applicability of genetic testing procedures have benefitted R&D activities in developing regions worldwide.Major market players are focusing on strategies and initiatives,such as agreements,collaborations,partnerships,and expansions,to improve their product availability,accessibility,and distribution networks in these countries,as it will help them address the growing need for early diagnosis and treatment.For instance,in 2019,GENOMIKA,one of the leading genetic testing laboratories in Brazil,reached an agreement with Veritas to incorporate Whole Genome Sequencing and all the services associated with these tests in the field of preventive medicine and clinical genetics into its portfolio.Therefore,emerging markets in developing countries are expected to offer significant opportunities to the players operating in the market and boost the market growth during the forecast period.4.4 Future Trends 4.4.1 Artificial Intelligence-Powered Genetic Testing Whole-genome sequencing and now whole-exome sequencing have also become more popular.To solve the growing problem of health data exhaust,the field of medicine is increasingly revolving around enhanced clinical tools,such as artificial intelligence(AI)and machine learning,which have been mentioned as a way to improve the acceptance of genomic medicine.Today,many companies have turned to machine learning to process the vast amount of data needed to correctly analyze and understand clinical data in fields such as radiology and cardiology.Many of the consumer-facing genetic testing technologies that are available in the market are using machine learning or AI to function.In numerous ways,genetic testing of diseases is the perfect field for machine learning because of the vast volumes of data that these programs need to struggle with.For example,working on the human genome includes reading billions of bits of information,and prior to the introduction of machine learning,many of these tasks were pretty tricky.AI offers great potential when it comes to analyzing genetic data and supporting clinical specialists in making diagnoses.Google has a program called Deep Variant that can now be used to plot the human genome thoroughly and can be used on the full range of a persons genetic information.Moreover,agencies such as the National Institutes of Health are working on ways through which machine learning and AI can add to a better understanding of genetics and genomics.Furthermore,Blueprint Genetics is using AI in clinical interpretation.Machine learning and AI are acting as a catalyst for faster and more diverse improvement in genetic research and engineering.These tools are simple to integrate and extremely scalable,putting genetic laboratories in a unique position to scale their operations and match the fast growth 21 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners of the genetic testing field.Thus,through the successful integration of these tools,clinicians will be able to diagnose rare genetic diseases more efficiently and effectively,bringing hope to the millions of people affected by them globally.4.5 Impact Analysis:The following figure depicts the impact of factors driving and restraining the South&Central America genetic testing services market.The factors driving the market growth include increasing prevalence of genetic diseases,increasing awareness and acceptance of personalized medicines,and growing preference for direct-to-consumer genetic testing.However,social and ethical implications of genetic testing and affordability of genetic services hinders the market growth.Figure 3.Impact Analysis of Drivers and Restraints Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources Rising Prevalence of Genetic DiseasesGrowing Preference towards for Direct-To-Consumer Genetic TestingSocial and Ethical Implications of Genetic TestingLOWMEDIUMHIGHIncreasing Awareness and Acceptance of Personalized Medicines 22 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 5.Genetic Testing Services Market-South&Central America Market Analysis The South&Central America genetic testing services market in South&Central America is segmented into Brazil,Argentina,and the Rest of South&Central America.The rising prevalence of genetic disease,growing demand for personalized medicines and genetic testing,and increasing technological advancements and product launches are expected to augment the growth of the market.5.1 South&Central America Genetic Testing Services Market Revenue(US$Mn),2022 2030 The South&Central America genetic testing services market is expected to reach US$436.36 million by 2030 from US$165.42 million in 2022.The market is estimated to grow at a CAGR of 12.9%from 2022 to 2030.The factors driving the market growth include the increasing prevalence of genetic diseases,growing preference for direct-to-consumer genetic testing,and increasing awareness and acceptance of personalized medicines.However,social and ethical implications of genetic testing and affordability of genetic services restrain the growth of the market.Figure 4.South&Central America Genetic Testing Services Market Revenue(US$Mn),2022 2030 Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 136.74150.35165.42183.07203.77228.12256.83290.79331.09379.06436.3610.0.0.7.3.9.6.2.9.5.1%0.0%2.0%4.0%6.0%8.0.0.0.0.0 2020212022202320242025202620272028202920300501001502002503003504004505002020-2030Historical YearBase YearForecast Year 23 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.South&Central America Genetic Testing Services Market Revenue and Forecast to 2030 by Service Type 6.1 Overview The South&Central America genetic testing services market,by service type,is segmented into predictive testing,carrier testing,prenatal testing,newborn screening,and others.In 2022,the predictive testing segment held the largest share of the market and is expected to register the highest CAGR in the market during the coming years.6.2 South&Central America Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%)Figure 5.South&Central America Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%)Source:The Insight Partners Analysis The predictive testing segment led the market in 2022 with a share of 41.3%and is expected to retain its dominance during 20222030 by accounting for 45.3%of the total market by 2030.41.3$.0.2.8%7.7 22Predictive TestingCarrier TestingPrenatal TestingNew-born ScreeningOthers45.3$.4.3.8%5.2 30 24 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.3 Predictive Testing 6.3.1 Overview Predictive genetic testing examines any genetic changes or mutations that are linked to disease.These tests are done prior to an individual displaying any signs of a disease.Predictive testing can be helpful to people who have a family history of a treatable genetic disorder and display no signs of illness.This testing can identify mutations that increase an individuals risk of developing disorders with a genetic foundation,such as certain types of cancer.An example is testing for the BRCA1 and BRCA2 gene variants(altered genes)linked with an increased risk of breast cancer.The results of predictive testing can provide information about the probability of developing a specific disorder and help in making decisions about medical care.The increasing demand for genetic counseling is expected to drive the market for predictive testing as more people understand the importance of genetics in disease etiology.The ongoing advancements and upgrading of platforms to improve the efficiency of genome analysis techniques are expected to boost the adoption of predictive testing solutions.A growing focus on reducing the growing healthcare burden of rare genetic diseases and rapid integration of technologies such as artificial intelligence and machine learning will enhance product development and fuel the need for predictive testing to assess and prevent future complications arising from diseases effectively.6.3.2 Predictive Testing:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Predictive testing segment was valued at US$68.29 million in 2022 and is expected to reach US$197.61 million by 2030.The growth rate of this segment is projected to be 14.2%during 20222030.Figure 6.Predictive Testing:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 55.1161.3368.2976.4786.1397.56111.12127.28146.58169.74197.61202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 25 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.4 Carrier Testing 6.4.1 Overview Carrier testing is a kind of genetic test that can tell whether one carries a gene for certain genetic disorders or not.When it is done before or during pregnancy,it helps to find out the chances of having a child with a genetic disorder.Carrier testing is used to identify people carrying one copy of a gene mutation(a genetic change)that,when present in two copies,results in a genetic disorder.Carriers generally do not have symptoms or have only mild symptoms.They often are unaware that they have a gene for a disorder.Carrier screening is offered for a limited number of diseases,including cystic fibrosis,sickle cell disease,fragile X syndrome,and TaySachs disease.A few of these disorders occur commonly in certain ethnic groups.For example,sickle cell disease occurs most frequently in African Americans.TaySachs disease is most common in Eastern or Central European Jewish people,French Canadian people,and Cajun descent.Although,anyone can have one of these disorders as they are not restricted to these groups.With the increasing prevalence of genetic diseases caused by chromosome and gene mutations,carrier testing has grown exponentially.The majority of cases of genetic mutations are due to preexisting conditions,a family history of abortion,or congenital disabilities.Pregnant women often undergo carrier screening in order to determine the risk of transmitting a specific genetic disease to their progeny.In addition,the increasing recognition of the importance of early diagnosis and screening of gene illness fuels the need to develop strategies to tackle these diseases.6.4.2 Carrier Testing:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Carrier testing segment was valued at US$39.72 million in 2022 and is expected to reach US$106.42 million by 2030.The growth rate of this segment is projected to be 13.1%during 20222030.Figure 7.Carrier Testing:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 32.7136.0339.7244.0449.1155.0962.1470.5080.4292.26106.42202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 26 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.5 Prenatal Testing 6.5.1 Overview Genetics can have an impact on the color of a babys eyes and hair and can also result in the development of some birth defects or genetic disorders.This testing helps to detect abnormalities in a fetuss genes or chromosomes and syndromes before birth.Thats why women are regularly offered a wide range of prenatal genetic testing in the first and second trimesters of pregnancy to evaluate the problems in their unborn babies.According to the WHO,congenital disabilities affect 8 million newborns every year.Nine out of every ten children are born with a serious birth defect in low-and middle-income countries.Congenital disabilities can occur at any point through the pregnancy;however,most of them occur during the first trimester when the babys organs are formed.6.5.2 Prenatal Testing:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Prenatal testing segment was valued at US$20.10 million in 2022 and is expected to reach US$45.12 million by 2030.The growth rate of this segment is projected to be 10.6%during 20222030.Figure 8.Prenatal Testing:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 17.2118.6020.1021.8423.8626.2028.9232.0935.7740.0845.12202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 27 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.6 Newborn Screening 6.6.1 Overview A newborn screening test looks for various developmental,genetic,and metabolic disease disorders in the newborn.Newborn screening allows measures to be taken before symptoms develop.Most of these illnesses are extremely rare but can be treated if detected early.The offspring has a high risk of having genetic diseases in cases where the parents have another child with a genetic disease,a family history of a genetic disorder,or if either of a parent has a chromosomal abnormality.Early testing for these conditions allows physicians and parents to take timely measures to manage,treat,or intervene in disease progression,allowing the baby to lead a healthy,normal life.These genetic diseases are also responsible for infant mortality worldwide.For instance,according to the World Health Organization 2023,an estimated 240,000 newborns across the world die within 28 days of birth every year due to congenital disorders.6.6.2 Newborn Screening:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Newborn screening segment was valued at US$24.52 million in 2022 and is expected to reach US$64.50 million by 2030.The growth rate of this segment is projected to be 12.9%during 20222030.Figure 9.Newborn Screening:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 20.2922.3024.5227.1330.1833.7838.0243.0348.9756.0564.50202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 28 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.7 Others 6.7.1 Overview The others segment is comprised of preimplantation testing and pharmacogenomics.These tests are performed to screen for genetic disorders.Pharmacogenomics testing is a type of genetic test that is used to identify the right medication for a person.Pharmacogenomics is one of the key emerging trends in the field of medical science,which significantly impacts the drug development process.With the use of pharmacogenomics,target identification by drugs has become comparatively easy,which confirms much higher chances of success for the approval of drugs.Currently,various ongoing initiatives of pharmacogenomics implementation have been launched in the US,Europe,and Asia.In the US,27 institutions are involved in programs that are applying pharmacogenomics,some of which have been using it for over ten years.In 2007,a wide network of several associations was introduced with the creation of the Electronic Medical Records and Genomics(eMERGE)Network.Afterward,they started a study named eMERGE-PGx together with the Pharmacogenomics Research Network(PGRN),with the aim of testing genetic variation in 82 pharmacogenes through targeted sequencing.Moreover,since September 2010,with the Vanderbilt Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment program(PREDICT),more than 10,000 patients have undergone preemptive,panel-based pharmacogenomic testing.In 2011,PGRN also commenced the Translational Pharmacogenetics Program to assess PGx implementation in routine care by identifying barriers and developing solutions.Preimplantation genetic testing is also for couples who are at risk of having a child with a specific genetic or chromosome disorder,e.g.,cystic fibrosis or sickle cell disease.In this procedure,egg cells are removed from the womans ovaries and fertilized with sperm cells outside the body.The fertilized embryos develop for three days,and subsequently,one or two cells are removed from each embryo.The genetic material(DNA and chromosomes)from the cells is tested for the genetic disorder in the family history.One or two of the unaltered embryos are then relocated into the mothers womb(uterus).If the pregnancy is successful,the baby will not be affected by the disorder it was tested for.6.7.2 Others:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Others segment was valued at US$12.79 million in 2022 and is expected to reach US$22.71 million by 2030.The growth rate of this segment is projected to be 7.4%during 20222030.29 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 10.Others:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 11.4212.0912.7913.5814.4815.4916.6317.9119.3420.9422.71202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 30 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 7.South&Central America Genetic Testing Services Market Revenue and Forecast to 2030 by Disease 7.1 Overview The South&Central America genetic testing services market,by disease,is segmented into cancer,cardiovascular diseases,metabolic diseases,and other diseases.In 2022,the cancer segment held the largest share of the market and is anticipated to grow at the highest CAGR during the coming years.7.2 South&Central America Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%)Figure 11.South&Central America Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%)Source:The Insight Partners Analysis The cancer segment led the market in 2022 with a share of 45.0%and is expected to retain its dominance during 20222030 by accounting for 48.2%of the total market by 2030.45.0.5.1.4 22CancerCardiovascularDiseasesMetabolic DiseasesOther Diseases48.2#.3.6.9 30 31 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 7.3 Cancer 7.3.1 Overview Genetic testing is a potential tool to identify individuals who are at higher risk for developing certain cancers because of family history.Genetic tests are available to examine inherited variants and alterations in the DNA sequence,which could result in excessive cell growth and can cause tumors or cancer.For example,genetic testing for the detection of PALB2(linked with increased risks of breast and pancreatic cancers),BRIP1(ovarian cancer),RAD51C and RAD51D(ovarian cancer),and CHEK2(breast and colorectal cancers).The worldwide growing prevalence of various cancers,such as breast,lung,and bowel,are the major drivers of this segment.7.3.2 Cancer:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Cancer segment was valued at US$74.41 million in 2022 and is expected to reach US$210.33 million by 2030.The growth rate of this segment is projected to be 13.9%during 20222030.Figure 12.Cancer:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 60.4167.0274.4183.0893.29105.36119.65136.64156.91181.18210.33202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 32 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 7.4 Cardiovascular Diseases 7.4.1 Overview Heart diseases are a prominent cause of death worldwide and often run in families.In addition,as per the World Heart Federation 2023,rare cardiovascular diseases(CVD)are common,affecting 5%of the global population.There are over 6,000 known rare diseases,a handful of which impact the heart and circulatory system.And 83%of physicians agree that genetic testing is useful in finding the diagnosis.Certain CVD conditions,such as cardiomyopathy,arrhythmia,and connective tissue disease,are caused by a single harmful DNA variation(or mutation).However,others,such as heart attack and high blood pressure,are usually caused by the combined effect of many smaller-impact DNA variations.More than 1 in 200 people have an inherited form of CVD disease,but most are unaware of it.Patients with an inherited cardiovascular condition display few or no symptoms but still face significant risk of heart disease,including sudden cardiovascular arrest.Genetic testing can help save lives and is informative and useful for the clinical management and treatment of numerous inherited CVDs.7.4.2 Cardiovascular Diseases:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Cardiovascular diseases segment was valued at US$37.24 million in 2022 and is expected to reach US$101.88 million by 2030.The growth rate of this segment is projected to be 13.4%during 20222030.Figure 13.Cardiovascular Diseases:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 30.5033.6937.2441.4046.3052.0758.8966.9876.6188.10101.88202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 33 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 7.5 Metabolic Diseases 7.5.1 Overview Diagnosis through genetic testing can strongly help discover the cause of persistent,often debilitating,undiagnosed signs in individuals suffering from suspected genetic metabolic disease disorders.With knowledge of variants in over 1,250 metabolic disease disorders genes,the rapid testing and experience of metabolic diseases can help to diagnose and manage the patients metabolic disease disorders quickly and correctly.Ultimately,this can provide new insights into treatment choices and the probability of passing the inherited condition on to the offspring or the presence of it elsewhere in the extended family.CentoICU is a comprehensive next-generation sequencing panel that includes genes explicitly chosen for the genetic testing of extremely ill newborns and children under 24 months in intensive care units.In addition,Prevention Genetics offers a wide variety of genetic testing for inherited metabolic disease disorders,also known as inborn errors of metabolism.Panels specific to one disorder are available,as well as comprehensive metabolic diseases panels that cover broader phenotypic features or groups of similar disorders are also offered,including tests for hyperammonemia(37 genes),metabolic diseases hypoglycemia(38 genes),and metabolic diseases myopathies,rhabdomyolysis,and exercise intolerance(83 genes).Over the past year,the company has started to offer several new tests related to these metabolic disorders,and many of the existing panels have been updated to include more genes and increase clinical sensitivity.7.5.2 Metabolic Diseases:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Metabolic diseases segment was valued at US$28.23 million in 2022 and is expected to reach US$72.41 million by 2030.The growth rate of this segment is projected to be 12.5%during 20222030.Figure 14.Metabolic Diseases:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 23.5125.7628.2331.1334.5338.5243.2248.7655.3263.1272.41202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 34 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 7.6 Other Diseases 7.6.1 Overview The others segment by disease comprises Duchenne Muscular Dystrophy(DMD),Thalassemia,Huntingtons Disease,and Fragile X Syndrome,among others.Genetic mutations that cause DMD fail to produce dystrophin protein.Recessive diseases caused by alterations in genes on the X chromosome include DMD and fragile X syndrome.Genetic testing is used to diagnose Duchenne,to access mutation-specific therapies,and for family planning.For Duchenne,the dystrophin gene is examined to detect the presence of any changes or mutations that can inhibit the gene from working properly.Genetic testing is generally performed on a blood or saliva sample.A thalassemia is a group of inherited,genetic blood disorders that occur when the production of hemoglobin is disrupted.The disease is passed to children by parents carrying the mutated thalassemia gene.A kid who inherits one mutated gene is a carrier,and most carriers lead a completely normal and healthy life.At the same time,a child who inherits two thalassemia trait genes,i.e.,one from each parent,will have the disease.A child of two carriers has a 25 percent chance of developing the disease and a 50 percent chance of being a carrier.Thus,in such cases,genetic testing is helpful in detecting and diagnosing thalassemia.Currently,two major approaches are used in DNA diagnosis and study of genetic disease,namely direct tests and indirect tests(linkage analysis).Direct tests are being conducted for thalassemia and DMD.Carrier testing can be conducted for X-linked recessive disorders,such as DMD or fragile X syndrome.In these cases,the mother of an affected child with no other affected relatives may desire carrier testing to confirm whether the disease is a heritable trait or a new mutation.Many diseases may become apparent only in middle age or later.Predictive or presymptomatic testing and screening can provide symptoms that people may later develop these disorders.In some cases,a family history of a monogenic disorder in a relative informs other members of the family that they are at high risk for developing the disease.Suitable genetic testing can help to resolve whether the mutant gene is present or not.Examples include Huntingtons disease.7.6.2 Other Diseases:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Other diseases segment was valued at US$25.54 million in 2022 and is expected to reach US$51.75 million by 2030.The growth rate of this segment is projected to be 9.2%during 20222030.35 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 15.Other Diseases:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 22.3223.8825.5427.4529.6532.1835.0838.4142.2546.6651.75202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 36 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 8.South&Central America Genetic Testing Services Market Revenue and Forecast to 2030 by Service Provider 8.1 Overview The South&Central America genetic testing services market,by service provider,is segmented into hospital-based laboratories,diagnostic laboratories,and others.In 2022,the hospital-based laboratories segment held the largest share of the market and is estimated to grow at the highest CAGR during 20222030.8.2 South&Central America Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%)Figure 16.South&Central America Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%)Source:The Insight Partners Analysis The hospital-based laboratories segment led the market in 2022 with a share of 62.9%and is expected to retain its dominance during 20222030 by accounting for 68.0%of the total market by 2030.62.9$.3.8 22Hospital-BasedLaboratoriesDiagnosticLaboratoriesOther End Users68.0$.2%7.8 30 37 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 8.3 Hospital-Based Laboratories 8.3.1 Overview Hospital-based laboratories are genetic testing service providers that operate within a hospital setting.For extremely specialized tests,samples may go to a research laboratory.Nearly all hospitals contain a laboratory,which is commonly proportionate in size to the population it serves.The hospitals process hundreds of samples in very les time.Tests that are performed include those needed in emergencies,such as markers for heart attack and tests where results are required rapidly for patient care.They may also offer carrier testing to determine if an individual is carriers of certain genetic conditions that can be passed on to their children.Hospital laboratories can be segmented by type of testing and staffed by personnel trained in particular specialties.For instance,some sections can focus on microbiology,hematology,chemistry,and blood banking.At the same time,some units may perform highly specialized genetic tests using electron microscopy and immunohistochemistry,and others can focus on surgical pathology and cytology,which are all linked with the investigation of cell and tissue structure.The market growth for the segment can be due to the compulsory newborn screening for genetic disorders and the growing prevalence of cancer in many regions.Seattle Childrens Hospital in Washington,Wyoming,Alaska,Montana,and Idaho(WWAMI)region provides comprehensive genetic testing and consultative services to healthcare workers and families.Their genetics laboratories consist of molecular genetics,cytogenetics,biochemical genetics,and a research and development laboratory devoted to bringing the most existing and specific research tests into the clinical field.Overall,these laboratories play a crucial role in helping to diagnose genetic disorders,guide treatment decisions,and improve patient outcomes.8.3.2 Hospital-Based Laboratories:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Hospital-based laboratories segment was valued at US$104.07 million in 2022 and is expected to reach US$296.68 million by 2030.The growth rate of this segment is projected to be 14.0%during 20222030.Figure 17.Hospital-Based Laboratories:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 84.3293.65104.07116.32130.76147.83168.06192.13220.86255.29296.68202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 38 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 8.4 Diagnostic Laboratories 8.4.1 Overview Diagnostics laboratories are independent entities that provide all the diagnostic tests,screening tests,and others to the patient.These centers may be found attached to a private or public hospital.The tests performed in the diagnostic centers are obtained earlier than hospitals.The diagnostic centers also offer packages for whole-body check-ups that are cost-effective for the patients.Tests such as cell-free fetal DNA testing,triple or quadruple screening tests,sequential screening,and others require advanced techniques,equipment,and skilled labor.However,some of the hospitals and clinics do not have all the required equipment and techniques for efficient diagnosis.Therefore,various hospitals and clinics prefer to outsource tests to diagnostics centers.The diagnostics centers are well equipped and offer better results for the tests performed for diseases and health conditions.The diagnostic centers provide multiple tests under one roof and offer all the prenatal diagnostics services such as screening,imaging,blood tests,chorionic villus sampling,and amniocentesis.Thus,it becomes easier for people to undergo genetic testing in such facilities.The growing partnerships and collaboration of diagnostic laboratories with genetic testing companies and the rise in the incidences of genetic diseases across the world are anticipated to offer growth to the market.For instance,Thermo Fisher Scientific allows laboratories to perform different genetic research and genetic testing by offering technologies such as NGS and quantitative PCR.8.4.2 Diagnostic Laboratories:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Diagnostic laboratories segment was valued at US$40.17 million in 2022 and is expected to reach US$105.70 million by 2030.The growth rate of this segment is projected to be 12.9%during 20222030.Figure 18.Diagnostic Laboratories:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 33.2136.5140.1744.4549.4755.3662.3170.5380.2791.87105.70202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 39 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 8.5 Others 8.5.1 Overview The others segment by service provider comprises academic and research institutions,pharmaceutical and biotechnology companies,and government agencies.Government agencies use genetic testing services to evaluate drugs for regulatory compliance for public health monitoring and research initiatives.Academic and research institutions are integral to the South&Central America genetic testing services market.They help in identifying genetic markers,developing new genetic testing methodologies,and improving existing tests.These institutions validate and ensure the quality of genetic tests through rigorous studies,establishing their reliability and credibility.Clinical trials and studies conducted by these institutions provide essential evidence on the clinical utility and effectiveness of genetic tests.Their expertise and research efforts advance the growth of the market,benefiting both patients and healthcare providers.In addition,research and academic institutes are among the leading users of genetic testing services.Academic institutes for medical sciences and biotechnology utilize analytical testing services to support their studies on drugs.Thus,the increasing demand for genetic testing services from government agencies and research institutes will likely continue to drive the South&Central America genetic testing services market for the segment.8.5.2 Others:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Others segment was valued at US$21.18 million in 2022 and is expected to reach US$33.97 million by 2030.The growth rate of this segment is projected to be 6.1%during 20222030.Figure 19.Others:South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 19.2120.1821.1822.3023.5424.9326.4628.1329.9531.9033.97202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 40 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.South&Central America Genetic Testing Services Market-Country Analysis 9.1 South&Central America Figure 20.South&Central America Genetic Testing Services Market,by Key Country Revenue,2022(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 9.1.1 South&Central America Genetic Testing Services Market,by Country Figure 21.South&Central America Genetic Testing Services Market,By Key Countries,2022 and 2030(%)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources SOUTH&CENTRAL AMERICA(2022)31.8031.48102.14Rest of South&Central AmericaArgentinaBrazil61.7.0.2 22BrazilArgentinaRest of South&CentralAmerica66.1.8.1 30 41 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.1 Brazil 9.1.1.1.1 Overview The rising prevalence of genetic disease,along with chronic illness,is the primary factor driving the growth of the genetic testing market in Brazil.As per a study titled Medical genetics workforce in Brazil:practitioners,services,and disease distribution,published in 2021,in 20192020,53,746 live births were with rare genetic diseases,and 498 live births were with a hereditary cancer syndrome in Brazil.Similarly,as per a study titled The Brazilian Rare Genomes Project,published in May 2022,13.2 million individuals were affected by rare diseases in Brazil.In addition,the growing demand for personalized medicines and genetic testing to detect and treat such conditions fuels the market.The introduction of technology in disease diagnosis,the focus of industry players in developing new molecular diagnostic techniques to provide faster results with high accuracy,and strategic initiatives by the manufacturers will favor the growth of the market.In 2019,GENOMIKA,one of the leading genetic testing laboratories in Brazil,reached an agreement with Veritas to incorporate Whole Genome Sequencing and all the services associated with these tests in the field of preventive medicine and clinical genetics into its portfolio.9.1.1.1.2 Brazil Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Brazil genetic testing services market accounted for US$102.14 Mn in 2022 and it is expected to grow at a CAGR of 13.9%during the period 2022-2030,to reach US$288.60 Mn in 2030.Figure 22.Brazil Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 82.9392.01102.14114.04128.06144.61164.23187.54215.34248.62288.60202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 42 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.1.3 Brazil Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 2.Brazil Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 36.46 40.81 45.70 51.46 58.28 66.37 76.01 87.53 101.34 117.96 138.04 14.8rdiovascular Diseases 18.34 20.44 22.79 25.56 28.82 32.69 37.28 42.75 49.30 57.16 66.63 14.4%Metabolic Diseases 14.18 15.69 17.38 19.35 21.68 24.42 27.67 31.52 36.10 41.57 48.14 13.6%Others 13.95 15.07 16.28 17.67 19.28 21.13 23.27 25.74 28.61 31.93 35.79 10.4%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The South&Central America genetic testing services market for the cancer segment was worth US$45.70 million in 2022 and is projected to reach US$138.04 million by 2030;it is expected to grow at a CAGR of 14.8%from 2022 to 2030.9.1.1.1.4 Brazil Genetic Testing Services Market,by Disease,20202030(US$Million)Table 3.Brazil Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 51.04 57.25 64.24 72.48 82.25 93.85 107.68 124.22 144.07 168.00 196.95 15.0%Diagnostic Laboratories 20.16 22.33 24.75 27.59 30.93 34.87 39.54 45.07 51.67 59.56 69.03 13.7%Others 11.73 12.43 13.16 13.97 14.88 15.90 17.02 18.25 19.60 21.06 22.63 7.0%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The South&Central America genetic testing services market for the hospital-based laboratories segment was worth US$64.24 million in 2022 and is projected to reach US$196.95 million by 2030;it is expected to grow at a CAGR of 15.0%from 2022 to 2030.43 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.1.5 Brazil Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 4.Brazil South&Central America Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 10.60 11.79 13.12 14.68 16.52 18.70 21.28 24.34 28.01 32.40 37.67 14.1rrier Testing 6.26 6.88 7.56 8.37 9.31 10.42 11.73 13.28 15.11 17.30 19.90 12.9%Prenatal Testing 3.44 3.70 3.99 4.33 4.72 5.17 5.70 6.31 7.02 7.86 8.84 10.4%Newborn Screening 3.95 4.33 4.75 5.24 5.81 6.49 7.28 8.21 9.32 10.63 12.20 12.5%Others 1.86 1.96 2.05 2.16 2.28 2.42 2.57 2.73 2.91 3.11 3.32 6.2%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The South&Central America genetic testing services market for the predictive testing segment was worth US$13.12 million in 2022 and is projected to reach US$37.67 million by 2030;it is expected to grow at a CAGR of 14.1%from 2022 to 2030.44 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.2 Argentina 9.1.1.2.1 Overview According to the data published by the International Agency for Research on Cancer,Argentina is facing alarming cancer problems.The source has stated that every 60 minutes,15 people are diagnosed with a type of cancer.Every year,129,000 new cases are registered in the country.According to The Global Cancer Observatory,in 2020,130,878 new cases of cancer were reported in the country in both genders,with 70,074 deaths.The country has the highest incidences of cervical,colorectal,and breast cancers.According to GLOBOCAN 2020,there were 15,895 new colorectal cancer cases in the country,representing 12.1%of all new cancer cases in both genders,including 13%in males and 10%in females among overall cancer cases in the country.Nearly 30 genes are associated with hereditary colon cancer,for which clinical testing is offered.This interprets to thousands of genetic mutations that can result in a predisposition to developing colon cancer.Down syndrome is a genetic disorder triggered by abnormal cell division that causes an additional full or partial copy of the chromosome.According to the National Registry of Congenital Anomalies(RENAC)published in March 2022,120 children are born yearly in the country with Down syndrome,which arises from a prevalence of 17.26 per 10,000 births,signifying a population of 5,000 individuals in the country.Genetic tests help to detect genetic abnormalities in the fetus,such as Down syndrome.9.1.1.2.2 Argentina Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Argentina genetic testing services market accounted for US$31.48 Mn in 2022 and it is expected to grow at a CAGR of 12.7%during the period 2022-2030,to reach US$81.93 Mn in 2030.Figure 23.Argentina Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 26.1128.6631.4834.7838.6543.1948.5554.8862.3871.2981.93202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 45 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.2.3 Argentina Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 5.Argentina Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 10.60 11.79 13.12 14.68 16.52 18.70 21.28 24.34 28.01 32.40 37.67 14.1rrier Testing 6.26 6.88 7.56 8.37 9.31 10.42 11.73 13.28 15.11 17.30 19.90 12.9%Prenatal Testing 3.44 3.70 3.99 4.33 4.72 5.17 5.70 6.31 7.02 7.86 8.84 10.4%Newborn Screening 3.95 4.33 4.75 5.24 5.81 6.49 7.28 8.21 9.32 10.63 12.20 12.5%Others 1.86 1.96 2.05 2.16 2.28 2.42 2.57 2.73 2.91 3.11 3.32 6.2%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The South&Central America genetic testing services market for the predictive testing segment was worth US$13.12 million in 2022 and is projected to reach US$37.67 million by 2030;it is expected to grow at a CAGR of 14.1%from 2022 to 2030.9.1.1.2.4 Argentina Genetic Testing Services Market,by Disease,20202030(US$Million)Table 6.Argentina Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 11.53 12.80 14.23 15.90 17.87 20.20 22.96 26.25 30.16 34.85 40.48 14.0rdiovascular Diseases 5.84 6.46 7.15 7.96 8.91 10.04 11.36 12.94 14.82 17.06 19.74 13.5%Metabolic Diseases 4.45 4.86 5.31 5.84 6.46 7.18 8.04 9.04 10.22 11.62 13.29 12.1%Others 4.29 4.53 4.79 5.07 5.40 5.77 6.19 6.65 7.18 7.77 8.42 7.3%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The South&Central America genetic testing services market for the cancer segment was worth US$14.23 million in 2022 and is projected to reach US$40.48 million by 2030;it is expected to grow at a CAGR of 14.0%from 2022 to 2030.9.1.1.2.5 Argentina Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 7.Argentina Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 16.23 18.00 19.97 22.28 25.01 28.23 32.03 36.56 41.95 48.40 56.15 13.8%Diagnostic Laboratories 6.32 6.95 7.65 8.47 9.44 10.57 11.91 13.50 15.38 17.61 20.29 13.0%Others 3.56 3.71 3.86 4.02 4.20 4.39 4.60 4.82 5.05 5.28 5.50 4.5%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 46 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners The South&Central America genetic testing services market for the hospital-based laboratories segment was worth US$19.97 million in 2022 and is projected to reach US$56.15 million by 2030;it is expected to grow at a CAGR of 13.8%from 2022 to 2030.9.1.1.3 Rest of South&Central America 9.1.1.3.1 Overview Chile,Colombia,Peru,Cuba,Venezuela,and Bolivia are the main countries contributing to the market growth in the Rest of South&Central America.According to GLOBOCAN data,Colombia registered 1.13 million cancer cases in 2020.According to GLOBOCAN 2020 data,Chile recorded 6,219 new colorectal cancer cases,representing 11.5%of all new cancer cases in both genders,and Peru recorded 4,636 new colorectal cancer cases in all ages.In Chile and Peru,colorectal cancer is among the top five most frequently occurring cancers,excluding non-melanoma skin cancer,in both genders.Colorectal cancer ranks as the second leading cause of cancer in both males(after prostate cancer)and females(after breast cancer)in Chile.In addition,in Peru,colorectal cancer ranks as the third leading cause of male cancer.With growing cases of cancer,the need for genetic testing helps in early detection of the chances of inheriting cancer.Technological advancements and product launches are expected to fuel the growth of the market further.For instance,Myriad Genetics introduced a polygenic breast cancer risk assessment score,MyRisk Hereditary Cancer test with RiskScore,worldwide,including in South America.The test is authenticated for women of all ancestries,along with the markets extended access to genetic cancer testing in August 2021.This test makes it easier to understand the current and possible complications of this genetic disorder.Henceforth,it is extensively accepted as a suitable approach for genetic testing.Thus,due to the factors above,the market for genetic testing services is expected to witness significant growth during 20222030.9.1.1.3.2 Rest of South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)The Rest of South&Central America genetic testing services market accounted for US$31.80 Mn in 2022 and it is expected to grow at a CAGR of 9.5%during the period 2022-2030,to reach US$65.82 Mn in 2030.Figure 24.Rest of South&Central America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 27.7029.6831.8034.2437.0640.3144.0648.3853.3759.1465.82202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 47 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.3.3 Rest of South&Central America Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 8.Rest of South&Central America Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 11.48 12.40 13.39 14.54 15.85 17.38 19.14 21.17 23.53 26.27 29.46 10.4rrier Testing 7.03 7.54 8.09 8.72 9.44 10.28 11.25 12.36 13.65 15.14 16.87 9.6%Prenatal Testing 2.98 3.17 3.37 3.60 3.87 4.18 4.53 4.94 5.41 5.95 6.57 8.7%Newborn Screening 3.45 3.69 3.94 4.23 4.56 4.94 5.39 5.90 6.49 7.16 7.95 9.2%Others 2.76 2.88 3.01 3.16 3.33 3.53 3.75 4.00 4.29 4.61 4.97 6.5%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The South&Central America genetic testing services market for the predictive testing segment was worth US$13.39 million in 2022 and is projected to reach US$29.46 million by 2030;it is expected to grow at a CAGR of 10.4%from 2022 to 2030.9.1.1.3.4 Rest of South&Central America Genetic Testing Services Market,by Disease,20202030(US$Million)Table 9.Rest of South&Central America Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 12.43 13.42 14.48 15.72 17.14 18.78 20.68 22.87 25.42 28.37 31.80 10.3rdiovascular Diseases 6.31 6.79 7.30 7.88 8.56 9.34 10.24 11.29 12.49 13.89 15.50 9.9%Metabolic Diseases 4.88 5.20 5.54 5.94 6.39 6.91 7.51 8.21 9.00 9.92 10.98 8.9%Others 4.08 4.27 4.48 4.71 4.97 5.28 5.62 6.01 6.46 6.97 7.54 6.7%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The South&Central America genetic testing services market for the cancer segment was worth US$14.48 million in 2022 and is projected to reach US$31.80 million by 2030;it is expected to grow at a CAGR of 10.3%from 2022 to 2030.48 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.3.5 Rest of South&Central America Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 10.Rest of South&Central America Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 17.05 18.41 19.87 21.56 23.50 25.75 28.35 31.36 34.84 38.88 43.58 10.3%Diagnostic Laboratories 6.73 7.23 7.77 8.38 9.10 9.92 10.87 11.96 13.22 14.69 16.39 9.8%Others 3.92 4.04 4.16 4.30 4.46 4.64 4.84 5.06 5.30 5.57 5.85 4.3%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The South&Central America genetic testing services market for the hospital-based laboratories segment was worth US$19.87 million in 2022 and is projected to reach US$43.58 million by 2030;it is expected to grow at a CAGR of 10.3%from 2022 to 2030.49 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 10.Genetic Testing Services MarketIndustry Landscape 10.1 Overview The developments in the South&Central America genetic testing services market have been characterized by organic and inorganic growth strategies.Various companies are focusing on organic growth strategies such as launches,expansion,enhancement,and relocation.Inorganic growth strategies witnessed in the market include mergers&acquisitions,partnerships,and collaborations.These activities have paved the way for the expansion of business and the customer base of market players.Additionally,growth strategies such as acquisitions and partnerships helped in strengthening their customer base and increase the product portfolio.The companies have maximized their growth with several inorganic strategies to enhance the market value and position in the market.The organic developments hold 73.33%of the total strategic developments in the market.Whereas the inorganic strategies helped by 26.67%for the growth of the companies.10.2 Growth Strategies in South&Central America Genetic Testing Services Market Figure 25.Growth Strategies in South&Central America Genetic Testing Services Market Source:The Insight Partners Analysis 26.67s.33%Inorganic StrategiesOrganic Strategies 50 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 10.3 Organic Growth Strategies 10.3.1 Overview Various companies have adopted organic growth strategies in genetic testing services market.Some of the activities that have helped the companies promote their growth are launches,expansion,relocation activities.23andMe Holding Co is among the companies that have been implementing organic strategies,which,in turn,have brought about various changes in the global health economics and outcomes research services market.The companies have utilized strategies such as new product launch to expand their geographic reach and capacity to cater to a large number of customers.Some of the organic developments are listed below.Table 11.Recent Organic Growth Strategies in South&Central America Genetic Testing Services Market CompanyCompany Month&YearMonth&Year CategoryCategory DescriptionDescription 23andMe Holding Co Nov-2023 Product Launch 23andMe Holding Co launched 23andMe Total Health,a new membership that offers that provides clinical grade exome sequencing,biannual blood testing,and access to genetics-based clinical care.Illumina Inc.Nov-2023 Company News Illumina Inc.announced the launch of the Global Health Access Initiative.It is anticipated that the effort will help low-and middle-income nations have access to pathogen sequencing tools for public health.The program will address major international logistics and supply chain challenges and offer discounted pricing structures for Illuminas eligible sequencing products to qualified global health funding entities.It was developed with input from customers,funders,and market facilitators,including the nonprofit FIND.23andMe Holding Co Oct-2023 Product Launch 23andMe Holding Co launched Health Action Plan,a new digital tool that utilizes results from genetic reports,health history survey data,and blood and biomarker data to provide a tailored set of health recommendations to its members.CENTOGENE Oct-2023 Product Launch The company expanded its Multiomic Diagnostic Portfolio with incorporation of transcriptomic analysis.It allows to combine DNA sequencing,biochemical testing,and RNA sequencing to improve testing capability.NeoGenomics Inc Oct-2023 Product Launch NeoGenomics Inc launched two new tests to expand its portfolio of cancer products including Early-stage Non-Small Cell Lung Cancer Panel and the Neo Comprehensive-Heme Cancers Panel.Quest Diagnostics Inc Jul-2023 Product Launch Quest Diagnostics Inc announced launch of first consumer-initiated genetic test,Genetic Insights.The test can be accessed at via its consumer health business.With the launch of advanced technology and end-to-end support,including personalized health reports and genetic counseling,consumers will be able to understand their potential risk of having certain inheritable health issues.Laboratory Corp of America Holdings Jun-2023 Company News Laboratory Corp of America Holdings announced it has completed the spin-off of Fortrea.Fortrea was the companys newly formed independent Contract Research Organization that provides Phase I-IV clinical trial management,patient access,and technology solutions to pharmaceutical and biotechnology organizations globally.After the spin-off,Fortrea will be enlisted as a new entity and will begin trading on the NASDAQ Stock Market under the symbol FTRE effective from July 3,2023.51 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners CompanyCompany Month&YearMonth&Year CategoryCategory DescriptionDescription CENTOGENE Apr-2023 Product Launch The company released FilterTool,a web-based application for interpreting genetic data.FilterTool connects with CentoCloud to effectively show,filter,select,and categorize pertinent genetic variations found through Next Generation Sequencing(NGS)data processing.Ambry Genetics Corp Nov-2022 Product News Ambry Genetics Corp launched a reproductive health program.It driven by its Comprehensive Assessment Risk and Education program,which is a digital platform that enhances the patient and provider experience through easier access to genetic education,testing,reporting and counseling.Eurofins Scientific Sep-2022 Product Launch The niPGT-A screening test aims to enable in vitro fertilization centers to produce quality embryo samples,avoiding the need for embryo biopsies.It will allow medical practitioners to determine chromosomal abnormalities in in vitro fertilization embryos,which may lead to complications during pregnancy.Eurofins Scientific Feb-2022 Expansion Eurofins Scientifics subsidiary,Eurofins Clinical Testing Lux Sarl,acquired Genetic Testing Service JSC,located in Vietnam.Through this acquisition,the company aims to expand its network in Asia and strengthen its global network of clinical diagnostic laboratories,which primarily focus on specialized and advanced genetic testing.Source:The Insight Partners Analysis 52 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 10.4 Inorganic Growth Strategies 10.4.1 Overview The inorganic growth strategies undertaken by the companies operating in the global market of genetic testing services include collaboration,partnership,agreement&joint venture.During 20202022,companies such as Ambry Genetics Corp has undertaken various inorganic strategies that have bought about remarkable developments in the South&Central America genetic testing services market due to the involvement of major players which has led to availability of better products in the market.Table 12.Recent Inorganic Growth Strategies in the South&Central America Genetic Testing Services Market CompanyCompany Month&YearMonth&Year CategoryCategory DescriptionDescription 23andMe Holding Co Oct-2023 Collaboration 23andMe Holding Co announced a non-exclusive data license collaboration with GSK plc,which enables GSK to conduct drug target discovery and other research using the 23andMe database.Ambry Genetics Corp Apr-2023 Collaboration Ambry Genetics Corp collaborated with LifeStrands Genomics to offer clinical genetic testing services in Singapore.Both the companies will support the Clinical Implementation Pilots(CIPs)for Phase II of Singapores National Precision Medicine(NPM)programme.Ambry Genetics Corp Jan-2023 Partnership Ambry Genetics Corp partnered with Unilabs to enhance genetic testing services for biopharma businesses in Europe,Latin America,and the Middle East,where it does not have a physical presence.It will cater to these markets by utilizing Unilabs genomic lab services and variant interpretation skills.Ambry,on the other hand,will provide Unilabs with its variant assessment skills.Exact Sciences Jan-2022 Mergers and Acquisitions Exact Sciences has acquired PreventionGenetics,a genetic testing laboratory,to accelerate the availability of hereditary cancer testing for more patients.Source:The Insight Partners Analysis 53 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 11.Company Profiles 11.1 Eurofins Scientific SE 11.1.1 Key Facts Eurofins Scientific SEEurofins Scientific SE Founded 1987 Corporate Address 23 Val Fleuri,L-1526,Luxembourg Headquarter Luxembourg Telephone 32 2 7661620 URL Location Global Exchange Ticker Symbol XLUX:ERF Number of Employees 61,379 Fiscal Year End Dec-2022 11.1.2 Business Description Eurofins Scientific SE is a life sciences company that provides analytical testing services to clients in various industries.It provides forensic services,food and feed testing,environmental testing,biopharma services,pharma discovery services,pharma early development,a pharma central laboratory,biopharma product testing,and product testing.The companys analytical techniques aid in assessing the purity,authenticity,and safety of biological goods and chemicals.To provide a variety of services,it makes use of its expertise in information technology and logistics.The company has operations in South America,the Middle East,Asia Pacific,Europe,and North America.As of December 2022,the company served 61 countries with 900 laboratories,a portfolio of over 200,000 analytical methods,and more than 450 million tests performed.The company operates its business through two segments:Biopharmaceutical Services,Food and Feed Testing,Environment Testing,Clinical Diagnostics,Consumer Product Testing,and In Vitro Diagnostics.Biopharmaceutical Services improves global health through a combination of scientific knowledge,bioanalytical regulatory expertise,and the capacity to provide accurate and trusted data required for the drug approval process.Testing of the drug ingredient,final product,intermediates,and starting materials for both small molecule and large molecule drug products are all included in its totally comprehensive testing services.Through a single,seasoned provider,the segmented network of businesses offers clients seamless,end-to-end solutions to assist them in moving through the drug development cycle.In order to satisfy clients specialized testing demands and strict quality and safety requirements around the world,its integrated solutions deliver analytical technologies with a wide geographic reach.Food and Feed offers analytic methods to help businesses meet their increasingly demanding quality and safety criteria.Each year,its laboratories and competence centers conduct hundreds of millions of assays to determine the purity,authenticity,traceability,authenticity,and safety of food and feed.The category provides a variety of testing laboratories and makes them accessible to a global audience from laboratories employing optimized business procedures,logistics,and IT services,including testing services,training,consulting,auditing and certification,and research and development.As of December 31,2022,the segment had 130,000 analytical methods assessing the safety,purity,composition,authenticity,and traceability of food products and 54 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners ingredients.Environment Testing contributes to the health and sustainability of the planet by offering a wide range of industrial companies,NGOs,environmental consultants,contractors,retailers,and government authorities a global network of technology-leading laboratory testing and monitoring services.Its services include testing for contaminants and their effects on the environment and human health through waste and contaminant testing,pandemic testing,and epidemiology.The segment also tests water and wastewater,air,soil,waste,tissue,biologics,building materials,and other components of the built environment.Clinical Diagnostics contribute to every stage of patient care,from genetic predisposition to prevention,treatment monitoring,diagnosis,and even prognosis.It offers testing services in all medical specialties,including oncology,infectious disease,womens health,and transplantation.Consumer Product Testing offers a global network of laboratories with extensive services and well-known competence.Testing,product compliance,and regulatory,as well as training,audits,and inspections,are among its offerings.In Vitro Diagnostics(IVD)supplies diagnostic technology and devices in the field of bioanalytical testing for the food,feed,environmental,animal health,and clinical diagnostics industries.It provides a range of goods and services.The need for internal supplies and tools to conduct laboratory testing services across all of Eurofins business lines,which were previously procured from outside suppliers;testing kits for pathogens,GMOs,mycotoxins,veterinary medicine residues,vitamins,food viruses,and animal species identification;one of the most diverse portfolios of veterinary diagnostic test kits on the market;ELISA analyzers,ELISA,and Lateral Flow readers,as well as an innovative suite of IVD devices,testing kits,and testing reagents for a wide variety of clinical diagnostic tests for infectious and vector-borne diseases,are the tools needed to finish the in-house testing process.11.1.3 Products and Services Service CategoryService Category Service NameService Name Service TypeService Type Genomic Services DNA&RNA Oligonucleotides Optimized Application Oligos,Express Oligos,Customized DNA Oligos,Customized RNA Oligos,Oligo Design Custom DNA Sequencing Tube Sequencing,Plate Sequencing,GLP-compliant Sequencing Next Generation Sequencing Genome Sequencing,Transcriptome Sequencing,Resequencing&Amplicons,Libraries&Bioinformatics Gene Synthesis&Molecular Biology Gene Synthesis Genotyping&Gene Expression Genotyping Services,Gene Expression Services,Mycoplasmacheck,Cell Line Authentication Service 55 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 11.1.4 Financial Overview ANNUAL REVENUE($MN)REVENUE BY BUSINESS SEGMENT,2022(%)REVENUE BY GEOGRAPHY,2022(%)Source:Press Release,Newsletters,and Company Annual Report 6,200.357,943.737,057.8702000400060008000100002020202120228.52%0.01%6.35.25%1.87%Study-based BusinessOtherFTE-based BusinessSample-based BusinessProduct-based Business10.597.16R.25%Rest of the WorldNorth AmericaEurope 56 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 11.1.5 SWOT Analysis STRENGTHS Positioned at Global Level Eurofins Scientific SE is positioned at a global level,which helps the company serve diverse customers and mitigate the risk of reliance on a single region.As of FY2022,the company had presence in 61 countries.Also,the company had over 200 laboratories in North America,over 20 laboratories in South America,over 500 laboratories in Europe,3 laboratories in Africa,and over 150 laboratories in APAC region.WEAKNESSES Declined Performance in European Region Eurofins Scientific SE has reported a decline in performance in the European region,which impacted the operational performance of the company.In FY2022,revenue from the European region declined YoY by 12%to EUR 3,507 million from EUR 3,999 million in the previous year.During the year,the European market accounted for over 60%of the total revenue.The decline was on the back of a record comparable in FY2021 related to COVID-19 testing and reagents revenues.OPPORTUNITIES Business Streamlining Eurofins Scientific SE takes strategic steps to streamline its business,such as business divestment,which might help the company focus on its core business.In September 2022,the company announced that it would divest its Digital Testing business to Stirling Square Capital Partners for over EUR 220 million.With this divestiture,the company aims to focus on its capital allocation priorities and improve its presence in bioanalytical testing and other life science areas.THREATS Changes in Foreign Currencies Eurofins Scientific SE is subjected to changes in foreign currencies,which might have an impact on the financial performance of the company.Subsequently,the company might need to enter into several hedging contracts.Hedging contracts might have a negative impact on the income statement and balance sheet of the company and might hamper the companys net worth,financial position,and operating results.57 South&Central America Genetic Testing Services Market,2020-2030 |The Insight Partners 11.1.6 Key Developments DateDate DevelopmentDevelopment CategoryCategory DescriptionDescription Sep-2022 Eurofins Genoma announces launch of niPGT-A,a non-invasive,embryo biopsy free,preimplantation genetic aneuploidy screening test Product Launch The niPGT-A screening test aims to enable in vitro fertilization centers to produce quality embryo samples,avoiding the need for embryo biopsies.It will allow medical practitioners to determine chromosomal abnormalities in in
2024-08-12
86页
5星级
Middle East&Africa Genetic Testing Services Market Market Size and Forecast(2020-2030)Regional Growth Opportunity Analysis Coverage:By Service Service TypeType(Predictive Testing,Carrier Testing,Prenatal Testing,Newborn Screening,and Others),DiseaseDisease(Cancer,Metabolic Diseases,Cardiovascular Diseases,and Other Diseases),Service Service ProviderProvider(Hospital-Based Laboratories,Diagnostic Laboratories,and Others),and CountryCountry 2 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners Table of Content 1.Introduction.12 1.1 The Insight Partners Research Report Guidance.12 1.2 Market Segmentation.13 2.Executive Summary.14 2.1 Key Insights.14 3.Research Methodology.15 3.1 Coverage.16 3.2 Secondary Research.16 3.3 Primary Research.16 4.Middle East&Africa Genetic Testing Services Market-Key Industry Dynamics.18 4.1 Key Market Drivers.18 4.1.1 Rising Prevalence of Genetic Diseases.18 4.1.2 Increasing Awareness and Acceptance of Personalized Medicines.19 4.1.3 Growing Preference for Direct-To-Consumer(DTC)Genetic Testing.19 4.2 Market Restraints.20 4.2.1 Social and Ethical Implications of Genetic Testing.20 4.2.2 Affordability of Genetic Services.20 4.3 Market Opportunities.21 4.3.1 Untapped Emerging Markets in Developing Countries.21 4.4 Future Trends.21 4.4.1 Artificial Intelligence-Powered Genetic Testing.21 4.5 Impact Analysis:.22 5.Genetic Testing Services Market-Middle East&Africa Market Analysis.23 5.1 Middle East&Africa Genetic Testing Services Market Revenue(US$Mn),2022 2030.23 6.Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030 by Service Type.24 6.1 Overview.24 6.2 Middle East&Africa Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%).24 6.3 Predictive Testing.25 6.3.1 Overview.25 3 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 6.3.2 Predictive Testing:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).25 6.4 Carrier Testing.26 6.4.1 Overview.26 6.4.2 Carrier Testing:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).26 6.5 Prenatal Testing.27 6.5.1 Overview.27 6.5.2 Prenatal Testing:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).27 6.6 Newborn Screening.28 6.6.1 Overview.28 6.6.2 Newborn Screening:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).28 6.7 Others.29 6.7.1 Overview.29 6.7.2 Others:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).29 7.Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030 by Disease.30 7.1 Overview.30 7.2 Middle East&Africa Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%).30 7.3 Cancer.31 7.3.1 Overview.31 7.3.2 Cancer:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).31 7.4 Cardiovascular Diseases.32 7.4.1 Overview.32 7.4.2 Cardiovascular Diseases:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).32 7.5 Metabolic Diseases.33 7.5.1 Overview.33 7.5.2 Metabolic Diseases:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).33 7.6 Other Diseases.34 7.6.1 Overview.34 7.6.2 Other Diseases:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).34 4 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 8.Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030 by Service Provider.36 8.1 Overview.36 8.2 Middle East&Africa Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%).36 8.3 Hospital-Based Laboratories.37 8.3.1 Overview.37 8.3.2 Hospital-Based Laboratories:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).37 8.4 Diagnostic Laboratories.38 8.4.1 Overview.38 8.4.2 Diagnostic Laboratories:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).38 8.5 Others.39 8.5.1 Overview.39 8.5.2 Others:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).39 9.Middle East&Africa Genetic Testing Services Market-Country Analysis.40 9.1 Middle East&Africa.40 9.1.1 Middle East&Africa Middle East&Africa Genetic Testing Services Market,by Country.40 9.1.1.1 Saudi Arabia.41 9.1.1.1.1 Overview.41 9.1.1.1.2 Saudi Arabia Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).41 9.1.1.1.3 Saudi Arabia Genetic Testing Services Market,by Service Type,20202030(US$Million).42 9.1.1.1.4 Saudi Arabia Genetic Testing Services Market,by Disease,20202030(US$Million).43 9.1.1.1.5 Saudi Arabia Genetic Testing Services Market,by Service Provider,20202030(US$Million).43 9.1.1.2 UAE.44 9.1.1.2.1 Overview.44 9.1.1.2.2 UAE Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).44 9.1.1.2.3 UAE Genetic Testing Services Market,by Service Type,20202030(US$Million).45 9.1.1.2.4 UAE Genetic Testing Services Market,by Disease,20202030(US$Million).45 9.1.1.2.5 UAE Genetic Testing Services Market,by Service Provider,20202030(US$Million).45 5 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.3 South Africa.46 9.1.1.3.1 Overview.46 9.1.1.3.2 South Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).46 9.1.1.3.3 South Africa Genetic Testing Services Market,by Service Type,20202030(US$Million).47 9.1.1.3.4 South Africa Genetic Testing Services Market,by Disease,20202030(US$Million).48 9.1.1.3.5 South Africa Genetic Testing Services Market,by Service Provider,20202030(US$Million).48 9.1.1.4 Rest of Middle East&Africa.49 9.1.1.4.1 Overview.49 9.1.1.4.2 Rest of Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).49 9.1.1.4.3 Rest of Middle East&Africa Genetic Testing Services Market,by Service Type,20202030(US$Million).50 9.1.1.4.4 Rest of Middle East&Africa Genetic Testing Services Market,by Disease,20202030(US$Million).50 9.1.1.4.5 Rest of Middle East&Africa Genetic Testing Services Market,by Service Provider,20202030(US$Million).51 10.Genetic Testing Services MarketIndustry Landscape.52 10.1 Overview.52 10.2 Growth Strategies in Middle East&Africa Genetic Testing Services Market.52 10.3 Organic Growth Strategies.53 10.3.1 Overview.53 10.4 Inorganic Growth Strategies.54 10.4.1 Overview.54 11.Company Profiles.56 11.1 Eurofins Scientific SE.56 11.1.1 Key Facts.56 11.1.2 Business Description.56 11.1.3 Products and Services.57 11.1.4 Financial Overview.58 11.1.5 SWOT Analysis.59 11.1.6 Key Developments.60 11.2 Exact Sciences Corp.61 11.2.1 Key Facts.61 11.2.2 Business Description.61 6 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 11.2.3 Products and Services.61 11.2.4 Financial Overview.62 11.2.5 SWOT Analysis.63 11.2.6 Key Developments.64 11.3 Laboratory Corp of America Holdings.65 11.3.1 Key Facts.65 11.3.2 Business Description.65 11.3.3 Products and Services.65 11.3.4 Financial Overview.66 11.3.5 SWOT Analysis.67 11.3.6 Key Developments.68 11.4 Quest Diagnostics Inc.69 11.4.1 Key Facts.69 11.4.2 Business Description.69 11.4.3 Products and Services.70 11.4.4 Financial Overview.70 11.4.5 SWOT Analysis.71 11.4.6 Key Developments.72 11.5 Illumina Inc.73 11.5.1 Key Facts.73 11.5.2 Business Description.73 11.5.3 Products and Services.74 11.5.4 Financial Overview.74 11.5.5 SWOT Analysis.75 11.5.6 Key Developments.76 11.6 F.Hoffmann-La Roche Ltd.77 11.6.1 Key Facts.77 11.6.2 Business Description.77 11.6.3 Products and Services.78 11.6.4 Financial Overview.78 11.6.5 SWOT Analysis.80 11.6.6 Key Developments.82 11.7 Centogene AG.83 11.7.1 Key Facts.83 11.7.2 Business Description.83 7 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 11.7.3 Products and Services.83 11.7.4 Financial Overview.84 11.7.5 SWOT Analysis.85 11.7.6 Key Developments.86 12.Appendix.87 12.1 About Us.87 12.2 Glossary of Terms.88 8 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners List of Tables Table 1.Middle East&Africa Genetic Testing Services Market Segmentation.13 Table 2.Saudi Arabia Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).42 Table 3.Saudi Arabia Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).43 Table 4.Saudi Arabia Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).43 Table 5.UAE Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).45 Table 6.UAE Middle East&Africa Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).45 Table 7.UAE Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).45 Table 8.South Africa Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).47 Table 9.South Africa Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).48 Table 10.South Africa Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).48 Table 11.Rest of Middle East&Africa Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).50 Table 12.Rest of Middle East&Africa Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).50 Table 13.Rest of Middle East&Africa Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).51 Table 14.Recent Organic Growth Strategies in Middle East&Africa Genetic Testing Services Market.53 Table 15.Recent Inorganic Growth Strategies in the Middle East&Africa Genetic Testing Services Market.54 Table 16.Glossary of Terms,Middle East&Africa Genetic Testing Services Market.88 9 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners List of Figures Figure 1.Middle East&Africa Genetic Testing Services Market Segmentation,By Country.13 Figure 2.Middle East&Africa Genetic Testing Services Market-Key Industry Dynamics.18 Figure 3.Impact Analysis of Drivers and Restraints.22 Figure 4.Middle East&Africa Genetic Testing Services Market Revenue(US$Mn),2022 2030.23 Figure 5.Middle East&Africa Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%).24 Figure 6.Predictive Testing:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).25 Figure 7.Carrier Testing:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).26 Figure 8.Prenatal Testing:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).27 Figure 9.Newborn Screening:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).28 Figure 10.Others:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).29 Figure 11.Middle East&Africa Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%).30 Figure 12.Cancer:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).31 Figure 13.Cardiovascular Diseases:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).32 Figure 14.Metabolic Diseases:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).33 Figure 15.Other Diseases:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).35 Figure 16.Middle East&Africa Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%).36 Figure 17.Hospital-Based Laboratories:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).37 Figure 18.Diagnostic Laboratories:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).38 10 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 19.Others:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).39 Figure 20.Middle East&Africa Middle East&Africa Genetic Testing Services Market,by Key Country Revenue,2022(US$Million).40 Figure 21.Middle East&Africa Middle East&Africa Genetic Testing Services Market,By Key Countries,2022 and 2030(%).40 Figure 22.Saudi Arabia Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).42 Figure 23.UAE Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).44 Figure 24.South Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).47 Figure 25.Rest of Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).49 Figure 26.Growth Strategies in Middle East&Africa Genetic Testing Services Market.52 11 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners NOTES:The list of companies included in the scope are as per standard report format and the list can be modified/expanded as per clients requirement The sequence/list of companies do not represent their current position in the market.The list of countries provided in the report are part of standard report and can be customized as per clients requirement RELATED REPORTS Newborn Genetic Testing Market DTC Genetic Testing Market 12 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 1.Introduction 1.1 The Insight Partners Research Report Guidance The report provides qualitative and quantitative trends of Middle East&Africa genetic testing services market across service type,disease,service provider,and country.The report starts with the key takeaways(chapter 2),highlighting the key trends and outlook of the Middle East&Africa genetic testing services market.Chapter 3 provides the research methodology of the study.Chapter 4 highlights the key industry dynamics in the Middle East&Africa genetic testing services market,including factors that are driving the market,prevailing deterrent,potential opportunities as well as future trends.Impact analysis of these drivers and restraints is also covered in this section.Chapter 5 discusses the Middle East&Africa genetic testing services market scenario,in terms of historical market revenues,and forecast till 2030.Chapter 6 to 9 discuss genetic testing services market segments by service type,disease,service provider,and countries across the Middle East&Africa.They cover market revenue forecast,and factors driving and governing growth.Chapter 10 describes the industry landscape analysis.It provides detailed description of various business activities such as market initiatives,new developments,mergers,and joint ventures globally along with a competitive landscape.Chapter 11 provides the detailed profiles of the key companies operating in the Middle East&Africa genetic testing services market.The companies have been profiled on the basis of their key facts,business description,products and services,financial overview,SWOT analysis,and key developments.Chapter 12,i.e.the appendix is inclusive of a brief overview of the company,glossary of terms,contact information,and the disclaimer section.13 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 1.2 Market Segmentation Table 1.Middle East&Africa Genetic Testing Services Market Segmentation SERVICE TYPESERVICE TYPE DISEASEDISEASE SERVICE PROVIDERSERVICE PROVIDER PREDICTIVE TESTING CANCER HOSPITAL-BASED LABORATORIES CARRIER TESTING CARDIOVASCULAR DISEASES DIAGNOSTIC LABORATORIES PRENATAL TESTING METABOLIC DISEASES OTHERS NEWBORN SCREENING OTHER DISEASES OTHERS Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources Figure 1.Middle East&Africa Genetic Testing Services Market Segmentation,By Country Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources The Middle East&Africa genetic testing services market is segmented based on service type,disease,service provider,and country.The segmentation in this research study has been finalized post in-depth secondary research and extensive primary research.In addition,the market is also segmented on the basis of services offered by the leading participants in the industry in order to understand widely used market specific terminologies.Thus,we have incorporated the segments of the research and have finalized the market segmentation.MIDDLE EAST&AFRICASAUDI ARABIASOUTH AFRICAUAEREST OF MEA 14 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 2.Executive Summary 2.1 Key Insights OverviewMarket SegmentationMarket DynamicsRegional OverviewMarket SegmentationKey PlayersMarket DynamicsCAGR(2022-2030)12.5%Market Size 2022$78.07MnMarket Size 2030$200.38MnService TypeDisease Predictive Testing Carrier Testing Prenatal Testing Newborn Screening Others Cancer Cardiovascular Diseases Metabolic Diseases Other Diseases Laboratory Corporation of America Holdings F.Hoffmann-La Roche Ltd Illumina,Inc.Quest Diagnostics Incorporated Exact Sciences Corp(Genomic Health)Eurofins Scientific Centogene AG 23andMe,IncGROWTH DRIVERSFUTURE TRENDSGROWTH DRIVERSFUTURE TRENDS Rising Prevalence of Genetic Diseases Increasing Awareness and Acceptance of Personalized Medicines Artificial Intelligence-Powered Genetic TestingRESTRAINTSOPPORTUNITY Social and Ethical Implications of Genetic Testing Affordability of Genetic Services Untapped Emerging Markets in Developing CountriesService Provider Hospital-Based Laboratories Diagnostic Laboratories OthersMIDDLE EAST&AFRICA12.5 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 3.Research Methodology The Insight Partners dedicated research and analysis team consist of experienced professionals with advanced statistical expertise in market research and consulting backgrounds in in various industries including Aerospace and Defense,Automotive and Transportation,Biotechnology,Chemicals and Materials,Food and Beverages,Electronics and Semiconductor,Healthcare IT,Manufacturing and Construction,Medical Device,Technology,Media and Telecommunications.Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources FinalMarket sizeValidation from Primary InterviewSummation of Revenue Generated from Companies to arrive Total Market SizeRevenue Generated by the Products and Services Offered by Companies in the Genetic Testing Service MarketFinal Market Size Break-Up To Rest Of Segmentation(i.e.,Service Type,Disease,Service Provider,and Region)Arriving at the Market Size of each Segment Validation of Number with Primary Interviews and Subject Matter Expert BOTTOM-UP ANALYSISTOP-DOWN ANALYSIS 16 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners The Insight Partners adheres to the codes of practice of the Market Research Society(www.mrs.org.uk)and Strategic and Competitive Intelligence Professionals(www.scip.org).The following methodology has been followed for the collection and analysis of data presented in this report:3.1 Coverage The objective of updating“The Insight Partners”coverage is to ensure that it represents the most up-to-date vision of the industry possible.The estimated revenues of all major companies,including private and governmental,are gathered and used to prioritize coverage.Companies which are making the news,or which are of particular interest due to their innovative approach,are prioritized.3.2 Secondary Research The research process begins with exhaustive secondary research using internal and external sources to obtain qualitative and quantitative information relating to each Market.The secondary research sources that are typically referred to include,but are not limited to:Company websites,annual reports,financial reports,broker reports and investor presentations Industry trade journals and other literature National government documents,statistical databases and market reports News articles,press releases and web-casts specific to the companies operating in the market NOTE:All the financials considered in Company Profiles section have been standardized to US$.This has been achieved after converting the financials(for those not in US$)with respective currency exchange rates of the particular year.3.3 Primary Research“The Insight Partners”conducts hundreds of primary interviews a year with industry participants and commentators in order to validate its data and analysis.A typical research interview fulfils the following functions:Provides first-hand information on the market size,market trends,growth trends,competitive landscape and future outlook Validates and strengthens secondary research findings Further develops the analysis teams expertise and market understanding 17 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners Primary research involves email interactions and telephone interviews for each market,category,segment and sub-segment across countries.The participants who typically take part in such a process include,but are not limited to:Industry participants:VPs,business development managers,market intelligence managers and national sales managers Outside experts:Valuation experts,research analysts and key opinion leaders specializing in the industry 18 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 4.Middle East&Africa Genetic Testing Services Market-Key Industry Dynamics Figure 2.Middle East&Africa Genetic Testing Services Market-Key Industry Dynamics Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 4.1 Key Market Drivers 4.1.1 Rising Prevalence of Genetic Diseases The prevalence of genetic diseases is rising across the world and impacting the health of people at a severe level.Genetic diseases show many symptoms that are uncommon and are mostly non-curable.Most of the genetic diseases are rare and are developed due to the mutation in the genetic makeup of the people.According to The World Health Organization(WHO)2021,10 out of every 1,000 people are affected by single-gene diseases,signifying that 70 million and 80 million people worldwide are living with any one type of single-gene disease.As per the Global Genes,7,000 known rare diseases and disorders have been identified worldwide,and more are being discovered every year.According to the University of Sheffield research,300 million people are living with genetic diseases around the world.In Asia Pacific and the Middle East,a very large population is diagnosed with genetic diseases due to consanguineous marriage favored in many communities.Marriages between relatives are the major concern for the rising prevalence of genetic diseases.The burden of autosomal recessive disease variations is high in Saudi Arabia due to the highly consanguineous population.To control these conditions,countries in the Middle East are mandatorily conducting genetic evaluations for couples getting married DROTDRIVERSRESTRAINTSOPPORTUNITIESTRENDSRising Prevalence of Genetic DiseasesIncreasing Awareness and Acceptance of Personalized MedicinesGrowing Preference for Direct-To-Consumer Genetic TestingSocial and Ethical Implications of Genetic TestingAffordability of Genetic ServicesArtificial Intelligence-Powered Genetic TestingUntapped Emerging Markets in Developing Countries 19 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners so that the prevalence of these diseases can be managed and treated timely.Thus,the rising prevalence of genetic diseases fuels the demand for genetic testing,which in turn drives genetic testing services market growth.4.1.2 Increasing Awareness and Acceptance of Personalized Medicines Personalized medicine is the field that utilizes patients genetic and environmental data to deliver optimal healthcare.It is based on the principle that every patient is unique and requires individualistic pharmacological treatment.Since it is a rapidly evolving area,it is presently incorporated into several healthcare systems.The successful completion of the Human Genome Project(HGP)in 2003 and the fast-decreasing human genome sequencing costs encouraged the development of a new medical approach,which is called personalized medicine.With an expanding repository of personalized data at the molecular level,molecular diagnostics companies are exceptionally positioned to unlock value.Large-scale drug discovery is a key to increasing the viability and usefulness of personalized medicines for the diagnosis of diseases and disorders.Genomics is one of the fastest-growing divisions of medical science.It is driving a paradigm shift in the research methodology of a disease,as well as diagnosing and treating illness.Genetic testing has been extensively used in pharmacogenomics,also known as drug-gene testing.It helps in accelerating drug discovery and its development.In January 2023,The Human Genome Project is ensuring an era of personalized healthcare.Now,new research shows that precision prescribing using genetic testing has ultimately reached a global tipping point for adoption.Published by Cambridge University Press,the peer-reviewed research examines the maturation of critical factors required for the use of clinical genetics at scale.These advancements pave the way for supporting genome-informed clinical decision-making to be established as the new standard of care.Genetically informed prescribing offers one of the realistic mechanisms to successfully reduce the overall costs of the healthcare system and improve individual patient care.Genetic testing encourages the adoption of a personalized medicine approach by understanding the science behind the disease,the impact of treatment,and the development of therapies for specific individual characteristics.It also helps healthcare personnel make informed decisions about disease diagnosis,treatment,and prevention by utilizing genetic testing results,leading to improved patient outcomes.4.1.3 Growing Preference for Direct-To-Consumer(DTC)Genetic Testing Personalized genetic testing and treatment have long been used globally to help individuals and families learn more about hereditary diseases.Most of the time,genetic testing is done through healthcare personnel,such as genetic counselors.Healthcare providers decide which test is needed,order the test from a test center,collect and send the DNA sample,read the test results,and share the results with the patient.Thus,these tests have traditionally been ordered and interpreted in a clinical or medical research setting.In contrast,DTC genetic testing has witnessed tremendous growth in the past decade and is becoming increasingly widespread.A genetic test offered,advertised,and sold by companies directly to the consumer,without the direct involvement of a conventional healthcare system,is called DTC genetic testing.DTC genetic testing is relatively new and helps people find out about the disease-associated genes they may carry without the need for a prescription or guidance from a genetic counselor or medical practitioner.Several consumers of DTC testing view it as another method of gathering medical information about themselves.Unlike other genetic tests performed in clinics or hospitals,the consumer independently initiates and completes a DTC genetic test.The public understanding and acceptance of genetic testing is gradually increasing.Additionally,there is a rise in consumers seeking customized products and experiences for the identification and addressing of unique needs.The launch of innovative products and the increase in the adoption of DTC genetic testing kits have made genetic testing 20 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners more accessible to people.These kits enable users to undergo personalized health management within the comfort of their homes.Key industry players are also developing DTC genetic tests and implementing special marketing efforts that positively impact sales of DTC tests.A rising number of manufacturers are providing direct-to-consumer genetic testing that covers various health conditions and traits.The increasing demand for direct-to-consumer genetic testing products to learn about the genetic makeup and assess the risk of developing hereditary conditions for early disease detection or prevention drives the market.4.2 Market Restraints 4.2.1 Social and Ethical Implications of Genetic Testing Genetic testing is poised to play an important role in the practice of obstetrics and gynecology.Physicians are required to become familiar with the presently accessible collection of genetic tests and their limitations to guarantee patients the utmost quality of care.However,the knowledge of genetic risks can result in potential social and psychological consequences for the people undergoing such tests.Socially,knowledge from genetic tests may lead to stigmatization and judgment within the community.Refusing to undergo genetic testing,as well as choosing to undergo genetic testing,can both lead to discrimination and stigmatization,depending on the prevalent public standards concerning acceptance and use of the technology.Privacy and security concerns also arise as the availability and commercialization of personal genetic data can lead to unauthorized access or misuse of sensitive information.The storage of genetic testing data and registries of patients generates concern,given that the results can negatively impact the family members.In addition,lack of informed consent can lead to adverse reactions,such as increased anxiety and unnecessary preventive measures during the disclosure of genetic test results.Lack of proper counseling regarding the information about genetic risk and choices regarding genetic testing and its management can cause potential psychological distress.Therefore,the reluctance of patients to prefer genetic testing due to the social and ethical stigma impedes market growth.4.2.2 Affordability of Genetic Services At present,genetic services are expensive and,therefore,not accessible to all.Genetic research is presently underrepresented in health research;however,studies are being conducted to establish the feasibility of such services.Present inequalities in the affordability and feasibility of genetic services are a cause of concern for the WHO and other prominent international organizations that are centered around public health and development concerns.The cost of the test also increases if more than one test is needed or if multiple family members need to be tested to obtain a significant result.For newborn screening,costs differ as per the state.Several states cover part of the overall cost,although most charge a fee of US$30 to US$150 per infant.Various factors,including the type of test,the complexity of analysis,and laboratory processing fees,influence the cost of these tests.Thus,the high costs,along with its affordability in emerging economies,restrain the market growth.21 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 4.3 Market Opportunities 4.3.1 Untapped Emerging Markets in Developing Countries Emerging countries such as China,India,Brazil,and Mexico offer significant growth opportunities to market players.The high growth can majorly be attributed to the increasing public healthcare expenditure,improving healthcare infrastructure,and the presence of a large target patient population.The need for genetic testing has also increased owing to a rise in awareness of genetic disorders in developing economies and their early diagnosis.The quality and availability of genetic services may differ between high-income countries and low-to middle-income countries.For instance,in the US,Australia,Canada,the UK,and other European countries,genetic services are well-advanced,established,and extensive.These services include newborn screening,carrier identification screening,and prenatal diagnosis.Yet,in many high-income countries,genetic services that are offered in multiple settings still need improved systems of assessment.The ease and applicability of genetic testing procedures have benefitted R&D activities in developing regions worldwide.Major market players are focusing on strategies and initiatives,such as agreements,collaborations,partnerships,and expansions,to improve their product availability,accessibility,and distribution networks in these countries,as it will help them address the growing need for early diagnosis and treatment.For instance,in 2024,in Almarkaziya,Abu Dhabi,Central Clinic has launched its most recent and cutting-edge genomic testing services.Also,in 2023,Burjeel Holdings teamed up with OncoHelix Inc.to open a state-of-the-art lab in Abu Dhabi that would offer patients in the UAE cutting-edge molecular genetics,cellular,and immunological profile testing.In addition,rising consumer awareness regarding DTC genetic tests in developing economies offers growth opportunities to the DTC industry.Therefore,emerging markets in developing countries are expected to offer significant opportunities to the players operating in the market and boost the market growth during the forecast period.4.4 Future Trends 4.4.1 Artificial Intelligence-Powered Genetic Testing Whole-genome sequencing and now whole-exome sequencing have also become more popular.To solve the growing problem of health data exhaust,the field of medicine is increasingly revolving around enhanced clinical tools,such as artificial intelligence(AI)and machine learning,which have been mentioned as a way to improve the acceptance of genomic medicine.Today,many companies have turned to machine learning to process the vast amount of data needed to correctly analyze and understand clinical data in fields such as radiology and cardiology.Many of the consumer-facing genetic testing technologies that are available in the market are using machine learning or AI to function.In numerous ways,genetic testing of diseases is the perfect field for machine learning because of the vast volumes of data that these programs need to struggle with.For example,working on the human genome includes reading billions of bits of information,and prior to the introduction of machine learning,many of these tasks were pretty tricky.AI offers great potential when it comes to analyzing genetic data and supporting clinical specialists in making diagnoses.Google has a program called Deep Variant that can now be used to plot the human genome thoroughly and can be used on the full range of a persons genetic information.Moreover,agencies such as the National Institutes of Health are working on ways through which machine learning and AI can add to a better understanding of genetics and genomics.Furthermore,Blueprint Genetics is using AI in clinical interpretation.Machine learning and AI are acting as a catalyst for faster and more diverse improvement in genetic research and engineering.These tools are simple to integrate and extremely scalable,putting genetic laboratories in a unique position to scale their operations and match the fast growth 22 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners of the genetic testing field.Thus,through the successful integration of these tools,clinicians will be able to diagnose rare genetic diseases more efficiently and effectively,bringing hope to the millions of people affected by them globally.4.5 Impact Analysis:The following figure depicts the impact of factors driving and restraining the Middle East&Africa genetic testing services market.The factors driving the market growth include increasing prevalence of genetic diseases,increasing awareness and acceptance of personalized medicines,and growing preference for direct-to-consumer genetic testing.However,social and ethical implications of genetic testing and affordability of genetic services hinders the market growth.Figure 3.Impact Analysis of Drivers and Restraints Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources Rising Prevalence of Genetic DiseasesGrowing Preference towards for Direct-To-Consumer Genetic TestingSocial and Ethical Implications of Genetic TestingLOWMEDIUMHIGHIncreasing Awareness and Acceptance of Personalized Medicines 23 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 5.Genetic Testing Services Market-Middle East&Africa Market Analysis The Middle East&Africa genetic testing services market in the Middle East&Africa is segmented into UAE,Saudi Arabia,South Africa,and the Rest of the Middle East&Africa.The market is driven by programs undertaken by a number of research institutes and the availability of infrastructure and facilities for research in the UAE and Saudi Arabia.The support by the government in these countries are likely to boost the growth of the market.Moreover,the increase in the incidence of genetic disorders and cancer plays an important role in the development of the genetic testing industry.5.1 Middle East&Africa Genetic Testing Services Market Revenue(US$Mn),2022 2030 The Middle East&Africa genetic testing services market is expected to reach US$200.38 million by 2030 from US$78.07 million in 2022.The market is estimated to grow at a CAGR of 12.5%from 2022 to 2030.The factors driving the market growth include the increasing prevalence of genetic diseases,growing preference for direct-to-consumer genetic testing,and increasing awareness and acceptance of personalized medicines.However,social and ethical implications of genetic testing and affordability of genetic services restrain the growth of the market.Figure 4.Middle East&Africa Genetic Testing Services Market Revenue(US$Mn),2022 2030 Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 64.9071.1678.0786.1595.60106.68119.71135.06153.22174.76200.389.7%9.7.3.0.6.2.8.4.1.7%0.0%2.0%4.0%6.0%8.0.0.0.0.0 2020212022202320242025202620272028202920300501001502002502020-2030Historical YearBase YearForecast Year 24 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 6.Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030 by Service Type 6.1 Overview The Middle East&Africa genetic testing services market,by service type,is segmented into predictive testing,carrier testing,prenatal testing,newborn screening,and others.In 2022,the predictive testing segment held the largest share of the market and is expected to register the highest CAGR in the market during the coming years.6.2 Middle East&Africa Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%)Figure 5.Middle East&Africa Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%)Source:The Insight Partners Analysis The predictive testing segment led the market in 2022 with a share of 43.2%and is expected to retain its dominance during 20222030 by accounting for 46.5%of the total market by 2030.43.2%.1.6.0%8.1 22Predictive TestingCarrier TestingPrenatal TestingNew-born ScreeningOthers46.5%.6%9.6.7%5.6 30 25 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 6.3 Predictive Testing 6.3.1 Overview Predictive genetic testing examines any genetic changes or mutations that are linked to disease.These tests are done prior to an individual displaying any signs of a disease.Predictive testing can be helpful to people who have a family history of a treatable genetic disorder and display no signs of illness.This testing can identify mutations that increase an individuals risk of developing disorders with a genetic foundation,such as certain types of cancer.An example is testing for the BRCA1 and BRCA2 gene variants(altered genes)linked with an increased risk of breast cancer.The results of predictive testing can provide information about the probability of developing a specific disorder and help in making decisions about medical care.The increasing demand for genetic counseling is expected to drive the market for predictive testing as more people understand the importance of genetics in disease etiology.The ongoing advancements and upgrading of platforms to improve the efficiency of genome analysis techniques are expected to boost the adoption of predictive testing solutions.A growing focus on reducing the growing healthcare burden of rare genetic diseases and rapid integration of technologies such as artificial intelligence and machine learning will enhance product development and fuel the need for predictive testing to assess and prevent future complications arising from diseases effectively.6.3.2 Predictive Testing:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Predictive testing segment was valued at US$33.73 million in 2022 and is expected to reach US$93.25 million by 2030.The growth rate of this segment is projected to be 13.6%during 20222030.Figure 6.Predictive Testing:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 27.4930.4433.7337.5742.1047.4253.7161.1770.0380.6093.25202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 26 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 6.4 Carrier Testing 6.4.1 Overview Carrier testing is a kind of genetic test that can tell whether one carries a gene for certain genetic disorders or not.When it is done before or during pregnancy,it helps to find out the chances of having a child with a genetic disorder.Carrier testing is used to identify people carrying one copy of a gene mutation(a genetic change)that,when present in two copies,results in a genetic disorder.Carriers generally do not have symptoms or have only mild symptoms.They often are unaware that they have a gene for a disorder.Carrier screening is offered for a limited number of diseases,including cystic fibrosis,sickle cell disease,fragile X syndrome,and TaySachs disease.A few of these disorders occur commonly in certain ethnic groups.For example,sickle cell disease occurs most frequently in African Americans.TaySachs disease is most common in Eastern or Central European Jewish people,French Canadian people,and Cajun descent.Although,anyone can have one of these disorders as they are not restricted to these groups.With the increasing prevalence of genetic diseases caused by chromosome and gene mutations,carrier testing has grown exponentially.The majority of cases of genetic mutations are due to preexisting conditions,a family history of abortion,or congenital disabilities.Pregnant women often undergo carrier screening in order to determine the risk of transmitting a specific genetic disease to their progeny.In addition,the increasing recognition of the importance of early diagnosis and screening of gene illness fuels the need to develop strategies to tackle these diseases.6.4.2 Carrier Testing:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Carrier testing segment was valued at US$19.59 million in 2022 and is expected to reach US$51.21 million by 2030.The growth rate of this segment is projected to be 12.8%during 20222030.Figure 7.Carrier Testing:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 16.2117.8119.5921.6624.1026.9530.3134.2838.9844.5651.21202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 27 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 6.5 Prenatal Testing 6.5.1 Overview Genetics can have an impact on the color of a babys eyes and hair and can also result in the development of some birth defects or genetic disorders.This testing helps to detect abnormalities in a fetuss genes or chromosomes and syndromes before birth.Thats why women are regularly offered a wide range of prenatal genetic testing in the first and second trimesters of pregnancy to evaluate the problems in their unborn babies.According to the WHO,congenital disabilities affect 8 million newborns every year.Nine out of every ten children are born with a serious birth defect in low-and middle-income countries.Congenital disabilities can occur at any point through the pregnancy;however,most of them occur during the first trimester when the babys organs are formed.6.5.2 Prenatal Testing:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Prenatal testing segment was valued at US$8.28 million in 2022 and is expected to reach US$19.28 million by 2030.The growth rate of this segment is projected to be 11.1%during 20222030.Figure 8.Prenatal Testing:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 7.047.648.289.039.9110.9212.1113.5015.1217.0319.28202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 28 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 6.6 Newborn Screening 6.6.1 Overview A newborn screening test looks for various developmental,genetic,and metabolic disease disorders in the newborn.Newborn screening allows measures to be taken before symptoms develop.Most of these illnesses are extremely rare but can be treated if detected early.The offspring has a high risk of having genetic diseases in cases where the parents have another child with a genetic disease,a family history of a genetic disorder,or if either of a parent has a chromosomal abnormality.Early testing for these conditions allows physicians and parents to take timely measures to manage,treat,or intervene in disease progression,allowing the baby to lead a healthy,normal life.6.6.2 Newborn Screening:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Newborn screening segment was valued at US$10.15 million in 2022 and is expected to reach US$25.49 million by 2030.The growth rate of this segment is projected to be 12.2%during 20222030.Figure 9.Newborn Screening:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 8.499.2810.1511.1712.3613.7515.3917.3219.5922.2925.49202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 29 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 6.7 Others 6.7.1 Overview The others segment is comprised of preimplantation testing and pharmacogenomics.These tests are performed to screen for genetic disorders.Pharmacogenomics testing is a type of genetic test that is used to identify the right medication for a person.Pharmacogenomics is one of the key emerging trends in the field of medical science,which significantly impacts the drug development process.With the use of pharmacogenomics,target identification by drugs has become comparatively easy,which confirms much higher chances of success for the approval of drugs.Preimplantation genetic testing is also for couples who are at risk of having a child with a specific genetic or chromosome disorder,e.g.,cystic fibrosis or sickle cell disease.In this procedure,egg cells are removed from the womans ovaries and fertilized with sperm cells outside the body.The fertilized embryos develop for three days,and subsequently,one or two cells are removed from each embryo.The genetic material(DNA and chromosomes)from the cells is tested for the genetic disorder in the family history.One or two of the unaltered embryos are then relocated into the mothers womb(uterus).If the pregnancy is successful,the baby will not be affected by the disorder it was tested for.6.7.2 Others:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Others segment was valued at US$6.33 million in 2022 and is expected to reach US$11.16 million by 2030.The growth rate of this segment is projected to be 7.3%during 20222030.Figure 10.Others:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 5.686.006.336.717.147.638.188.809.5010.2811.16202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 30 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 7.Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030 by Disease 7.1 Overview The Middle East&Africa genetic testing services market,by disease,is segmented into cancer,cardiovascular diseases,metabolic diseases,and other diseases.In 2022,the cancer segment held the largest share of the market and is anticipated to grow at the highest CAGR during the coming years.7.2 Middle East&Africa Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%)Figure 11.Middle East&Africa Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%)Source:The Insight Partners Analysis The cancer segment led the market in 2022 with a share of 45.2%and is expected to retain its dominance during 20222030 by accounting for 49.0%of the total market by 2030.45.2.7.1.0 22CancerCardiovascular DiseasesMetabolic DiseasesOther Diseases49.0#.7.4.0 30 31 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 7.3 Cancer 7.3.1 Overview Genetic testing is a potential tool to identify individuals who are at higher risk for developing certain cancers because of family history.Genetic tests are available to examine inherited variants and alterations in the DNA sequence,which could result in excessive cell growth and can cause tumors or cancer.For example,genetic testing for the detection of PALB2(linked with increased risks of breast and pancreatic cancers),BRIP1(ovarian cancer),RAD51C and RAD51D(ovarian cancer),and CHEK2(breast and colorectal cancers).The worldwide growing prevalence of various cancers,such as breast,lung,and bowel,are the major drivers of this segment.CDCs Cancer Genomics Program develops best practices in education,surveillance,and policy and systems transformation approaches.It establishes an evidence base for the application of family history and cancer genomics in public health practice.Other factors that might impact cancer genetic testing awareness include DTC marketing of cancer genetic testing and federal regulations of genetic information,high awareness regarding the availability of quality cancer diagnostics tests,and the escalating incidence of hereditary diseases.In addition,a growing number of companies providing genomic profiling services for health assessment,including cancer risk prediction,and the availability of numerous laboratories offering genetic testing for BRCA,and other genes associated with hereditary breast,ovarian,and related cancers propel the market for the segment.7.3.2 Cancer:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Cancer segment was valued at US$35.31 million in 2022 and is expected to reach US$98.19 million by 2030.The growth rate of this segment is projected to be 13.6%during 20222030.Figure 12.Cancer:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 28.7331.8435.3139.3644.1349.7656.4064.2773.6484.8198.19202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 32 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 7.4 Cardiovascular Diseases 7.4.1 Overview Heart diseases are a prominent cause of death worldwide and often run in families.In addition,as per the World Heart Federation 2023,rare cardiovascular diseases(CVD)are common,affecting 5%of the global population.There are over 6,000 known rare diseases,a handful of which impact the heart and circulatory system.And 83%of physicians agree that genetic testing is useful in finding the diagnosis.Certain CVD conditions,such as cardiomyopathy,arrhythmia,and connective tissue disease,are caused by a single harmful DNA variation(or mutation).However,others,such as heart attack and high blood pressure,are usually caused by the combined effect of many smaller-impact DNA variations.More than 1 in 200 people have an inherited form of CVD disease,but most are unaware of it.Patients with an inherited cardiovascular condition display few or no symptoms but still face significant risk of heart disease,including sudden cardiovascular arrest.Genetic testing can help save lives and is informative and useful for the clinical management and treatment of numerous inherited CVDs.7.4.2 Cardiovascular Diseases:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Cardiovascular diseases segment was valued at US$17.74 million in 2022 and is expected to reach US$47.39 million by 2030.The growth rate of this segment is projected to be 13.1%during 20222030.Figure 13.Cardiovascular Diseases:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 14.6016.0917.7419.6821.9524.6127.7631.4835.8841.1347.39202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 33 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 7.5 Metabolic Diseases 7.5.1 Overview Diagnosis through genetic testing can strongly help discover the cause of persistent,often debilitating,undiagnosed signs in individuals suffering from suspected genetic metabolic disease disorders.With knowledge of variants in over 1,250 metabolic disease disorders genes,the rapid testing and experience of metabolic diseases can help to diagnose and manage the patients metabolic disease disorders quickly and correctly.Ultimately,this can provide new insights into treatment choices and the probability of passing the inherited condition on to the offspring or the presence of it elsewhere in the extended family.CentoICU is a comprehensive next-generation sequencing panel that includes genes explicitly chosen for the genetic testing of extremely ill newborns and children under 24 months in intensive care units.In addition,Prevention Genetics offers a wide variety of genetic testing for inherited metabolic disease disorders,also known as inborn errors of metabolism.Panels specific to one disorder are available,as well as comprehensive metabolic diseases panels that cover broader phenotypic features or groups of similar disorders are also offered,including tests for hyperammonemia(37 genes),metabolic diseases hypoglycemia(38 genes),and metabolic diseases myopathies,rhabdomyolysis,and exercise intolerance(83 genes).Over the past year,the company has started to offer several new tests related to these metabolic disorders,and many of the existing panels have been updated to include more genes and increase clinical sensitivity.7.5.2 Metabolic Diseases:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Metabolic diseases segment was valued at US$13.32 million in 2022 and is expected to reach US$32.82 million by 2030.The growth rate of this segment is projected to be 11.9%during 20222030.Figure 14.Metabolic Diseases:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 11.1812.2013.3214.6216.1417.9220.0122.4625.3528.7732.82202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 34 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 7.6 Other Diseases 7.6.1 Overview The others segment by disease comprises Duchenne Muscular Dystrophy(DMD),Thalassemia,Huntingtons Disease,and Fragile X Syndrome,among others.Genetic mutations that cause DMD fail to produce dystrophin protein.Recessive diseases caused by alterations in genes on the X chromosome include DMD and fragile X syndrome.Genetic testing is used to diagnose Duchenne,to access mutation-specific therapies,and for family planning.For Duchenne,the dystrophin gene is examined to detect the presence of any changes or mutations that can inhibit the gene from working properly.Genetic testing is generally performed on a blood or saliva sample.A thalassemia is a group of inherited,genetic blood disorders that occur when the production of hemoglobin is disrupted.The disease is passed to children by parents carrying the mutated thalassemia gene.A kid who inherits one mutated gene is a carrier,and most carriers lead a completely normal and healthy life.At the same time,a child who inherits two thalassemia trait genes,i.e.,one from each parent,will have the disease.A child of two carriers has a 25 percent chance of developing the disease and a 50 percent chance of being a carrier.Thus,in such cases,genetic testing is helpful in detecting and diagnosing thalassemia.Currently,two major approaches are used in DNA diagnosis and study of genetic disease,namely direct tests and indirect tests(linkage analysis).Direct tests are being conducted for thalassemia and DMD.Carrier testing can be conducted for X-linked recessive disorders,such as DMD or fragile X syndrome.In these cases,the mother of an affected child with no other affected relatives may desire carrier testing to confirm whether the disease is a heritable trait or a new mutation.Many diseases may become apparent only in middle age or later.Predictive or presymptomatic testing and screening can provide symptoms that people may later develop these disorders.In some cases,a family history of a monogenic disorder in a relative informs other members of the family that they are at high risk for developing the disease.Suitable genetic testing can help to resolve whether the mutant gene is present or not.Examples include Huntingtons disease.7.6.2 Other Diseases:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Other diseases segment was valued at US$11.71 million in 2022 and is expected to reach US$21.97 million by 2030.The growth rate of this segment is projected to be 8.2%during 20222030.35 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 15.Other Diseases:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 10.3811.0311.7112.4913.3714.3915.5416.8618.3520.0521.97202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 36 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 8.Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030 by Service Provider 8.1 Overview The Middle East&Africa genetic testing services market,by service provider,is segmented into hospital-based laboratories,diagnostic laboratories,and others.In 2022,the hospital-based laboratories segment held the largest share of the market and is estimated to grow at the highest CAGR during 20222030.8.2 Middle East&Africa Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%)Figure 16.Middle East&Africa Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%)Source:The Insight Partners Analysis The hospital-based laboratories segment led the market in 2022 with a share of 63.3%and is expected to retain its dominance during 20222030 by accounting for 67.6%of the total market by 2030.63.3$.3.4 22Hospital-BasedLaboratoriesDiagnostic LaboratoriesOther End Users67.6$.6%7.8 30 37 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 8.3 Hospital-Based Laboratories 8.3.1 Overview Hospital-based laboratories are genetic testing service providers that operate within a hospital setting.For extremely specialized tests,samples may go to a research laboratory.Nearly all hospitals contain a laboratory,which is commonly proportionate in size to the population it serves.The hospitals process hundreds of samples in very les time.Tests that are performed include those needed in emergencies,such as markers for heart attack and tests where results are required rapidly for patient care.They may also offer carrier testing to determine if an individual is carriers of certain genetic conditions that can be passed on to their children.Hospital laboratories can be segmented by type of testing and staffed by personnel trained in particular specialties.For instance,some sections can focus on microbiology,hematology,chemistry,and blood banking.At the same time,some units may perform highly specialized genetic tests using electron microscopy and immunohistochemistry,and others can focus on surgical pathology and cytology,which are all linked with the investigation of cell and tissue structure.The market growth for the segment can be due to the compulsory newborn screening for genetic disorders and the growing prevalence of cancer in many regions.8.3.2 Hospital-Based Laboratories:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Hospital-based laboratories segment was valued at US$49.42 million in 2022 and is expected to reach US$135.52 million by 2030.The growth rate of this segment is projected to be 13.4%during 20222030.Figure 17.Hospital-Based Laboratories:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 40.3844.6649.4255.0061.5569.2678.3789.15101.97117.25135.52202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 38 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 8.4 Diagnostic Laboratories 8.4.1 Overview Diagnostics laboratories are independent entities that provide all the diagnostic tests,screening tests,and others to the patient.These centers may be found attached to a private or public hospital.The tests performed in the diagnostic centers are obtained earlier than hospitals.The diagnostic centers also offer packages for whole-body check-ups that are cost-effective for the patients.Tests such as cell-free fetal DNA testing,triple or quadruple screening tests,sequential screening,and others require advanced techniques,equipment,and skilled labor.However,some of the hospitals and clinics do not have all the required equipment and techniques for efficient diagnosis.Therefore,various hospitals and clinics prefer to outsource tests to diagnostics centers.The diagnostics centers are well equipped and offer better results for the tests performed for diseases and health conditions.The diagnostic centers provide multiple tests under one roof and offer all the prenatal diagnostics services such as screening,imaging,blood tests,chorionic villus sampling,and amniocentesis.Thus,it becomes easier for people to undergo genetic testing in such facilities.The growing partnerships and collaboration of diagnostic laboratories with genetic testing companies and the rise in the incidences of genetic diseases across the world are anticipated to offer growth to the market.For instance,Thermo Fisher Scientific allows laboratories to perform different genetic research and genetic testing by offering technologies such as NGS and quantitative PCR.8.4.2 Diagnostic Laboratories:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Diagnostic laboratories segment was valued at US$18.94 million in 2022 and is expected to reach US$49.23 million by 2030.The growth rate of this segment is projected to be 12.7%during 20222030.Figure 18.Diagnostic Laboratories:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 15.7017.2418.9420.9323.2626.0029.2233.0237.5242.8649.23202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 39 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 8.5 Others 8.5.1 Overview The others segment by service provider comprises academic and research institutions,pharmaceutical and biotechnology companies,and government agencies.Government agencies use genetic testing services to evaluate drugs for regulatory compliance for public health monitoring and research initiatives.Academic and research institutions are integral to the Middle East&Africa genetic testing services market.They help in identifying genetic markers,developing new genetic testing methodologies,and improving existing tests.These institutions validate and ensure the quality of genetic tests through rigorous studies,establishing their reliability and credibility.Clinical trials and studies conducted by these institutions provide essential evidence on the clinical utility and effectiveness of genetic tests.Their expertise and research efforts advance the growth of the market,benefiting both patients and healthcare providers.In addition,research and academic institutes are among the leading users of genetic testing services.Academic institutes for medical sciences and biotechnology utilize analytical testing services to support their studies on drugs.Thus,the increasing demand for genetic testing services from government agencies and research institutes will likely continue to drive the Middle East&Africa genetic testing services market for the segment.8.5.2 Others:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Others segment was valued at US$9.71 million in 2022 and is expected to reach US$15.63 million by 2030.The growth rate of this segment is projected to be 6.1%during 20222030.Figure 19.Others:Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 8.829.269.7110.2210.7911.4212.1212.8913.7414.6515.63202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 40 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 9.Middle East&Africa Genetic Testing Services Market-Country Analysis 9.1 Middle East&Africa Figure 20.Middle East&Africa Middle East&Africa Genetic Testing Services Market,by Key Country Revenue,2022(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 9.1.1 Middle East&Africa Middle East&Africa Genetic Testing Services Market,by Country Figure 21.Middle East&Africa Middle East&Africa Genetic Testing Services Market,By Key Countries,2022 and 2030(%)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources MIDDLE EAST&AFRICA(2022)22.206.8525.4223.60RoMEAUAESouth AfricaSaudi Arabia30.22.6%8.8(.4 22Saudi ArabiaSouth AfricaUAERest of Middle East&Africa33.22.4%8.5&.0 30 41 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.1 Saudi Arabia 9.1.1.1.1 Overview In Saudi Arabia,the burden of genetic diseases and congenital disabilities is rising constantly due to the culture of consanguineous marriage.The genetic diseases show up in the form of severe inherited diseases;they affect 8%of births in the Kingdom of Saudi Arabia.The Government of Saudi Arabia has made it mandatory to undergo premarital genetic testing before marriage to check genetic compatibility to reduce hereditary blood diseases such as sickle cell and beta-thalassemia,which are most prevalent in the country.Therefore,the rising prevalence of genetic diseases and increasing premarital genetic testing in the country offer opportunities to the market.The growing number of cancer cases has also fueled cancer research in Saudi Arabia.As per Globocan 2020 data,the country recorded 27,885 new cancer cases.The 5-year prevalence rate for cancer in all ages was found to be 237.4 per 100,000 people.As per the IEEE Pulse,a magazine of the IEEE Engineering in Medicine and Biology Society,there is a high burden on the national health system due to these diseases.According to the IEEE Pulse,the cost of these diseases per year is nearly US$27 billion.If there is a reduction in the number of babies born with genetic diseases,it could save up to US$270 million.In June 2023,Centogene NV and Lifera,a biopharmaceutical company,entered into a strategic collaboration to increase local and regional access,rapid delivery of world-class multiomic testing to patients in Saudi Arabia and countries of the Gulf Cooperation Council,as well as to establish a network for genetic testing services in the country.Centogene provides its leading diagnostics and multiomics expertise to the joint venture,which,together with Liferas strong local presence and resources,help to establish widespread access to local state-of-the-art genetic sequencing tailored to regional needs.The joint venture will develop capabilities for genetic testing and interpretation,working collaboratively with Centogene globally.Thus,the factors mentioned above support the growth of the market.9.1.1.1.2 Saudi Arabia Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Saudi Arabia genetic testing services market accounted for US$23.60 Mn in 2022 and it is expected to grow at a CAGR of 13.8%during the period 2022-2030,to reach US$66.45 Mn in 2030.42 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 22.Saudi Arabia Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 9.1.1.1.3 Saudi Arabia Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 2.Saudi Arabia Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 7.76 8.71 9.78 11.04 12.53 14.30 16.40 18.92 21.93 25.55 29.92 15.0rrier Testing 4.62 5.13 5.71 6.39 7.19 8.13 9.24 10.57 12.14 14.03 16.30 14.0%Prenatal Testing 2.40 2.63 2.88 3.17 3.51 3.90 4.37 4.91 5.54 6.29 7.18 12.1%Newborn Screening 2.77 3.07 3.40 3.80 4.25 4.79 5.43 6.19 7.09 8.16 9.44 13.6%Others 1.60 1.71 1.83 1.97 2.12 2.30 2.50 2.73 2.99 3.28 3.61 8.9%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Middle East&Africa genetic testing services market for the predictive testing segment was worth US$9.78 million in 2022 and is projected to reach US$29.92 million by 2030;it is expected to grow at a CAGR of 15.0%from 2022 to 2030.19.1421.2523.6026.3629.6033.4237.9443.3149.6957.3166.45202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 43 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.1.4 Saudi Arabia Genetic Testing Services Market,by Disease,20202030(US$Million)Table 3.Saudi Arabia Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 8.50 9.52 10.68 12.03 13.64 15.54 17.80 20.50 23.74 27.62 32.30 14.8rdiovascular Diseases 4.30 4.80 5.36 6.01 6.79 7.71 8.80 10.10 11.65 13.51 15.74 14.4%Metabolic Diseases 3.30 3.65 4.04 4.50 5.04 5.67 6.41 7.29 8.34 9.58 11.07 13.4%Others 3.05 3.28 3.53 3.81 4.14 4.51 4.93 5.42 5.97 6.61 7.34 9.6%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Middle East&Africa genetic testing services market for the cancer segment was worth US$10.68 million in 2022 and is projected to reach US$32.30 million by 2030;it is expected to grow at a CAGR of 14.8%from 2022 to 2030.9.1.1.1.5 Saudi Arabia Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 4.Saudi Arabia Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 11.87 13.30 14.91 16.81 19.05 21.71 24.87 28.65 33.16 38.59 45.14 14.9%Diagnostic Laboratories 4.64 5.16 5.74 6.43 7.23 8.18 9.31 10.65 12.24 14.15 16.44 14.1%Others 2.64 2.79 2.95 3.12 3.32 3.53 3.76 4.01 4.28 4.57 4.86 6.5%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Middle East&Africa genetic testing services market for the hospital-based laboratories segment was worth US$14.91 million in 2022 and is projected to reach US$45.14 million by 2030;it is expected to grow at a CAGR of 14.9%from 2022 to 2030.44 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.2 UAE 9.1.1.2.1 Overview The UAE is always at the forefront of providing the best facilities to its citizens and believes in building a healthy society for its citizens.In 2019,the UAE government launched an initiative to set up a state-of-the-art Genome Center to use the benefits of genetic science.It also focused on the implementation of modern and novel techniques,which consist of DNA sequencing,profiling,and microarray.The initiative intends to control the spread of non-communicable diseases such as cancer and provide the platform to create personalized medicine programs for patients.The Ministry of Health and Prevention(MOHAP)also collaborated with Pure Health Laboratory Network to launch the first phase of the genome center in the country.The aim is to create a genome database for all genetic diseases in the UAE.In November 2023,the Department of HealthAbu Dhabi(DoH),in line with its continuous efforts to upskill the national healthcare workforce,launched the Clinical Genomic Medicine and Genetic Counselling Program for 100 Emirati physicians from diverse healthcare facilities across the country.The six-month program is the regions first program offered by experts from Harvard Medical School Teaching Hospitals.It aims to equip medical professionals with the essential knowledge and skills to handle genetic and genomic issues in the clinical setting.Similarly,in November 2022,Illumina inaugurated its Illumina Solutions Centre in Dubai.The Centre is furnished with genetic testing equipment,such as a fully operational lab with the latest NGS technologies.It offers training in diagnostic tests,such as noninvasive prenatal screening or genomic tests for cancer.Thus,the factors mentioned above are likely to support the Middle East&Africa genetic testing services market growth in the country during 20222030.9.1.1.2.2 UAE Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)The UAE genetic testing services market accounted for US$6.85 Mn in 2022 and it is expected to grow at a CAGR of 12.0%during the period 2022-2030,to reach US$16.94 Mn in 2030.Figure 23.UAE Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 5.756.286.857.538.319.2310.3111.5813.0814.8416.94202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 45 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.2.3 UAE Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 5.UAE Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 2.34 2.58 2.84 3.15 3.51 3.93 4.43 5.01 5.71 6.53 7.51 12.9rrier Testing 1.38 1.51 1.65 1.82 2.01 2.24 2.50 2.81 3.18 3.62 4.13 12.2%Prenatal Testing 0.69 0.75 0.81 0.88 0.96 1.06 1.17 1.31 1.46 1.64 1.86 10.9%Newborn Screening 0.78 0.85 0.93 1.02 1.12 1.24 1.38 1.55 1.74 1.97 2.24 11.7%Others 0.55 0.59 0.62 0.66 0.71 0.77 0.83 0.90 0.99 1.08 1.19 8.4%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Middle East&Africa genetic testing services market for the predictive testing segment was worth US$2.84 million in 2022 and is projected to reach US$7.51 million by 2030;it is expected to grow at a CAGR of 12.9%from 2022 to 2030.9.1.1.2.4 UAE Genetic Testing Services Market,by Disease,20202030(US$Million)Table 6.UAE Middle East&Africa Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 2.58 2.83 3.11 3.44 3.82 4.27 4.79 5.42 6.15 7.03 8.06 12.7rdiovascular Diseases 1.29 1.42 1.56 1.72 1.91 2.13 2.39 2.69 3.05 3.48 3.99 12.5%Metabolic Diseases 1.00 1.10 1.20 1.31 1.45 1.61 1.80 2.03 2.29 2.60 2.96 12.0%Others 0.88 0.93 0.99 1.06 1.14 1.23 1.33 1.45 1.58 1.74 1.92 8.6%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Middle East&Africa genetic testing services market for the cancer segment was worth US$3.11 million in 2022 and is projected to reach US$8.06 million by 2030;it is expected to grow at a CAGR of 12.7%from 2022 to 2030.9.1.1.2.5 UAE Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 7.UAE Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 3.58 3.95 4.35 4.82 5.37 6.02 6.79 7.69 8.76 10.03 11.54 13.0%Diagnostic Laboratories 1.39 1.52 1.67 1.84 2.04 2.28 2.55 2.88 3.26 3.72 4.26 12.4%Others 0.78 0.81 0.83 0.86 0.90 0.93 0.97 1.01 1.06 1.10 1.14 4.0%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 46 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners The Middle East&Africa genetic testing services market for the hospital-based laboratories segment was worth US$4.35 million in 2022 and is projected to reach US$11.54 million by 2030;it is expected to grow at a CAGR of 13.0%from 2022 to 2030.9.1.1.3 South Africa 9.1.1.3.1 Overview South Africa is undergoing significant developments in healthcare facilities and infrastructure.Developments in healthcare systems are likely to trigger the adoption of advanced technologies for the diagnosis and treatment of various conditions among a large patient population,which creates lucrative opportunities for the market.As per the Globocan 2020 data,a total of 108,168 new cancer cases were diagnosed in the country in 2020.Of the total,51,059 cases were observed in males and 57,109 in females.As per the same source,cancer-related mortality accounted for 56,802 in the same year.In South Africa,the incidences of breast cancer among women are increasing,and it is one of the most common cancers among women in the country.As per the Risk factors for breast cancer among women in Ekurhuleni Metropolitan Municipality,Gauteng province of South Africa,a study published in 2023,breast cancer is common cancer among women in South Africa,with an age-standardized incidence rate of 52.6 and an age-standardized mortality rate of 16.0 per 100,000 population.In 2020,breast cancer accounted for 23%of all cancers in women.Additionally,according to the Stellenbosch University data,more than 4.1 million individuals in the country are living with a rare disease.In addition,one in 15 people is estimated to contract a rare disease at some point in their lives in the country.Various universities and organizations work toward raising awareness regarding these diseases in the country.Rare Disease Genomics in South Africa research group,based at Stellenbosch Universitys Faculty of Medicine and Health Sciences and Tygerberg Hospital,hosts a social media campaign every February to enhance awareness about rare diseases.Thus,the increasing number of genetic diseases requiring genetic testing and growing efforts to raise awareness about the diseases among the countrys population are likely to augment the market.9.1.1.3.2 South Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)South Africa genetic testing services market accounted for US$25.42 Mn in 2022 and it is expected to grow at a CAGR of 12.4%during the period 2022-2030,to reach US$64.92 Mn in 2030.47 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 24.South Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 9.1.1.3.3 South Africa Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 8.South Africa Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 9.15 10.10 11.15 12.37 13.81 15.51 17.50 19.87 22.67 26.01 29.99 13.2rrier Testing 5.40 5.94 6.53 7.23 8.05 9.01 10.14 11.47 13.05 14.93 17.16 12.8%Prenatal Testing 2.19 2.38 2.59 2.83 3.11 3.44 3.83 4.28 4.81 5.44 6.18 11.5%Newborn Screening 2.61 2.86 3.13 3.46 3.83 4.27 4.79 5.41 6.13 6.99 8.01 12.5%Others 1.81 1.91 2.02 2.14 2.28 2.44 2.62 2.82 3.04 3.30 3.58 7.4%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Middle East&Africa genetic testing services market for the predictive testing segment was worth US$11.15 million in 2022 and is projected to reach US$29.99 million by 2030;it is expected to grow at a CAGR of 13.2%from 2022 to 2030.21.1623.1825.4228.0331.0934.6738.8843.8449.7056.6664.92202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 48 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.3.4 South Africa Genetic Testing Services Market,by Disease,20202030(US$Million)Table 9.South Africa Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 9.38 10.42 11.57 12.91 14.50 16.37 18.58 21.20 24.32 28.05 32.51 13.8rdiovascular Diseases 4.76 5.24 5.78 6.40 7.13 7.98 8.99 10.19 11.60 13.28 15.29 12.9%Metabolic Diseases 3.66 3.99 4.35 4.78 5.27 5.85 6.53 7.33 8.27 9.38 10.70 11.9%Others 3.35 3.54 3.73 3.94 4.19 4.46 4.77 5.12 5.51 5.94 6.42 7.0%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Middle East&Africa genetic testing services market for the cancer segment was worth US$11.57 million in 2022 and is projected to reach US$32.51 million by 2030;it is expected to grow at a CAGR of 13.8%from 2022 to 2030.9.1.1.3.5 South Africa Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 10.South Africa Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 13.19 14.55 16.07 17.85 19.93 22.38 25.27 28.69 32.75 37.58 43.35 13.2%Diagnostic Laboratories 5.11 5.63 6.19 6.86 7.63 8.55 9.63 10.90 12.40 14.19 16.33 12.9%Others 2.86 3.01 3.16 3.33 3.52 3.74 3.98 4.25 4.55 4.88 5.24 6.5%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Middle East&Africa genetic testing services market for the hospital-based laboratories segment was worth US$16.07 million in 2022 and is projected to reach US$43.35 million by 2030;it is expected to grow at a CAGR of 13.2%from 2022 to 2030.49 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.4 Rest of Middle East&Africa 9.1.1.4.1 Overview Israel,Iraq,Oman,Iran,Egypt,Turkey,Kuwait,and Kenya are among the major countries in the Rest of Middle East&Africa.The increasing number of cancer cases across the Middle East&Africa is boosting the market growth.According to Globocan 2020,30,000 cancer cases and 11,000 cancer-related death cases are reported yearly in Israel.As per the same source,a total of 131,191 new cancer cases(380.7 per 100,000 people)were reported in 2020 in Iran.Among the total,70,704 new cases were diagnosed in males,while 60,487 were diagnosed in females.The source further stated that 79,136 deaths occurred due to cancer in the same year.In addition,134,632 new cancer cases were diagnosed in 2020,and 89,042 cancer-related deaths occurred in 2020 in Egypt.Of the total,66,542 cancer cases were diagnosed in men and 68,090 in women.The increasing number of breast cancer cases across the Rest of the Middle East&Africa is boosting the growth of the market.According to Globocan 2020,7,515 new breast cancer cases were diagnosed in Iraq,of which 3,019 deaths were reported in the country.The five-year prevalence rate of breast cancer in all ages in the country was 102.46 per 100,000 population.As per the same source,16,967 new breast cancer cases were reported in Iran.The five-year prevalence rate of breast cancer in all ages was 134.46 per 100,000 population in the country.Genetic tests help to detect the probability of the development of a genetic disorder or the same being passed on to the next generation.It helps to detect cancers such as breast,prostate,and colon.The growing healthcare facilities in these countries and the increasing presence of international market players are also estimated to offer a favorable environment for market growth.9.1.1.4.2 Rest of Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)The Rest of Middle East&Africa genetic testing services market accounted for US$22.20 Mn in 2022 and it is expected to grow at a CAGR of 11.2%during the period 2022-2030,to reach US$52.07 Mn in 2030.Figure 25.Rest of Middle East&Africa Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 18.8520.4522.2024.2326.5929.3532.5736.3440.7545.9552.07202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 50 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.4.3 Rest of Middle East&Africa Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 11.Rest of Middle East&Africa Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 8.23 9.05 9.96 11.01 12.25 13.69 15.38 17.38 19.73 22.51 25.82 12.7rrier Testing 4.81 5.23 5.69 6.23 6.85 7.58 8.44 9.43 10.61 11.99 13.62 11.5%Prenatal Testing 1.76 1.88 2.01 2.15 2.32 2.52 2.74 3.00 3.30 3.65 4.06 9.2%Newborn Screening 2.32 2.50 2.68 2.90 3.15 3.44 3.78 4.18 4.64 5.17 5.80 10.1%Others 1.72 1.79 1.85 1.93 2.02 2.12 2.23 2.35 2.48 2.62 2.77 5.2%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Middle East&Africa genetic testing services market for the predictive testing segment was worth US$9.96 million in 2022 and is projected to reach US$25.82 million by 2030;it is expected to grow at a CAGR of 12.7%from 2022 to 2030.9.1.1.4.4 Rest of Middle East&Africa Genetic Testing Services Market,by Disease,20202030(US$Million)Table 12.Rest of Middle East&Africa Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 8.27 9.07 9.95 10.98 12.18 13.58 15.22 17.15 19.43 22.12 25.31 12.4rdiovascular Diseases 4.25 4.63 5.05 5.55 6.12 6.79 7.58 8.50 9.58 10.86 12.37 11.8%Metabolic Diseases 3.22 3.46 3.73 4.03 4.38 4.79 5.26 5.81 6.46 7.21 8.09 10.2%Others 3.11 3.28 3.46 3.67 3.92 4.19 4.51 4.87 5.28 5.76 6.30 7.8%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Middle East&Africa genetic testing services market for the cancer segment was worth US$9.95 million in 2022 and is projected to reach US$25.31 million by 2030;it is expected to grow at a CAGR of 12.4%from 2022 to 2030.51 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.4.5 Rest of Middle East&Africa Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 13.Rest of Middle East&Africa Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 11.74 12.86 14.09 15.52 17.19 19.15 21.44 24.13 27.30 31.05 35.49 12.2%Diagnostic Laboratories 4.56 4.93 5.33 5.80 6.35 6.98 7.73 8.59 9.61 10.80 12.20 10.9%Others 2.55 2.66 2.77 2.90 3.05 3.22 3.41 3.61 3.85 4.10 4.39 5.9%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Middle East&Africa genetic testing services market for the hospital-based laboratories segment was worth US$14.09 million in 2022 and is projected to reach US$35.49 million by 2030;it is expected to grow at a CAGR of 12.2%from 2022 to 2030.52 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 10.Genetic Testing Services MarketIndustry Landscape 10.1 Overview The developments in the Middle East&Africa genetic testing services market have been characterized by organic and inorganic growth strategies.Various companies are focusing on organic growth strategies such as launches,expansion,enhancement,and relocation.Inorganic growth strategies witnessed in the market include mergers&acquisitions,partnerships,and collaborations.These activities have paved the way for the expansion of business and the customer base of market players.Additionally,growth strategies such as acquisitions and partnerships helped in strengthening their customer base and increase the product portfolio.The companies have maximized their growth with several inorganic strategies to enhance the market value and position in the market.The organic developments hold 73.33%of the total strategic developments in the market.Whereas the inorganic strategies helped by 26.67%for the growth of the companies.10.2 Growth Strategies in Middle East&Africa Genetic Testing Services Market Figure 26.Growth Strategies in Middle East&Africa Genetic Testing Services Market Source:The Insight Partners Analysis 26.67s.33%Inorganic StrategiesOrganic Strategies 53 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 10.3 Organic Growth Strategies 10.3.1 Overview Various companies have adopted organic growth strategies in genetic testing services market.Some of the activities that have helped the companies promote their growth are launches,expansion,relocation activities.23andMe Holding Co is among the companies that have been implementing organic strategies,which,in turn,have brought about various changes in the global health economics and outcomes research services market.The companies have utilized strategies such as new product launch to expand their geographic reach and capacity to cater to a large number of customers.Some of the organic developments are listed below.Table 14.Recent Organic Growth Strategies in Middle East&Africa Genetic Testing Services Market CompanyCompany Month&YearMonth&Year CategoryCategory DescriptionDescription 23andMe Holding Co Nov-2023 Product Launch 23andMe Holding Co launched 23andMe Total Health,a new membership that offers that provides clinical grade exome sequencing,biannual blood testing,and access to genetics-based clinical care.Illumina Inc.Nov-2023 Company News Illumina Inc.announced the launch of the Global Health Access Initiative.It is anticipated that the effort will help low-and middle-income nations have access to pathogen sequencing tools for public health.The program will address major international logistics and supply chain challenges and offer discounted pricing structures for Illuminas eligible sequencing products to qualified global health funding entities.It was developed with input from customers,funders,and market facilitators,including the nonprofit FIND.23andMe Holding Co Oct-2023 Product Launch 23andMe Holding Co launched Health Action Plan,a new digital tool that utilizes results from genetic reports,health history survey data,and blood and biomarker data to provide a tailored set of health recommendations to its members.CENTOGENE Oct-2023 Product Launch The company expanded its Multiomic Diagnostic Portfolio with incorporation of transcriptomic analysis.It allows to combine DNA sequencing,biochemical testing,and RNA sequencing to improve testing capability.NeoGenomics Inc Oct-2023 Product Launch NeoGenomics Inc launched two new tests to expand its portfolio of cancer products including Early-stage Non-Small Cell Lung Cancer Panel and the Neo Comprehensive-Heme Cancers Panel.Quest Diagnostics Inc Jul-2023 Product Launch Quest Diagnostics Inc announced launch of first consumer-initiated genetic test,Genetic Insights.The test can be accessed at via its consumer health business.With the launch of advanced technology and end-to-end support,including personalized health reports and genetic counseling,consumers will be able to understand their potential risk of having certain inheritable health issues.Laboratory Corp of America Holdings Jun-2023 Company News Laboratory Corp of America Holdings announced it has completed the spin-off of Fortrea.Fortrea was the companys newly formed independent Contract Research Organization that provides Phase I-IV clinical trial management,patient access,and technology solutions to pharmaceutical and biotechnology organizations globally.After the spin-off,Fortrea will be enlisted as a new entity and will begin trading on the NASDAQ Stock Market under the symbol FTRE effective from July 3,2023.54 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners CompanyCompany Month&YearMonth&Year CategoryCategory DescriptionDescription CENTOGENE Apr-2023 Product Launch The company released FilterTool,a web-based application for interpreting genetic data.FilterTool connects with CentoCloud to effectively show,filter,select,and categorize pertinent genetic variations found through Next Generation Sequencing(NGS)data processing.Ambry Genetics Corp Nov-2022 Product News Ambry Genetics Corp launched a reproductive health program.It driven by its Comprehensive Assessment Risk and Education program,which is a digital platform that enhances the patient and provider experience through easier access to genetic education,testing,reporting and counseling.Eurofins Scientific Sep-2022 Product Launch The niPGT-A screening test aims to enable in vitro fertilization centers to produce quality embryo samples,avoiding the need for embryo biopsies.It will allow medical practitioners to determine chromosomal abnormalities in in vitro fertilization embryos,which may lead to complications during pregnancy.Eurofins Scientific Feb-2022 Expansion Eurofins Scientifics subsidiary,Eurofins Clinical Testing Lux Sarl,acquired Genetic Testing Service JSC,located in Vietnam.Through this acquisition,the company aims to expand its network in Asia and strengthen its global network of clinical diagnostic laboratories,which primarily focus on specialized and advanced genetic testing.Source:The Insight Partners Analysis 10.4 Inorganic Growth Strategies 10.4.1 Overview The inorganic growth strategies undertaken by the companies operating in the global market of genetic testing services include collaboration,partnership,agreement&joint venture.During 20202022,companies such as Ambry Genetics Corp has undertaken various inorganic strategies that have bought about remarkable developments in the Middle East&Africa genetic testing services market due to the involvement of major players which has led to availability of better products in the market.Table 15.Recent Inorganic Growth Strategies in the Middle East&Africa Genetic Testing Services Market CompanyCompany Month&YearMonth&Year CategoryCategory DescriptionDescription 23andMe Holding Co Oct-2023 Collaboration 23andMe Holding Co announced a non-exclusive data license collaboration with GSK plc,which enables GSK to conduct drug target discovery and other research using the 23andMe database.Ambry Genetics Corp Apr-2023 Collaboration Ambry Genetics Corp collaborated with LifeStrands Genomics to offer clinical genetic testing services in Singapore.Both the companies will support the Clinical Implementation Pilots(CIPs)for Phase II of Singapores National Precision Medicine(NPM)programme.Ambry Genetics Corp Jan-2023 Partnership Ambry Genetics Corp partnered with Unilabs to enhance genetic testing services for biopharma businesses in Europe,Latin America,and the Middle East,where it does not have a physical presence.It will cater to these markets by utilizing Unilabs genomic lab services and variant interpretation skills.Ambry,on the other hand,will provide Unilabs with its variant assessment skills.55 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners CompanyCompany Month&YearMonth&Year CategoryCategory DescriptionDescription Exact Sciences Jan-2022 Mergers and Acquisitions Exact Sciences has acquired PreventionGenetics,a genetic testing laboratory,to accelerate the availability of hereditary cancer testing for more patients.Source:The Insight Partners Analysis 56 Middle East&Africa Genetic Testing Services Market,2020-2030 |The Insight Partners 11.Company Profiles 11.1 Eurofins Scientific SE 11.1.1 Key Facts Eurofins Scientific SEEurofins Scientific SE Founded 1987 Corporate Address 23 Val Fleuri,L-1526,Luxembourg Headquarter Luxembourg Telephone 32 2 7661620 URL Location Global Exchange Ticker Symbol XLUX:ERF Number of Employees 61,379 Fiscal Year End Dec-2022 11.1.2 Business Description Eurofins Scientific SE is a life sciences company that provides analytical testing services to clients in various industries.It provides forensic services,food and feed testing,environmental testing,biopharma services,pharma discovery services,pharma early development,a pharma central laboratory,biopharma product testing,and product testing.The companys analytical techniques aid in assessing the purity,authenticity,and safety of biological goods and chemicals.To provide a variety of services,it makes use of its expertise in information technology and logistics.The company has operations in South America,the Middle East,Asia Pacific,Europe,and North America.As of December 2022,the company served 61 countries with 900 laboratories,a portfolio of over 200,000 analytical methods,and mo
2024-08-12
89页
5星级
Europe Bioreactors Market Market Size and Forecasts(2020-2030)and Regional Growth Opportunity Analysis Coverage:Scale(Lab-Scale Production,Pilot-Scale Production,and Full-Scale Production),Application(Microbial Application,Cell Culture Application,and Others),Technology(Fed-Batch Bioreactors,Perfusion Bioreactors),End User(Biopharma Manufacturers,Research and Development Organizations,and Contract Manufacturing Organization),and Country 2 Europe Bioreactors Market,2020-2030 |The Insight Partners Table of Content 1.Introduction.11 1.1 The Insight Partners Research Report Guidance.11 1.2 Market Segmentation.12 2.Executive Summary.13 2.1 Key Insights.13 3.Research Methodology.14 3.1 Coverage.15 3.2 Secondary Research.16 3.3 Primary Research.16 4.Europe Bioreactors Market-Key Industry Dynamics.17 4.1 Bioreactors Market-Key Industry Dynamics.17 4.2 Market Drivers.17 4.2.1 Increasing Adoption of Single-Use Bioreactors.17 4.2.2 Rapid Growth of Pharmaceutical and Biotechnology Industry.18 4.3 Market Restraints.18 4.3.1 Stringent Regulatory Framework.18 4.4 Market Opportunities.18 4.4.1 Rising Demand for Personalized Medicine.18 4.5 Future Trends.19 4.5.1 Technological Advancements in Bioreactors.19 4.6 Impact of Drivers and Restraints:.20 5.Bioreactors Market-Europe Market Analysis.21 5.1 Overview.21 5.1.1 Bioreactors Market Revenue(US$Million),2020 2030.21 6.Europe Bioreactors Market Analysis-Scale.22 6.1 Overview.22 6.2 Bioreactors Market Revenue Share,by Scale 2022&2030(%).22 6.3 Lab-Scale Production.22 6.3.1 Overview.22 6.3.2 Lab-Scale Production Market,Revenue and Forecast to 2030(US$Million).23 6.4 Pilot-Scale Production.24 3 Europe Bioreactors Market,2020-2030 |The Insight Partners 6.4.1 Overview.24 6.4.2 Pilot-Scale Production Market,Revenue and Forecast to 2030(US$Million).24 6.5 Full-Scale Production.25 6.5.1 Overview.25 6.5.2 Full-Scale Production Market,Revenue and Forecast to 2030(US$Million).25 7.Europe Bioreactors Market Analysis-Application.26 7.1 Overview.26 7.2 Bioreactors Market Revenue Share,by Application 2022&2030(%).26 7.3 Microbial Application.26 7.3.1 Overview.26 7.3.2 Microbial Application Market,Revenue and Forecast to 2030(US$Million).27 7.4 Cell Culture Application.28 7.4.1 Overview.28 7.4.2 Cell Culture Application Market,Revenue and Forecast to 2030(US$Million).28 7.5 Others.29 7.5.1 Overview.29 7.5.2 Others Market,Revenue and Forecast to 2030(US$Million).30 8.Europe Bioreactors Market Analysis-Technology.31 8.1 Overview.31 8.2 Bioreactors Market Revenue Share,by Technology 2022&2030(%).31 8.3 Fed-Batch Bioreactors.31 8.3.1 Overview.31 8.3.2 Fed-Batch Bioreactors Market,Revenue and Forecast to 2030(US$Million).32 8.4 Perfusion Bioreactors.33 8.4.1 Overview.33 8.4.2 Perfusion Bioreactors Market,Revenue and Forecast to 2030(US$Million).33 9.Europe Bioreactors Market Analysis-End User.34 9.1 Overview.34 9.2 Bioreactors Market Revenue Share,by End User 2022&2030(%).34 9.3 Biopharma Manufacturers.35 9.3.1 Overview.35 9.3.2 Biopharma Manufacturers Market,Revenue and Forecast to 2030(US$Million).35 9.4 Research and Development Organizations.36 9.4.1 Overview.36 4 Europe Bioreactors Market,2020-2030 |The Insight Partners 9.4.2 Research and Development Organizations Market,Revenue and Forecast to 2030(US$Million).36 9.5 Contract Manufacturing Organization.37 9.5.1 Overview.37 9.5.2 Contract Manufacturing Organization Market,Revenue and Forecast to 2030(US$Million).37 10.Europe Bioreactors Market by Country Analysis.38 10.1 Europe:Bioreactors Market.38 10.1.1 Europe Bioreactors Market Revenue and Forecasts and Analysis-By Country.38 10.1.1.1 Germany.38 10.1.1.2 Overview.38 10.1.1.3 Germany:Bioreactors Market Revenue and Forecast to 2030(US$Million).39 10.1.1.3.1 Germany Bioreactors Market Breakdown by Scale.39 10.1.1.3.2 Germany Bioreactors Market Breakdown by Application.40 10.1.1.3.3 Germany Bioreactors Market Breakdown by Technology.40 10.1.1.3.4 Germany Bioreactors Market Breakdown by End User.41 10.1.1.4 France.42 10.1.1.5 Overview.42 10.1.1.6 France:Bioreactors Market Revenue and Forecast to 2030(US$Million).42 10.1.1.6.1 France Bioreactors Market Breakdown by Scale.42 10.1.1.6.2 France Bioreactors Market Breakdown by Application.43 10.1.1.6.3 France Bioreactors Market Breakdown by Technology.43 10.1.1.6.4 France Bioreactors Market Breakdown by End User.44 10.1.1.7 UK.45 10.1.1.8 Overview.45 10.1.1.9 UK:Bioreactors Market Revenue and Forecast to 2030(US$Million).45 10.1.1.9.1 UK Bioreactors Market Breakdown by Scale.46 10.1.1.9.2 UK Bioreactors Market Breakdown by Application.46 10.1.1.9.3 UK Bioreactors Market Breakdown by Technology.46 10.1.1.9.4 UK Bioreactors Market Breakdown by End User.47 10.1.1.10 Italy.47 10.1.1.11 Overview.47 10.1.1.12 Italy:Bioreactors Market Revenue and Forecast to 2030(US$Million).48 10.1.1.12.1 Italy Bioreactors Market Breakdown by Scale.48 10.1.1.12.2 Italy Bioreactors Market Breakdown by Application.49 10.1.1.12.3 Italy Bioreactors Market Breakdown by Technology.49 5 Europe Bioreactors Market,2020-2030 |The Insight Partners 10.1.1.12.4 Italy Bioreactors Market Breakdown by End User.49 10.1.1.13 Spain.50 10.1.1.14 Overview.50 10.1.1.15 Spain:Bioreactors Market Revenue and Forecast to 2030(US$Million).50 10.1.1.15.1 Spain Bioreactors Market Breakdown by Scale.51 10.1.1.15.2 Spain Bioreactors Market Breakdown by Application.51 10.1.1.15.3 Spain Bioreactors Market Breakdown by Technology.51 10.1.1.15.4 Spain Bioreactors Market Breakdown by End User.52 10.1.1.16 Rest of Europe.53 10.1.1.17 Overview.53 10.1.1.18 Rest of Europe:Bioreactors Market Revenue and Forecast to 2030(US$Million).53 10.1.1.18.1 Rest of Europe Bioreactors Market Breakdown by Scale.54 10.1.1.18.2 Rest of Europe Bioreactors Market Breakdown by Application.54 10.1.1.18.3 Rest of Europe Bioreactors Market Breakdown by Technology.54 10.1.1.18.4 Rest of Europe Bioreactors Market Breakdown by End User.55 11.Bioreactors Market-Industry Landscape.56 11.1 Overview.56 11.2 Growth Strategies in the Bioreactors Market.56 11.3 Inorganic Growth Strategies.57 11.3.1 Overview.57 11.4 Organic Growth Strategies.58 11.4.1 Overview.58 12.Company Profiles.59 12.1 PBS Biotech Inc.59 12.1.1 Key Facts.59 12.1.2 Business Description.59 12.1.3 Products and Services.59 12.1.4 Financial Overview.60 12.1.5 SWOT Analysis.60 12.1.6 Key Developments.61 12.2 Cellexus International Ltd.62 12.2.1 Key Facts.62 12.2.2 Business Description.62 12.2.3 Products and Services.62 6 Europe Bioreactors Market,2020-2030 |The Insight Partners 12.2.4 Financial Overview.62 12.2.5 SWOT Analysis.63 12.2.6 Key Developments.64 12.3 General Electric Co.65 12.3.1 Key Facts.65 12.3.2 Business Description.65 12.3.3 Products and Services.66 12.3.4 Financial Overview.66 12.3.5 SWOT Analysis.68 12.3.6 Key Developments.68 12.4 Merck KGaA.69 12.4.1 Key Facts.69 12.4.2 Business Description.69 12.4.3 Products and Services.70 12.4.4 Financial Overview.70 12.4.5 SWOT Analysis.72 12.4.6 Key Developments.73 12.5 Thermo Fisher Scientific Inc.74 12.5.1 Key Facts.74 12.5.2 Business Description.74 12.5.3 Products and Services.75 12.5.4 Financial Overview.76 12.5.5 SWOT Analysis.77 12.5.6 Key Developments.78 12.6 bbi-biotech GmbH.79 12.6.1 Key Facts.79 12.6.2 Business Description.79 12.6.3 Products and Services.79 12.6.4 SWOT Analysis.80 12.6.5 Key Developments.80 12.7 Sartorius AG.81 12.7.1 Key Facts.81 12.7.2 Business Description.81 12.7.3 Products and Services.82 12.7.4 Financial Overview.82 7 Europe Bioreactors Market,2020-2030 |The Insight Partners 12.7.5 SWOT Analysis.84 12.7.6 Key Developments.84 12.8 Pall Corp.85 12.8.1 Key Facts.85 12.8.2 Business Description.85 12.8.3 Products and Services.85 12.8.4 Financial Overview.85 12.8.5 SWOT Analysis.86 12.8.6 Key Developments.86 12.9 Solaris Biotechnology SRL.87 12.9.1 Key Facts.87 12.9.2 Business Description.87 12.9.3 Products and Services.87 12.9.4 Financial Overview.87 12.9.5 SWOT Analysis.88 12.9.6 Key Developments.88 12.10 Applikon Biotechnology BV.89 12.10.1 Key Facts.89 12.10.2 Business Description.89 12.10.3 Products and Services.89 12.10.4 Financial Overview.89 12.10.5 SWOT Analysis.90 12.10.6 Key Developments.90 13.Appendix.91 13.1 About The Insight Partners.91 13.2 Glossary of Terms.92 8 Europe Bioreactors Market,2020-2030 |The Insight Partners List of Tables Table 1.Bioreactors Market Segmentation.12 Table 2.Germany Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Scale.39 Table 3.Germany Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Application.40 Table 4.Germany Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Technology.40 Table 5.Germany Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By End User.41 Table 6.France Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Scale.42 Table 7.France Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Application.43 Table 8.France Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Technology.43 Table 9.France Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By End User.44 Table 10.UK Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Scale.46 Table 11.UK Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Application.46 Table 12.UK Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Technology.46 Table 13.UK Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By End User.47 Table 14.Italy Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Scale.48 Table 15.Italy Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Application.49 Table 16.Italy Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Technology.49 Table 17.Italy Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By End User.49 Table 18.Spain Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Scale.51 Table 19.Spain Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Application.51 Table 20.Spain Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Technology.51 Table 21.Spain Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By End User.52 Table 22.Rest of Europe Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Scale.54 9 Europe Bioreactors Market,2020-2030 |The Insight Partners Table 23.Rest of Europe Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Application.54 Table 24.Rest of Europe Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Technology.54 Table 25.Rest of Europe Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By End User.55 Table 26.Recent Inorganic Growth Strategies in the Bioreactors Market.57 Table 27.Recent Organic Growth Strategies in the Bioreactors Market.58 Table 28.Glossary of Terms,Bioreactors Market.92 10 Europe Bioreactors Market,2020-2030 |The Insight Partners List of Figures Figure 1.Bioreactors Market Segmentation,By Country.12 Figure 2.Impact Analysis of Drivers and Restraints.20 Figure 3.Bioreactors Market Revenue(US$Million),2020 2030.21 Figure 4.Bioreactors Market Revenue Share,by Scale 2022&2030(%).22 Figure 5.Lab-Scale Production Market Revenue and Forecasts to 2030(US$Million).23 Figure 6.Pilot-Scale Production Market Revenue and Forecasts to 2030(US$Million).24 Figure 7.Full-Scale Production Market Revenue and Forecasts to 2030(US$Million).25 Figure 8.Bioreactors Market Revenue Share,by Application 2022&2030(%).26 Figure 9.Microbial Application Market Revenue and Forecasts to 2030(US$Million).27 Figure 10.Cell Culture Application Market Revenue and Forecasts to 2030(US$Million).28 Figure 11.Others Market Revenue and Forecasts to 2030(US$Million).30 Figure 12.Bioreactors Market Revenue Share,by Technology 2022&2030(%).31 Figure 13.Fed-Batch Bioreactors Market Revenue and Forecasts to 2030(US$Million).32 Figure 14.Perfusion Bioreactors Market Revenue and Forecasts to 2030(US$Million).33 Figure 15.Bioreactors Market Revenue Share,by End User 2022&2030(%).34 Figure 16.Biopharma Manufacturers Market Revenue and Forecasts to 2030(US$Million).35 Figure 17.Research and Development Organizations Market Revenue and Forecasts to 2030(US$Million).36 Figure 18.Contract Manufacturing Organization Market Revenue and Forecasts to 2030(US$Million).37 Figure 19.Europe:Bioreactors Market,by Key Country Revenue(2022)(US$Million).38 Figure 20.Europe Bioreactors Market Breakdown by Key Countries,2022 and 2030(%).38 Figure 21.Germany Bioreactors Market Revenue and Forecasts to 2030(US$Mn).39 Figure 22.France Bioreactors Market Revenue and Forecasts to 2030(US$Mn).42 Figure 23.UK Bioreactors Market Revenue and Forecasts to 2030(US$Mn).45 Figure 24.Italy Bioreactors Market Revenue and Forecasts to 2030(US$Mn).48 Figure 25.Spain Bioreactors Market Revenue and Forecasts to 2030(US$Mn).50 Figure 26.Rest of Europe Bioreactors Market Revenue and Forecasts to 2030(US$Mn).53 Figure 27.Growth Strategies in the Bioreactors Market.56 11 Europe Bioreactors Market,2020-2030 |The Insight Partners 1.Introduction 1.1 The Insight Partners Research Report Guidance The report provides qualitative and quantitative trends of Europe bioreactors market across scale,application,technology,end user,and country.The report starts with the key takeaways(chapter two),highlighting the key trends and outlook of the Europe bioreactors market.Chapter 3 provides the research methodology of the study.Chapter 4 highlights the key industry dynamics in the bioreactors market,including factors that are driving the market,prevailing deterrent,potential opportunities as well as future trends.Impact analysis of these drivers and restraints is also covered in this section.Chapter 5 discusses the Europe bioreactors market scenario,in terms of historical market revenues,and forecast till the year 2030.Chapter 6 to 10 discuss bioreactors market segments by scale,application,technology,end user,and country across Europe.They cover market revenue forecast,and factors driving and governing growth.Chapter 11 describes the industry landscape analysis.It provides detailed description of various business activities such as market initiatives,new developments,mergers,and joint ventures globally along with a competitive landscape.Chapter 12 provides the detailed profiles of the key companies operating in the Europe Bioreactors Market.The companies have been profiled on the basis of their key facts,business description,products and services,financial overview,SWOT analysis,and key developments.Chapter 13,i.e.,the appendix is inclusive of a brief overview of the company,glossary of terms,contact information,and the disclaimer section.12 Europe Bioreactors Market,2020-2030 |The Insight Partners 1.2 Market Segmentation Table 1.Bioreactors Market Segmentation SCALESCALE APPLICATIONAPPLICATION TECHNOLOGYTECHNOLOGY END USEREND USER LAB-SCALE PRODUCTION PILOT-SCALE PRODUCTION FULL-SCALE PRODUCTION MICROBIAL APPLICATION CELL CULTURE APPLICATION OTHERS FED-BATCH BIOREACTORS PERFUSION BIOREACTORS BIOPHARMA MANUFACTURERS RESEARCH AND DEVELOPMENT ORGANIZATIONS CONTRACT MANUFACTURING ORGANIZATION Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources Figure 1.Bioreactors Market Segmentation,By Country Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources The Europe bioreactors market is segmented based on scale,application,technology,end user,and country.The segmentation in this research study has been finalized post in-depth secondary research and extensive primary research.EUROPEFRANCE GERMANY UK SPAINITALY RoE 13 Europe Bioreactors Market,2020-2030 |The Insight Partners 2.Executive Summary 2.1 Key Insights GROWTH DRIVERSRESTRAINTSFUTURE TRENDSOPPORTUNITY Driver 1 Driver 2 Restraints 1 Restraints 2 Trends 1 Trends 2 Opportunity 1 Opportunity 2Key PlayersGROWTH DRIVERSRESTRAINTSFUTURE TRENDSOPPORTUNITY Increasing Adoption of Single-Use Bioreactors Rapid Growth of Pharmaceutical and Biotechnology Industry Stringent Regulatory Framework Technological Advancements in Bioreactors Rising Demand of for Personalized MedicineCAGR(2022-2030)8.2%Market Size 2022$919.86 MnMarket Size 2030$1,732.95MnTechnology Fed-Batch Bioreactors Perfusion Bioreactors Microbial Application Cell-Culture Application OthersApplicationMarket DynamicsMarket SegmentationOverview Lab-Scale Production Pilot-Scale Production Full Scale ProductionScale Thermo Fisher Scientific Inc.Sartorius AG Pall Corporation(Danaher)PBS Biotech,Inc.General Electric Company Merck KGaACellexus bbi-biotech GmbH Solaris Biotechnology SRL Applikon Biotechnology BVEnd User Biopharma Manufacturers Research and Development Organizations Contract Manufacturing OrganizationsEUROPE8.2 Europe Bioreactors Market,2020-2030 |The Insight Partners 3.Research Methodology The Insight Partners dedicated research and analysis teams consist of experienced professionals with advanced statistical expertise in market research and consulting backgrounds in various industries including Aerospace and Defense,Automotive and Transportation,Biotechnology,Chemicals and Materials,Food and Beverages,Electronics and Semiconductor,Healthcare IT,Manufacturing and Construction,Medical Device,Technology,Media,and Telecommunications.FinalMarket sizeValidation from Primary InterviewSummation of Revenue Generated from Companies to arrive Total Market SizeRevenue Generated by the Product Offered by Companies in the BioreactorsMarketFinal Market Size Break-Up To Rest Of Segmentation(i.e Technology,Application,Scale and End User,and Geography)Arriving at the Market Size of each Segment Validation of Number with Primary Interviews and Subject Matter Expert BOTTOM-UP ANALYSISTOP-DOWN ANALYSIS 15 Europe Bioreactors Market,2020-2030 |The Insight Partners Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources The Insight Partners adheres to the codes of practice of the Market Research Society(www.mrs.org.uk)and Strategic and Competitive Intelligence Professionals(www.scip.org).The following methodology has been followed for the collection and analysis of data presented in this report:3.1 Coverage The objective of updating“The Insight Partners”coverage is to ensure that it represents the most up-to-date vision of the industry possible.The estimated revenues of all major companies,including private and governmental,are gathered,and used to prioritize coverage.Companies which are making the news,or which are of particular interest due to their innovative approach,are prioritized.16 Europe Bioreactors Market,2020-2030 |The Insight Partners 3.2 Secondary Research The research process begins with exhaustive secondary research using internal and external sources to obtain qualitative and quantitative information relating to each Market.The secondary research sources that are typically referred to include,but are not limited to:Company websites,annual reports,financial reports,broker reports and investor presentations Industry trade journals and other literature National government documents,statistical databases,and market reports News articles,press releases and web-casts specific to the companies operating in the market NOTE:All the financials considered in Company Profiles section have been standardized to US$.This has been achieved after converting the financials(for those not in US$)with respective currency exchange rates of the particular year.3.3 Primary Research“The Insight Partners”conducts hundreds of primary interviews a year with industry participants and commentators in order to validate its data and analysis.A typical research interview fulfils the following functions:Provides first-hand information on the market size,market trends,growth trends,competitive landscape,and future outlook Validates and strengthens secondary research findings Further develops the analysis teams expertise and market understanding Primary research involves email interactions and telephone interviews for each market,category,segment,and sub-segment across geographies.The participants who typically take part in such a process include,but are not limited to:Industry participants:VPs,business development managers,market intelligence managers and national sales managers Outside experts:Valuation experts,research analysts and key opinion leaders specializing in the industry 17 Europe Bioreactors Market,2020-2030 |The Insight Partners 4.Europe Bioreactors Market-Key Industry Dynamics 4.1 Bioreactors Market-Key Industry Dynamics Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 4.2 Market Drivers 4.2.1 Increasing Adoption of Single-Use Bioreactors Various manufacturers are developing single-use bioreactors(SUBs)as they are robust and provide the high performance required for commercial manufacturing of biopharmaceuticals.Advantages such as film technologies,stirring mechanisms,bioreactor designs,and sensor systems have contributed toward increasing the adoption of disposable reactors from the lab to the production scale.The single-use bioreactors provide next-generation cell and gene therapies and continuous bioprocessing.The advancements in cell-culture processes have developed higher titers and cell densities,which have facilitated the adoption of SUBs.Single-use bioreactors reduce the risks of contamination and decrease production turnaround times.In the last few years,the use of single-use bioreactors has increased in modern biopharmaceutical processes owing to their unique ability to enhance flexibility,reduce investment,and limit operational costs.Also,many companies have developed single-use bioreactors for producing a wide range of therapeutics.For instance,in March 2021,Thermo Fischer Scientific launched the 3,000 L and 5,000 L HyPerforma DynaDrive single-use bioreactors.DROTDRIVERSRESTRAINTSOPPORTUNITIESTRENDS Increasing Adoption of Single-Use Bioreactors Rapid Growth of Pharmaceutical and Biotechnology IndustryStringent Regulatory FrameworkRising Demand of for Personalized MedicineTechnological Advancements in Bioreactors 18 Europe Bioreactors Market,2020-2030 |The Insight Partners The reduction in validation time has been one of the essential benefits of single-use bioreactors.The rising adoption of single-use bioreactors for upstream bioprocessing is driving the market growth.For instance,Sartorius AG offers a wide range of single-use bioreactors.The company provides ambr 15 for a 1015 mL micro bioreactor scale and Biostat STR for 502000L.The increasing acceptance of single-use bioreactors for the production of therapeutics is driving the market for bioreactors.4.2.2 Rapid Growth of Pharmaceutical and Biotechnology Industry In recent years,the pharmaceutical industry has been growing at an unprecedented pace.Big pharmaceutical companies and contract research organizations(CROs)are coming up with new medicines and therapy forms to treat a wide range of indications.The biopharmaceuticals market is increasing.The strong demand for biologics and biosimilars has driven the growth of the industry.The biopharmaceutical industry is one of the most significant contributors to the economy.With a high labor productivity,biotechnology is one of the EUs most rapidly expanding innovative industries.Biotechnology directly boosted the countrys GDP by US$33.45 billion(EUR 31 billion),supported 625,700 employments(indirect and induced)in the overall economy,and produced 210,700 direct jobs in the healthcare,industrial,and agricultural sectors.Factors such as increasing biologics approval,growing biosimilar pipeline,and rising investment in research activities are facilitating the growth of the industry.Apart from this,increasing approvals in gene and cell therapies are favoring market growth.The approved gene therapies are Glybera-used to treat Lipoprotein Lipase Deficiency and Strimvelis-treating ADA-Severe Combined Immuno Deficiency.Thus,the factors mentioned above are increasing the demand for the large-scale production of various therapeutics,thereby facilitating the growth of the bioreactors market globally.4.3 Market Restraints 4.3.1 Stringent Regulatory Framework Regulatory authorities,such as the Food&Drug Administration and the European Medicine Agency(EMA),have consistently shown a tough stance toward pharmaceutical manufacturers.The industry players are bound to abide by the updated regulations about current good manufacturing practices(cGMP)and good laboratory practices(GLP)for assuring control of manufacturing processes and facilities,proper design,and monitoring.Currently,the FDAs CBER regulations do not mention anything about singleuse bioreactors.Any variations from the registered protocols,demands,and requirements of this guidance may lead to the termination of the clinical trials undertaken by the manufacturers or outsourced organizations.Apart from this,the biggest concern with the use of SUBs is that the molecules might not give the same results as in clinical trials.The mixing principle of SUBs has also increased the stringency of the regulations and restricted their use.For instance,in wave-type SUBs,the mixing principle is limited to a rocking movement that leads to uneven mixing and causes errors.Hence,the safety and efficacy of biologics may raise significant concerns in the application of SUBs.Therefore,the stringent regulations associated with bioreactors are expected to affect the demand for bioreactors.4.4 Market Opportunities 4.4.1 Rising Demand for Personalized Medicine The transformation of the healthcare industry from one-size-fits-all to a targeted approach is expanding the demand for personalized medicine.Precision medicine is being considered as one of the most promising approaches to tackle diseases such as cancer,neurodegenerative diseases,and rare genetic conditions.Innovations in the production of 19 Europe Bioreactors Market,2020-2030 |The Insight Partners personalized medicines are likely to impact the entire sector,and single-use technologies aimed at smaller-volume production have potential applications in protein bioproduction,particularly in downstream processes.Personalized and differentiated approaches to medicine are leading to a need for a wider range of products,many of them for a relatively small number of patients.A fundamentally different approach to the production and delivery of biological products may be required.Precision medicine utilizes the genomic information of an individual to offer targeted treatment for a particular indication.The rising prevalence of a number of chronic diseases has increased the demand for biologics,drugs for orphan diseases,and personalized medicines.For instance,in 2019,the FDA approved 12 personalized medications to address the root causes of disease and further integrate precision medicine with clinical care.Also,increasing government efforts are strengthening personalized medicine research activities.The rising demand for personalized medicine is anticipated to offer significant growth opportunities to the players operating in the bioreactors market during the forecast period.4.5 Future Trends 4.5.1 Technological Advancements in Bioreactors Advancement in the field of bioreactors has opened many opportunities for the market players.Leading players have come up with innovative products in the last few years.The improvement in the bioreactors offers a faster and easier production of biopharmaceuticals at reduced production costs.Also,the investments from public and private investors are rising for the bioreactors.The rise in the venture is enabling technological developments and standard biological parts.In February 2021,WuXi Biologics MFG5 Drug Substance(DS)manufacturing facility in China launched a GMP operation with a capacity of 36,000L and deployed nine 4,000L single-use bioreactors.As a major milestone in the companys global capacity planning,the GMP implementation of MFG5 increases WuXi Biologics current capacity to 90,000L,significantly expanding its ability to support global partners.The new bioreactors are developed for the growth of adherent cells on microcarriers that enable rapid,scalable cell culture processes in the development of vaccines.The launch of such new bioreactors enhanced the portfolio of the company in the bioreactors market.In June 2022,ABEC announced that mAbxience plans to add a 4,000L single-use custom single-run(CSR)bioreactor to its state-of-the-art cGMP facility in Len,Spain.In May 2021,Beckman Coulter Life Sciences launched its next-generation Biolector XT microbioreactor in Germany.The BioLector XT microbioreactor enables monitoring of cultivation parameters,high-throughput strain screening,and optimization of feeding strategy.Advancement in bioreactors has added various solutions for most industries,such as pharmaceutical,petrochemical,food,and agriculture.Therefore,technological advancements are expected to boost innovations in the bioreactors market in the coming years.20 Europe Bioreactors Market,2020-2030 |The Insight Partners 4.6 Impact of Drivers and Restraints:The figure below depicts the impact of factors driving or restraining the bioreactors market growth.Factors such as the increasing adoption of single-use bioreactors and rapid growth of the pharmaceutical and biotechnology industry are expected to propel the growth of the market.However,the stringent regulatory framework is the major factor hindering the market growth.Figure 2.Impact Analysis of Drivers and Restraints Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources Increasing Adoption of Single-Use BioreactorsRapid Growth of Pharmaceutical and Biotechnology IndustryStringent Regulatory FrameworkLOWMEDIUMHIGHDrivers Drivers Restraints 21 Europe Bioreactors Market,2020-2030 |The Insight Partners 5.Bioreactors Market-Europe Market Analysis 5.1 Overview The Europe bioreactors market is segmented into Germany,the UK,France,Italy,Spain,and the Rest of Europe.Europe.It is expected to register a robust growth rate owing to government and private funding for research in biologics and pharmaceuticals and the launch of innovative technologies.The region has various organizations and bodies that look after the practices being carried out in the pharmaceutical industry through conferences and other events.Companies in Europe have been focusing on showcasing their products at various events through which they would be able to strengthen their customer base as well as collect information regarding developments made by any other players in the region.Owing to the presence of research initiatives,the introduction of innovative products,and events such as conferences,the market of bioreactors is anticipated to witness significant growth in Europe during the forecast period.5.1.1 Bioreactors Market Revenue(US$Million),2020 2030 The Europe bioreactors market is expected to reach US$1,732.95 million in 2030 from US$919.86 million in 2022.The market is estimated to grow with a CAGR of 8.2%from 2022 to 2030.The increasing adoption of single-use bioreactors and rapid growth of the pharmaceutical and biotechnology industry are the key driving factors behind the market development.However,the stringent regulatory framework is hampering the market growth.Figure 3.Bioreactors Market Revenue(US$Million),2020 2030 Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 810.79862.34919.86983.831,055.521,136.101,227.001,329.911,446.831,580.201,732.956.4%6.7%7.0%7.3%7.6%8.0%8.4%8.8%9.2%9.7%0.0%2.0%4.0%6.0%8.0.0.0 20202120222023202420252026202720282029203002004006008001,0001,2001,4001,6001,8002,0002020-2030Historical YearBase YearForecast Year 22 Europe Bioreactors Market,2020-2030 |The Insight Partners 6.Europe Bioreactors Market Analysis-Scale 6.1 Overview The bioreactors market,by scale,is segmented into lab-scale production,pilot-scale production,and full-scale production.The pilot-scale production segment held a larger market share in 2022.However,the full-scale production segment is anticipated to register a higher CAGR of 8.9%during 20222030.6.2 Bioreactors Market Revenue Share,by Scale 2022&2030(%)Figure 4.Bioreactors Market Revenue Share,by Scale 2022&2030(%)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources The pilot-scale production segment led the market in 2022 with a share of 48.4%and is expected to retain its dominance during the forecast period by accounting for 47.7%of the total market by 2030.6.3 Lab-Scale Production 6.3.1 Overview For laboratory purposes,benchtop bioreactors(up to 15 liters)are used widely.They are used for cultures up to 15L.Benchtop bioreactors are used for growth studies of microbial,mammalian,insect,and plant cells,culture media optimization,clone screening,multivariate process optimization studies,and small-scale protein and mAB expression.These bioreactors have been used extensively for processes such as process development and optimization,scale-up and scale-down studies,seed expansion,cell bank production,and protein supply.Infors AG,Sartorius AG,and Eppendorf are among the companies offering benchtop bioreactors.Sartorius offers a wide range of benchtop bioreactors.These benchtop bioreactors are used for cell cultivation as well as for microbial fermentation.These are autoclavable culture vessels and are available from 1-10 liters,and single-use vessels of 250 milli liters and 2 liters.Benefits offered by benchtop reactors are saving valuable bench space in the development lab,easy cleaning,additional storage space for a tidy workplace,and increased measurement safety and control of the process according to the latest standards.12.3H.49.3 22Lab-Scale ProductionPilot-Scale ProductionFull Scale Production10.9G.7A.4 30 23 Europe Bioreactors Market,2020-2030 |The Insight Partners 6.3.2 Lab-Scale Production Market,Revenue and Forecast to 2030(US$Million)The bioreactors market for the lab-scale production segment was worth US$113.46 million in 2022 and is projected to reach US$189.46 million by 2030;it is expected to grow at a CAGR of 6.6%during 20222030.Figure 5.Lab-Scale Production Market Revenue and Forecasts to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 102.78107.79113.46119.52126.30133.90142.44152.08162.98175.36189.46202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 24 Europe Bioreactors Market,2020-2030 |The Insight Partners 6.4 Pilot-Scale Production 6.4.1 Overview The bioreactors for pilot scale production are used largely for scale-up purposes more economically and within less time.The applications of pilot-scale bioreactors include scale-up studies,medium optimization,process optimization,small-scale production,microbial and cell culture,batch,fed-batch,perfusion,and continuous cultivation.These bioreactors are designed to simplify or carry forward batch,fed-batch,and continuous cultivation strategies such as chemostats or perfusion processes.Companies offering pilot-scale bioreactors(15-1,000 liters)in the market include Infors AG,SOLARIS BIOTECHNOLOGY SRL,and Applikon Biotechnology BV.Solaris offers pilot-scale bioreactors to simplify scale-up bioprocessing challenges.Its pilot scale bioreactors are designed for in situ sterilization and can be managed automatically through the controlling software.The rise in the use of pilot-scale bioreactors for research purposes is expected to provide significant growth opportunities in the coming years.6.4.2 Pilot-Scale Production Market,Revenue and Forecast to 2030(US$Million)The bioreactors market for the pilot-scale production segment was worth US$444.87 million in 2022 and is projected to reach US$825.98 million by 2030;it is expected to grow at a CAGR of 8.0%during 20222030.Figure 6.Pilot-Scale Production Market Revenue and Forecasts to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 393.50417.78444.87474.96508.65546.50589.15637.40692.16754.57825.98202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 25 Europe Bioreactors Market,2020-2030 |The Insight Partners 6.5 Full-Scale Production 6.5.1 Overview Bioreactors with larger volumes ranging from 500 to 50,000 liters are used for full-scale production for commercial purposes.They are powerful tools for process development and production.The fields of application include microbial and cell cultivation for the production of enzymes,therapeutic proteins,vaccines,monoclonal antibodies,and biomass.Various manufacturers in the pharmaceutical and biotechnology industry prefer the use of industrial bioreactors as they have large working volumes and are cost-effective.A single bioreactor system can be used for the production of a single product for more than a decade.Since these systems are well equipped,the chances of leakage or absence of a proper working system are significantly less as compared to other types of bioreactors.Many companies are offering industrial-scale bioreactors for a wide range of applications.For instance,SYSBIOTECH offers an advanced C-BIO2TM control system.This system allows easy integration of upstream and downstream equipment in a unified production line.Industrial-scale bioreactors are used widely in the biotechnology industry,which is expected to be a major factor driving the growth of the segment in the coming years.6.5.2 Full-Scale Production Market,Revenue and Forecast to 2030(US$Million)The bioreactors market for the full-scale production segment was worth US$361.52 million in 2022 and is projected to reach US$717.51 million by 2030;it is expected to grow at a CAGR of 8.9%during 20222030.Figure 7.Full-Scale Production Market Revenue and Forecasts to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 314.51336.77361.52389.35420.57455.71495.41540.43591.68650.27717.51202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 26 Europe Bioreactors Market,2020-2030 |The Insight Partners 7.Europe Bioreactors Market Analysis-Application 7.1 Overview The bioreactors market,by application,is segmented into microbial application,cell culture application,and others.The cell culture application segment held a larger market share in 2022.However,the microbial application segment is anticipated to register a higher CAGR of 9.1%during 20222030.7.2 Bioreactors Market Revenue Share,by Application 2022&2030(%)Figure 8.Bioreactors Market Revenue Share,by Application 2022&2030(%)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources The cell culture application segment led the market in 2022 with a share of 48.6%and is expected to retain its dominance during the forecast period by accounting for 47.9%of the total market by 2030.7.3 Microbial Application 7.3.1 Overview A broad range of microorganisms,including bacteria,yeasts,fungi,and algae,can be cultivated in bioreactors.Bacterial and viral cells are cultivated for various purposes,such as for basic research and development and the manufacturing of biopharmaceuticals,chemicals,and other products.The bacterial culture of E.coli is the preferred microorganism for the production of recombinant proteins.It is widely used for cloning,genetic modification,and small-scale production for research purposes.Additionally,bioreactors are crucial for the production of large-scale viral vaccines in cell culture.According to an article published by Frontiers in February 2020,bioreactors have evolved into a platform for producing various viral vectors,live viruses,and virus-based vaccines using cells.The development of fed-batch culture,perfusion culture,and genetic engineering has contributed to this advancement.In addition,the application of smart sensors and actuators to bioreactor control systems holds great promise for improving bioprocess control in the near future.As vaccine production processes have advanced,more scalable bioreactors and cell lines with high virus affinity have been utilized to produce several vaccines.Yeasts can also be used for high-density cell cultures in bioreactors owing to its qualities such as cost-effectiveness,fast,and technical feasibility as bacteria.It has also been recognized by the FDA as generally regarded as safe(GRAS)status 35.3H.6.1 22Microbial ApplicationCell-CultureApplicationOthers37.5G.9.6 30 27 Europe Bioreactors Market,2020-2030 |The Insight Partners for food and pharmaceutical applications.To date,over 150 recombinant proteins have been produced using Y.lipolytica.Of these,25 were produced at a bioreactor scale.Furthermore,bioreactors are being used to treat wastewater using microbes to degrade the harmful chemicals present in it.For instance,in an article published by SpringerLink in July 2023,a study was carried out for microbial remediation of cyclonite and octogen by treating wastewater from an explosive manufacturing facility in a continuously stirred bioreactor with cyclonite and octogen degrading bacteria Paenibacillus aestuarii isolated from an explosive contaminated site.The study showed that the bacteria were able to degrade 83.4%Cyclonite and 70.66%Octogen in bioreactor-simulated wastewater.7.3.2 Microbial Application Market,Revenue and Forecast to 2030(US$Million)The bioreactors market for the microbial application segment was worth US$324.99 million in 2022 and is projected to reach US$650.19 million by 2030;it is expected to grow at a CAGR of 9.1%during 20222030.Figure 9.Microbial Application Market Revenue and Forecasts to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 281.95302.23324.99350.22378.57410.54446.73487.85534.74588.44650.19202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 28 Europe Bioreactors Market,2020-2030 |The Insight Partners 7.4 Cell Culture Application 7.4.1 Overview Plants have been used for thousands of years by humans for pain relief,pleasure,religious ceremonies,and treating illnesses.According to the World Health Organization(WHO),80%of people worldwide rely on herbal medicines for some aspect of their primary healthcare.Medicinal plants are highly significant in the healthcare industry,and 25%of modern medicines are derived from natural sources.The organic molecules responsible for the biological activity in medicinal plants are secondary metabolites.As the demand for phytochemicals obtained from plant-derived secondary metabolites(PDSM)increases,the use of biotechnologies based on plant tissue and cell culture(PTCC)seems to be a promising,sustainable,and eco-friendly solution for the issues related to the traditional cultivation of medicinal plants.Academia and bio-pharmaceutical industry are currently focusing on their research on Plant tissue and Cell Culture(PTCC)as a means of producing bioactive compounds at a large scale.Bioreactors are widely used in plant research and have undergone significant technological advancements over time,leading to remarkable achievements in the field of PTCC.They offer stability,operational ease,improved nutrient uptake capacity,time-and cost-effectiveness,and large quantities of biomass production,making them a suitable alternative to conventional plant tissue and cell culture(PTCC)methods.According to an article published by Wiley Biotechnology Journal in April 2019,a study was carried out using a compact benchtop bioreactor system for monitoring 3D perfusion cultures of cells with local environment control.Similarly,in another article published by MDPI in April 2020,a novel multimodal bioreactor developed allowed the application of dual stimulation(electrical and mechanical)of a scaffold cell culture for tissue engineering.The rise in the development and use of bioreactors for cell cultures is expected to provide significant growth opportunities in the coming years.7.4.2 Cell Culture Application Market,Revenue and Forecast to 2030(US$Million)The bioreactors market for the cell culture application segment was worth US$446.72 million in 2022 and is projected to reach US$830.04 million by 2030;it is expected to grow at a CAGR of 8.1%during 20222030.Figure 10.Cell Culture Application Market Revenue and Forecasts to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 395.10419.50446.72476.97510.84548.90591.79640.31695.41758.19830.04202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 29 Europe Bioreactors Market,2020-2030 |The Insight Partners 7.5 Others 7.5.1 Overview Production of monoclonal antibodies,stem cells,and gene therapy are other applications of bioreactors.Monoclonal antibodies are identical immunoglobulins synthesized from a single B-cell clone,and they target a specific antigen.Monoclonal antibodies(mAb)are the most significant contributor to the bioreactor market owing to increasing application in the treatment of a wide range of indications such as asthma,cancers,rheumatoid arthritis,psoriasis,and gastrointestinal inflammatory disease.Additionally,many companies offer to scale up monoclonal antibody production to meet the increasing demand globally.For instance,FUJIFILM Diosynth Biotechnologies,which is a leading contract development and manufacturing organization,provides monoclonal antibody production in its high-throughput manufacturing facility scaled to multiple 2,000 liters bioreactors.The commercial production of human stem cells,growth factors,and mediators is fueling the growth of the bioreactors market.Increasing research activities and growing clinical trials in the field of regenerative medicines are driving the bioreactors market of stem cell production.For instance,according to the Alliance for Regenerative Medicine 2019 report,there are 959 regenerative medicine companies worldwide sponsoring 1,052 active clinical trials.it implies that nearly US$7.4 billion has been invested in regenerative medicine companies in 2019.Bioreactors have become vital tools in the gene therapy industry.Different bioreactors are used to maintain microenvironments to regulate cell growth,differentiation,and tissue development.They are essential for providing standardized,reproducible cell-based products for regenerative medicine applications.Bioreactors provide controlled delivery of nutrients and biomimetic stimuli to influence cell growth,differentiation,and tissue formation.To address the growing demand for gene therapies,leading companies in the bioreactor market are launching products as per specific requirements.For instance,In June 2019,Sartorius Stedim Biotech launched an Ambr 250 modular bioreactor vessel for cell and gene therapy applications.The system is suitable for culturing cell lines,such as HEK293 and CAR-T,as well as other therapeutic cell lines.30 Europe Bioreactors Market,2020-2030 |The Insight Partners 7.5.2 Others Market,Revenue and Forecast to 2030(US$Million)The bioreactors market for the others segment was worth US$148.14 million in 2022 and is projected to reach US$252.72 million by 2030;it is expected to grow at a CAGR of 6.9%during 20222030.Figure 11.Others Market Revenue and Forecasts to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 133.75140.61148.14156.65166.11176.67188.48201.75216.68233.57252.72202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 31 Europe Bioreactors Market,2020-2030 |The Insight Partners 8.Europe Bioreactors Market Analysis-Technology 8.1 Overview The bioreactors market,by technology,is segmented into fed-batch bioreactors and perfusion bioreactors.The fed-batch bioreactors segment held a larger market share in 2022.However,the perfusion bioreactors segment is anticipated to register a higher CAGR of 9.1%during 20222030.8.2 Bioreactors Market Revenue Share,by Technology 2022&2030(%)Figure 12.Bioreactors Market Revenue Share,by Technology 2022&2030(%)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources The fed-batch bioreactors segment led the market in 2022 with a share of 62.1%and is expected to retain its dominance during the forecast period by accounting for 59.6%of the total market by 2030.8.3 Fed-Batch Bioreactors 8.3.1 Overview In fed-batch systems,fresh medium or medium components are continuously,intermittently,or singularly added while the batch volume increases over time.During fed-batch fermentation,the nutritional environment can be maintained at a consistent level.This can prevent the production of byproducts that are typically caused by high concentrations of substrate.By using this method,it is possible to extend the operating time and achieve high cell concentrations,which can lead to improved productivity(measured as mass of product per volume and time).This method is particularly useful in the production of growth-associated products.This method also allows for the replacement of water loss through evaporation and can decrease the viscosity of the broth.If dealing with toxic or low-solubility substrates,fed-batch fermentation may be the only viable option due to the advantages mentioned above of fed-batch bioreactors used for the production of cell cultures.In an article published by Science Direct in 2021,the process of producing butanol from algal biomass using acetone-butanol-ethanol(ABE)fermentation was studied.62.17.9 22Fed-Batch BioreactorsPerfusion Bioreactors59.6.4 30 32 Europe Bioreactors Market,2020-2030 |The Insight Partners The study aimed to investigate the effectiveness of upscale fed-batch fermentation in reducing toxic compounds while increasing butanol formation.The study concluded that the in-situ fed-batch operation was more effective in producing biobutanol than the traditional ABE fermentation.8.3.2 Fed-Batch Bioreactors Market,Revenue and Forecast to 2030(US$Million)The bioreactors market for the fed-batch bioreactors segment was worth US$570.80 million in 2022 and is projected to reach US$1,032.35 million by 2030;it is expected to grow at a CAGR of 7.7%during 20222030.Figure 13.Fed-Batch Bioreactors Market Revenue and Forecasts to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 508.06537.71570.80607.40648.35694.30746.04804.49870.76946.181,032.35202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 33 Europe Bioreactors Market,2020-2030 |The Insight Partners 8.4 Perfusion Bioreactors 8.4.1 Overview Perfusion Bioreactors utilize continuous bioprocessing of cell culture.The bioreactor is operated at a constant volume and fixed concentration of cells for a period ranging from 30 to 90 days or even longer,depending on the cell line.During this time,the feed media is continuously renewed,and the harmful byproducts are removed while the cells are simultaneously extracted for further processing.Perfusion technology is a relatively new approach to cell culture processes.It offers several advantages,such as maintaining product quality,and it promotes effective facility utilization by allowing the use of smaller bioreactors.Perfusion cell culture,as opposed to batch or fed-batch procedures,permits cells to remain in the exponential growth phase for a longer period and achieve higher viable cell densities.Several market players provide perfusion bioreactors with a wide range of applications.For instance,MilliporeSigmas Mobius iFlex Bioreactor enables perfusion procedures and has a unique,ergonomic single-use design that accommodates ultra-high cell densities.8.4.2 Perfusion Bioreactors Market,Revenue and Forecast to 2030(US$Million)The bioreactors market for the perfusion bioreactors segment was worth US$349.06 million in 2022 and is projected to reach US$700.59 million by 2030;it is expected to grow at a CAGR of 9.1%during 20222030.Figure 14.Perfusion Bioreactors Market Revenue and Forecasts to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 302.73324.64349.06376.44407.17441.80480.97525.42576.07634.02700.59202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 34 Europe Bioreactors Market,2020-2030 |The Insight Partners 9.Europe Bioreactors Market Analysis-End User 9.1 Overview The bioreactors market,by end user,is bifurcated into biopharma manufacturers,research and development organizations,and contract manufacturing organizations(CMOs).The research and development organizations segment held the largest share of the market in 2022 and the same is anticipated to register the highest CAGR of 8.9%in the market during the forecast period.9.2 Bioreactors Market Revenue Share,by End User 2022&2030(%)Figure 15.Bioreactors Market Revenue Share,by End User 2022&2030(%)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources The research and development organizations segment led the market in 2022 with a share of 60.4%and is expected to retain its dominance during the forecast period,thereby accounting for 63.6%of the total market by 2030.10.6.4).0 22BiopharmaManufacturersResearch andDevelopmentOrganizationsContractManufacturingOrganizations10.3c.6&.1 30 35 Europe Bioreactors Market,2020-2030 |The Insight Partners 9.3 Biopharma Manufacturers 9.3.1 Overview Pharmaceutical companies hold a major share in the production of medicines that cure or manage chronic diseases and protect people from infection.The major line of biopharma manufacturers includes vitamins,drugs,medicines,livestock feed supplements,and animal health products.The main characteristic of biopharma medicines and drug products is that they are manufactured in living organisms such as bacteria,yeast,and mammalian cells.The biopharma industry has witnessed growth in the past decade due to extensively increasing research and development activities and regulatory approvals for the introduction of new microbe-based products.This growth is expected to have a positive impact on the biopharma manufacturer segment.Additionally,a significant number of research activities and bioprocesses are being conducted in biopharma companies.Such a massive number of innovation processes are projected to drive the adoption of bioreactors in biopharma manufacturers,which will eventually drive the market for the biopharma manufacturers segment.9.3.2 Biopharma Manufacturers Market,Revenue and Forecast to 2030(US$Million)The bioreactors market for the biopharma manufacturers segment was worth US$97.64 million in 2022 and is projected to reach US$177.76 million by 2030;it is expected to grow at a CAGR of 7.8%during 20222030.Figure 16.Biopharma Manufacturers Market Revenue and Forecasts to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 86.7891.9197.64103.98111.08119.05128.03138.17149.68162.78177.76202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 36 Europe Bioreactors Market,2020-2030 |The Insight Partners 9.4 Research and Development Organizations 9.4.1 Overview In industries such as biotechnology,healthcare,and pharmaceuticals,research and development play a crucial role.Research and development organizations are engaged in the processes and activities to innovate and introduce new products,technologies,and services in the bioreactor market.For instance,in an article published by the Good Food Institute(GFI)in 2022,bioreactors are being developed for the large-scale cultivation of meat.Additionally,these research and development organizations are also important to leverage the capabilities of the currently available infrastructure.For instance,RegenMed Development Organization(ReMDO),a biotechnology research organization,offers the ReMDO Bioreactor Program to develop a universal standardized bioreactor platform for the maturation of regenerative medicine clinical products.Research and development institutes are constantly engaged to discover ways to increase their products effectiveness and efficiency with new concepts that will shape the market.Research and development is also important to accelerate product introductions.The growth of research and development organizations is majorly attributed to the increasing adoption of bioreactors for research and innovation processes.Additionally,the research institutes are investing heavily to boost the bioprocesses,leading to market growth.9.4.2 Research and Development Organizations Market,Revenue and Forecast to 2030(US$Million)The bioreactors market for the research and development organizations segment was worth US$555.84 million in 2022 and is projected to reach US$1,102.99 million by 2030;it is expected to grow at a CAGR of 8.9%during 20222030.Figure 17.Research and Development Organizations Market Revenue and Forecasts to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 483.22517.46555.84598.40646.21700.08761.03830.22909.07999.301,102.99202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 37 Europe Bioreactors Market,2020-2030 |The Insight Partners 9.5 Contract Manufacturing Organization 9.5.1 Overview Contract Manufacturing Organizations(CMOs)offer outsourcing services to pharmaceutical companies along with volume capabilities extending from small components for preclinical research and development to larger volumes that are required for commercialization.Based on the involvement in operations,these organizations are divided into two types,which are primary manufacturing and secondary manufacturing.Primary contract manufacturing organizations deal in the synthesis of drug substances,while secondary manufacturing companies are engaged in the formulation of the drug substances into the final product.The majority of CMOs primarily focus on secondary manufacturing,which involves the combination of active pharmaceutical ingredients(APIs)with a variety of excipients to create final products.While CMOs do not have their product portfolios,they play a crucial role in the pharmaceutical supply chain.Healthcare systems across the globe are witnessing a shift from conventional manufacturing to contract manufacturing.The major reason for this shift is cost and resource optimization.Additionally,a significant number of companies are engaged in establishing various strategies by launching or partnering with CMOs in order to utilize resources for their core competencies.For instance,in December 2022,Thermo Fisher Scientific launched a cGMP biologics manufacturing facility in Hangzhou,China,which is equipped with Thermo Fisher 2,000-liter HyPerforma single-use bioreactors.The increasing involvement of CMOs in bioprocesses is anticipated to drive the growth of the global bioreactors market for the contract manufacturing organization during the forecast period.9.5.2 Contract Manufacturing Organization Market,Revenue and Forecast to 2030(US$Million)The bioreactors market for the contract manufacturing organization segment was worth US$266.38 million in 2022 and is projected to reach US$452.20 million by 2030;it is expected to grow at a CAGR of 6.8%during 20222030.Figure 18.Contract Manufacturing Organization Market Revenue and Forecasts to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 240.79252.97266.38281.45298.23316.97337.95361.52388.08418.11452.20202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 38 Europe Bioreactors Market,2020-2030 |The Insight Partners 10.Europe Bioreactors Market by Country Analysis 10.1 Europe:Bioreactors Market Figure 19.Europe:Bioreactors Market,by Key Country Revenue(2022)(US$Million)Source:The Insight Partners Analysis 10.1.1 Europe Bioreactors Market Revenue and Forecasts and Analysis-By Country Figure 20.Europe Bioreactors Market Breakdown by Key Countries,2022 and 2030(%)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 10.1.1.1 Germany 10.1.1.2 Overview In Germany,new product development,extensive research&development activities in pharmaceutical and biotechnology companies,and the growth of biologics and life sciences drive the market growth.In August 2023,Sartorius,one of the leading suppliers for the biopharmaceutical industry,collaborated with global technology and software leader Emerson to integrate Sartoriuss Biostat STR Generation 3 family of bioreactors with Emersons DeltaVTM distributed control system EUROPE(2022)149.6671.7595.85145.34185.81271.45Rest ofEuropeSpainItalyUKFranceGermany29.5 .2.8.4%7.8.3 22GermanyFranceUKItalySpainRoE35.3.6.8%8.8%5.9.7 30 39 Europe Bioreactors Market,2020-2030 |The Insight Partners(DCS).The biotechnology sector in Germany exhibits tremendous growth owing to the presence of numerous biotechnology companies,high-tech research labs,and massive funding for research and development.Moreover,the cutting-edge and high-quality research in the country and the presence of an established market for bioreactors creates lucrative opportunities.The growth of research and development in biopharmaceuticals and biologics is majorly driven by the adoption of various organic strategies by companies in the healthcare industry.For instance,in June 2021,Rentschler Biopharma expanded its production capacity with a 2,000-liter bioreactor to address the increasing demand for complex antibodies,a class of biopharmaceutical drugs with continued high potential.The pharmaceutical sector in the country is growing due to increasing R&D expenditure by pharmaceutical companies.Thus,collaborative research efforts by pharmaceutical and biotechnology companies in the country influence the market.10.1.1.3 Germany:Bioreactors Market Revenue and Forecast to 2030(US$Million)The bioreactors market in Germany was valued at US$271.45 million in 2022 and is expected to reach value of US$610.86 million by 2030;it is expected to grow at a CAGR of 10.7%during 20222030.Figure 21.Germany Bioreactors Market Revenue and Forecasts to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 10.1.1.3.1 Germany Bioreactors Market Breakdown by Scale Table 2.Germany Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Scale Scale 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Lab-Scale Production 28.76 30.95 33.50 36.10 39.04 42.34 46.09 50.34 55.19 60.74 67.13 9.1%Pilot-Scale Production 110.58 120.37 131.65 143.66 157.25 172.69 190.28 210.42 233.56 260.26 291.20 10.4%Full-Scale Production 87.70 96.34 106.30 117.08 129.35 143.34 159.37 177.80 199.09 223.78 252.53 11.4%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 227.04247.66271.45296.85325.64358.37395.74438.57487.84544.78610.8620202021202220232024202520262027202820292030Historical YearBase YearForecast Year 40 Europe Bioreactors Market,2020-2030 |The Insight Partners The bioreactors market for the pilot-scale production segment was worth US$131.65 million in 2022 and is projected to reach US$291.20 million by 2030;it is expected to grow at a CAGR of 10.4%from 2022 to 2030.The market for the lab-scale production segment is estimated to be worth US$67.13 million by 2030 and is expected to grow at a CAGR of 9.1%during 2022-2030.10.1.1.3.2 Germany Bioreactors Market Breakdown by Application Table 3.Germany Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Application Application 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Microbial Application 78.95 86.80 95.90 105.67 116.79 129.50 144.08 160.88 180.31 202.87 229.20 11.5ll Culture Application 110.76 120.61 131.95 144.03 157.71 173.25 190.96 211.24 234.54 261.43 292.60 10.5%Others 37.33 40.26 43.59 47.15 51.14 55.63 60.70 66.45 73.00 80.48 89.06 9.3%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The bioreactors market for the cell culture application segment was worth US$131.95 million in 2022 and is projected to reach US$292.60 million by 2030;it is expected to grow at a CAGR of 10.5%from 2022 to 2030.The market for the microbial application segment is estimated to be worth US$229.20 million by 2030 and is expected to grow at a CAGR of 11.5%during 2022-2030.10.1.1.3.3 Germany Bioreactors Market Breakdown by Technology Table 4.Germany Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Technology Technology 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Fed-Batch Bioreactors 142.67 154.80 168.79 183.57 200.27 219.20 240.73 265.32 293.52 325.98 363.52 10.1%Perfusion Bioreactors 84.37 92.86 102.66 113.28 125.37 139.17 155.01 173.24 194.32 218.80 247.34 11.6%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The bioreactors market for the fed-batch bioreactors segment was worth US$168.79 million in 2022 and is projected to reach US$363.52 million by 2030;it is expected to grow at a CAGR of 10.1%from 2022 to 2030.41 Europe Bioreactors Market,2020-2030 |The Insight Partners 10.1.1.3.4 Germany Bioreactors Market Breakdown by End User Table 5.Germany Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By End User End User 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Biopharma Manufacturers 24.35 26.47 28.91 31.50 34.43 37.75 41.53 45.85 50.82 56.54 63.16 10.3%Research and Development Organizations 135.35 148.60 163.96 180.42 199.16 220.56 245.08 273.31 305.93 343.78 387.90 11.4%Contract Manufacturing Organization 67.34 72.59 78.58 84.93 92.05 100.07 109.13 119.40 131.10 144.46 159.80 9.3%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The bioreactors market for the research and development organizations segment was worth US$163.96 million in 2022 and is projected to reach US$387.90 million by 2030;it is expected to grow at a CAGR of 11.4%from 2022 to 2030.The market for the biopharma manufacturers segment is estimated to be worth US$63.16 million by 2030 and is expected to grow at a CAGR of 10.3%during 2022-2030.42 Europe Bioreactors Market,2020-2030 |The Insight Partners 10.1.1.4 France 10.1.1.5 Overview Extensive research and development activities,demand for quality healthcare services,and growing investment in R&D studies by the government drive the bioreactors market in France.The pharmaceutical industry was among the five sectors that accounted for more than half of all business enterprise R&D expenditure in the country.France is well positioned in several high-tech sectors that are crucial for future competitiveness.French startups are entering the biotechnology sector.In November 2021,Sartorius planned to expand and modernize the Aubagne,Cergy,and Lourdes plants in France by investing US$108.53 million between 2021 and 2025.The expansion will increase the companys production,innovation,and storage capacities,thus helping to meet the strong demand of the biopharmaceutical industry.Additionally,public-private partnerships with various institutes across the globe accelerate the pace of research activities in the country.10.1.1.6 France:Bioreactors Market Revenue and Forecast to 2030(US$Million)The bioreactors market in France was valued at US$185.81 million in 2022 and is expected to reach value of US$391.90 million by 2030;it is expected to grow at a CAGR of 9.8%during 20222030.Figure 22.France Bioreactors Market Revenue and Forecasts to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 10.1.1.6.1 France Bioreactors Market Breakdown by Scale Table 6.France Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Scale Scale 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Lab-Scale Production 20.05 21.37 22.87 24.46 26.24 28.25 30.50 33.06 35.96 39.28 43.07 8.2%Pilot-Scale Production 76.92 82.92 89.73 97.16 105.53 115.00 125.75 137.98 151.98 168.05 186.58 9.6%Full-Scale Production 61.76 67.13 73.21 79.94 87.54 96.17 106.00 117.24 130.14 145.02 162.25 10.5%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 158.73171.42185.81201.56219.32239.42262.25288.28318.09352.35391.9020202021202220232024202520262027202820292030Historical YearBase YearForecast Year 43 Europe Bioreactors Market,2020-2030 |The Insight Partners The bioreactors market for the pilot-scale production segment was worth US$89.73 million in 2022 and is projected to reach US$186.58 million by 2030;it is expected to grow at a CAGR of 9.6%from 2022 to 2030.The market for the lab-scale production segment is estimated to be worth US$43.07 million by 2030 and is expected to grow at a CAGR of 8.2%during 2022-2030.10.1.1.6.2 France Bioreactors Market Breakdown by Application Table 7.France Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Application Application 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Microbial Application 55.14 60.02 65.59 71.69 78.60 86.45 95.42 105.68 117.49 131.14 146.96 10.6ll Culture Application 77.35 83.40 90.25 97.74 106.17 115.71 126.53 138.86 152.97 169.16 187.84 9.6%Others 26.24 28.00 29.97 32.13 34.55 37.26 40.30 43.74 47.63 52.05 57.10 8.4%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The bioreactors market for the cell culture application segment was worth US$90.25 million in 2022 and is projected to reach US$187.84 million by 2030;it is expected to grow at a CAGR of 9.6%from 2022 to 2030.The market for the microbial application segment is estimated to be worth US$146.96 million by 2030 and is expected to grow at a CAGR of 10.6%during 2022-2030.10.1.1.6.3 France Bioreactors Market Breakdown by Technology Table 8.France Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Technology Technology 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Fed-Batch Bioreactors 99.73 107.14 115.54 124.65 134.90 146.47 159.57 174.46 191.45 210.93 233.34 9.2%Perfusion Bioreactors 59.00 64.28 70.27 76.91 84.42 92.95 102.68 113.82 126.63 141.42 158.56 10.7%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The bioreactors market for the fed-batch bioreactors segment was worth US$115.54 million in 2022 and is projected to reach US$233.34 million by 2030;it is expected to grow at a CAGR of 9.2%from 2022 to 2030.44 Europe Bioreactors Market,2020-2030 |The Insight Partners 10.1.1.6.4 France Bioreactors Market Breakdown by End User Table 9.France Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By End User End User 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Biopharma Manufacturers 17.03 18.30 19.73 21.29 23.04 25.02 27.25 29.80 32.70 36.03 39.86 9.2%Research and Development Organizations 94.79 103.02 112.38 122.64 134.25 147.44 162.48 179.69 199.47 222.29 248.74 10.4%Contract Manufacturing Organization 46.90 50.11 53.70 57.63 62.02 66.96 72.51 78.79 85.92 94.03 103.30 8.5%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The bioreactors market for the research and development organizations segment was worth US$112.38 million in 2022 and is projected to reach US$248.74 million by 2030;it is expected to grow at a CAGR of 10.4%from 2022 to 2030.The market for the biopharma manufacturers segment is estimated to be worth US$39.86 million by 2030 and is expected to grow at a CAGR of 9.2%during 2022-2030.45 Europe Bioreactors Market,2020-2030 |The Insight Partners 10.1.1.7 UK 10.1.1.8 Overview The market in the UK is driven by an increase in R&D investment,the presence of market players offering bioreactors,and a rising focus on biologics and biotechnology research.The worlds top 100 prescription medicines are developed in the UK as it is one of the largest prescription medicine manufacturers across the globe.R&D investment by the government,business enterprises,higher education institutes,and research councils encourage new product development and launch of innovative technologies in the country.The UK biopharmaceutical sector consists of over 250 companies and 10,000 workforce that are part of the supply chain involved in research,development,and manufacture.In April 2021,Sartorius,one of the leading international partners in life science research and the biopharmaceutical industry,expanded its operations in the UK.Various biopharmaceutical companies are developing innovative ideas and technologies for new therapies.Due to various developments in the biopharmaceutical industry in the UK,the market of bioreactors is expected to grow during the forecast period.10.1.1.9 UK:Bioreactors Market Revenue and Forecast to 2030(US$Million)The bioreactors market in the UK was valued at US$145.34 million in 2022 and is expected to reach value of US$255.96 million by 2030,growing at a CAGR of 7.3%during 20222030.Figure 23.UK Bioreactors Market Revenue and Forecasts to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 130.15137.32145.34154.14163.98175.02187.44201.46217.33235.37255.9620202021202220232024202520262027202820292030Historical YearBase YearForecast Year 46 Europe Bioreactors Market,2020-2030 |The Insight Partners 10.1.1.9.1 UK Bioreactors Market Breakdown by Scale Table 10.UK Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Scale Scale 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Lab-Scale Production 16.43 17.10 17.86 18.66 19.56 20.56 21.69 22.97 24.41 26.04 27.90 5.7%Pilot-Scale Production 63.09 66.45 70.21 74.34 78.94 84.11 89.92 96.48 103.90 112.33 121.94 7.1%Full-Scale Production 50.63 53.77 57.26 61.14 65.48 70.35 75.82 82.01 89.02 97.00 106.12 8.0%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The bioreactors market for the pilot-scale production segment was worth US$70.21 million in 2022 and is projected to reach US$121.94 million by 2030;it is expected to grow at a CAGR of 7.1%from 2022 to 2030.The market for the lab-scale production segment is estimated to be worth US$27.90 million by 2030 and is expected to grow at a CAGR of 5.7%during 2022-2030.10.1.1.9.2 UK Bioreactors Market Breakdown by Application Table 11.UK Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Application Application 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Microbial Application 45.30 48.17 51.39 54.91 58.86 63.29 68.29 73.95 80.37 87.70 96.09 8.1ll Culture Application 63.29 66.66 70.45 74.59 79.22 84.42 90.26 96.85 104.31 112.79 122.45 7.2%Others 21.56 22.48 23.50 24.64 25.90 27.31 28.89 30.66 32.64 34.89 37.42 6.0%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The bioreactors market for the cell culture application segment was worth US$70.45 million in 2022 and is projected to reach US$122.45 million by 2030;it is expected to grow at a CAGR of 7.2%from 2022 to 2030.The market for the microbial application segment is estimated to be worth US$96.09 million by 2030 and is expected to grow at a CAGR of 8.1%during 2022-2030.10.1.1.9.3 UK Bioreactors Market Breakdown by Technology Table 12.UK Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Technology Technology 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Fed-Batch Bioreactors 80.17 84.34 89.02 94.14 99.86 106.28 113.49 121.62 130.83 141.28 153.19 7.0%Perfusion Bioreactors 49.98 52.97 56.32 60.00 64.12 68.75 73.95 79.83 86.50 94.09 102.77 7.8%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 47 Europe Bioreactors Market,2020-2030 |The Insight Partners The bioreactors market for the fed-batch bioreactors segment was worth US$89.02 million in 2022 and is projected to reach US$153.19 million by 2030;it is expected to grow at a CAGR of 7.0%from 2022 to 2030.10.1.1.9.4 UK Bioreactors Market Breakdown by End User Table 13.UK Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By End User End User 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Biopharma Manufacturers 13.89 14.58 15.36 16.21 17.17 18.23 19.43 20.79 22.32 24.05 26.03 6.8%Research and Development Organizations 77.75 82.52 87.89 93.76 100.33 107.71 116.03 125.44 136.12 148.28 162.20 8.0%Contract Manufacturing Organization 38.52 40.21 42.09 44.17 46.49 49.08 51.98 55.23 58.89 63.03 67.73 6.1%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The bioreactors market for the research and development organizations segment was worth US$87.89 million in 2022 and is projected to reach US$162.20 million by 2030;it is expected to grow at a CAGR of 8.0%from 2022 to 2030.The market for the biopharma manufacturers segment is estimated to be worth US$26.03 million by 2030 and is expected to grow at a CAGR of 6.8%during 2022-2030.10.1.1.10 Italy 10.1.1.11 Overview Bioreactors play a major role in the development of useful microbes in a controlled environment.Also,this bioprocessing or development of microbes is directly associated with the production of drugs,vaccines,and antibodies.Extensive growth of these associated manufacturing benefits is anticipated to offer lucrative opportunities for the Italy bioreactors market.According to data published in Reuters in 2023,Italy generated US$2.23 billion from its pharmaceutical business.The government of Italy provides massive support and financial aid for pharmaceutical development.This research and development is likely to create a lucrative environment for the adoption of bioreactors,which will eventually drive market growth in Italy.In July 2021,Viralgen VC opened its new production facility in Basque,Italy.This facility is associated with the production of adeno-associated virus gene therapies.In July 2021,Catalent,Inc.invested US$100 million to expand the capacity of a facility in Anagni,Italy,by adding biologics manufacturing capacity.Such events are likely to drive the adoption of bioreactors,which will accelerate the Italy bioreactors market growth during the forecast period.48 Europe Bioreactors Market,2020-2030 |The Insight Partners 10.1.1.12 Italy:Bioreactors Market Revenue and Forecast to 2030(US$Million)The bioreactors market in Italy was valued at US$95.85 million in 2022 and is expected to reach value of US$151.80 million by 2030,growing at a CAGR of 5.9%during 20222030.Figure 24.Italy Bioreactors Market Revenue and Forecasts to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 10.1.1.12.1 Italy Bioreactors Market Breakdown by Scale Table 14.Italy Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Scale Scale 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Lab-Scale Production 11.18 11.48 11.86 12.20 12.59 13.03 13.54 14.11 14.77 15.51 16.36 4.1%Pilot-Scale Production 42.48 44.24 46.29 48.36 50.68 53.29 56.23 59.53 63.27 67.50 72.32 5.7%Full-Scale Production 34.02 35.74 37.71 39.76 42.04 44.60 47.46 50.68 54.32 58.44 63.12 6.7%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The bioreactors market for the pilot-scale production segment was worth US$46.29 million in 2022 and is projected to reach US$72.32 million by 2030;it is expected to grow at a CAGR of 5.7%from 2022 to 2030.The market for the lab-scale production segment is estimated to be worth US$16.36 million by 2030 and is expected to grow at a CAGR of 6.7%during 2022-2030.87.6891.4695.85100.32105.31110.92117.23124.33132.36141.46151.8020202021202220232024202520262027202820292030Historical YearBase YearForecast Year 49 Europe Bioreactors Market,2020-2030 |The Insight Partners 10.1.1.12.2 Italy Bioreactors Market Breakdown by Application Table 15.Italy Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Application Application 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Microbial Application 30.45 32.02 33.83 35.68 37.75 40.07 42.67 45.61 48.93 52.70 56.99 6.7ll Culture Application 42.74 44.50 46.55 48.64 50.97 53.59 56.53 59.85 63.60 67.85 72.68 5.7%Others 14.49 14.94 15.46 15.99 16.59 17.27 18.02 18.87 19.83 20.91 22.13 4.6%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The bioreactors market for the cell culture application segment was worth US$46.55 million in 2022 and is projected to reach US$72.68 million by 2030;it is expected to grow at a CAGR of 5.7%from 2022 to 2030.The market for the microbial application segment is estimated to be worth US$56.99 million by 2030 and is expected to grow at a CAGR of 6.7%during 2022-2030.10.1.1.12.3 Italy Bioreactors Market Breakdown by Technology Table 16.Italy Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Technology Technology 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Fed-Batch Bioreactors 55.09 57.17 59.61 62.05 64.79 67.88 71.35 75.27 79.70 84.72 90.43 5.3%Perfusion Bioreactors 32.58 34.29 36.24 38.26 40.52 43.04 45.88 49.06 52.66 56.74 61.37 6.8%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The bioreactors market for the fed-batch bioreactors segment was worth US$59.61 million in 2022 and is projected to reach US$90.43 million by 2030;it is expected to grow at a CAGR of 5.3%from 2022 to 2030.10.1.1.12.4 Italy Bioreactors Market Breakdown by End User Table 17.Italy Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By End User End User 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Biopharma Manufacturers 9.37 9.75 10.19 10.63 11.13 11.69 12.31 13.02 13.82 14.73 15.76 5.6%Research and Development Organizations 51.67 54.50 57.78 61.11 64.83 69.00 73.69 78.98 84.96 91.76 99.50 7.0%Contract Manufacturing Organization 26.63 27.21 27.88 28.58 29.36 30.24 31.22 32.33 33.58 34.97 36.54 3.4%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 50 Europe Bioreactors Market,2020-2030 |The Insight Partners The bioreactors market for the research and development organizations segment was worth US$57.78 million in 2022 and is projected to reach US$99.50 million by 2030;it is expected to grow at a CAGR of 7.0%from 2022 to 2030.The market for the biopharma manufacturers segment is estimated to be worth US$15.76 million by 2030 and is expected to grow at a CAGR of 5.6%during 2022-2030.10.1.1.13 Spain 10.1.1.14 Overview The growth of Spain bioreactors market is primarily attributed to the extensive research and development activities,the expanding pharmaceutical industry,and the benefits offered by bioreactors during bioprocessing.Additionally,increasing awareness and emphasis on drug development is anticipated to offer significant opportunities for the Spain bioreactors market.For instance,as per the data published by the American Association for the Advancement of Science in January 2020,ERA4TB:European Accelerator of Tuberculosis Regime Project,which is projected to be implemented in 13 European countries,including Spain,will focus on the development of new therapy for the treatment of tuberculosis.In this project,a Spanish organization,ARAID Foundation,and the University of Zaragoza will conduct a study on human pathogens,such as Mycobacterium tuberculosis,with the help of bioreactors.This applicability of the bioreactors for the comprehensive analysis of microbes is likely to boost the market.Further,increasing technology collaborations and partnerships are also expected to drive market growth in the country.10.1.1.15 Spain:Bioreactors Market Revenue and Forecast to 2030(US$Million)The bioreactors market in Spain was valued at US$71.75 million in 2022 and is expected to reach value of US$102.18 million by 2030,growing at a CAGR of 4.5%during 20222030.Figure 25.Spain Bioreactors Market Revenue and Forecasts to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 66.7868.9771.7574.1076.7779.7983.2187.0991.4996.49102.1820202021202220232024202520262027202820292030Historical YearBase YearForecast Year 51 Europe Bioreactors Market,2020-2030 |The Insight Partners 10.1.1.15.1 Spain Bioreactors Market Breakdown by Scale Table 18.Spain Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Scale Scale 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Lab-Scale Production 8.49 8.64 8.86 9.01 9.18 9.39 9.64 9.93 10.26 10.65 11.10 2.9%Pilot-Scale Production 32.39 33.41 34.70 35.79 37.03 38.44 40.03 41.84 43.89 46.23 48.88 4.4%Full-Scale Production 25.90 26.93 28.18 29.30 30.56 31.96 33.55 35.33 37.34 39.62 42.20 5.2%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The bioreactors market for the pilot-scale production segment was worth US$34.70 million in 2022 and is projected to reach US$48.88 million by 2030;it is expected to grow at a CAGR of 4.4%from 2022 to 2030.The market for the lab-scale production segment is estimated to be worth US$11.10 million by 2030 and is expected to grow at a CAGR of 2.9%during 2022-2030.10.1.1.15.2 Spain Bioreactors Market Breakdown by Application Table 19.Spain Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Application Application 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Microbial Application 23.32 24.26 25.43 26.45 27.59 28.88 30.33 31.96 33.81 35.91 38.30 5.3ll Culture Application 32.52 33.54 34.83 35.92 37.16 38.56 40.15 41.96 44.01 46.34 49.00 4.4%Others 10.94 11.17 11.49 11.74 12.02 12.35 12.74 13.17 13.67 14.24 14.89 3.3%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The bioreactors market for the cell culture application segment was worth US$34.83 million in 2022 and is projected to reach US$49.00 million by 2030;it is expected to grow at a CAGR of 4.4%from 2022 to 2030.The market for the microbial application segment is estimated to be worth US$38.30 million by 2030 and is expected to grow at a CAGR of 5.3%during 2022-2030.10.1.1.15.3 Spain Bioreactors Market Breakdown by Technology Table 20.Spain Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Technology Technology 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Fed-Batch Bioreactors 42.02 43.16 44.65 45.85 47.22 48.80 50.60 52.65 55.00 57.67 60.72 3.9%Perfusion Bioreactors 24.76 25.81 27.10 28.25 29.54 30.99 32.61 34.44 36.50 38.82 41.47 5.5%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 52 Europe Bioreactors Market,2020-2030 |The Insight Partners The bioreactors market for the fed-batch bioreactors segment was worth US$44.65 million in 2022 and is projected to reach US$60.72 million by 2030;it is expected to grow at a CAGR of 3.9%from 2022 to 2030.10.1.1.15.4 Spain Bioreactors Market Breakdown by End User Table 21.Spain Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By End User End User 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Biopharma Manufacturers 7.12 7.34 7.61 7.84 8.10 8.39 8.73 9.11 9.54 10.03 10.60 4.2%Research and Development Organizations 39.82 41.40 43.36 45.07 46.99 49.15 51.59 54.34 57.45 60.98 64.99 5.2%Contract Manufacturing Organization 19.84 20.24 20.78 21.20 21.68 22.25 22.90 23.64 24.50 25.48 26.60 3.1%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The bioreactors market for the research and development organizations segment was worth US$43.36 million in 2022 and is projected to reach US$64.99 million by 2030;it is expected to grow at a CAGR of 5.2%from 2022 to 2030.The market for the biopharma manufacturers segment is estimated to be worth US$10.60 million by 2030 and is expected to grow at a CAGR of 4.2%during 2022-2030.53 Europe Bioreactors Market,2020-2030 |The Insight Partners 10.1.1.16 Rest of Europe 10.1.1.17 Overview The bioreactors market in the Rest of Europe is segmented into Belgium,Ireland,Russia,Sweden,Austria,Switzerland,Denmark,and Norway.Factors driving the large share of this market include increasing pharmaceutical exports,government subsidies,an increase in vaccinations,and funding for biotech and biopharmaceutical companies that are expanding their biologics capabilities to meet increasing market demand.For example,in 2021,the Irish government allocated US$4.9 billion for research and development to ICON plc(Ireland),a drug development solutions and services company to the biotechnology,pharmaceutical,and medical device industries.These funds were allocated for clinical trials to expand patient access to clinical research through technology.Additionally,as of January 2021,Circa Group Europe Limited(Ireland)invested US$2.2 billion annually in biopharmaceutical research and development through IDA Irelands client companies.Such an investment plan stimulates the demand for biopharmaceutical products in Europe and drives the market forward.Among the regions with strong clusters in the biopharmaceutical industry are Belgium,Sweden,and Norway.There are also several above-average regions in Denmark and Ireland.The strongest biopharmaceutical industry clusters are in Belgium,Norway,and Sweden.Belgium can be identified as an important player in terms of biopharmaceuticals.Major Belgian pharmaceutical companies include Janssen Pharmaceutica,Solvay,Union Chimique Belge(UCB),GMED Healthcare,and subsidiaries such as BASF Antwerpen and GlaxoSmithKline Biologicals.Thus,the factors mentioned above are expected to drive the market growth in the region.10.1.1.18 Rest of Europe:Bioreactors Market Revenue and Forecast to 2030(US$Million)The bioreactors market in the Rest of Europe was valued at US$149.66 million in 2022 and is expected to reach value of US$220.25 million by 2030;it is expected to grow at a CAGR of 4.9%during 20222030.Figure 26.Rest of Europe Bioreactors Market Revenue and Forecasts to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 140.42145.51149.66156.86164.50172.58181.13190.18199.72209.75220.2520202021202220232024202520262027202820292030Historical YearBase YearForecast Year 54 Europe Bioreactors Market,2020-2030 |The Insight Partners 10.1.1.18.1 Rest of Europe Bioreactors Market Breakdown by Scale Table 22.Rest of Europe Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Scale Scale 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Lab-Scale Production 17.88 18.25 18.51 19.09 19.69 20.32 20.98 21.67 22.39 23.13 23.90 3.2%Pilot-Scale Production 68.03 70.39 72.29 75.65 79.20 82.97 86.94 91.14 95.57 100.21 105.06 4.8%Full-Scale Production 54.51 56.87 58.86 62.13 65.60 69.29 73.21 77.36 81.76 86.41 91.29 5.6%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The bioreactors market for the pilot-scale production segment was worth US$72.29 million in 2022 and is projected to reach US$105.06 million by 2030;it is expected to grow at a CAGR of 4.8%from 2022 to 2030.The market for the lab-scale production segment is estimated to be worth US$23.90 million by 2030 and is expected to grow at a CAGR of 3.2%during 2022-2030.10.1.1.18.2 Rest of Europe Bioreactors Market Breakdown by Application Table 23.Rest of Europe Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Application Application 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Microbial Application 48.79 50.96 52.85 55.81 58.98 62.35 65.94 69.76 73.82 78.12 82.66 5.8ll Culture Application 68.44 70.80 72.69 76.05 79.61 83.38 87.36 91.56 95.98 100.63 105.48 4.8%Others 23.19 23.75 24.13 25.00 25.91 26.85 27.84 28.86 29.92 31.00 32.11 3.6%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The bioreactors market for the cell culture application segment was worth US$72.69 million in 2022 and is projected to reach US$105.48 million by 2030;it is expected to grow at a CAGR of 4.8%from 2022 to 2030.The market for the microbial application segment is estimated to be worth US$82.66 million by 2030 and is expected to grow at a CAGR of 5.8%during 2022-2030.10.1.1.18.3 Rest of Europe Bioreactors Market Breakdown by Technology Table 24.Rest of Europe Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By Technology Technology 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Fed-Batch Bioreactors 88.38 91.09 93.19 97.14 101.29 105.68 110.30 115.17 120.27 125.61 131.16 4.4%Perfusion Bioreactors 52.04 54.42 56.47 59.73 63.20 66.90 70.83 75.02 79.45 84.15 89.09 5.9%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 55 Europe Bioreactors Market,2020-2030 |The Insight Partners The bioreactors market for the fed-batch bioreactors segment was worth US$93.19 million in 2022 and is projected to reach US$131.16 million by 2030;it is expected to grow at a CAGR of 4.4%from 2022 to 2030.10.1.1.18.4 Rest of Europe Bioreactors Market Breakdown by End User Table 25.Rest of Europe Bioreactors Market Revenue and Forecasts to 2030(US$Mn)By End User End User 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Biopharma Manufacturers 15.01 15.47 15.83 16.51 17.22 17.98 18.77 19.61 20.48 21.40 22.35 4.4%Research and Development Organizations 83.85 87.43 90.48 95.41 100.65 106.22 112.15 118.46 125.14 132.21 139.66 5.6%Contract Manufacturing Organization 41.57 42.62 43.34 44.95 46.63 48.38 50.21 52.12 54.09 56.14 58.23 3.8%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The bioreactors market for the research and development organizations segment was worth US$90.48 million in 2022 and is projected to reach US$139.66 million by 2030;it is expected to grow at a CAGR of 5.6%from 2022 to 2030.The market for the biopharma manufacturers segment is estimated to be worth US$22.35 million by 2030 and is expected to grow at a CAGR of 4.4%during 2022-2030.56 Europe Bioreactors Market,2020-2030 |The Insight Partners 11.Bioreactors Market-Industry Landscape 11.1 Overview The developments in global bioreactors market have been characterized as organic and inorganic growth strategies.Various companies are focusing on organic growth strategies such as launches,approval,expansion,enhancement as well as relocation.Inorganic growth strategies witnessed in the market were partnerships.These activities have paved way for expansion of business and customer base of market players.11.2 Growth Strategies in the Bioreactors Market Figure 27.Growth Strategies in the Bioreactors Market Source:The Insight Partners Analysis 50.00P.00%Organic StrategiesInorganic Strategies 57 Europe Bioreactors Market,2020-2030 |The Insight Partners 11.3 Inorganic Growth Strategies 11.3.1 Overview The inorganic growth strategies undertaken by the companies operating in the global bioreactors market include partnerships and collaborations.During 2020 to 2023,Sartorius AG,PBS Biotech,Merck have undertaken various inorganic strategies that have bought about remarkable developments in the bioreactors market.Inorganic growth strategies in the bioreactors market accounted for a share of around 50%among the growth strategies undertaken in the market.Table 26.Recent Inorganic Growth Strategies in the Bioreactors Market Company NameCompany Name DateDate CategoryCategory DescriptionDescription Sartorius AG Aug-2023 Collaboration Emerson collaborated with life science group Sartorius to natively integrate Sartoriuss Biostat STR Generation 3 family of bioreactors with Emersons DeltaVTM distributed control system(DCS).DeltaV control system natively integrated into Sartorius Biostat STR bioreactors provides a foundation for semi-autonomous operations and up to 80%less integration time.PBS Biotech Jul-2023 Partnership PBS Biotech Inc and Stemcell Technologies Inc have entered into a supply arrangement that will enable researchers to access PBS-MINI Bioreactors.Through this partnership,PBS will support researchers who wish to grow their cultures of human pluripotent stem cells,or hPSCs,which are essential for drug discovery,disease modeling,future cell-based therapeutics,and pharmaceutical applications.Merck Dec-2022 Mergers and Acquisitions Merck KGaA announced the acquisition of Erbi Biosystems,a developer of 2 ml micro-bioreactor platform technology.The acquisition has allowed Merck KGaA to incorporate Erbi Biosystemss bioreactor,Breez,into its portfolio and strengthen its therapeutic proteins portfolio.After the acquisition,Merck KGaA aims to increase its Group sales to approximately US$26.7 billion(25 billion)by 2025.Cellexus Mar-2022 Partnership Cellexus partnered with Castleford-based Verder Liquids to provide pumps to be used for the acid/base pump,included as standard with the CellMaker Plus and Low Flow bioreactor systems.This pump allows the CellMaker to inject acids or alkali from their reservoir directly into the bioreactor bag by manual or automated operation.Thermo Fisher Scientific Oct-2021 Collaboration Thermo Fisher Scientific Inc and 3M Separation and Purification Sciences have collaborated on biologics manufacturing.Under the agreement,both companies will incorporate their technologies to produce biologics.The collaboration has enabled their customers to pair the 3M Harvest RC Chromatographic Clarifier,which is a single-stage purification solution,with Thermo Scientific HyPerforma Single-Use Bioreactor Systems.The integration of two technologies will provide great efficiency and scalability in the therapeutic manufacturing process.Source:The Insight Partners Analysis 58 Europe Bioreactors Market,2020-2030 |The Insight Partners 11.4 Organic Growth Strategies 11.4.1 Overview During the year 2020-2023 various companies have made organic growth strategies in bioreactors market.Some of the activities undertaken by the company,which have promoted its growth are,approval,launches,enhancements and expansion.Sartorius AG,Getinge,Cytiva are among the companies that have been implementing various organic strategies that have helped the growth of the company and in turn have brought about various changes in the global bioreactors market.Organic growth strategies in the bioreactors market accounted for a share of around 50%among the growth strategies undertaken in the market.Table 27.Recent Organic Growth Strategies in the Bioreactors Market Company NameCompany Name DateDate CategoryCategory DescriptionDescription Sartorius AG Aug-2023 Product Launch Sartorius and Repligen have collaborated to launch an advanced bioreactor system that incorporates Repligen XCell ATF upstream intensification technology into Sartorius Biostat STR bioreactor.The aim of this collaboration is to simplify intensified seed train and N perfusion implementation for biopharmaceutical manufacturers,as per the announcement by both companies.Getinge Aug-2023 Product Launch Getinge unveiled a new product,the AppliFlex ST GMP-a state-of-the-art single-use bioreactor system.The main aim of this system is to facilitate the transition from research to clinical production in cell and gene therapy,as well as mRNA production.With the AppliFlex ST GMP,Getinge is introducing a cutting-edge solution t
2024-08-12
93页
5星级
2 Asia Pacific Genetic Testing Services Market Market Size and Forecast(2020-2030)Regional Growth Opportunity Analysis Coverage:by Service Service TypeType(Predictive Testing,Carrier Testing,Prenatal Testing,Newborn Screening,and Others),DiseaseDisease(Cancer,Metabolic Diseases,Cardiovascular Diseases,and Other Diseases),Service Service ProviderProvider(Hospital-Based Laboratories,Diagnostic Laboratories,and Others),and CountryCountry 2 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners Table of Content 1.Introduction.13 1.1 The Insight Partners Research Report Guidance.13 1.2 Market Segmentation.14 2.Executive Summary.15 2.1 Key Insights.15 3.Research Methodology.16 3.1 Coverage.17 3.2 Secondary Research.17 3.3 Primary Research.17 4.Asia Pacific Genetic Testing Services Market-Key Industry Dynamics.19 4.1 Key Market Drivers.19 4.1.1 Rising Prevalence of Genetic Diseases.19 4.1.2 Increasing Awareness and Acceptance of Personalized Medicines.20 4.1.3 Growing Preference for Direct-To-Consumer(DTC)Genetic Testing.20 4.2 Market Restraints.21 4.2.1 Social and Ethical Implications of Genetic Testing.21 4.2.2 Affordability of Genetic Services.21 4.3 Market Opportunities.22 4.3.1 Untapped Emerging Markets in Developing Countries.22 4.4 Future Trends.22 4.4.1 Artificial Intelligence-Powered Genetic Testing.22 4.5 Impact Analysis:.23 5.Genetic Testing Services Market-Asia Pacific Market Analysis.24 5.1 Asia Pacific Genetic Testing Services Market Revenue(US$Mn),2022 2030.24 6.Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030 by Service Type.25 6.1 Overview.25 6.2 Asia Pacific Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%).25 6.3 Predictive Testing.26 6.3.1 Overview.26 3 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 6.3.2 Predictive Testing:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).26 6.4 Carrier Testing.27 6.4.1 Overview.27 6.4.2 Carrier Testing:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).27 6.5 Prenatal Testing.28 6.5.1 Overview.28 6.5.2 Prenatal Testing:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).28 6.6 Newborn Screening.29 6.6.1 Overview.29 6.6.2 Newborn Screening:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).29 6.7 Others.30 6.7.1 Overview.30 6.7.2 Others:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).30 7.Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030 by Disease.31 7.1 Overview.31 7.2 Asia Pacific Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%).31 7.3 Cancer.32 7.3.1 Overview.32 7.3.2 Cancer:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).32 7.4 Cardiovascular Diseases.33 7.4.1 Overview.33 7.4.2 Cardiovascular Diseases:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).33 7.5 Metabolic Diseases.34 7.5.1 Overview.34 7.5.2 Metabolic Diseases:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).34 7.6 Other Diseases.35 7.6.1 Overview.35 7.6.2 Other Diseases:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).35 4 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 8.Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030 by Service Provider.37 8.1 Overview.37 8.2 Asia Pacific Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%).37 8.3 Hospital-Based Laboratories.38 8.3.1 Overview.38 8.3.2 Hospital-Based Laboratories:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).38 8.4 Diagnostic Laboratories.39 8.4.1 Overview.39 8.4.2 Diagnostic Laboratories:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).39 8.5 Others.40 8.5.1 Overview.40 8.5.2 Others:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).40 9.Asia Pacific Genetic Testing Services Market-Country Analysis.41 9.1 Asia Pacific.41 9.1.1 Asia Pacific Genetic Testing Services Market,by Country.41 9.1.1.1 China.42 9.1.1.1.1 Overview.42 9.1.1.1.2 China Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).42 9.1.1.1.3 China Genetic Testing Services Market,by Service Type,20202030(US$Million).43 9.1.1.1.4 China Genetic Testing Services Market,by Disease,20202030(US$Million).43 9.1.1.1.5 China Genetic Testing Services Market,by Service Provider,20202030(US$Million).43 9.1.1.2 Japan.44 9.1.1.2.1 Overview.44 9.1.1.2.2 Japan Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).44 9.1.1.2.3 Japan:Asia Pacific Genetic Testing Services Market,by Service Type,20202030(US$Million).45 9.1.1.2.4 Japan:Asia Pacific Genetic Testing Services Market,by Disease,20202030(US$Million).45 9.1.1.2.5 Japan:Asia Pacific Genetic Testing Services Market,by Service Provider,20202030(US$Million).45 5 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.3 India.46 9.1.1.3.1 Overview.46 9.1.1.3.2 India Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).46 9.1.1.3.3 India Genetic Testing Services Market,by Service Type,20202030(US$Million).47 9.1.1.3.4 India Genetic Testing Services Market,by Disease,20202030(US$Million).48 9.1.1.3.5 India Genetic Testing Services Market,by Service Provider,20202030(US$Million).48 9.1.1.4 Australia.49 9.1.1.4.1 Overview.49 9.1.1.4.2 Australia Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).49 9.1.1.4.3 Australia Genetic Testing Services Market,by Service Type,20202030(US$Million).50 9.1.1.4.4 Australia Genetic Testing Services Market,by Disease,20202030(US$Million).50 9.1.1.4.5 Australia Genetic Testing Services Market,by Service Provider,20202030(US$Million).50 9.1.1.5 South Korea.51 9.1.1.5.1 Overview.51 9.1.1.5.2 South Korea Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).51 9.1.1.5.3 South Korea Genetic Testing Services Market,by Service Type,20202030(US$Million).52 9.1.1.5.4 South Korea Genetic Testing Services Market,by Disease,20202030(US$Million).52 9.1.1.5.5 South Korea Genetic Testing Services Market,by Service Provider,20202030(US$Million).52 9.1.1.6 Rest of Asia Pacific.53 9.1.1.6.1 Overview.53 9.1.1.6.2 Rest of Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).53 9.1.1.6.3 Rest of Asia Pacific Genetic Testing Services Market,by Service Type,20202030(US$Million).54 9.1.1.6.4 Rest of Asia Pacific Genetic Testing Services Market,by Disease,20202030(US$Million).54 9.1.1.6.5 Rest of Asia Pacific Genetic Testing Services Market,by Service Provider,20202030(US$Million).55 10.Genetic Testing Services MarketIndustry Landscape.56 10.1 Overview.56 6 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 10.2 Growth Strategies in Asia Pacific Genetic Testing Services Market.56 10.3 Organic Growth Strategies.57 10.3.1 Overview.57 10.4 Inorganic Growth Strategies.59 10.4.1 Overview.59 11.Company Profiles.60 11.1 Eurofins Scientific SE.60 11.1.1 Key Facts.60 11.1.2 Business Description.60 11.1.3 Products and Services.61 11.1.4 Financial Overview.62 11.1.5 SWOT Analysis.63 11.1.6 Key Developments.64 11.2 Exact Sciences Corp.65 11.2.1 Key Facts.65 11.2.2 Business Description.65 11.2.3 Products and Services.65 11.2.4 Financial Overview.66 11.2.5 SWOT Analysis.67 11.2.6 Key Developments.68 11.3 Laboratory Corp of America Holdings.69 11.3.1 Key Facts.69 11.3.2 Business Description.69 11.3.3 Products and Services.69 11.3.4 Financial Overview.70 11.3.5 SWOT Analysis.71 11.3.6 Key Developments.72 11.4 Quest Diagnostics Inc.73 11.4.1 Key Facts.73 11.4.2 Business Description.73 11.4.3 Products and Services.74 11.4.4 Financial Overview.74 11.4.5 SWOT Analysis.75 11.4.6 Key Developments.76 11.5 Illumina Inc.77 7 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 11.5.1 Key Facts.77 11.5.2 Business Description.77 11.5.3 Products and Services.78 11.5.4 Financial Overview.78 11.5.5 SWOT Analysis.79 11.5.6 Key Developments.80 11.6 F.Hoffmann-La Roche Ltd.81 11.6.1 Key Facts.81 11.6.2 Business Description.81 11.6.3 Products and Services.82 11.6.4 Financial Overview.82 11.6.5 SWOT Analysis.84 11.6.6 Key Developments.86 11.7 NeoGenomics Inc.87 11.7.1 Key Facts.87 11.7.2 Business Description.87 11.7.3 Products and Services.87 11.7.4 Financial Overview.88 11.7.5 SWOT Analysis.89 11.7.6 Key Developments.90 11.8 Centogene AG.91 11.8.1 Key Facts.91 11.8.2 Business Description.91 11.8.3 Products and Services.91 11.8.4 Financial Overview.92 11.8.5 SWOT Analysis.93 11.8.6 Key Developments.94 12.Appendix.95 12.1 About Us.95 12.2 Glossary of Terms.96 8 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners List of Tables Table 1.Asia Pacific Genetic Testing Services Market Segmentation.14 Table 2.China Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).43 Table 3.China Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).43 Table 4.China Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).43 Table 5.Japan:Asia Pacific Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).45 Table 6.Japan:Asia Pacific Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).45 Table 7.Japan:Asia Pacific Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).45 Table 8.India Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).47 Table 9.India Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).48 Table 10.India Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).48 Table 11.Australia Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).50 Table 12.Australia Asia Pacific Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).50 Table 13.Australia Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).50 Table 14.South Korea Asia Pacific Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).52 Table 15.South Korea Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).52 Table 16.South Korea Asia Pacific Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).52 Table 17.Rest of Asia Pacific Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).54 9 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners Table 18.Rest of Asia Pacific Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).54 Table 19.Rest of Asia Pacific Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).55 Table 20.Recent Organic Growth Strategies in Asia Pacific Genetic Testing Services Market.57 Table 21.Recent Inorganic Growth Strategies in the Asia Pacific Genetic Testing Services Market.59 Table 22.Glossary of Terms,Asia Pacific Genetic Testing Services Market.96 10 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners List of Figures Figure 1.Asia Pacific Genetic Testing Services Market Segmentation,By Country.14 Figure 2.Asia Pacific Genetic Testing Services Market-Key Industry Dynamics.19 Figure 3.Impact Analysis of Drivers and Restraints.23 Figure 4.Asia Pacific Genetic Testing Services Market Revenue(US$Mn),2022 2030.24 Figure 5.Asia Pacific Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%).25 Figure 6.Predictive Testing:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).26 Figure 7.Carrier Testing:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).27 Figure 8.Prenatal Testing:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).28 Figure 9.Newborn Screening:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).29 Figure 10.Others:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).30 Figure 11.Asia Pacific Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%).31 Figure 12.Cancer:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).32 Figure 13.Cardiovascular Diseases:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).33 Figure 14.Metabolic Diseases:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).34 Figure 15.Other Diseases:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).36 Figure 16.Asia Pacific Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%).37 Figure 17.Hospital-Based Laboratories:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).38 Figure 18.Diagnostic Laboratories:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).39 Figure 19.Others:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).40 11 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 20.Asia Pacific Genetic Testing Services Market,by Key Country Revenue,2022(US$Million).41 Figure 21.Asia Pacific Genetic Testing Services Market,By Key Countries,2022 and 2030(%).41 Figure 22.China Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).42 Figure 23.Japan Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).44 Figure 24.India Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).47 Figure 25.Australia Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).49 Figure 26.South Korea Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).51 Figure 27.Rest of Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).53 Figure 28.Growth Strategies in Asia Pacific Genetic Testing Services Market.56 12 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners NOTES:The list of companies included in the scope are as per standard report format and the list can be modified/expanded as per clients requirement The sequence/list of companies do not represent their current position in the market.The list of countries provided in the report are part of standard report and can be customized as per clients requirement RELATED REPORTS Newborn Genetic Testing Market DTC Genetic Testing Market 13 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 1.Introduction 1.1 The Insight Partners Research Report Guidance The report provides qualitative and quantitative trends of Asia Pacific genetic testing services market across service type,disease,service provider,and country.The report starts with the key takeaways(chapter 2),highlighting the key trends and outlook of the Asia Pacific genetic testing services market.Chapter 3 provides the research methodology of the study.Chapter 4 highlights the key industry dynamics in the Asia Pacific genetic testing services market,including factors that are driving the market,prevailing deterrent,potential opportunities as well as future trends.Impact analysis of these drivers and restraints is also covered in this section.Chapter 5 discusses the Asia Pacific genetic testing services market scenario,in terms of historical market revenues,and forecast till 2030.Chapter 6 to 9 discuss genetic testing services market segments by service type,disease,service provider,and countries across Asia Pacific.They cover market revenue forecast,and factors driving and governing growth.Chapter 10 describes the industry landscape analysis.It provides detailed description of various business activities such as market initiatives,new developments,mergers,and joint ventures globally along with a competitive landscape.Chapter 11 provides the detailed profiles of the key companies operating in the Asia Pacific genetic testing services market.The companies have been profiled on the basis of their key facts,business description,products and services,financial overview,SWOT analysis,and key developments.Chapter 12,i.e.the appendix is inclusive of a brief overview of the company,glossary of terms,contact information,and the disclaimer section.14 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 1.2 Market Segmentation Table 1.Asia Pacific Genetic Testing Services Market Segmentation SERVICE TYPESERVICE TYPE DISEASEDISEASE SERVICE PROVIDERSERVICE PROVIDER PREDICTIVE TESTING CANCER HOSPITAL-BASED LABORATORIES CARRIER TESTING CARDIOVASCULAR DISEASES DIAGNOSTIC LABORATORIES PRENATAL TESTING METABOLIC DISEASES OTHERS NEWBORN SCREENING OTHER DISEASES OTHERS Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources Figure 1.Asia Pacific Genetic Testing Services Market Segmentation,By Country Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources The Asia Pacific genetic testing services market is segmented based on service type,disease,service provider,and country.The segmentation in this research study has been finalized post in-depth secondary research and extensive primary research.In addition,the market is also segmented on the basis of services offered by the leading participants in the industry in order to understand widely used market specific terminologies.Thus,we have incorporated the segments of the research and have finalized the market segmentation.ASIA PACIFIC(APAC)AUSTRALIAINDIACHINAJAPANSOUTH KOREAREST OF APAC 15 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 2.Executive Summary 2.1 Key Insights OverviewMarket SegmentationMarket DynamicsRegional OverviewMarket SegmentationKey PlayersMarket DynamicsCAGR(2022-2030)16.3%Market Size 2022$646.31MnMarket Size 2030$2,156.88MnService TypeDisease Predictive Testing Carrier Testing Prenatal Testing Newborn Screening Others Cancer Cardiovascular Diseases Metabolic Diseases Other Diseases Laboratory Corporation of America Holdings F.Hoffmann-La Roche Ltd Illumina,Inc.Quest Diagnostics Incorporated Exact Sciences Corp(Genomic Health)NeoGenomics Laboratories,Inc.Eurofins Scientific Centogene AG 23andMe,IncGROWTH DRIVERSFUTURE TRENDSGROWTH DRIVERSFUTURE TRENDS Rising Prevalence of Genetic Diseases Increasing Awareness and Acceptance of Personalized Medicines Artificial Intelligence-Powered Genetic TestingRESTRAINTSOPPORTUNITY Social and Ethical Implications of Genetic Testing Affordability of Genetic Services Untapped Emerging Markets in Developing CountriesService Provider Hospital-Based Laboratories Diagnostic Laboratories OthersASIA PACIFIC16.3 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 3.Research Methodology The Insight Partners dedicated research and analysis team consist of experienced professionals with advanced statistical expertise in market research and consulting backgrounds in in various industries including Aerospace and Defense,Automotive and Transportation,Biotechnology,Chemicals and Materials,Food and Beverages,Electronics and Semiconductor,Healthcare IT,Manufacturing and Construction,Medical Device,Technology,Media and Telecommunications.Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources FinalMarket sizeValidation from Primary InterviewSummation of Revenue Generated from Companies to arrive Total Market SizeRevenue Generated by the Products and Services Offered by Companies in the Genetic Testing Service MarketFinal Market Size Break-Up To Rest Of Segmentation(i.e.,Service Type,Disease,Service Provider,and Region)Arriving at the Market Size of each Segment Validation of Number with Primary Interviews and Subject Matter Expert BOTTOM-UP ANALYSISTOP-DOWN ANALYSIS 17 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners The Insight Partners adheres to the codes of practice of the Market Research Society(www.mrs.org.uk)and Strategic and Competitive Intelligence Professionals(www.scip.org).The following methodology has been followed for the collection and analysis of data presented in this report:3.1 Coverage The objective of updating“The Insight Partners”coverage is to ensure that it represents the most up-to-date vision of the industry possible.The estimated revenues of all major companies,including private and governmental,are gathered and used to prioritize coverage.Companies which are making the news,or which are of particular interest due to their innovative approach,are prioritized.3.2 Secondary Research The research process begins with exhaustive secondary research using internal and external sources to obtain qualitative and quantitative information relating to each Market.The secondary research sources that are typically referred to include,but are not limited to:Company websites,annual reports,financial reports,broker reports and investor presentations Industry trade journals and other literature National government documents,statistical databases and market reports News articles,press releases and web-casts specific to the companies operating in the market NOTE:All the financials considered in Company Profiles section have been standardized to US$.This has been achieved after converting the financials(for those not in US$)with respective currency exchange rates of the particular year.3.3 Primary Research“The Insight Partners”conducts hundreds of primary interviews a year with industry participants and commentators in order to validate its data and analysis.A typical research interview fulfils the following functions:Provides first-hand information on the market size,market trends,growth trends,competitive landscape and future outlook Validates and strengthens secondary research findings Further develops the analysis teams expertise and market understanding 18 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners Primary research involves email interactions and telephone interviews for each market,category,segment and sub-segment across countries.The participants who typically take part in such a process include,but are not limited to:Industry participants:VPs,business development managers,market intelligence managers and national sales managers Outside experts:Valuation experts,research analysts and key opinion leaders specializing in the industry 19 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 4.Asia Pacific Genetic Testing Services Market-Key Industry Dynamics Figure 2.Asia Pacific Genetic Testing Services Market-Key Industry Dynamics Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 4.1 Key Market Drivers 4.1.1 Rising Prevalence of Genetic Diseases The prevalence of genetic diseases is rising across the world and impacting the health of people at a severe level.Genetic diseases show many symptoms that are uncommon and are mostly non-curable.Most of the genetic diseases are rare and are developed due to the mutation in the genetic makeup of the people.According to The World Health Organization(WHO)2021,10 out of every 1,000 people are affected by single-gene diseases,signifying that 70 million and 80 million people worldwide are living with any one type of single-gene disease.As per the Global Genes,7,000 known rare diseases and disorders have been identified worldwide,and more are being discovered every year.According to the University of Sheffield research,300 million people are living with genetic diseases around the world.In Asia Pacific and the Middle East,a very large population is diagnosed with genetic diseases due to consanguineous marriage favored in many communities.Marriages between relatives are the major concern for the rising prevalence of genetic diseases.The burden of autosomal recessive disease variations is high in Saudi Arabia due to the highly consanguineous population.To control these conditions,countries in the Middle East are mandatorily conducting genetic evaluations for couples getting married so that the prevalence of these diseases can be managed and treated timely.DROTDRIVERSRESTRAINTSOPPORTUNITIESTRENDSRising Prevalence of Genetic DiseasesIncreasing Awareness and Acceptance of Personalized MedicinesGrowing Preference for Direct-To-Consumer Genetic TestingSocial and Ethical Implications of Genetic TestingAffordability of Genetic ServicesArtificial Intelligence-Powered Genetic TestingUntapped Emerging Markets in Developing Countries 20 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners Thus,the rising prevalence of genetic diseases fuels the demand for genetic testing,which in turn drives genetic testing services market growth.4.1.2 Increasing Awareness and Acceptance of Personalized Medicines Personalized medicine is the field that utilizes patients genetic and environmental data to deliver optimal healthcare.It is based on the principle that every patient is unique and requires individualistic pharmacological treatment.Since it is a rapidly evolving area,it is presently incorporated into several healthcare systems.The successful completion of the Human Genome Project(HGP)in 2003 and the fast-decreasing human genome sequencing costs encouraged the development of a new medical approach,which is called personalized medicine.With an expanding repository of personalized data at the molecular level,molecular diagnostics companies are exceptionally positioned to unlock value.Large-scale drug discovery is a key to increasing the viability and usefulness of personalized medicines for the diagnosis of diseases and disorders.Genomics is one of the fastest-growing divisions of medical science.It is driving a paradigm shift in the research methodology of a disease,as well as diagnosing and treating illness.Genetic testing has been extensively used in pharmacogenomics,also known as drug-gene testing.It helps in accelerating drug discovery and its development.In January 2023,The Human Genome Project is ensuring an era of personalized healthcare.Now,new research shows that precision prescribing using genetic testing has ultimately reached a global tipping point for adoption.Published by Cambridge University Press,the peer-reviewed research examines the maturation of critical factors required for the use of clinical genetics at scale.These advancements pave the way for supporting genome-informed clinical decision-making to be established as the new standard of care.Genetically informed prescribing offers one of the realistic mechanisms to successfully reduce the overall costs of the healthcare system and improve individual patient care.Genetic testing encourages the adoption of a personalized medicine approach by understanding the science behind the disease,the impact of treatment,and the development of therapies for specific individual characteristics.It also helps healthcare personnel make informed decisions about disease diagnosis,treatment,and prevention by utilizing genetic testing results,leading to improved patient outcomes.4.1.3 Growing Preference for Direct-To-Consumer(DTC)Genetic Testing Personalized genetic testing and treatment have long been used globally to help individuals and families learn more about hereditary diseases.Most of the time,genetic testing is done through healthcare personnel,such as genetic counselors.Healthcare providers decide which test is needed,order the test from a test center,collect and send the DNA sample,read the test results,and share the results with the patient.Thus,these tests have traditionally been ordered and interpreted in a clinical or medical research setting.In contrast,DTC genetic testing has witnessed tremendous growth in the past decade and is becoming increasingly widespread.A genetic test offered,advertised,and sold by companies directly to the consumer,without the direct involvement of a conventional healthcare system,is called DTC genetic testing.DTC genetic testing is relatively new and helps people find out about the disease-associated genes they may carry without the need for a prescription or guidance from a genetic counselor or medical practitioner.Several consumers of DTC testing view it as another method of gathering medical information about themselves.Unlike other genetic tests performed in clinics or hospitals,the consumer independently initiates and completes a DTC genetic test.The public understanding and acceptance of genetic testing is gradually increasing.Additionally,there is a rise in consumers seeking customized products and experiences for the identification and addressing of unique needs.The launch of innovative products and the increase in the adoption of DTC genetic testing kits have made genetic testing 21 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners more accessible to people.These kits enable users to undergo personalized health management within the comfort of their homes.Key industry players are also developing DTC genetic tests and implementing special marketing efforts that positively impact sales of DTC tests.In September 2021,MedGenome Labs introduced its DTC category under the brand name Genessense for consumers in India.The brand offers specialized,evidence-based genetic screening tests that provide insights into ones health prior to the onset of symptoms.A rising number of manufacturers are providing direct-to-consumer genetic testing that covers various health conditions and traits.The increasing demand for direct-to-consumer genetic testing products to learn about the genetic makeup and assess the risk of developing hereditary conditions for early disease detection or prevention drives the market.4.2 Market Restraints 4.2.1 Social and Ethical Implications of Genetic Testing Genetic testing is poised to play an important role in the practice of obstetrics and gynecology.Physicians are required to become familiar with the presently accessible collection of genetic tests and their limitations to guarantee patients the utmost quality of care.However,the knowledge of genetic risks can result in potential social and psychological consequences for the people undergoing such tests.Socially,knowledge from genetic tests may lead to stigmatization and judgment within the community.Refusing to undergo genetic testing,as well as choosing to undergo genetic testing,can both lead to discrimination and stigmatization,depending on the prevalent public standards concerning acceptance and use of the technology.Privacy and security concerns also arise as the availability and commercialization of personal genetic data can lead to unauthorized access or misuse of sensitive information.The storage of genetic testing data and registries of patients generates concern,given that the results can negatively impact the family members.In addition,lack of informed consent can lead to adverse reactions,such as increased anxiety and unnecessary preventive measures during the disclosure of genetic test results.Lack of proper counseling regarding the information about genetic risk and choices regarding genetic testing and its management can cause potential psychological distress.Therefore,the reluctance of patients to prefer genetic testing due to the social and ethical stigma impedes market growth.4.2.2 Affordability of Genetic Services At present,genetic services are expensive and,therefore,not accessible to all.Genetic research is presently underrepresented in health research;however,studies are being conducted to establish the feasibility of such services.Present inequalities in the affordability and feasibility of genetic services are a cause of concern for the WHO and other prominent international organizations that are centered around public health and development concerns.The cost of the test also increases if more than one test is needed or if multiple family members need to be tested to obtain a significant result.For newborn screening,costs differ as per the state.Several states cover part of the overall cost,although most charge a fee of US$30 to US$150 per infant.Various factors,including the type of test,the complexity of analysis,and laboratory processing fees,influence the cost of these tests.Thus,the high costs,along with its affordability in emerging economies,restrain the market growth.22 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 4.3 Market Opportunities 4.3.1 Untapped Emerging Markets in Developing Countries Emerging countries such as China,India,Brazil,and Mexico offer significant growth opportunities to market players.The high growth can majorly be attributed to the increasing public healthcare expenditure,improving healthcare infrastructure,and the presence of a large target patient population.The need for genetic testing has also increased owing to a rise in awareness of genetic disorders in developing economies and their early diagnosis.The quality and availability of genetic services may differ between high-income countries and low-to middle-income countries.For instance,in the US,Australia,Canada,the UK,and other European countries,genetic services are well-advanced,established,and extensive.These services include newborn screening,carrier identification screening,and prenatal diagnosis.Yet,in many high-income countries,genetic services that are offered in multiple settings still need improved systems of assessment.The ease and applicability of genetic testing procedures have benefitted R&D activities in developing regions worldwide.Major market players are focusing on strategies and initiatives,such as agreements,collaborations,partnerships,and expansions,to improve their product availability,accessibility,and distribution networks in these countries,as it will help them address the growing need for early diagnosis and treatment.For instance,in 2023,Progenesis,a well-known international genetic testing company with its headquarters in the US,has opened its first Genetic Laboratory in New Delhi and its AI&Bioinformatics Data Center in Chennai,marking the companys official entry into the Indian market.The Chinese government identifies genomics as an important strategic field in its 14th Five-Year Plan(20162020)for the countrys economic and social development.In 2016,the Chinese Academy of Sciences launched the Precision Medicine Initiative,a 14-year project worth US$9.2 billion to sequence more than 100 million human genomes by 2030.In December 2017,Chinas Ministry of Science and Technology collaborated with a human genome research project to document the genetic makeup of 100,000 people.Using the genetic data of nine different minority groups,researchers desire to decode hereditary information within genes.In addition,rising consumer awareness regarding DTC genetic tests in developing economies offers growth opportunities to the DTC industry.Therefore,emerging markets in developing countries are expected to offer significant opportunities to the players operating in the market and boost the market growth during the forecast period.4.4 Future Trends 4.4.1 Artificial Intelligence-Powered Genetic Testing Whole-genome sequencing and now whole-exome sequencing have also become more popular.To solve the growing problem of health data exhaust,the field of medicine is increasingly revolving around enhanced clinical tools,such as artificial intelligence(AI)and machine learning,which have been mentioned as a way to improve the acceptance of genomic medicine.Today,many companies have turned to machine learning to process the vast amount of data needed to correctly analyze and understand clinical data in fields such as radiology and cardiology.Many of the consumer-facing genetic testing technologies that are available in the market are using machine learning or AI to function.In numerous ways,genetic testing of diseases is the perfect field for machine learning because of the vast volumes of data that these programs need to struggle with.For example,working on the human genome includes reading billions of bits of information,and prior to the introduction of machine learning,many of these tasks were pretty tricky.AI offers great potential when it comes to analyzing genetic data and supporting clinical specialists in making diagnoses.23 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners Google has a program called Deep Variant that can now be used to plot the human genome thoroughly and can be used on the full range of a persons genetic information.Moreover,agencies such as the National Institutes of Health are working on ways through which machine learning and AI can add to a better understanding of genetics and genomics.Furthermore,Blueprint Genetics is using AI in clinical interpretation.Machine learning and AI are acting as a catalyst for faster and more diverse improvement in genetic research and engineering.These tools are simple to integrate and extremely scalable,putting genetic laboratories in a unique position to scale their operations and match the fast growth of the genetic testing field.Thus,through the successful integration of these tools,clinicians will be able to diagnose rare genetic diseases more efficiently and effectively,bringing hope to the millions of people affected by them globally.4.5 Impact Analysis:The following figure depicts the impact of factors driving and restraining the Asia Pacific genetic testing services market.The factors driving the market growth include increasing prevalence of genetic diseases,increasing awareness and acceptance of personalized medicines,and growing preference for direct-to-consumer genetic testing.However,social and ethical implications of genetic testing and affordability of genetic services hinders the market growth.Figure 3.Impact Analysis of Drivers and Restraints Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources Rising Prevalence of Genetic DiseasesGrowing Preference towards for Direct-To-Consumer Genetic TestingSocial and Ethical Implications of Genetic TestingLOWMEDIUMHIGHIncreasing Awareness and Acceptance of Personalized Medicines 24 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 5.Genetic Testing Services Market-Asia Pacific Market Analysis The Asia Pacific genetic testing services market in Asia Pacific is segmented into China,Japan,India,South Korea,Australia,and the Rest of Asia Pacific.The market growth is driven by a large pool of patients living with genetic conditions and increasing investments by the governments of the respective countries in the region.An increase in affordability,surge in healthcare expenditure,and rise in awareness toward early screening of genetic disorders are expected to fuel the market growth in the forecast period.In addition,the rise in the development and research for genomics and the rise in the programs for genomics further augment the market growth.5.1 Asia Pacific Genetic Testing Services Market Revenue(US$Mn),2022 2030 The Asia Pacific genetic testing services market is expected to reach US$2,156.88 million by 2030 from US$646.31 million in 2022.The market is estimated to grow at a CAGR of 16.3%from 2022 to 2030.The factors driving the market growth include the increasing prevalence of genetic diseases,growing preference for direct-to-consumer genetic testing,and increasing awareness and acceptance of personalized medicines.However,social and ethical implications of genetic testing and affordability of genetic services restrain the growth of the market.Figure 4.Asia Pacific Genetic Testing Services Market Revenue(US$Mn),2022 2030 Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 505.01571.06646.31735.92843.00971.461,126.161,313.241,540.421,817.482,156.8813.1.2.9.6.2.9.6.3.0.7%0.0%2.0%4.0%6.0%8.0.0.0.0.0.0 .0 20202120222023202420252026202720282029203005001,0001,5002,0002,5002020-2030Historical YearBase YearForecast Year 25 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 6.Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030 by Service Type 6.1 Overview The Asia Pacific genetic testing services market,by service type,is segmented into predictive testing,carrier testing,prenatal testing,newborn screening,and others.In 2022,the predictive testing segment held the largest share of the market and is expected to register the highest CAGR in the market during the coming years.6.2 Asia Pacific Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%)Figure 5.Asia Pacific Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%)Source:The Insight Partners Analysis The predictive testing segment led the market in 2022 with a share of 40.8%and is expected to retain its dominance during 20222030 by accounting for 44.6%of the total market by 2030.40.8#.9.4.5%6.3 22Predictive TestingCarrier TestingPrenatal TestingNew-born ScreeningOthers44.6$.3.2.4%3.6 30 26 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 6.3 Predictive Testing 6.3.1 Overview Predictive genetic testing examines any genetic changes or mutations that are linked to disease.These tests are done prior to an individual displaying any signs of a disease.Predictive testing can be helpful to people who have a family history of a treatable genetic disorder and display no signs of illness.This testing can identify mutations that increase an individuals risk of developing disorders with a genetic foundation,such as certain types of cancer.An example is testing for the BRCA1 and BRCA2 gene variants(altered genes)linked with an increased risk of breast cancer.The results of predictive testing can provide information about the probability of developing a specific disorder and help in making decisions about medical care.The increasing demand for genetic counseling is expected to drive the market for predictive testing as more people understand the importance of genetics in disease etiology.The ongoing advancements and upgrading of platforms to improve the efficiency of genome analysis techniques are expected to boost the adoption of predictive testing solutions.A growing focus on reducing the growing healthcare burden of rare genetic diseases and rapid integration of technologies such as artificial intelligence and machine learning will enhance product development and fuel the need for predictive testing to assess and prevent future complications arising from diseases effectively.6.3.2 Predictive Testing:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Predictive testing segment was valued at US$264.00 million in 2022 and is expected to reach US$961.55 million by 2030.The growth rate of this segment is projected to be 17.5%during 20222030.Figure 6.Predictive Testing:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 201.55230.59264.00304.04352.22410.43481.05567.09672.37801.78961.55202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 27 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 6.4 Carrier Testing 6.4.1 Overview Carrier testing is a kind of genetic test that can tell whether one carries a gene for certain genetic disorders or not.When it is done before or during pregnancy,it helps to find out the chances of having a child with a genetic disorder.Carrier testing is used to identify people carrying one copy of a gene mutation(a genetic change)that,when present in two copies,results in a genetic disorder.Carriers generally do not have symptoms or have only mild symptoms.They often are unaware that they have a gene for a disorder.With the increasing prevalence of genetic diseases caused by chromosome and gene mutations,carrier testing has grown exponentially.The majority of cases of genetic mutations are due to preexisting conditions,a family history of abortion,or congenital disabilities.Pregnant women often undergo carrier screening in order to determine the risk of transmitting a specific genetic disease to their progeny.In addition,the increasing recognition of the importance of early diagnosis and screening of gene illness fuels the need to develop strategies to tackle these diseases.6.4.2 Carrier Testing:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Carrier testing segment was valued at US$154.29 million in 2022 and is expected to reach US$523.57 million by 2030.The growth rate of this segment is projected to be 16.5%during 20222030.Figure 7.Carrier Testing:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 120.06136.04154.29176.04202.07233.35271.08316.77372.35440.25523.57202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 28 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 6.5 Prenatal Testing 6.5.1 Overview Genetics can have an impact on the color of a babys eyes and hair and can also result in the development of some birth defects or genetic disorders.This testing helps to detect abnormalities in a fetuss genes or chromosomes and syndromes before birth.Thats why women are regularly offered a wide range of prenatal genetic testing in the first and second trimesters of pregnancy to evaluate the problems in their unborn babies.According to the WHO,congenital disabilities affect 8 million newborns every year.Nine out of every ten children are born with a serious birth defect in low-and middle-income countries.Congenital disabilities can occur at any point through the pregnancy;however,most of them occur during the first trimester when the babys organs are formed.6.5.2 Prenatal Testing:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Prenatal testing segment was valued at US$86.90 million in 2022 and is expected to reach US$262.95 million by 2030.The growth rate of this segment is projected to be 14.8%during 20222030.Figure 8.Prenatal Testing:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 69.5277.7086.9097.78110.67126.00144.30166.22192.57224.38262.95202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 29 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 6.6 Newborn Screening 6.6.1 Overview A newborn screening test looks for various developmental,genetic,and metabolic disease disorders in the newborn.Newborn screening allows measures to be taken before symptoms develop.Most of these illnesses are extremely rare but can be treated if detected early.The offspring has a high risk of having genetic diseases in cases where the parents have another child with a genetic disease,a family history of a genetic disorder,or if either of a parent has a chromosomal abnormality.Early testing for these conditions allows physicians and parents to take timely measures to manage,treat,or intervene in disease progression,allowing the baby to lead a healthy,normal life.6.6.2 Newborn Screening:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Newborn screening segment was valued at US$100.23 million in 2022 and is expected to reach US$331.30 million by 2030.The growth rate of this segment is projected to be 16.1%during 20222030.Figure 9.Newborn Screening:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 78.5188.67100.23113.99130.42150.11173.81202.44237.18279.50331.30202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 30 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 6.7 Others 6.7.1 Overview The others segment is comprised of preimplantation testing and pharmacogenomics.These tests are performed to screen for genetic disorders.Pharmacogenomics testing is a type of genetic test that is used to identify the right medication for a person.Pharmacogenomics is one of the key emerging trends in the field of medical science,which significantly impacts the drug development process.With the use of pharmacogenomics,target identification by drugs has become comparatively easy,which confirms much higher chances of success for the approval of drugs.the Southeast Asian Pharmacogenomics Research Network(SEAPharm)platform was introduced by five Asian countries(Korea,Indonesia,Malaysia,Taiwan,and Thailand)to conduct pilot studies of adverse drug effects and develop strategies modified for Asian populations,which could guide drug usage and prove useful in disease prediction and diagnosis.Pharmacogenomics has also found diseases in the cure of cancer patients by anticipating the possible changes in drug response,efficacy,resistance,and toxicity of the chemotherapeutic and targeted immune biological agents.Therefore,pharmacogenomics for cancer therapy has achieved a number of important discoveries in the existing cancer treatment,thereby driving market growth.Preimplantation genetic testing is also for couples who are at risk of having a child with a specific genetic or chromosome disorder,e.g.,cystic fibrosis or sickle cell disease.In this procedure,egg cells are removed from the womans ovaries and fertilized with sperm cells outside the body.The fertilized embryos develop for three days,and subsequently,one or two cells are removed from each embryo.The genetic material(DNA and chromosomes)from the cells is tested for the genetic disorder in the family history.One or two of the unaltered embryos are then relocated into the mothers womb(uterus).If the pregnancy is successful,the baby will not be affected by the disorder it was tested for.6.7.2 Others:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Others segment was valued at US$40.89 million in 2022 and is expected to reach US$77.50 million by 2030.The growth rate of this segment is projected to be 8.3%during 20222030.Figure 10.Others:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 35.3638.0640.8944.0647.6151.5655.9360.7265.9571.5777.50202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 31 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 7.Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030 by Disease 7.1 Overview The Asia Pacific genetic testing services market,by disease,is segmented into cancer,cardiovascular diseases,metabolic diseases,and other diseases.In 2022,the cancer segment held the largest share of the market and is anticipated to grow at the highest CAGR during the coming years.7.2 Asia Pacific Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%)Figure 11.Asia Pacific Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%)Source:The Insight Partners Analysis The cancer segment led the market in 2022 with a share of 45.3%and is expected to retain its dominance during 20222030 by accounting for 49.9%of the total market by 2030.45.3.7.9.1 22CancerCardiovascular DiseasesMetabolic DiseasesOther Diseases49.9$.2.4%9.6 30 32 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 7.3 Cancer 7.3.1 Overview Genetic testing is a potential tool to identify individuals who are at higher risk for developing certain cancers because of family history.Genetic tests are available to examine inherited variants and alterations in the DNA sequence,which could result in excessive cell growth and can cause tumors or cancer.For example,genetic testing for the detection of PALB2(linked with increased risks of breast and pancreatic cancers),BRIP1(ovarian cancer),RAD51C and RAD51D(ovarian cancer),and CHEK2(breast and colorectal cancers).The worldwide growing prevalence of various cancers,such as breast,lung,and bowel,are the major drivers of this segment.For instance,CDCs Cancer Genomics Program develops best practices in education,surveillance,and policy and systems transformation approaches.It establishes an evidence base for the application of family history and cancer genomics in public health practice.Other factors that might impact cancer genetic testing awareness include DTC marketing of cancer genetic testing and federal regulations of genetic information,high awareness regarding the availability of quality cancer diagnostics tests,and the escalating incidence of hereditary diseases.In addition,a growing number of companies providing genomic profiling services for health assessment,including cancer risk prediction,and the availability of numerous laboratories offering genetic testing for BRCA,and other genes associated with hereditary breast,ovarian,and related cancers propel the market for the segment.7.3.2 Cancer:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Cancer segment was valued at US$292.78 million in 2022 and is expected to reach US$1,076.25 million by 2030.The growth rate of this segment is projected to be 17.7%during 20222030.Figure 12.Cancer:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 222.97255.41292.78337.59391.56456.81536.03632.62750.92896.441,076.25202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 33 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 7.4 Cardiovascular Diseases 7.4.1 Overview Heart diseases are a prominent cause of death worldwide and often run in families.In addition,as per the World Heart Federation 2023,rare cardiovascular diseases(CVD)are common,affecting 5%of the global population.There are over 6,000 known rare diseases,a handful of which impact the heart and circulatory system.And 83%of physicians agree that genetic testing is useful in finding the diagnosis.Certain CVD conditions,such as cardiomyopathy,arrhythmia,and connective tissue disease,are caused by a single harmful DNA variation(or mutation).However,others,such as heart attack and high blood pressure,are usually caused by the combined effect of many smaller-impact DNA variations.More than 1 in 200 people have an inherited form of CVD disease,but most are unaware of it.Patients with an inherited cardiovascular condition display few or no symptoms but still face significant risk of heart disease,including sudden cardiovascular arrest.Genetic testing can help save lives and is informative and useful for the clinical management and treatment of numerous inherited CVDs.7.4.2 Cardiovascular Diseases:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Cardiovascular diseases segment was valued at US$146.76 million in 2022 and is expected to reach US$521.76 million by 2030.The growth rate of this segment is projected to be 17.2%during 20222030.Figure 13.Cardiovascular Diseases:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 112.82128.63146.76168.47194.53225.97264.04310.34366.89436.27521.76202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 34 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 7.5 Metabolic Diseases 7.5.1 Overview Diagnosis through genetic testing can strongly help discover the cause of persistent,often debilitating,undiagnosed signs in individuals suffering from suspected genetic metabolic disease disorders.With knowledge of variants in over 1,250 metabolic disease disorders genes,the rapid testing and experience of metabolic diseases can help to diagnose and manage the patients metabolic disease disorders quickly and correctly.Ultimately,this can provide new insights into treatment choices and the probability of passing the inherited condition on to the offspring or the presence of it elsewhere in the extended family.CentoICU is a comprehensive next-generation sequencing panel that includes genes explicitly chosen for the genetic testing of extremely ill newborns and children under 24 months in intensive care units.In addition,Prevention Genetics offers a wide variety of genetic testing for inherited metabolic disease disorders,also known as inborn errors of metabolism.Panels specific to one disorder are available,as well as comprehensive metabolic diseases panels that cover broader phenotypic features or groups of similar disorders are also offered,including tests for hyperammonemia(37 genes),metabolic diseases hypoglycemia(38 genes),and metabolic diseases myopathies,rhabdomyolysis,and exercise intolerance(83 genes).Over the past year,the company has started to offer several new tests related to these metabolic disorders,and many of the existing panels have been updated to include more genes and increase clinical sensitivity.7.5.2 Metabolic Diseases:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Metabolic diseases segment was valued at US$109.16 million in 2022 and is expected to reach US$352.74 million by 2030.The growth rate of this segment is projected to be 15.8%during 20222030.Figure 14.Metabolic Diseases:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 85.9996.84109.16123.79141.23162.09187.15217.36253.94298.42352.74202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 35 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 7.6 Other Diseases 7.6.1 Overview The others segment by disease comprises Duchenne Muscular Dystrophy(DMD),Thalassemia,Huntingtons Disease,and Fragile X Syndrome,among others.Genetic mutations that cause DMD fail to produce dystrophin protein.Recessive diseases caused by alterations in genes on the X chromosome include DMD and fragile X syndrome.Genetic testing is used to diagnose Duchenne,to access mutation-specific therapies,and for family planning.For Duchenne,the dystrophin gene is examined to detect the presence of any changes or mutations that can inhibit the gene from working properly.Genetic testing is generally performed on a blood or saliva sample.A thalassemia is a group of inherited,genetic blood disorders that occur when the production of hemoglobin is disrupted.The disease is passed to children by parents carrying the mutated thalassemia gene.A kid who inherits one mutated gene is a carrier,and most carriers lead a completely normal and healthy life.At the same time,a child who inherits two thalassemia trait genes,i.e.,one from each parent,will have the disease.A child of two carriers has a 25 percent chance of developing the disease and a 50 percent chance of being a carrier.Thus,in such cases,genetic testing is helpful in detecting and diagnosing thalassemia.Currently,two major approaches are used in DNA diagnosis and study of genetic disease,namely direct tests and indirect tests(linkage analysis).Direct tests are being conducted for thalassemia and DMD.Carrier testing can be conducted for X-linked recessive disorders,such as DMD or fragile X syndrome.In these cases,the mother of an affected child with no other affected relatives may desire carrier testing to confirm whether the disease is a heritable trait or a new mutation.Many diseases may become apparent only in middle age or later.Predictive or presymptomatic testing and screening can provide symptoms that people may later develop these disorders.In some cases,a family history of a monogenic disorder in a relative informs other members of the family that they are at high risk for developing the disease.Suitable genetic testing can help to resolve whether the mutant gene is present or not.Examples include Huntingtons disease.7.6.2 Other Diseases:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Other diseases segment was valued at US$97.62 million in 2022 and is expected to reach US$206.12 million by 2030.The growth rate of this segment is projected to be 9.8%during 20222030.36 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 15.Other Diseases:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 83.2390.1997.62106.07115.68126.59138.94152.91168.66186.35206.12202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 37 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 8.Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030 by Service Provider 8.1 Overview The Asia Pacific genetic testing services market,by service provider,is segmented into hospital-based laboratories,diagnostic laboratories,and others.In 2022,the hospital-based laboratories segment held the largest share of the market and is estimated to grow at the highest CAGR during 20222030.8.2 Asia Pacific Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%)Figure 16.Asia Pacific Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%)Source:The Insight Partners Analysis The hospital-based laboratories segment led the market in 2022 with a share of 63.6%and is expected to retain its dominance during 20222030 by accounting for 68.7%of the total market by 2030.63.6$.3.1 22Hospital-BasedLaboratoriesDiagnostic LaboratoriesOther End Users68.7%.1%6.2 30 38 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 8.3 Hospital-Based Laboratories 8.3.1 Overview Hospital-based laboratories are genetic testing service providers that operate within a hospital setting.For extremely specialized tests,samples may go to a research laboratory.Nearly all hospitals contain a laboratory,which is commonly proportionate in size to the population it serves.The hospitals process hundreds of samples in very les time.Tests that are performed include those needed in emergencies,such as markers for heart attack and tests where results are required rapidly for patient care.They may also offer carrier testing to determine if an individual is carriers of certain genetic conditions that can be passed on to their children.Hospital laboratories can be segmented by type of testing and staffed by personnel trained in particular specialties.For instance,some sections can focus on microbiology,hematology,chemistry,and blood banking.At the same time,some units may perform highly specialized genetic tests using electron microscopy and immunohistochemistry,and others can focus on surgical pathology and cytology,which are all linked with the investigation of cell and tissue structure.The market growth for the segment can be due to the compulsory newborn screening for genetic disorders and the growing prevalence of cancer in many regions.Seattle Childrens Hospital in Washington,Wyoming,Alaska,Montana,and Idaho(WWAMI)region provides comprehensive genetic testing and consultative services to healthcare workers and families.Their genetics laboratories consist of molecular genetics,cytogenetics,biochemical genetics,and a research and development laboratory devoted to bringing the most existing and specific research tests into the clinical field.Overall,these laboratories play a crucial role in helping to diagnose genetic disorders,guide treatment decisions,and improve patient outcomes.8.3.2 Hospital-Based Laboratories:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Hospital-based laboratories segment was valued at US$411.07 million in 2022 and is expected to reach US$1,482.57 million by 2030.The growth rate of this segment is projected to be 17.4%during 20222030.Figure 17.Hospital-Based Laboratories:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 314.75359.56411.07472.76546.95636.52745.11877.321,038.991,237.571,482.57202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 39 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 8.4 Diagnostic Laboratories 8.4.1 Overview Diagnostics laboratories are independent entities that provide all the diagnostic tests,screening tests,and others to the patient.These centers may be found attached to a private or public hospital.The tests performed in the diagnostic centers are obtained earlier than hospitals.The diagnostic centers also offer packages for whole-body check-ups that are cost-effective for the patients.Tests such as cell-free fetal DNA testing,triple or quadruple screening tests,sequential screening,and others require advanced techniques,equipment,and skilled labor.However,some of the hospitals and clinics do not have all the required equipment and techniques for efficient diagnosis.Therefore,various hospitals and clinics prefer to outsource tests to diagnostics centers.The diagnostics centers are well equipped and offer better results for the tests performed for diseases and health conditions.The diagnostic centers provide multiple tests under one roof and offer all the prenatal diagnostics services such as screening,imaging,blood tests,chorionic villus sampling,and amniocentesis.Thus,it becomes easier for people to undergo genetic testing in such facilities.The growing partnerships and collaboration of diagnostic laboratories with genetic testing companies and the rise in the incidences of genetic diseases across the world are anticipated to offer growth to the market.For instance,Thermo Fisher Scientific allows laboratories to perform different genetic research and genetic testing by offering technologies such as NGS and quantitative PCR.8.4.2 Diagnostic Laboratories:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Diagnostic laboratories segment was valued at US$157.36 million in 2022 and is expected to reach US$540.79 million by 2030.The growth rate of this segment is projected to be 16.7%during 20222030.Figure 18.Diagnostic Laboratories:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 122.05138.53157.36179.84206.77239.15278.26325.68383.42454.04540.79202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 40 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 8.5 Others 8.5.1 Overview The others segment by service provider comprises academic and research institutions,pharmaceutical and biotechnology companies,and government agencies.Government agencies use genetic testing services to evaluate drugs for regulatory compliance for public health monitoring and research initiatives.Academic and research institutions are integral to the Asia Pacific genetic testing services market.They help in identifying genetic markers,developing new genetic testing methodologies,and improving existing tests.These institutions validate and ensure the quality of genetic tests through rigorous studies,establishing their reliability and credibility.Clinical trials and studies conducted by these institutions provide essential evidence on the clinical utility and effectiveness of genetic tests.Their expertise and research efforts advance the growth of the market,benefiting both patients and healthcare providers.In addition,research and academic institutes are among the leading users of genetic testing services.Academic institutes for medical sciences and biotechnology utilize analytical testing services to support their studies on drugs.Thus,the increasing demand for genetic testing services from government agencies and research institutes will likely continue to drive the Asia Pacific genetic testing services market for the segment.8.5.2 Others:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Others segment was valued at US$77.89 million in 2022 and is expected to reach US$133.51 million by 2030.The growth rate of this segment is projected to be 7.0%during 20222030.Figure 19.Others:Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 68.2172.9877.8983.3289.2895.78102.79110.24118.01125.88133.51202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 41 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 9.Asia Pacific Genetic Testing Services Market-Country Analysis 9.1 Asia Pacific Figure 20.Asia Pacific Genetic Testing Services Market,by Key Country Revenue,2022(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 9.1.1 Asia Pacific Genetic Testing Services Market,by Country Figure 21.Asia Pacific Genetic Testing Services Market,By Key Countries,2022 and 2030(%)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources ASIA PACIFIC(2022)95.0856.6456.36127.66109.95200.62Rest of AsiaPacificSouth KoreaAustraliaIndiaJapanChina33.2.7 .4%8.4%7.7.7 3031.0.0.8%8.7%8.8.7 22ChinaJapanIndiaAustraliaSouth KoreaRest of Asia Pacific 42 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.1 China 9.1.1.1.1 Overview Over the past few years,there has been a significant rise in awareness levels about the benefits of genetic testing in the country.Moreover,a rise in the availability of DTC tests has increased the convenience and accessibility of such tests,creating a positive impact on the growth of the market.In recent years,the countrys scientists and authorities have highlighted how genetic material could be effectively utilized to study and treat diseases,develop pharmaceuticals and medical devices,and better understand how congenital disabilities are formed.According to the study titled Spotlight on Gene Therapy in China,published in July 2020,over 57 million people suffer from genetic diseases in the country,and 4 million new cancer cases are recorded per year.According to the Global Cancer Observatory data,a total of 4,568,754 cancer cases were reported in 2020 in the country.According to the article titled Rare Disease Day:why Chinas Rare Disease Burden Could be an Opportunity for Innovation,published in February 2023,20 million Chinese people suffer from rare diseases.In October 2015,China stated that the iconic one-child policy had been exchanged for a universal two-child policy.This is anticipated to increase the number of children born yearly and create a positive impact on the demand for newborn genetic testing.In 2016,the Chinese Academy of Sciences initiated the Precision Medicine Initiative,a 14-year,US$9.2 billion project to sequence over 100 million human genomes by 2030.In July 2021,Chinese gene company BGI Group developed a prenatal test in collaboration with the countrys military.It is used to collect genetic data from millions of women for sweeping research on the traits of people.BGI states that it stores and re-analyzes left-over blood samples and genetic data from the prenatal tests sold in nearly 52 countries to detect abnormalities such as Down syndrome in the baby.Therefore,the factors mentioned above are expected to propel the Asia Pacific genetic testing services market growth in China.9.1.1.1.2 China Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)China genetic testing services market accounted for US$200.62 Mn in 2022 and it is expected to grow at a CAGR of 17.2%during the period 2022-2030,to reach US$716.16 Mn in 2030.Figure 22.China Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 154.03175.72200.62230.42266.23309.43361.75425.39503.15598.56716.16202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 43 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.1.3 China Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 2.China Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 59.06 67.98 78.31 90.73 105.74 123.96 146.16 173.34 206.75 248.01 299.19 18.2rrier Testing 35.90 41.11 47.10 54.29 62.95 73.43 86.14 101.66 120.66 144.05 172.95 17.7%Prenatal Testing 22.19 25.26 28.77 32.98 38.02 44.09 51.43 60.34 71.21 84.53 100.91 17.0%Newborn Screening 24.65 28.12 32.11 36.89 42.62 49.54 57.93 68.13 80.59 95.88 114.73 17.3%Others 12.22 13.25 14.33 15.54 16.90 18.41 20.08 21.93 23.93 26.09 28.38 8.9%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Asia Pacific genetic testing services market for the predictive testing segment was worth US$78.31 million in 2022 and is projected to reach US$299.19 million by 2030;it is expected to grow at a CAGR of 18.2%from 2022 to 2030.9.1.1.1.4 China Genetic Testing Services Market,by Disease,20202030(US$Million)Table 3.China Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 67.64 78.16 90.37 105.10 122.94 144.64 171.15 203.67 243.76 293.37 355.07 18.7rdiovascular Diseases 33.99 39.16 45.15 52.37 61.09 71.68 84.60 100.42 119.88 143.93 173.79 18.4%Metabolic Diseases 26.09 29.68 33.79 38.71 44.61 51.70 60.28 70.69 83.38 98.92 118.04 16.9%Others 26.32 28.72 31.30 34.25 37.59 41.40 45.72 50.61 56.13 62.33 69.27 10.4%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Asia Pacific genetic testing services market for the cancer segment was worth US$90.37 million in 2022 and is projected to reach US$355.07 million by 2030;it is expected to grow at a CAGR of 18.7%from 2022 to 2030.9.1.1.1.5 China Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 4.China Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 96.00 110.78 127.93 148.59 173.59 203.98 241.07 286.54 342.53 411.79 497.85 18.5%Diagnostic Laboratories 37.22 42.64 48.88 56.36 65.39 76.30 89.55 105.73 125.55 149.95 180.11 17.7%Others 20.80 22.30 23.82 25.47 27.26 29.15 31.12 33.12 35.06 36.82 38.20 6.1%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Asia Pacific genetic testing services market for the hospital-based laboratories segment was worth US$127.93 million in 2022 and is projected to reach US$497.85 million by 2030;it is expected to grow at a CAGR of 18.5%from 2022 to 2030.44 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.2 Japan 9.1.1.2.1 Overview Since the initiative to promote the realization of genomic medicine became a national policy of Japan in 2015,the establishment of medical genetics and genomic medicine systems from research to clinical practice has gained momentum.Japanese physicians,researchers,and members of associations related to medical genetics in Japan have been exploring and practicing the establishment of medical genetics and genomic medicine systems that can be applied to the Japanese culture and society.The Japanese Society for Genetic Counseling(JSGC)aims to support the advancement,development,and distribution of clinical genetics in Japan and contribute to the advancement of medical care and welfare through the practice of clinical genetics research.The society manages an endorsement system for clinical geneticists and certified genetic counselors along with the Japan Society of Human Genetics(JSHG).Various government initiatives are likely to propel the Japanese genetic testing services market growth.According to the World Cancer Research Fund International Data,1,017,282 cases of cancer were diagnosed in 2020 in the country.The age-standardized rate for all cancers was 282.9 per 100,000 in 2020.Genetic tests help cancer patients investigate the best drugs and therapies for their treatment and are covered by the public health insurance system.The tests cover nearly 10,000 to 20,000 citizens among those who are diagnosed with cancer in Japan annually.The growing investment in the market for the development of innovative products augments the growth of the market.For instance,SoftBank(Tokyo)led an investment of US$1.2 billion in genetic-testing company Invitae Corp in April 2021.Invitae offers genetic testing services for various diseases,such as skin and eye conditions,cancers,and reproductive health.9.1.1.2.2 Japan Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Japan genetic testing services market accounted for US$109.95 Mn in 2022 and it is expected to grow at a CAGR of 16.0%during the period 2022-2030,to reach US$359.85 Mn in 2030.Figure 23.Japan Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 86.3397.38109.95124.89142.72164.07189.73220.71258.26303.97359.85202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 45 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.2.3 Japan:Asia Pacific Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 5.Japan:Asia Pacific Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 33.44 38.10 43.45 49.83 57.50 66.74 77.91 91.49 108.05 128.35 153.34 17.1rrier Testing 19.72 22.30 25.25 28.75 32.94 37.97 44.02 51.34 60.23 71.07 84.36 16.3%Prenatal Testing 13.48 15.09 16.89 19.04 21.57 24.60 28.21 32.54 37.75 44.06 51.71 15.0%Newborn Screening 15.27 17.21 19.42 22.04 25.17 28.91 33.41 38.83 45.40 53.39 63.16 15.9%Others 4.42 4.68 4.95 5.23 5.54 5.86 6.19 6.51 6.82 7.09 7.28 5.0%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Asia Pacific genetic testing services market for the predictive testing segment was worth US$43.45 million in 2022 and is projected to reach US$153.34 million by 2030;it is expected to grow at a CAGR of 17.1%from 2022 to 2030.9.1.1.2.4 Japan:Asia Pacific Genetic Testing Services Market,by Disease,20202030(US$Million)Table 6.Japan:Asia Pacific Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 38.29 43.80 50.14 57.73 66.86 77.88 91.24 107.51 127.41 151.84 182.00 17.5rdiovascular Diseases 19.43 22.00 24.93 28.42 32.59 37.60 43.63 50.94 59.81 70.64 83.92 16.4%Metabolic Diseases 14.77 16.58 18.64 21.07 23.96 27.41 31.55 36.53 42.53 49.82 58.69 15.4%Others 13.83 15.00 16.25 17.68 19.31 21.18 23.31 25.74 28.51 31.67 35.25 10.2%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Asia Pacific genetic testing services market for the cancer segment was worth US$50.14 million in 2022 and is projected to reach US$182.00 million by 2030;it is expected to grow at a CAGR of 17.5%from 2022 to 2030.9.1.1.2.5 Japan:Asia Pacific Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 7.Japan:Asia Pacific Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 53.81 61.20 69.66 79.76 91.88 106.46 124.08 145.47 171.53 203.44 242.68 16.9%Diagnostic Laboratories 20.86 23.60 26.73 30.46 34.91 40.25 46.69 54.48 63.94 75.48 89.63 16.3%Others 11.66 12.58 13.56 14.68 15.94 17.36 18.96 20.77 22.79 25.04 27.54 9.3%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 46 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners The Asia Pacific genetic testing services market for the hospital-based laboratories segment was worth US$69.66 million in 2022 and is projected to reach US$242.68 million by 2030;it is expected to grow at a CAGR of 16.9%from 2022 to 2030.9.1.1.3 India 9.1.1.3.1 Overview India is witnessing an upsurge in genetic diseases,with congenital malformations and genetic disorders being the third most common cause of mortality in newborns.Hence,there is a need for adequate and effective genetic testing and counseling services.According to the United Nations International Childrens Emergency Fund(UNICEF),67,385 babies are born in India each day,accounting for one-sixth of childbirths recorded globally in a day.In addition,India has become the most populated nation;as per Worldmapper,23 million babies were born in 2022,followed by China with the birth of 10 million babies.The same source further stated that 1.7 million babies are born with congenital disabilities in the country.The child has a high risk of having genetic diseases in cases where the parents have another child with a genetic disease or a family history of a genetic disorder.In such cases,newborn genetic testing allows measures to be taken before symptoms develop.Early testing for genetic conditions allows physicians and parents to take timely actions to manage and treat the disease.India has an increasing interest in genomics projects and initiatives,and these may aid in increasing the accessibility of Indian genetic data.IndiGen,a project started in April 2019,analyzed the whole genome sequences of 1,008 individuals from 25 states.The initiative attracted private companies that focused on using their knowledge to help in providing commercial diagnostic services to the people.Genetic testing is gaining popularity in the country and may replace a number of conventional laboratory tests in the future.Initially,genetic tests cost US$2,4003,002(INR 22.5 lakh)in the country,although now the price ranges from US$36840(INR 3,00070,000)per test.The cost of these tests is going down as volumes rise,and there are about half a dozen major companies in the sector,headed by MedGenome and Strand Life Sciences.Thus,these factors support the growth of the market in the country.9.1.1.3.2 India Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)India genetic testing services market accounted for US$127.66 Mn in 2022 and it is expected to grow at a CAGR of 16.7%during the period 2022-2030,to reach US$439.10 Mn in 2030.47 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 24.India Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 9.1.1.3.3 India Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 8.India Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 42.82 49.43 57.09 66.32 77.49 91.06 107.61 127.89 152.85 183.71 222.04 18.5rrier Testing 25.26 28.68 32.61 37.29 42.90 49.65 57.81 67.70 79.76 94.51 112.63 16.8%Prenatal Testing 10.76 11.83 13.01 14.38 15.97 17.81 19.96 22.47 25.40 28.83 32.85 12.3%Newborn Screening 12.32 13.95 15.80 18.01 20.65 23.81 27.63 32.25 37.86 44.70 53.09 16.4%Others 7.82 8.47 9.15 9.92 10.78 11.76 12.85 14.06 15.40 16.88 18.49 9.2%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Asia Pacific genetic testing services market for the predictive testing segment was worth US$57.09 million in 2022 and is projected to reach US$222.04 million by 2030;it is expected to grow at a CAGR of 18.5%from 2022 to 2030.98.98112.36127.66145.91167.78194.09225.85264.36311.26368.63439.10202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 48 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.3.4 India Genetic Testing Services Market,by Disease,20202030(US$Million)Table 9.India Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 43.90 50.48 58.08 67.22 78.26 91.64 107.93 127.85 152.32 182.50 219.90 18.1rdiovascular Diseases 22.29 25.55 29.32 33.84 39.28 45.88 53.89 63.67 75.67 90.44 108.72 17.8%Metabolic Diseases 16.93 19.19 21.76 24.83 28.51 32.92 38.24 44.69 52.52 62.10 73.84 16.5%Others 15.86 17.14 18.50 20.02 21.73 23.65 25.78 28.15 30.75 33.59 36.64 8.9%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Asia Pacific genetic testing services market for the cancer segment was worth US$58.08 million in 2022 and is projected to reach US$219.90 million by 2030;it is expected to grow at a CAGR of 18.1%from 2022 to 2030.9.1.1.3.5 India Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 10.India Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 61.69 70.76 81.22 93.79 108.93 127.27 149.56 176.79 210.17 251.30 302.19 17.9%Diagnostic Laboratories 23.92 27.29 31.17 35.80 41.38 48.10 56.26 66.18 78.30 93.19 111.55 17.3%Others 13.37 14.31 15.27 16.32 17.47 18.71 20.03 21.40 22.79 24.14 25.36 6.6%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Asia Pacific genetic testing services market for the hospital-based laboratories segment was worth US$81.22 million in 2022 and is projected to reach US$302.19 million by 2030;it is expected to grow at a CAGR of 17.9%from 2022 to 2030.49 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.4 Australia 9.1.1.4.1 Overview According to the Government of Western Australia,genetic conditions and birth defects occur in about 3 to 5 percent of babies born in Australia.According to the Australian Government Department of Health and Aged Care,8%of the population(2 million people)live with a rare disease in the country.In addition,265 babies were born with Down syndrome yearly between 2016 and 2020.This represents that 1 in every 1,158 babies born in the country will live with Down syndrome.Genome testing in such conditions helps to analyze an individuals DNA to identify any genetic variations or mutations that may cause or increase the probability of developing these diseases.The National Health Genomics Policy Framework,sanctioned by the Council of Australian Governments Health Council in November 2017,was adopted to integrate genetics and genomics into the Australian health system.The Australian Genomics Flagship model is designed to drive research throughout the country,as well as the implementation of genomic testing,integrating it with research programs as frameworks for the translation of new genetic tests,which are continually being developed as a result of ongoing research both internationally and within Australia.For instance,87 Australian laboratories delivered various categories of gene testing,comprising biochemical genetics,newborn bloodspot screening,pregnancy-related,or population screening tests from 2016 to 2017.Similarly,from November 2023,112,000 people per year will benefit from 34 new,expanded,or increased Medicare rebates for genetic testing to diagnose,prevent,and treat genetic conditions.It is a four-year US$148.5 million investment to strengthen Medicare and make healthcare more affordable and accessible to people.During 20222023,over 376,000 genetic and genomic tests were financed under Medicare,totaling US$76.8 million in Medicare benefits.With new genetic tests becoming available in Australia and the efforts of governments and organizations to make them accessible to the people,the market is expected to expand at a steady pace.9.1.1.4.2 Australia Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Australia genetic testing services market accounted for US$56.36 Mn in 2022 and it is expected to grow at a CAGR of 15.7%during the period 2022-2030,to reach US$180.59 Mn in 2030.Figure 25.Australia Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 44.4850.0556.3663.8572.7883.4596.25111.66130.31152.96180.59202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 50 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.4.3 Australia Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 11.Australia Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 17.40 19.82 22.59 25.90 29.88 34.66 40.44 47.45 56.01 66.48 79.36 17.0rrier Testing 10.26 11.57 13.05 14.80 16.90 19.40 22.41 26.04 30.43 35.78 42.30 15.8%Prenatal Testing 6.60 7.35 8.19 9.18 10.35 11.73 13.38 15.35 17.70 20.54 23.97 14.4%Newborn Screening 7.56 8.48 9.53 10.76 12.23 13.98 16.07 18.59 21.63 25.31 29.79 15.3%Others 2.65 2.82 3.01 3.21 3.43 3.68 3.95 4.23 4.54 4.85 5.17 7.0%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Asia Pacific genetic testing services market for the predictive testing segment was worth US$22.59 million in 2022 and is projected to reach US$79.36 million by 2030;it is expected to grow at a CAGR of 17.0%from 2022 to 2030.9.1.1.4.4 Australia Genetic Testing Services Market,by Disease,20202030(US$Million)Table 12.Australia Asia Pacific Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 19.53 22.28 25.44 29.22 33.75 39.22 45.83 53.86 63.66 75.67 90.46 17.2rdiovascular Diseases 9.92 11.26 12.79 14.61 16.80 19.42 22.59 26.43 31.10 36.80 43.80 16.6%Metabolic Diseases 7.53 8.39 9.37 10.51 11.87 13.48 15.39 17.69 20.44 23.75 27.76 14.5%Others 7.50 8.11 8.76 9.51 10.36 11.33 12.43 13.69 15.12 16.74 18.57 9.8%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Asia Pacific genetic testing services market for the cancer segment was worth US$25.44 million in 2022 and is projected to reach US$90.46 million by 2030;it is expected to grow at a CAGR of 17.2%from 2022 to 2030.9.1.1.4.5 Australia Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 13.Australia Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 27.72 31.52 35.86 41.04 47.25 54.72 63.74 74.68 88.00 104.29 124.30 16.8%Diagnostic Laboratories 10.75 12.11 13.65 15.48 17.66 20.26 23.39 27.16 31.73 37.28 44.05 15.8%Others 6.01 6.42 6.85 7.34 7.87 8.46 9.11 9.82 10.58 11.39 12.23 7.5%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 51 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners The Asia Pacific genetic testing services market for the hospital-based laboratories segment was worth US$35.86 million in 2022 and is projected to reach US$124.30 million by 2030;it is expected to grow at a CAGR of 16.8%from 2022 to 2030.9.1.1.5 South Korea 9.1.1.5.1 Overview The increasing incidences of genetic diseases,the use of genetic testing solutions,and growing awareness and acceptance of personalized medicine are key factors driving the market growth.According to Orphanet,a representative portal dealing with rare diseases,6172 rare disorders were registered by 2020 in the country.In addition,according to an article published in PubMed Central titled Prediction of Cancer Incidence and Mortality in Korea,2022,the country reported 274,488 new cancer cases in 2022.As personalized medicine is believed to improve health outcomes significantly,efforts have recently been made for its clinical implementation in the country.Society is more likely to realize the benefits of genetic testing for personalized medicine.Recently,the Korean government introduced a regulatory framework that comprises DTC genetic tests.Several genetic testing companies received approval for predictive DTC genetic tests for conditions ranging from cancer to chronic diseases.In June 2023,South Koreas leading cosmetics maker,Amorepacific,stated that it would offer beauty consulting and products based on DTC genetic testing.The test will help the users to learn about their skin condition and its genetic features.Additionally,Korean patients with cancer and dementia are permitted to have genetic tests without going to hospitals by using DTC devices,which are performed using their saliva.9.1.1.5.2 South Korea Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)South Korea genetic testing services market accounted for US$56.64 Mn in 2022 and it is expected to grow at a CAGR of 14.3%during the period 2022-2030,to reach US$165.37 Mn in 2030.Figure 26.South Korea Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 45.6550.8356.6463.4971.5781.1492.52106.09122.33141.84165.37202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 52 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.5.3 South Korea Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 14.South Korea Asia Pacific Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 18.58 20.93 23.58 26.73 30.46 34.91 40.23 46.62 54.32 63.64 74.96 15.6rrier Testing 10.97 12.22 13.62 15.28 17.22 19.53 22.28 25.56 29.48 34.19 39.87 14.4%Prenatal Testing 6.06 6.63 7.25 7.97 8.81 9.80 10.95 12.30 13.89 15.76 17.98 12.0%Newborn Screening 6.89 7.67 8.54 9.57 10.78 12.22 13.93 15.97 18.40 21.33 24.86 14.3%Others 3.14 3.39 3.65 3.95 4.29 4.68 5.13 5.65 6.24 6.92 7.70 9.8%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Asia Pacific genetic testing services market for the predictive testing segment was worth US$23.58 million in 2022 and is projected to reach US$74.96 million by 2030;it is expected to grow at a CAGR of 15.6%from 2022 to 2030.9.1.1.5.4 South Korea Genetic Testing Services Market,by Disease,20202030(US$Million)Table 15.South Korea Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 20.24 22.78 25.66 29.06 33.10 37.92 43.68 50.59 58.92 69.00 81.24 15.5rdiovascular Diseases 10.29 11.54 12.96 14.63 16.61 18.97 21.79 25.16 29.22 34.12 40.06 15.2%Metabolic Diseases 7.80 8.63 9.56 10.65 11.93 13.43 15.22 17.34 19.86 22.88 26.50 13.6%Others 7.32 7.88 8.47 9.15 9.93 10.82 11.84 13.00 14.32 15.84 17.57 9.6%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Asia Pacific genetic testing services market for the cancer segment was worth US$25.66 million in 2022 and is projected to reach US$81.24 million by 2030;it is expected to grow at a CAGR of 15.5%from 2022 to 2030.9.1.1.5.5 South Korea Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 16.South Korea Asia Pacific Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 28.44 31.97 35.96 40.68 46.28 52.94 60.91 70.46 81.97 95.87 112.75 15.4%Diagnostic Laboratories 11.04 12.34 13.80 15.53 17.57 20.00 22.89 26.34 30.49 35.49 41.53 14.8%Others 6.17 6.52 6.88 7.28 7.72 8.20 8.72 9.28 9.87 10.48 11.10 6.2%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 53 Asia Pacific Genetic Testing Services Market,2020-2030 |The Insight Partners The Asia Pacific genetic testing services market for the hospital-based laboratories segment was worth US$35.96 million in 2022 and is projected to reach US$112.75 million by 2030;it is expected to grow at a CAGR of 15.4%from 2022 to 2030.9.1.1.6 Rest of Asia Pacific 9.1.1.6.1 Overview The Rest of the Asia Pacific genetic testing services market is segmented into Malaysia,Indonesia,New Zealand,Myanmar,Vietnam,the Philippines,Singapore,and Thailand.As per Globocan 2020,there were 23,632 new cancer cases and 12,130 deaths due to cancer in Singapore.According to the same source,in Thailand,190,636 new cancer cases and 124,866 deaths were recorded due to cancer in 2020.As per the Globocan 2020 report,prostate cancer is the most common cancer in New Zealand.In 2020,3,938 new cases of prostate cancer were diagnosed in the country.The 5-year prevalence rate was 650.76 per 100,000 population.Genetic tests help to rule out a suspected cancer and the probability of the development of cancer or the same being passed on to the next generation.Strategic efforts made by companies operating in the region also create growth opportunities for the market.In April 2023,LifeStrands Genomics and Ambry Genetics collaborated to provide clinical genetic testing services in Singapore.Together,they support the Clinical Implementation Pilots(CIPs)for Phase II of Singapores National Precision Medicine(NPM)program through an open tender commissioned by Precision Health Research,Singapore(PRECISE).9.1.1.6.2 Rest of Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)The Rest of Asia Pacific genetic testing services market accounted for US$95.08 Mn in 2022 and it is expected to grow at a CAGR of 15.2%during the period 2022-2030,to reach US$295.81 Mn in 2030.Figure 27.Rest of Asia Pacific Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Source
2024-08-12
97页
5星级
Accelerating the tech-driven bioeconomyI N S I G H T R E P O R TJ U N E 2 0 2 4Centre for the Fourth.
2024-08-07
39页
5星级
April 2024Unleash AIs potentialMeasuring the return frompharmaceutical innovation 14th editionForewo.
2024-08-07
32页
5星级
Growth Equity in European HealthtechJune 2024Page/2 Pan-European growth investor focused on the Heal.
2024-08-07
31页
5星级
|Confidential|Draft1These materials are intended to supplement a discussion with L.E.K.Consulting.Th.
2024-08-07
18页
5星级
Pressing issues and critical imperatives that will shape the new model for the industrythe connected.
2024-08-06
19页
5星级
“During the COVID-19 pandemic,telemedicine valuations peakeddue to the urgent need for remote health.
2024-08-02
22页
5星级
futurehealthindex2024Global reportBetter care for more peopleBridging the gaps in healthcareFuture Health Index 2024 2Future Health Index 2024 Better care for more peopleResearch premise03Foreword04Executive summary05Chapter one Bridging the staffing gap 06Chapter two Bridging the insights gap 14Chapter three Bridging the sustainability gap 20Appendices Research methodology Glossary of terms 26 27 ContentsFuture Health Index 2024 Better care for more people3Research premiseIn 2024,the Future Health Index,now in its ninth edition,explores how healthcare leaders view their organizations ability to deliver timely,high-quality care to everyone.The report focuses on the gaps that stand in the way,as well as examining ways of overcoming them.This year,the Future Health Index is based on proprietary quantitative research conducted in 14 countries and supported by qualitative interviews in four of these countries:Singapore,South Africa,the United Kingdom,and the United States.This is the largest global survey of its kind,analyzing the priorities and perspectives of healthcare leaders.3,000healthcare leadersResponses from almost United StatesSaudi ArabiaBrazilChinaNetherlandsJapanUnited KingdomPolandIndonesiaAustraliaSingaporeSouth AfricaItalyIndiaAcross14countriesTimely access to care is a cornerstone of a well-functioning healthcare system.But increasingly,long wait times and staff shortages are making it difficult for people to get the care they need,when they need it.Not just in remote and rural regions,but even in metropolitan areas.And for those who already struggled to get timely and appropriate care,the barriers may only be getting bigger.The result:delays in screening,diagnosis,treatment and follow-up care,which are putting patients at risk and adding even further pressure to healthcare systems in the long run.Thats the stark reality painted by healthcare leaders in this years Future Health Index.They recognize that to keep healthcare systems sustainable in the face of growing patient demand,we urgently need to rethink how and where care is delivered.The good news is that healthcare leaders are taking firm steps in this direction.Through new care delivery models and AI-enabled innovation,healthcare Future Health Index 2024 Better care for more people4Better care for more peopleleaders are addressing the critical gaps in todays healthcare systems.Increasingly,they are automating workflows to free up time for staff and reduce waiting lists.They are embracing virtual care and remote patient monitoring to extend the reach of care.And they are implementing AI to turn information overload into meaningful insights that elevate the expertise of healthcare professionals,helping them to consistently deliver high-quality care.At Philips,we are committed to partnering with healthcare providers on this journey.We see the potential for a future where people everywhere,no matter who they are or where they live,can access the care they need,when they need it.What we hear from healthcare leaders is that they believe in the same future.A future that can only be achieved in partnership,by bringing together stakeholders from across the healthcare ecosystem to collaborate and develop scalable solutions.Thats how we can ultimately deliver better care to more people.Foreword 4How can healthcare providers deliver high-quality care everywhere regardless of patient location,staff availability,and other resource constraints?Thats the question we must address through innovation and collaboration.”Shez Partovi Chief Innovation&Strategy Officer and Chief Business Leader of Enterprise Informatics at Philips“As we shape this future together,we must do so in a sustainable way.By now,it has been well demonstrated that environmental health and human health are inextricably linked.Encouragingly,a vast majority of healthcare leaders in our report recognize that reducing the environmental impact of healthcare should be a top priority.But many grapple with unprecedented financial pressures at the same time.This shows the urgent need for technological solutions that are both green and help reduce the cost of care.It cant be either/or because we cant have healthy people without a healthy planet.As you navigate these challenges with your organization,I hope you take inspiration from the path that other healthcare leaders set out in this report.Future Health Index 2024 Better care for more people5Executive summaryThe 2024 Future Health Index examines three gaps that stand in the way of delivering better care for all.For each of these gaps,it outlines actions that healthcare leaders are taking to overcome them,and highlights their benefits for both healthcare professionals and patients.Bridging the insights gapTo turn a growing volume of data into meaningful insights,healthcare leaders are increasingly implementing AI for clinical decision support within and beyond hospital walls while also calling for guardrails to ensure the safe and responsible use of AI.Bridging the sustainability gapBalancing financial viability with the need to reduce environmental impact,healthcare leaders are looking for sustainable strategies that will not only ensure the future of healthcare but also contribute to a healthier planet.2Bridging the staffing gapIn the face of widespread staffing shortages,healthcare leaders are turning to automation,virtual care and remote patient monitoring to alleviate the pressure on hospital staff,reduce waiting lists and extend the reach of patient care.13Future Health Index 2024 61Bridging the staffing gapA lack of qualified healthcare professionals is putting a heavy strain on health systems worldwide.Healthcare leaders believe automation and virtual care are part of the answer.Future Health Index 2024 Better care for more peopleStaff shortages are taking a toll The global statistics paint an alarming picture:healthcare professionals are overloaded,overworked,and overwhelmed.Almost two-thirds(66%)of healthcare leaders in our survey report increased incidence of burnout,stress and mental health issues in their workforce,deterioration of work-life balance,and/or reduced morale and engagement.The unrelenting workload is making many healthcare professionals question whether they want to keep working under the same conditions or even pursue a different career altogether.More than half of healthcare leaders(55%)are concerned about an increased likelihood of staff leaving.Our survey findings show the extent to which staff shortages in healthcare are impacting both caregivers and patients.This can create a vicious cycle of mounting stress and declining well-being among remaining staff,which then leads to further turnover.More than 1 in 3 healthcare leaders(37%)believe attracting and retaining staff requires help from external partnerships.Leaders interviewed as part of our qualitative study in the US and South Africa noted the value of partnering more closely with local colleges and universities,to ensure a steady pipeline of qualified healthcare professionals.They also emphasized the importance of offering more educational opportunities to existing staff,to keep them engaged in their careers and prevent further attrition.Healthcare professionals are burning outIn healthcare,the number one issue everywhere is staffing.”National Patient Liaison Manager Hospital,UK“Healthcare leaders report staff impacts from workforce shortages55%see an increased likelihood of staff leaving66%see deteriorating staff well-being and mental healthFuture Health Index 2024 Better care for more people7Chapter 1 Bridging the staffing gapPatients,too,are experiencing the consequences of staff shortages and the burden that under-staffed medical units put on their healthcare professionals.More than three in four healthcare leaders(77%)say delays in care are an issue whether its because of increased waiting lists for appointments(60%),longer waiting times for treatments or procedures(57%),or delayed or limited access to screening,diagnosis,and preventive care(54%).77%of leaders report care delays due to staff shortagesThe impact on patients can be significant,as delays in care can result in worse health outcomes,lower quality of life,and higher healthcare costs in the long run.One leader in our qualitative research raised concerns that healthcare professionals are being asked to fill staffing gaps by working beyond their professional scope.This may lead to patient safety risks if these professionals lack the appropriate training,experience,or support.While timely access to care is a challenge everywhere,healthcare leaders recognize that staff shortages may disproportionately affect some patients.More than half of leaders(53%)say that decreased capacity to meet the needs of underserved communities is an issue in their organization.This could be due to several reasons,including challenges in recruiting qualified staff in remote areas,difficulty in attracting staff from backgrounds who are representative of the communities they serve,or increased pressure on the affordability of care due to higher costs associated with hiring(temporary)staff.SpotlightAs a result,patients who encounter economic,geographic,cultural,or linguistic barriers may experience limited access to care and longer wait times for appointments.In addition,one in two healthcare leaders(50%)is concerned about patients having to travel farther to receive appropriate care highlighting the importance of new care delivery models that improve access to care for patients in both rural and urban areas.For example,in our interviews,healthcare leaders in the UK and the US mentioned how they are investing in smaller and specialized community-based clinics,such as diabetes centers,as well as mobile care vehicles equipped with imaging solutions so that clinical staff can scan patients closer to their home.Staff shortages impact underserved communitiesLets say we have 15 or 20 patients in our emergency department(ED)for triage.We only have one ED doctor on and two nurses.Theyre going to be really stressed to get those patients through in a timely manner.So,you might have patients that wait 8,10,12 hours to be seen in an ED.”Chief Information Officer Hospital,US“Patients have to wait longer for careFuture Health Index 2024 Better care for more peopleChapter 1 Bridging the staffing gap8Automation can ease staff shortages,if used right With staff being chronically stretched,healthcare leaders are turning to automation to alleviate the burden on healthcare professionals.But they also face skepticism from staff about its use.A vast majority of healthcare leaders(92%)think automation is critical for addressing staff shortages in healthcare by automating repetitive tasks and processes.They believe it will save healthcare professionals time by reducing their day-to-day administrative tasks,and allow them to perform at their highest skill level.Yet their own people seem not so sure.Almost two-thirds(65%)of healthcare leaders say that healthcare professionals are skeptical about the use of automation in healthcare.An even higher number of radiology leaders(77%)have that concern.When probed more deeply as to why some staff are skeptical about automation,interviewed healthcare leaders offered several reasons.Quality assurance stood out in particular,with several leaders stressing the importance of appropriate research and validation before implementing automation.Another concern that some healthcare leaders expressed about automation is that if healthcare professionals become overly reliant on it,they may lose touch with essential skills and knowledge in their field.Healthcare organizations therefore need to ensure that staff continue to receive adequate training and opportunities to develop their expertise,with automation supporting rather than replacing their professional judgment.If you invest in automation,then youre able to do far more scans and far more procedures in a day,which can help reduce patient waiting lists.”Chief Purchasing Officer Hospital,UK“Leaders optimistic,staff skeptical about automationbelieve automating repetitive tasks is crucial for addressing staff shortages92%think it will save healthcare professionals time by reducing administrative tasks92%say it will allow healthcare professionals to perform at their highest skill level89lieve healthcare professionals are skeptical about the use of automation65%Healthcare leaders see the potential of automation to support staffBut healthcare leaders also face skepticism from staffFuture Health Index 2024 Better care for more people9Chapter 1 Bridging the staffing gapToday,healthcare leaders are mainly using automation to reduce the administrative burden on healthcare professionals and streamline services for patients,such as appointment scheduling.In the next three years,they see workflow prioritization as the biggest opportunity for automation.This can help healthcare professionals deal with high volumes of patients without compromising on quality for example,through automated triaging systems that can assist emergency department staff,or through initial screening of medical images that can prioritize cases and delegate them to the right sub-specialty radiologist.Equipment maintenance and monitoring is another area for planned automation.By identifying potential repair needs before they occur,healthcare organizations can prevent costly equipment downtime and interruptions to patient care.Healthcare leaders are also keen to automate manual notetaking,allowing clinicians to spend more time focusing on patient care and less on documentation.Healthcare leaders seek time savings through automation We have automated point-of-care systems which can triage patients immediately based on a urine sample or a blood sample.”Chief Purchasing Officer Hospital,UK“Workflow prioritization a key focusBy automating tasks such as patient triaging healthcare professionals can focus on the most critical patients first.Automation has already been implementedPlan to implement automation in the next three yearsCurrent and future implementation of automationClinical documentation/notetakingEquipment maintenance and monitoringWorkflow prioritizationPatient check-inBilling processesMedication management Clinical data entry Staff schedulingAppointment scheduling%*413337323833363027365349544251475955231415142016171118Not implemented or dont know*Due to rounding,totals may add to more or less than 100Chapter 1 Bridging the staffing gapFuture Health Index 2024 Better care for more peopleVirtual care extends the reach of patient care Healthcare leaders see virtual care as another way of bridging the staffing gap,by connecting healthcare professionals and patients regardless of location.Last years Future Health Index showed how healthcare leaders continued to build out virtual care services both within and beyond the walls of their organization after investments peaked during the pandemic.This year,almost 9 in 10(89%)are seeing a positive impact on easing staff shortages in their organization.Some of the most-cited benefits of virtual care include increased capacity to serve patients(38%),improved collaboration between healthcare professionals in different locations(37%),and reduced on-site staff required for certain roles(34%).Several healthcare leaders interviewed for our research shared how virtual care has helped them elevate their facilitys standards of care,improve patient throughput,and reduce waiting times.Patients can now get many basic There are many situations where we would be unable to provide a certain procedure or a certain type of care due to staff shortages,so having care delivered virtually improves overall quality,timeliness,and accessibility of care.”Chief Information Officer Hospital,US“89%of leaders see the positive impact of virtual care in easing staff shortagescare needs met in the comfort of their home through telehealth consultations,freeing up hospital staff to focus on acute or complex cases.Almost 1 in 3 healthcare leaders worldwide(32%)say virtual care is also enabling them to expand specialist care to underserved communities in the face of staff shortages.This is especially the case in China(42%),India(41%),and the US(40%),where patients may have to travel long distances to access specialist care.As a result,healthcare leaders from those countries also report decreased clinical response time in our survey.This gives patients a better chance of early screening,diagnosis,and treatment,which in turn can lead to improved health outcomes.Virtual care helps ease staff shortages across care locationsFuture Health Index 2024 Better care for more people11Chapter 1 Bridging the staffing gapHealthcare leaders also see investments in virtual care as a strategy to keep staff on board,recognizing that workforce expectations have changed.More than half(54%)believe virtual care enables more flexible work schedules and creates new career options for healthcare professionals who want to work remotely.By using virtual care to offer flexible work arrangements,healthcare organizations can attract and retain staff seeking a Virtual care creates more flexible career options68%UK37%Italy33%Japan74%Chinabetter work-life balance including older,experienced staff who may not want to continue providing bedside care,but who have a wealth of knowledge.Offering new career paths to seasoned staff,such as virtual nursing,can prevent a critical loss of expertise while supporting the ongoing professional development of frontline caregivers.Workplace flexibility is also likely to appeal to future generations of healthcare professionals,who have Virtual care helps to attract doctors and nurses to stay at our facilities,because they want to see how these new technologies work and can assist them.”Chief Purchasing Officer Hospital,UK“grown up in a digital world and value autonomy in their schedule and location.However,our data show large cross-country variability in how healthcare leaders assess the career benefits of virtual care for healthcare professionals.These benefits are rated most positively in countries where healthcare leaders believe staff have a positive attitude toward virtual care.Healthcare leaders who agree integrating virtual care enables more flexible work schedules and/or creates new career options for healthcare professionals54%Global average12Chapter 1 Bridging the staffing gapFuture Health Index 2024 Better care for more peopleAs most healthcare leaders around the world continue to embrace virtual care,the message from our research is clear:remote patient monitoring is here to stay.In fact,healthcare leaders see an even bigger role for it in the future.Remote patient monitoring solutions can help healthcare professionals offer the same level of care outside of conventional clinical settings,for example in the comfort of a patients home offering a better experience to the patient while reducing the strain on overstretched hospital staff.Among the most used types of remote patient monitoring today are chronic disease management,medication adherence and post-operative monitoring.Healthcare leaders Top three areas where remote patient monitoring has already been implementedPost-operative monitoringMedication adherenceChronic disease management504443%Top three areas where remote patient monitoring implementation is planned within the next three yearsPost-operative monitoringMaternal and fetal healthTelestroke care403635%While virtual care can help make healthcare services more accessible for patients regardless of location,healthcare leaders recognize that it can also contribute to a growing digital divide by limiting access to care for those who lack the necessary technology or skills.For example,in an interview one healthcare leader pointed out how not all elderly patients may feel comfortable using virtual care,unless they receive the appropriate support from caregivers or family members.In addition,internet connectivity in some areas or among certain populations may be limited.SpotlightTo advance the effective delivery of virtual care,66%of healthcare leaders say accessibility and internet connectivity are critical success factors.They also highlight the importance of digital literacy for patients(41%).As healthcare organizations continue to adopt virtual care,it is important no patient gets left behind.Collaboration between government,non-profit,and private sector partners is needed to expand the necessary digital infrastructure.These efforts should be accompanied by accessible user experience design and investments in digital literacy programs to help patients navigate virtual care technologies more easily.Leaving no patient behindRemote patient monitoring brings the hospital to the homeplan expansion of remote patient monitoring into areas such as telestroke care,maternal and fetal health,and post-operative monitoring further supporting the health and well-being of patients outside the hospital.When asked about their predictions for healthcare in 2030,leaders interviewed for our qualitative research mentioned a continued shift to out-of-hospital care,with one leader envisioning“a huge reduction in in-patient care and a transition to outpatient and home care all relieving the stress and burnout of providing care in inpatient settings”.This will need to be met by appropriate investments in primary care and community health services to ensure that patients receive adequate care and support before and after receiving hospital treatment.Future Health Index 2024 Better care for more people13Chapter 1 Bridging the staffing gapFuture Health Index 2024 142Bridging the insights gapHealthcare organizations have a wealth of data but a poverty of insights,which is hampering their ability to provide timely,high-quality care.To bridge this insights gap,healthcare leaders are increasingly embracing AI for clinical decision support.Future Health Index 2024 Better care for more people Healthcare leaders aim for better data integrationEffective patient care relies on accurate and timely access to data,but healthcare professionals often face significant challenges in accessing disparate data and then integrating it into a cohesive patient story.The vast majority of healthcare leaders(94%)say their organization experiences data integration challenges that impact its ability to provide timely,high-quality care.Our findings show healthcare leaders grappling with a lack of integration of data across different systems and devices.But they also recognize the potential to improve patient care through data-driven insights.As a result,almost 4 in 10 healthcare leaders(38%)say that staff lose precious time pulling patient data together,leaving less time to care for patients.They also see increased operational costs due to data inefficiencies and limited coordination between care providers or departments,as well as unnecessary repeat scans and increased risk of errors.Staff lose precious time pulling patient data together94%of healthcare leaders say their organization experiences at least one data integration challenge that impacts its ability to provide timely,high-quality careTop five data integration challenges that impact the ability to provide timely,high-quality care*35%Unnecessary repeat tests/scans due to data inefficiencies37%Limited coordination between care providers/departments34%Increased risk of errors,reduced patient safety and/or quality of care38%Spending time accessing/integrating data results means less time caring for patients38%Increased operational costs due to inefficiencies*Respondents were able to select multiple answers,therefore all combined answers exceed 94%.Future Health Index 2024 Better care for more people15Chapter 2 Bridging the insights gapHealthcare leaders see a wide range of opportunities to improve patient care by bringing data from disparate sources together in a meaningful way.For example,they believe data-driven insights could help optimize treatment plans and care pathways(43%),identify evidence-based practices(37%),and reduce waiting lists for diagnostic and elective procedures(36%).But to deliver on these possibilities,healthcare leaders recognize they need to get the foundations right first.For too many patients,access to care remains out of reach.Can data-driven insights help make a difference?Our survey shows that healthcare leaders recognize the potential of data-driven insights to facilitate targeted outreach and interventions for specific populations(42%).They also believe such insights can help identify and address delays in care delivery that may disproportionately affect certain communities(41%).For example,by analyzing data on patient demographics,medical histories,and social determinants of health,providers can identify patient populations who may be at high risk Spotlightfor chronic conditions and take proactive steps to provide preventive care,such as offering screenings for diabetes and heart disease.However,despite seeing the benefits of data-driven insights for improving access to care,76%of healthcare leaders face the challenge of inadequate healthcare data for underserved communities in their area,and 69%lack data on social determinants of health.These challenges underscore the need for more comprehensive data collection and analysis to reduce health disparities.Addressing gaps in data can provide healthcare leaders with valuable insights that enable them to deliver better care to more patients.Improving access to care with data-driven insightsHealthcare leaders see potential to improve patient care through data Healthcare leaders believe data-driven insights can improve their organizations ability to provide timely,high-quality care by:When asked what needs to change in how healthcare data is handled,they highlight the importance of improved accuracy of patient data(40%),interoperability among different platforms and healthcare settings(39%),and data security and privacy(38%)long-standing challenges in healthcare that must be effectively addressed to harness the full potential of data-driven insights for better patient care.Echoing last years Future Health Index findings,this is where many healthcare leaders see an important role for external partnerships.Optimizing treatment plans and care pathwaysIdentifying evidence-based practicesReducing waiting lists for diagnosis and elective proceduresPredicting and reducing adverse eventsForecasting and managing patient demand437363634Future Health Index 2024 Better care for more people16Chapter 2 Bridging the insights gap16The AI evolution:from exploration to implementationThis years Future Health Index findings show how healthcare leaders have already implemented AI for clinical decision support across different areas of the hospital,with in-hospital patient For the past few years,AI in healthcare has been an area of intense research and development.Now,it is increasingly finding its way into clinical practice.However,concerns about data bias remain.Healthcare leaders are implementing AI from the hospital to the home Current and planned implementation of AI for clinical decision supportmonitoring,medication management,treatment planning,radiology,and preventative care leading the pack.As healthcare leaders increasingly focus on expanding care beyond hospital walls,implementing AI in remote patient monitoring is an area of focus for the next three years.AI has already been implemented32Clinical command centres373226In-hospital patient monitoring3143Plan to implement AI in the next three yearsNot implemented or dont know 26Remote patient monitoring413325Medication management373728Preventive care363628Treatment planning353729Radiology353633Pathology3335%*Due to rounding,totals may add to more or less than 100Chapter 2 Bridging the insights gapFuture Health Index 2024 Better care for more peopleGenerative AI has caught the attention of healthcare leaders in the past year,since its rapid emergence into the public domain.They recognize the benefits that generative AI could bring to patient care by unlocking new efficiencies and insights from patient data.Generative AI adoption in healthcare set to rise within the next three yearsFuture adoption of AI is going to be driven by our clinical leadership working together with our technology leadership,to make sure we have a deep understanding of how the technology is used but also how it benefits patients.”Chief Information Officer Hospital,US“Our research shows that 85%of healthcare leaders across the surveyed countries are already investing or plan to invest in generative AI within the next three years.However,there are significant cross-country differences in how quickly healthcare leaders plan to invest in generative AI,which are consistent with overall differences in speed of adoption of AI for clinical decision support.Currently investing Plan to invest within the next three years29V%Say their organization is currently or planning to invest in generative AI technologies85%Investments in generative AI by healthcare leaders globallyTop countries planning to invest in generative AI within the next three yearsIndonesia74%UK60%Saudi Arabia60%China69%India70%Singapore64%Poland58%US56%Future Health Index 2024 Better care for more people18Chapter 2 Bridging the insights gapWe have a lot of work to do to really verify and understand how AI is used,the benefits but also the safeguards needed,especially when it involves delivery of patient care.”Chief Information Officer Hospital,US“Clinicians will be concerned about the question:whose responsibility is an AI-generated diagnosis?What if something goes wrong?”Operations Director Hospital,Singapore“Responsible use of AI requires appropriate safeguardsWhile there is widespread excitement about the possibilities of AI in healthcare,there is also a shared recognition that it needs to be implemented in a responsible way to avoid unintended consequences.Almost 9 in 10 healthcare leaders(87%)are concerned about the possibility of data bias in AI applications widening existing disparities in health outcomes.To address this risk,healthcare leaders say it is important to make AI more transparent and interpretable for healthcare professionals and offer continuous training and education in AI.Another strategy that healthcare leaders pointed to is policies for the ethical use of data and AI.This can only be achieved through cross-sector collaboration and coalition-building.In our qualitative interviews,several leaders also raised concerns about who is accountable and liable when AI gives faulty recommendations,which could have potentially serious consequences for patient safety and well-being.Its critical to ensure that appropriate checks and balances are in place to mitigate these risks,including adequate human oversight in clinical decision-making.Strategies for mitigating risk of data bias in AI applications for healthcare:Making AI more transparent and interpretablePolicies for ethical use of data and AIContinuous training and education in AIBias detection and monitoringEnsuring staff diversity in data and AIDiverse and representative data collection48FCA87%of healthcare leaders are concerned about the possibility of data bias in AI applications widening disparities in health outcomesFuture Health Index 2024 Better care for more people19Chapter 2 Bridging the insights gapFuture Health Index 2024 Better care for more peopleFuture Health Index 2024 203Bridging the sustainability gapHealthcare leaders are facing financial challenges,while at the same time grappling with the need to reduce their environmental footprint.Our research shows they are embracing new strategies to balance these two priorities to ensure healthcare systems remain sustainable in the long term.Future Health Index 2024 Better care for more peopleHealthcare leaders pursue new financial strategiesOur survey findings show that an overwhelming majority of healthcare leaders(96%)report that their organization is experiencing financial challenges.This is directly impacting the quality and timeliness of care,according to 81%of leaders,because limited resources are resulting in longer waiting The economic sustainability of healthcare systems is under increasing pressure as the cost of care delivery continues to rise.Operating on razor-thin or even negative margins,healthcare leaders are adapting their financial strategies accordingly.times,treatments are being offered more selectively,and patients are more frequently referred to other healthcare organizations.Financial challenges are also limiting the ability of healthcare organizations to implement new innovations.Financial challenges are impacting patient careHow financial challenges are impacting patient care96%of healthcare leaders report that their organization is experiencing financial challenges81%of leaders say financial challenges are having a direct impact on patient care59%of leaders are delaying investment or unable to invest in new medical technology due to financial challengesAlmost 3 in 5 leaders(59%)are unable to invest in new or more advanced medical equipment or technologies,or they have to delay or limit such investments.21Chapter 3 Bridging the sustainability gapFuture Health Index 2024 Better care for more peopleRapid advances in technology are outpacing budget availability for many healthcare organizations.This is prompting healthcare leaders to consider new ways of purchasing technology solutions without large upfront capital expenditures including subscription-based models.Almost three in four(74%)of healthcare leaders are considering using at least one type of healthcare technology subscription within the next three years,with usage-based models being most popular today.Adoption of subscription-based models can reduce the need for upfront capital investments and improve the predictability of expenses.Subscription-based models can also help healthcare organizations stay up to date with the latest technology and software more easily,offering them a way to address financial challenges while supporting continual optimization of patient care.SpotlightHealthcare leaders embrace subscription-based buying modelsFinancial strategies currently used or being consideredIncreasing patient volumes or expanding servicesImplementing cost reductionsImproving operational efficienciesInvesting in community health to lower overall healthcare costsInvesting in preventive care to reduce long-term healthcare costsValue-based care modelsBetter reimbursement rates with payersNew business models(e.g.,community care centers)%*5543494055424436374140423641414381611189171521Currently usingConsidering using within the next three yearsNot currently using or considering using in the next three yearsHealthcare leaders are taking necessary measures within their organizations to remain financially viable and ensure continuity of care.Their most frequently used or planned strategies to address financial challenges are improving operational efficiencies(92%)and implementing cost reductions(91%).At the same time,healthcare leaders realize they cannot cut or streamline their way to long-term financial sustainability,with 89%of them using or planning strategies to serve more patients or expand services.Thinking long term,healthcare leaders also plan to invest in preventive care and community health to lower overall healthcare costs,supported by new business models(such as community care centers)and value-based care models that incentivize improved patient outcomes rather than the volume of care delivered.These models can drive down the cost per patient,by minimizing the need for avoidable acute or chronic care further down the track.Healthcare leaders cut costs while pursuing growth*Due to rounding,totals may add to more or less than 100%Future Health Index 2024 Better care for more people22Chapter 3 Bridging the sustainability gap22Setting targets for decarbonization and tracking emissionsSelecting suppliers with sustainable targets/initiativesEnvironmental sustainability is a key priorityThe vast majority(86%)of healthcare leaders believe that reducing CO2 emissions and the environmental impact of healthcare should be a top priority for healthcare organizations,and an even larger percentage(90%)thinks it should be a top priority for governments.With this sense of urgency in mind,healthcare leaders are actively implementing sustainability strategies to reduce their environmental impact.Healthcare leaders overwhelmingly acknowledge that addressing the impact of the healthcare sector on the planet is no longer a matter of if it is a matter of how.The most implemented strategies today include recycling waste,reduction or elimination of hazardous substances,water conservation,and reducing energy usage.In the next three years,healthcare leaders plan to implement further strategies,such as selecting suppliers with sustainability targets,implementing sustainable procurement,including circular equipment,and investing in green buildings and infrastructure.Healthcare leaders cut back on waste,energy,and waterTop 5 environmental sustainability strategies healthcare leaders plan to implement in the next three yearsInvesting in green buildings and infrastructurePrioritizing reusable medical equipment and supplies Sustainable procurement,including circular equipment4141404140%Top 5 environmental sustainability strategies healthcare leaders have implementedWater conservationPrioritizing reusable medical equipment and suppliesReduction or elimination of hazardous substancesReducing energy usage/being more efficient with energyRecycling waste wherever possible4946424339%Our doctors want products that can be reused or that are recyclable,so that our facility doesnt generate so much waste.”Chief Executive Officer Hospital,South Africa“86%of healthcare leaders believe that reducing CO2 emissions and the environmental impact of healthcare should be a top priority for healthcare organizationsFuture Health Index 2024 Better care for more people23Chapter 3 Bridging the sustainability gapThese sustainability strategies demonstrate how healthcare leaders are taking significant steps to reduce their environmental impact,but there is still a long way to go toward achieving a carbon-neutral healthcare sector.Encouragingly,71%of healthcare leaders have set targets for decarbonization and tracking emissions,or plan to do so in the next three years.However,29%either do not have,or are not sure about,plans for decarbonization.Moreover,in our interviews with healthcare leaders,we found that,when exploring sustainability initiatives,they need to strike a balance between economic and environmental considerations.This is in line with findings from last years Future Health Index,which showed that many healthcare leaders struggle to balance sustainability with other(financial)priorities.As one US healthcare leader said during this years interviews,“Were fighting for survival so being very frank,sustainability is lower on the list.”Decarbonization of healthcare requires further collective effortWhile it is crucial to maintain financial viability,sustainability and economic considerations are not mutually exclusive.Rather,sustainable practices can help healthcare organizations achieve economic sustainability,both in the short term(for example,through waste reduction and energy savings)and in the long term(for example,through circular financing structures that help customers maximize the lifetime value of their medical equipment).This shows the need for further collaboration across the healthcare ecosystem including healthcare systems,policymakers,health technology companies,the supply chain,and other stakeholders to address health systems environmental challenges and at the same time lower the total cost of care.We obviously want to operate as greenly as possible,but also as financially efficiently as possible.So,if the greener ways are the cheaper ways,that will definitely sway our opinion on pursuing them more quickly.”National Patient Liaison Manager Hospital,UK“71%of leaders have set or plan to set targets for decarbonization and tracking emissionsFuture Health Index 2024 Better care for more people24Chapter 3 Bridging the sustainability gap24Future Health Index 2024 25AppendicesFuture Health Index 2024 Better care for more peopleFuture Health Index 2024 Better care for more people26Research methodologyThe quantitative study was executed by GemSeek,a global business and consumer research services firm employing a methodology of online(CAWI)surveying.2,800 healthcare leaders,200 in each of the 14 countries included(Australia,Brazil,China*,India,Indonesia,Italy,Japan,the Netherlands,Poland,Saudi Arabia,Singapore,South Africa,the United Kingdom,and the United States),participated in a 15-to-20-minute survey from December 2023 to February 2024.Where relevant,the survey was translated into the local language.In some instances,certain questions needed to be adjusted slightly for relevance within specific countries.Care was taken to ensure the meaning of the question remained as close to the original,English,version as possible.Below shows the specific sample size,estimated margin of error*at the 95%confidence level,and interviewing methodology used for each country.2024 qualitative interview methodology The qualitative portion of the Future Health Index 2024 was also conducted by GemSeek.To provide context and additional depth to the quantitative data,the survey results were supplemented with findings from a series of 45-minute,English language interviews with healthcare leaders.These interviews were conducted February to March 2024.There were eight participants,two from each of the following countries:Singapore,South Africa,the United Kingdom,and the United States.Unweighted sample size (N=)Estimated margin of error(percentage points)Interview methodologyAustralia200 /-7.0OnlineBrazil200 /-7.0OnlineChina200 /-7.0OnlineIndia200 /-7.0OnlineIndonesia200 /-7.0OnlineItaly200 /-7.0OnlineJapan200 /-7.0OnlineNetherlands200 /-7.0OnlinePoland200 /-7.0OnlineSaudi Arabia200 /-7.0OnlineSingapore200 /-7.0OnlineSouth Africa200 /-7.0OnlineUnited Kingdom200 /-7.0OnlineUnited States200 /-7.0OnlineTotal2,800 /-2.02024 quantitative survey methodology*Survey data is representative of mainland China only and does not include Taiwan or Hong Kong.*Estimated margin of error is the margin of error that would be associated with a sample of this size for the full healthcare leader population in each country.However,this is estimated since robust data is not available on the number of healthcare leaders in each country surveyed.Future Health Index 2024 Better care for more people27Glossary of termsArtificial intelligence(AI)AI refers to the use of machine learning and other methods that may mimic intelligent human behaviors,resulting in a machine or program that can sense,reason,act and adapt to assist with different tasks.Automation The use of technology and software solutions to perform tasks and processes with limited human involvement.It may involve the application of digital tools,machines,and computer systems to streamline and optimize various aspects of healthcare delivery,administration,and management.Clinical decision supportThe provision of information to help inform decisions about patient care.Data biasA flaw that occurs when certain elements of a dataset are missing,underrepresented or overrepresented.Data-driven insightsInformation gathered from the analysis of raw data and used to inform decision-making.Data integration Used here to refer to a variety of clinical and/or operational information amassed from numerous sources including but not limited to electronic medical records(EMRs),medical devices,and workflow management tools.DecarbonizationThe process of removing carbon,or material containing carbon,from a substance or object.Generative AIArtificial intelligence algorithms that can be used to produce content such as text,images,audio or other data in response to inputted prompts.Healthcare ecosystem Describes the locations of care and services provided,the people involved in care delivery(including patients,family members and caregivers),and how they work together to improve efficiencies and optimize experiences.Healthcare leader A C-suite or senior executive working in a hospital,medical practice,imaging center/office-based lab,or urgent care facility who is a final decision-maker or has influence in making decisions.Healthcare organizationThe hospital or healthcare facility for or in which the healthcare leader works.Healthcare professional Individuals who are directly involved in providing healthcare services to patients(including doctors,nurses,surgeons,specialists,technologists,technicians,etc.).Interoperability The ability of health information systems to work together within and across organizational boundaries,regardless of brand,operating system or hardware.Remote patient monitoring Technology that provides care teams with the tools they need to remotely track the health of their patients outside of conventional clinical settings(e.g.,at home),collaborate with the patients other healthcare professional(s)and help detect problems before they lead to readmissions.Examples of this include cardiac implant surveillance,vital-sign sensors at home,etc.Social determinants of healthNon-medical factors that influence health outcomes,such as the conditions in which people are born,grow,work and live.Staff This refers to all employees within a healthcare organization,including healthcare professionals,IT,financial services,administrative support,facilities,etc.Sustainability Meeting the environmental needs of the present without compromising the ability of future generations to meet their own needs.Technology infrastructure Foundational technology services,software,equipment,facilities and structures upon which the capabilities of nations,cities and organizations are built.This includes both IT infrastructure and traditional infrastructure that is sufficiently advanced such that it can be considered modern technology.Timely,high-quality care For the purposes of this survey,this phrase reflects healthcare being provided to all patients and the communities served by a healthcare organization.Underserved communitiesIncludes people who receive fewer health care services and/or encounter barriers to accessing health care services(e.g.,economic,geographic,cultural,and/or linguistic barriers).Virtual care The use of telecommunication technologies that remotely connects a patient to a healthcare professional,or a healthcare professional to a healthcare professional.Workflows A process involving a series of tasks performed by various people within and between work environments to deliver care.Accomplishing each task may require actions by one person,between people,or across organizations and can occur sequentially or Future Health Index is commissioned by Philips.To see the full report,visit Future Health Index 2024 report explores how healthcare leaders view their hospitals ability to deliver timely,high-quality care to everyone.A quantitative survey was conducted among almost 3,000 healthcare leaders from 14 countries(Australia,Brazil,China,India,Indonesia,Italy,Japan,the Netherlands,Poland,Saudi Arabia,Singapore,South Africa,the United Kingdom and the United States).This was supplemented by eight qualitative interviews of healthcare leaders,two from each of the following countries:Singapore,South Africa,the United Kingdom and the United States.Both the quantitative and qualitative research stages were conducted between December 2023 March 2024.
2024-08-01
28页
5星级
THE MALARIADIVIDENDWHY INVESTING IN MALARIA ELIMINATIONCREATES RETURNS FOR ALL23Key figures at a gla.
2024-07-26
11页
5星级
罗兰贝格：预见2026：中国行业趋势报告（90页）.pdf
智源研究院：2026十大AI技术趋势报告（34页）.pdf
中国互联网协会：智能体应用发展报告（2025）（124页）.pdf
三个皮匠报告：2025银发经济生态：中国与全球实践白皮书（150页）.pdf
三个皮匠报告：2025中国商业航天市场洞察报告-中国商业航天新格局全景洞察（25页）.pdf
国声智库：全球AI创造力发展报告2025（77页）.pdf
三个皮匠报告：2025中国情绪消费市场洞察报告（24页）.pdf
中国电子技术标准化研究院：2025知识图谱与大模型融合实践案例集（354页）.pdf
艺恩：2026“情绪疗愈”消费市场趋势盘点报告（31页）.pdf
三个皮匠报告：2025中国固态电池市场洞察报告-产业爆发前夕如何重塑锂电新格局（26页）.pdf
0731-84720580
商务合作：really158d
友链申请 (QQ)：1737380874
最新报告
中英对照
全文搜索
报告精选
PDF上传翻译
多格式文档互转
入驻&报告售卖
会员权益
机构报告
券商研报
财报库
专题合集
英文报告
数据图表
会议报告
其他资源
研报
新质生产力
DeepSeek
低空经济
大模型
AI Agent
AI Infra
具身智能
自动驾驶
宠物
银发经济
人形机器人
企业出海
算力
微短剧
薪酬
白皮书
创新药
行业分析
个股研究
年报财报
IPO招股书
会议纪要
宏观策略
政策法规
其他
人工智能
信息科技
互联网
消费经济
汽车交通
电商零售
传媒娱乐
医疗健康
投资金融
能源环境
地产建筑
传统产业
英文报告
其它
行业聚焦
芯片产业
热点概念
全球咨询智库
人工智能
500强
新质生产力
会议峰会
新能源汽车
企业年报
互联网
公司研究
行业综观
消费教育
科技通信
医药健康
人力资源
投资金融
汽车产业
物流地产
电子商务
传统产业
传媒营销
其它
十五五规划系列报告合集（共48套打包）
2026低空经济/低空产业报告合集（共47套打包）
AI、科技与通信
广告、传媒与营销
消费、零售与支付
HR、文化与旅游
金融、保险与投资
能源、环境与工业
医疗制药与大健康
物流、地产与建筑
其他行业
AI ▪ 科技 ▪ 通信
数字化
金融财经
智能制造
电商传媒
地产建筑
医疗医学
能源化工
其他行业
收藏
下载
2026-02-02
AI查数
行业数据
政策法规
商业模式
产业链
竞争格局
市场规模
产业概述
其它
2026年
AI读财报
年报
一季报
半年报
三季报
IPO招股书
社会责任报告
A股
IPO申报
港股
美股&全球
新三板
微信扫码登录
手机快捷登录
账号登录
